0001829126-22-018581.txt : 20221103 0001829126-22-018581.hdr.sgml : 20221103 20221103061045 ACCESSION NUMBER: 0001829126-22-018581 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20220924 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MedMen Enterprises, Inc. CENTRAL INDEX KEY: 0001776932 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-RETAIL STORES, NEC [5990] IRS NUMBER: 981431779 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56199 FILM NUMBER: 221356002 BUSINESS ADDRESS: STREET 1: 10115 JEFFERSON BOULEVARD CITY: CULVER CITY STATE: CA ZIP: 90232 BUSINESS PHONE: 4243302082 MAIL ADDRESS: STREET 1: 10115 JEFFERSON BOULEVARD CITY: CULVER CITY STATE: CA ZIP: 90232 10-Q 1 medmenenter_10q.htm 10-Q
0001776932 false --06-30 2023 Q1 0001776932 2022-06-26 2022-09-24 0001776932 2022-10-31 0001776932 2022-09-24 0001776932 2022-06-25 0001776932 mmen:SubordinateVotingStockMember 2022-09-24 0001776932 mmen:SubordinateVotingStockMember 2022-06-25 0001776932 2021-06-27 2021-09-25 0001776932 mmen:SubordinateVotingMember 2022-06-26 0001776932 us-gaap:AdditionalPaidInCapitalMember 2022-06-26 0001776932 us-gaap:RetainedEarningsMember 2022-06-26 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2022-06-26 0001776932 us-gaap:NoncontrollingInterestMember 2022-06-26 0001776932 2022-06-26 0001776932 mmen:SubordinateVotingMember 2021-06-27 0001776932 us-gaap:AdditionalPaidInCapitalMember 2021-06-27 0001776932 us-gaap:RetainedEarningsMember 2021-06-27 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2021-06-27 0001776932 us-gaap:NoncontrollingInterestMember 2021-06-27 0001776932 2021-06-27 0001776932 mmen:SubordinateVotingMember 2022-06-27 2022-09-24 0001776932 us-gaap:AdditionalPaidInCapitalMember 2022-06-27 2022-09-24 0001776932 us-gaap:RetainedEarningsMember 2022-06-27 2022-09-24 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2022-06-27 2022-09-24 0001776932 us-gaap:NoncontrollingInterestMember 2022-06-27 2022-09-24 0001776932 2022-06-27 2022-09-24 0001776932 mmen:SubordinateVotingMember 2021-06-28 2021-09-25 0001776932 us-gaap:AdditionalPaidInCapitalMember 2021-06-28 2021-09-25 0001776932 us-gaap:RetainedEarningsMember 2021-06-28 2021-09-25 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2021-06-28 2021-09-25 0001776932 us-gaap:NoncontrollingInterestMember 2021-06-28 2021-09-25 0001776932 2021-06-28 2021-09-25 0001776932 mmen:SubordinateVotingMember 2022-09-24 0001776932 us-gaap:AdditionalPaidInCapitalMember 2022-09-24 0001776932 us-gaap:RetainedEarningsMember 2022-09-24 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2022-09-24 0001776932 us-gaap:NoncontrollingInterestMember 2022-09-24 0001776932 mmen:SubordinateVotingMember 2021-09-25 0001776932 us-gaap:AdditionalPaidInCapitalMember 2021-09-25 0001776932 us-gaap:RetainedEarningsMember 2021-09-25 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2021-09-25 0001776932 us-gaap:NoncontrollingInterestMember 2021-09-25 0001776932 2021-09-25 0001776932 2021-06-26 0001776932 2022-06-01 2022-06-25 0001776932 mmen:DiscontinuedOperationsMember 2022-06-25 0001776932 mmen:OtherAssetMember 2022-06-25 0001776932 mmen:TotalMember 2022-06-25 0001776932 mmen:DiscontinuedOperationsMember 2022-06-26 2022-09-24 0001776932 mmen:OtherAssetMember 2022-06-26 2022-09-24 0001776932 mmen:TotalMember 2022-06-26 2022-09-24 0001776932 mmen:DiscontinuedOperationsMember 2022-09-24 0001776932 mmen:OtherAssetMember 2022-09-24 0001776932 mmen:TotalMember 2022-09-24 0001776932 mmen:DispensaryLicenseMember 2022-09-24 0001776932 mmen:DispensaryLicenseMember 2022-06-25 0001776932 mmen:CustomerRelationshipMember 2022-09-24 0001776932 mmen:CustomerRelationshipMember 2022-06-25 0001776932 mmen:CapitalizedSoftwareMember 2022-09-24 0001776932 mmen:CapitalizedSoftwareMember 2022-06-25 0001776932 us-gaap:IntellectualPropertyMember 2022-09-24 0001776932 us-gaap:IntellectualPropertyMember 2022-06-25 0001776932 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2022-09-24 0001776932 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2022-06-25 0001776932 mmen:DerivativeLiabilitiesOneMember 2022-06-25 0001776932 mmen:DerivativeLiabilitiesOneMember 2022-06-26 2022-09-24 0001776932 mmen:DerivativeLiabilitiesOneMember 2022-09-24 0001776932 mmen:TopUpProvisionMember 2022-09-24 0001776932 mmen:TopUpProvisionMember 2022-06-26 2022-09-24 0001776932 us-gaap:ConvertibleNotesPayableMember 2022-09-24 0001776932 us-gaap:ConvertibleNotesPayableMember 2022-06-25 0001776932 mmen:NotesPayableMember 2022-06-25 0001776932 mmen:NotesPayableMember 2022-06-26 2022-09-24 0001776932 mmen:NotesPayableMember 2022-09-24 0001776932 2022-01-29 2022-02-02 0001776932 mmen:SecuredConvertibleNoteMember 2022-09-24 0001776932 mmen:SecuredConvertibleNoteMember 2022-06-25 0001776932 mmen:SecuredConvertibleNote1Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote1Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote2Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote2Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote3Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote3Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote4Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote4Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote5Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote5Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote6Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote6Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote7Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote7Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote8Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote8Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote9Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote9Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote10Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote10Member 2022-06-25 0001776932 mmen:TrancheOneMember 2022-06-25 0001776932 mmen:TrancheTwoMember 2022-06-25 0001776932 mmen:TrancheThreeMember 2022-06-25 0001776932 mmen:TrancheFourMember 2022-06-25 0001776932 mmen:IncrementalAdvanceOneMember 2022-06-25 0001776932 mmen:IncrementalAdvanceTwoMember 2022-06-25 0001776932 mmen:Advance3rdMember 2022-06-25 0001776932 mmen:AmendmentFeeNotesMember 2022-06-25 0001776932 mmen:RestatementFeeNotesMember 2022-06-25 0001776932 mmen:SecondRestatementFeeNotesMember 2022-06-25 0001776932 mmen:SeniorSecuredConvertibleTotalMember 2022-06-25 0001776932 mmen:TrancheOneMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheTwoMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheThreeMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheFourMember 2022-06-26 2022-09-24 0001776932 mmen:IncrementalAdvanceOneMember 2022-06-26 2022-09-24 0001776932 mmen:IncrementalAdvanceTwoMember 2022-06-26 2022-09-24 0001776932 mmen:Advance3rdMember 2022-06-26 2022-09-24 0001776932 mmen:AmendmentFeeNotesMember 2022-06-26 2022-09-24 0001776932 mmen:RestatementFeeNotesMember 2022-06-26 2022-09-24 0001776932 mmen:SecondRestatementFeeNotesMember 2022-06-26 2022-09-24 0001776932 mmen:SeniorSecuredConvertibleTotalMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheOneMember 2022-09-24 0001776932 mmen:TrancheTwoMember 2022-09-24 0001776932 mmen:TrancheThreeMember 2022-09-24 0001776932 mmen:TrancheFourMember 2022-09-24 0001776932 mmen:IncrementalAdvanceOneMember 2022-09-24 0001776932 mmen:IncrementalAdvanceTwoMember 2022-09-24 0001776932 mmen:Advance3rdMember 2022-09-24 0001776932 mmen:AmendmentFeeNotesMember 2022-09-24 0001776932 mmen:RestatementFeeNotesMember 2022-09-24 0001776932 mmen:SecondRestatementFeeNotesMember 2022-09-24 0001776932 mmen:SeniorSecuredConvertibleTotalMember 2022-09-24 0001776932 mmen:MmCanUsaClassBRedeemableUnitsMember 2022-06-25 0001776932 mmen:MmEnterprisesUsaCommonUnitsMember 2022-06-25 0001776932 mmen:SubordinateVotingStockMember 2022-06-26 2022-09-24 0001776932 mmen:MmCanUsaClassBRedeemableUnitsMember 2022-06-26 2022-09-24 0001776932 mmen:MmEnterprisesUsaCommonUnitsMember 2022-06-26 2022-09-24 0001776932 mmen:MmCanUsaClassBRedeemableUnitsMember 2022-09-24 0001776932 mmen:MmEnterprisesUsaCommonUnitsMember 2022-09-24 0001776932 mmen:MMCANUSAMember 2022-09-24 0001776932 mmen:MMCANUSAMember 2022-06-25 0001776932 mmen:MMEnterprisesUSAMember 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember 2022-09-24 0001776932 mmen:NaturesCureIncMember 2022-09-24 0001776932 mmen:ViesTotalMember 2022-09-24 0001776932 mmen:VeniceCaregiversFoundationIncMember 2022-06-26 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember 2022-06-26 2022-09-24 0001776932 mmen:NaturesCureIncMember 2022-06-26 2022-09-24 0001776932 mmen:ViesTotalMember 2022-06-26 2022-09-24 0001776932 mmen:VeniceCaregiversFoundationIncMember 2022-06-25 0001776932 mmen:LAXFundTwoGroupLLCMember 2022-06-25 0001776932 mmen:NaturesCureIncMember 2022-06-25 0001776932 mmen:ViesTotalMember 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember 2021-06-27 2022-06-25 0001776932 mmen:LAXFundTwoGroupLLCMember 2021-06-27 2022-06-25 0001776932 mmen:NaturesCureIncMember 2021-06-27 2022-06-25 0001776932 mmen:ViesTotalMember 2021-06-27 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:LAXFundTwoGroupLLCMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:NaturesCureIncMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:OtherNonControllingInterestsMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:TotalMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:NaturesCureIncMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:OtherNonControllingInterestsMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:TotalMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:VeniceCaregiversFoundationIncMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:NaturesCureIncMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:OtherNonControllingInterestsMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:TotalMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 srt:MinimumMember 2022-06-26 2022-09-24 0001776932 srt:MaximumMember 2022-06-26 2022-09-24 0001776932 us-gaap:StockOptionMember 2022-06-26 2022-09-24 0001776932 us-gaap:StockOptionMember 2021-06-27 2021-09-25 0001776932 mmen:StockGrantsMember 2022-06-26 2022-09-24 0001776932 mmen:StockGrantsMember 2021-06-27 2021-09-25 0001776932 mmen:RestrictedStockGrantsMember 2022-06-26 2022-09-24 0001776932 mmen:RestrictedStockGrantsMember 2021-06-27 2021-09-25 0001776932 us-gaap:WarrantMember mmen:SubordinateVotingsSharesMember 2022-06-26 2022-09-24 0001776932 us-gaap:WarrantMember mmen:MmCanUsaClassBRedeemableUnitsMember 2022-06-26 2022-09-24 0001776932 us-gaap:WarrantMember 2022-06-26 2022-09-24 0001776932 srt:BoardOfDirectorsChairmanMember 2022-06-26 2022-09-24 0001776932 stpr:CA 2022-06-26 2022-09-24 0001776932 stpr:CA 2021-06-27 2021-09-25 0001776932 stpr:NV 2022-06-26 2022-09-24 0001776932 stpr:NV 2021-06-27 2021-09-25 0001776932 stpr:IL 2022-06-26 2022-09-24 0001776932 stpr:IL 2021-06-27 2021-09-25 0001776932 stpr:AZ 2022-06-26 2022-09-24 0001776932 stpr:AZ 2021-06-27 2021-09-25 0001776932 stpr:MA 2022-06-26 2022-09-24 0001776932 stpr:MA 2021-06-27 2021-09-25 0001776932 2022-08-01 2022-08-22 0001776932 2022-09-01 2022-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 24, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission file number 000-56199 

 

MEDMEN ENTERPRISES INC.

(Exact name of registrant as specified in its charter)

 

British Columbia   98-1431779

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. employer

identification no.)

     

8740 S Sepulveda Blvd, Suite 105,

Los Angeles, California

  90045
(Address of principal executive offices)   (Zip code)

 

(424) 330-2082

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

None.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐   No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer Accelerated Filer
Non-Accelerated Filer Smaller Reporting Company
    Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financing accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐   No

 

As of October 31, 2022, the registrant had 1,301,683,764 Class B Subordinate Voting Shares outstanding.

 

 

 

 

 

 

MEDMEN ENTERPRISES, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 24, 2022

 

TABLE OF CONTENTS

 

    Page 
FINANCIAL INFORMATION    
Part I    
ITEM 1: Condensed Consolidated Balance Sheets (Unaudited)   1
Condensed Consolidated Statements of Operations (Unaudited)   2
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited)   3
Condensed Consolidated Statements of Cash Flows (Unaudited)   4
Notes to Condensed Consolidated Financial Statements (Unaudited)   6
ITEM 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations   38
ITEM 3: Quantitative and Qualitative Disclosure About Market Risk   47
ITEM 4: Controls and Procedures   47
       
OTHER INFORMATION    
Part II    
ITEM 1: Legal Proceedings   49
ITEM 1A: Risk Factors   49
ITEM 2: Unregistered Sales of Equity Securities   49
ITEM 3: Defaults Upon Senior Securities   49
ITEM 4: Mine Safety Disclosure   49
ITEM 5: Other Information   50
ITEM 6: Exhibits   51
Signatures   52

 

i

 

 

Use of Names

 

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms “we,” “us,” “our,” “Company,” “Corporation” or “MedMen” refer to MedMen Enterprises Inc. together with its wholly-owned subsidiaries.

 

Disclosure Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains statements that we believe are, or may be considered to be, “forward-looking statements”. All statements other than statements of historical fact included in this document regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as “may,” “will,” “expect,” “intend,” “estimate,” “foresee,” “project,” “anticipate,” “believe,” “plan,” “forecast,” “continue” or “could” or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (the “SEC”), press releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. These known and unknown risks include, without limitation: marijuana remains illegal under U.S. federal law, and enforcement of cannabis laws could change; the Company may face limitations on ownership of cannabis licenses; the Company may become subject to U.S. Food and Drug Administration or the U.S. Bureau of Alcohol, Tobacco and Firearms; the Company may face difficulties acquiring additional financing; the Company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business; the Company is subject to general economic risks; the Company may be negatively impacted by challenging global economic condition; the Company is subject to risks arising from epidemic diseases, such as the recent outbreak of COVID-19; the Company may face difficulties in enforcing its contracts; the Company is subject to taxation in Canada and the United States; cannabis businesses are subject to unfavorable tax treatment; cannabis businesses may be subject to civil asset forfeiture; the Company is subject to proceeds of crime statutes; the Company faces security risks; competition for the acquisition and leasing of properties suitable for the cultivation, production and sale of medical and adult use cannabis may impede our ability to make acquisitions or increase the cost of these acquisitions, which could adversely affect our operating results and financial condition; the Company faces risks related to its products; the Company is dependent on the popularity of consumer acceptance of the Company’s brand portfolio; the Company faces risks related to its insurance coverage and uninsurable risks; the Company is dependent on key inputs, suppliers and skilled labor; the Company must attract and maintain key personnel; the Company’s business is subject to the risks inherent in agricultural operations; the Company’s sales are difficult to forecast; the Company’s products may be subject to product recalls; the Company may face unfavorable publicity or consumer perception; the Company faces intense competition; and additional issuances of Subordinate Voting Shares may result in dilution. Further information on these and other potential factors that could affect the Company’s business and financial condition and the results of operations are included in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the SEC on September 9, 2022, and elsewhere in the Company’s filings with the SEC, which are available on the SEC’s website or on the Company’s website at https://investors.medmen.com/. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this document, which reflect management’s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this document.

 

ii

 

 

PART I — FINANCIAL INFORMATION

 

MEDMEN ENTERPRISES INC.

Condensed Consolidated Balance Sheets (Unaudited)

As of September 24, 2022 and June 25, 2022

(Amounts Expressed in United States Dollars, Except for Share Data)

 

 

           
   September 24,   June 25, 
   2022   2022 
  (unaudited)   (audited) 
ASSETS        
           
Current Assets:          
Cash and Cash Equivalents  $21,097,057   $10,795,999 
Accounts Receivable and Prepaid Expenses   5,376,069    7,539,767 
Inventory   9,117,809    10,010,731 
Assets Held for Sale   44,185,218    123,158,751 
Receivable for Assets Held for Sale   11,500,000    - 
Other Assets   7,403,829    9,990,992 
           
Total Current Assets   98,679,982    161,496,240 
           
Operating Lease Right-of-Use Assets   44,461,062    47,649,270 
Property and Equipment, Net   59,965,935    64,107,792 
Intangible Assets, Net   34,057,051    35,746,114 
Goodwill   9,810,049    9,810,049 
Other Non-Current Assets   4,157,513    4,414,219 
           
TOTAL ASSETS  $251,131,592   $323,223,684 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
           
LIABILITIES:          
Current Liabilities:          
Accounts Payable and Accrued Liabilities  $35,355,136   $38,905,818 
Income Taxes Payable   64,710,033    58,646,291 
Other Liabilities   17,121,093    16,704,283 
Derivative Liabilities   7,555,153    6,749,563 
Current Portion of Operating Lease Liabilities   12,199,351    10,925,128 
Current Portion of Finance Lease Liabilities   4,150,484    4,061,273 
Current Portion of Notes Payable   66,294,249    97,003,922 
Liabilities Held for Sale   26,195,800    86,595,102 
           
Total Current Liabilities   233,581,299    319,591,380 
           
Operating Lease Liabilities   47,280,217    50,917,244 
Finance Lease Liabilities   26,905,824    26,553,287 
Other Non-Current Liabilities   2,987,812    3,082,277 
Deferred Tax Liability   40,295,319    35,213,671 
Senior Secured Convertible Credit Facility   138,746,070    132,005,663 
Notes Payable   74,898,640    74,372,898 
           
TOTAL LIABILITIES   564,695,181    641,736,420 
           
SHAREHOLDERS’ EQUITY:          
Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding)   -    - 
Subordinate Voting Shares (no par value, unlimited shares authorized, 1,301,683,764 and 1,301,423,950 shares issued and outstanding as of September 24, 2022 and June 26, 2022, respectively)   -    - 
Additional Paid-In Capital   1,058,145,437    1,057,228,873 
Accumulated Deficit   (897,613,980)   (901,758,875)
           
Total Equity Attributable to Shareholders of MedMen Enterprises Inc.   160,531,457    155,469,998 
Non-Controlling Interest   (474,095,046)   (473,982,734)
           
TOTAL SHAREHOLDERS’ EQUITY   (313,563,589)   (318,512,736)
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $251,131,592   $323,223,684 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

 

1

 

 

MEDMEN ENTERPRISES INC.

Condensed Consolidated Statements of Operations (Unaudited)

Three Months Ended September 24, 2022 and September 25, 2021

(Amounts Expressed in United States Dollars, Except for Share Data)

 

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Revenue  $30,044,048   $36,735,904 
Cost of Goods Sold   15,187,672    19,349,990 
           
Gross Profit   14,856,376    17,385,914 
           
Operating Expenses:          
General and Administrative   17,846,117    32,649,234 
Sales and Marketing   443,790    593,224 
Depreciation and Amortization   3,946,523    5,823,617 
Realized and Unrealized Changes in Fair Value of Contingent Consideration   (863,856)   - 
Impairment Expense   1,663,911    435,241 
Other Operating (Income) Expense   (2,555,118)   2,199,028 
           
Total Operating Expenses   20,481,367    41,700,344 
           
Loss from Operations   (5,624,991)   (24,314,430)
           
Non-Operating (Income) Expenses:          
Interest Expense   10,052,691    8,171,764 
Interest Income   (33)   (23,008)
Accretion of Debt Discount and Loan Origination Fees   1,581,967    6,347,471 
Change in Fair Value of Derivatives   805,590    (2,105,415)
Gain on Extinguishment of Debt   -    (10,233,610)
           
Total Non-Operating Expenses   12,440,215    2,157,202 
           
Loss from Continuing Operations Before Provision for Income Taxes   (18,065,206)   (26,471,632)
Provision for Income Tax Expense   (2,193,542)   (19,691,908)
           
Net Loss from Continuing Operations   (20,258,748)   (46,163,540)
Net Income (Loss) from Discontinued Operations, Net of Taxes   24,306,649    (14,446,491)
           
Net Income (Loss)   4,047,901    (60,610,031)
           
Net Loss Attributable to Non-Controlling Interest   (112,312)   (5,280,003)
           
Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc.  $4,160,213   $(55,330,028)
           
Earnings (Loss) Per Share - Basic and Diluted:          
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.  $(0.02)  $(0.04)
           
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.  $0.02   $(0.02)
           
Weighted-Average Shares Outstanding - Basic and Diluted   1,301,659,701    942,696,052 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

 

2

 

 

MEDMEN ENTERPRISES INC.

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited)

Three Months Ended September 24, 2022 and September 25, 2021

(Amounts Expressed in United States Dollars, Except for Share Data)

 

 

                                    
   Units   $ Amount         

TOTAL EQUITY

ATTRIBUTABLE

        
  

Subordinate

Voting
Shares

   Subordinate
Voting
Shares
   Additional
Paid-In
Capital
   Accumulated
Deficit
   TO
SHAREHOLDERS
OF MEDMEN
  

Non-
Controlling

Interest

   TOTAL
SHAREHOLDERS’
DEFICIENCY
 
BALANCE AS OF JUNE 26, 2022   1,301,423,950   $-   $1,057,228,873   $(901,758,875)  $155,469,998   $(473,982,734)  $(318,512,736)
                                    
Net Income (Loss)   -    -    -    4,160,213    4,160,213    (112,312)   4,047,901 
                                    
Controlling Interest Equity Transactions                                   
Partner Contributions   -    -    37,561    -    37,561    -    37,561 
Redemption of MedMen Corp Redeemable Shares   259,814    -    15,318    (15,318)   -    -    - 
Share-Based Compensation   -    -    863,685    -    863,685    -    863,685 
                                    
BALANCE AS OF SEPTEMBER 24, 2022   1,301,683,764   $-   $1,058,145,437   $(897,613,980)  $160,531,457   $(474,095,046)  $(313,563,589)

 

   Units   $ Amount          TOTAL EQUITY ATTRIBUTABLE        
  

Subordinate

Voting
Shares

   Subordinate
Voting
Shares
   Additional
Paid-In
Capital
   Accumulated
Deficit
   TO
SHAREHOLDERS
OF MEDMEN
  

Non-
Controlling

Interest

   TOTAL
SHAREHOLDERS’
DEFICIENCY
 
BALANCE AS OF JUNE 27, 2021   726,866,374   $-   $908,992,686   $(717,232,706)  $191,759,980   $(445,393,599)  $(253,633,619)
                                    
Net Loss   -    -    -    (55,330,028)   (55,330,028)   (5,280,003)   (60,610,031)
                                    
Controlling Interest Equity Transactions                                   
Shares Issued for Cash, Net of Fees   406,249,973    -    73,393,745    -    73,393,745    -    73,393,745 
Shares Issued to Settle Debt and Accrued Interest   20,833,333    -    4,030,000    -    4,030,000    -    4,030,000 
Shares Issued to Settle Accounts Payable and Liabilities   4,182,730    -    700,000    -    700,000    -    700,000 
Equity Component of Debt - New and Amended   -    -    41,388,048    -    41,388,048    -    41,388,048 
Redemption of MedMen Corp Redeemable Shares   4,054,278    -    1,121,441    374,701    1,496,142    (1,496,142)   - 
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options   8,473,868    -    -    -    -    -    - 
Shares Issued for Exercise of Warrants   8,807,605    -    1,273,679    -    1,273,679    -    1,273,679 
Shares Issued for Conversion of Debt   16,014,665    -    2,371,100    -    2,371,100    -    2,371,100 
Stock Grants for Compensation   1,455,415    -    1,421,400    -    1,421,400    -    1,421,400 
Deferred Tax Impact On Conversion Feature   -    -    (13,057,730)   -    (13,057,730)   -    (13,057,730)
Share-Based Compensation   -    -    1,682,677    -    1,682,677    -    1,682,677 
                                    
BALANCE AS OF SEPTEMBER 25, 2021   1,196,938,241   $-   $1,023,317,046   $(772,188,033)  $251,129,013   $(452,169,744)  $(201,040,731)

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

 

3

 

 

MEDMEN ENTERPRISES INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

Three Months Ended September 24, 2022 and September 25, 2021

(Amounts Expressed in United States Dollars)

 

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net Loss from Continuing Operations  $(20,258,748)  $(46,163,540)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:          
Deferred Tax Expense   -    (4,497,141)
Depreciation and Amortization   3,971,473    6,256,917 
Non-Cash Operating Lease Costs   3,453,863    4,442,077 
Accretion of Debt Discount and Loan Origination Fees   1,581,970    6,347,471 
Loss on Disposals of Assets   205,595    - 
Gain on Lease Terminations   (1,587,670)   - 
Accretion of Deferred Gain on Sale of Property   (141,657)   (141,657)
Impairment of Assets   1,663,911    435,241 
Realized and Unrealized Changes in Fair Value of Contingent Consideration   863,856    - 
Change in Fair Value of Derivative Liabilities   805,590    (2,105,415)
Gain on Extinguishment of Debt   -    (10,233,610)
Share-Based Compensation   863,685    3,104,077 
Interest Capitalized to Senior Secured Convertible Debt and Notes Payable   6,416,426    7,837,693 
Interest Capitalized to Finance Lease Liabilities   444,232    377,885 
Changes in Operating Assets and Liabilities:          
Accounts Receivable and Prepaid Expenses   2,163,698    617,325 
Inventory   892,922    (1,710,735)
Other Current Assets   2,587,163    282,230 
Other Assets   256,706    - 
Accounts Payable and Accrued Liabilities   (1,746,175)   4,827,997 
Interest Payments on Finance Leases   (1,804,507)   (1,784,541)
Cash Payments - Operating Lease Liabilities   (1,026,792)   (3,478,891)
Income Taxes Payable   11,145,390    21,707,961 
Other Current Liabilities   (447,046)   (2,413,113)
Other Non-Current Liabilities    47,192    - 
           
NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES   10,351,077    (16,291,769)
           
Net Cash Used in Discontinued Operating Activities   (19,961,041)   (6,684,431)
           
NET CASH USED IN OPERATING ACTIVITIES   (9,609,964)   (22,976,200)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of Property and Equipment   -    (391,730)
Additions to Intangible Assets   (24,056)   (461,456)
Proceeds from the Sale of Assets Held for Sale   51,500,000    - 
Restricted Cash   -    730 
           
NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES   51,475,944   (852,456)
           
Net Cash Used in Discontinued Investing Activities   -    (2,764,417)
           
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES   51,475,944    (3,616,873)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Issuance of Subordinate Voting Shares for Cash   -    95,000,000 
Payment of Stock Issuance Costs Relating to Private Placement   -    (5,352,505)
Exercise of Warrants for Cash   -    1,273,679 
Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility   -    (2,608,964)
Proceeds from Issuance of Notes Payable   -    5,000,000 
Principal Repayments of Notes Payable   (31,599,999)   (75,605)
Principal Repayments of Finance Lease Liability   (2,484)   (959)
Distributions - Non-Controlling Interest   37,561    - 
           
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES   (31,564,922)   93,235,646 
           
NET INCREASE IN CASH AND CASH EQUIVALENTS   10,301,058    66,642,573 
Cash Included in Assets Held for Sale   -    (275,178)
Cash and Cash Equivalents, Beginning of Period   10,795,999    11,575,138 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $21,097,057   $77,942,533 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

 

4

 

 

MEDMEN ENTERPRISES INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

Three Months Ended September 24, 2022 and September 25, 2021

(Amounts Expressed in United States Dollars)

 

 

   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION          
Cash Paid for Interest  $1,260,562   $2,336,120 
           
Non-Cash Investing and Financing Activities:          
Net Assets Transferred to Held for Sale  $-   $4,476,993 
Redemption of MedMen Corp Redeemable Shares  $-   $1,496,142 
Derivative Liability Incurred on Convertible Facility and Equity Financing  $-   $30,500,000 
Conversion of Convertible Debentures  $-   $2,371,100 
Shares Issued to Settle Debt and Lender Fees  $-   $4,030,000 
Shares Issued to Settle Accounts Payable and Liabilities  $-   $700,000 
Equity Component of Debt - New and Amended  $-   $41,388,047 
Deferred Tax Impact on Conversion Feature  $-   $13,057,730 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

 

5

 

 

MEDMEN ENTERPRISES INC.

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three Months Ended September 24, 2022 and September 25, 2021

(Amounts Expressed in United States Dollars, Except for Share and Per Share Data)

 

1. NATURE OF OPERATIONS

 

MedMen Enterprises Inc. and its subsidiaries over which the company has control (collectively, “MedMen”, the “Company”, “we” or “us”) is a premier cannabis retailer based in the U.S. with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands – MedMen Red and LuxLyte – through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. MedMen Buds provides exclusive access to promotions, product drops and content.

 

As of September 24, 2022, the Company owns 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4). The Company continues to market its assets in New York and thus classifies all assets and liabilities and profit or loss allocable to its operations in the state of New York as discontinued operations. In August 2022, the Company completed the sale of its operations in the state of Florida of which all assets and liabilities and profit or loss allocable to Florida are classified as discontinued operations until the day of sale, or August 22, 2022. As of September 24, 2022, the remaining post-acquisition assets and liabilities and profit or loss allocable to Florida have been reclassified as continuing operations.

 

6

 

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Preparation

 

The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.

 

In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

 

The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”).

 

Going Concern

 

As of September 24, 2022, the Company had cash and cash equivalents of $21.1 million and working capital deficit of $134.9 million. The Company has incurred net losses from continuing operations of $20.3 million and $46.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.

 

The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.

 

7

 

 

COVID-19

 

In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. During the current reporting period, aspects of the Company’s business continue to be affected by impacts of the COVID-19 pandemic, as the Company’s retail stores strive to operate within the local rules and regulations of the states and localities in which the Company operates. While the Company saw continued recovery from the impacts of the COVID 19-pandemic during the first quarter of 2023, the Company continues to closely monitor the potential impact that a resurgence of the COVID-19 virus, including as a result of the emergence of new variants and strains, could have on the Company’s operations. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liabilities. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.

 

Basis of Consolidation

 

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of September 24, 2022.

 

Significant Accounting Policies

 

The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended September 24, 2022.

 

Earnings (Loss) per Share

 

The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.

 

Reclassifications

 

Certain amounts reported in the Notes to the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. These non-material corrections and reclassifications impacted leasehold improvements and furniture and fixtures in the amount of approximately $940,000 between the categories. Customer relationships and accumulated amortization of customer relationships in the amount of $1,440,000 between the categories were reclassed between the two categories. Fully amortized management agreements and its related accumulated amortization in the amount of $964,000 were also reclassed. Non-controlling interest and accumulated deficit in the amount of approximately $3,662,000 have been reclassed between the two categories. In addition, the Company reclassified short-term and long-term operating lease liabilities between the two categories in the amount of approximately $6,825,000. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections.

 

8

 

 

Recently Adopted Accounting Standards

 

In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.

 

Recently Issued Accounting Standards

 

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

 

In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50)” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

 

9

 

 

3. INVENTORY

 

Inventory consists of the following:

 

           
   September 24,   June 25, 
   2022   2022 
Raw Materials  $612,901   $521,777 
Work-in-Process   1,142,397    671,541 
Finished Goods   7,362,511    8,817,413 
           
Total Inventory  $9,117,809   $10,010,731 

 

During the three months ended September 24, 2022 and September 25, 2021, the Company recognized impairment of nil and $864,314, respectively, to write down inventory to its net realizable value.

 

10

 

 

4. ASSETS HELD FOR SALE

 

A reconciliation of our assets held for sale is as follows:

 

               
   Discontinued
Operations (1)
   Other
Assets
   TOTAL 
Balance as of June 25, 2022  $123,128,406   $30,345   $123,158,751 
Ongoing Activities   (47,881,618)   248,324    (47,633,294)
Proceeds from Sale   (67,000,000)   -    (67,000,000)
Gain on Sale of Assets Held for Sale   35,659,761    -    35,659,761 
                
Balance as of September 24, 2022  $43,906,549   $278,669   $44,185,218 

 

 
(1) See “Note 22 – Discontinued Operations” for further information.

 

11

 

 

5. PROPERTY AND EQUIPMENT

 

As of September 24, 2022 and June 25, 2022, property and equipment consists of the following:

 

          
   September 24,   June 25, 
   2022   2022 
Land and Buildings  $29,933,999   $29,933,999 
Capital Leases   5,318,516    5,315,625 
Furniture and Fixtures   8,325,228    8,776,994 
Leasehold Improvements   33,625,893    33,069,524 
Equipment and Software   16,316,334    16,897,649 
Construction in Progress   4,528,762    6,828,923 
           
Total Property and Equipment   98,048,732    100,822,714 
           
Less Accumulated Depreciation   (38,082,797)   (36,714,922)
           
Property and Equipment, Net  $59,965,935   $64,107,792 

 

Depreciation expense related to continuing operations of $2,258,354 and $3,031,080 was recorded for the three months ended September 24, 2022 and September 25, 2021, respectively, of which $24,950 and $433,300, respectively, is included in cost of goods sold. The amount of depreciation recognized for the capital leases during the three months ended September 24, 2022 and September 25, 2021 was $347,406 and $283,406, respectively, see “Note 9 – Leases” for further information.

 

Borrowing costs were not capitalized as there were no active construction projects in progress during the three months ended September 24, 2022. During the three months ended September 25, 2021, borrowing costs totaling $375,241 were capitalized using an average capitalization rate of 11.95%.

 

12

 

 

6. INTANGIBLE ASSETS

 

As of September 24, 2022 and June 25, 2022, intangible assets consist of the following:

 

           
   September 24,   June 25, 
   2022   2022 
Dispensary Licenses  $49,253,452   $49,253,452 
Customer Relationships   16,409,600    16,409,600 
Capitalized Software   7,413,470    7,413,470 
Intellectual Property   4,016,597    4,016,597 
           
Total Intangible Assets   77,093,119    77,093,119 
           
Dispensary Licenses   (17,477,268)   (16,876,912)
Customer Relationships   (16,589,651)   (15,870,284)
Capitalized Software   (4,681,748)   (4,413,974)
Intellectual Property   (4,287,401)   (4,185,835)
           
Less Accumulated Amortization   (43,036,068)   (41,347,005)
           
Intangible Assets, Net  $34,057,051   $35,746,114 

 

The Company recorded amortization expense related to continuing operations of $1,713,119 and $3,225,837 for the three months ended September 24, 2022 and September 25, 2021, respectively.

 

13

 

 

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

As of September 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following:

 

          
   September 24,   June 25, 
   2022   2022 
Accounts Payable  $19,078,177   $14,627,746 
Accrued Liabilities   7,784,119    10,031,194 
Accrued Inventory   3,129,868    5,868,831 
Accrued Payroll   2,081,284    1,682,517 
Local & State Taxes Payable   3,281,687    6,695,532 
           
Total Accounts Payable and Accrued Liabilities  $35,355,136   $38,905,818 

 

14

 

 

8. DERIVATIVE LIABILITIES

 

A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three months ended September 24, 2022 is as follows:

 

      
   September 24, 
   2022 
Balance at Beginning of Period  $6,749,563 
      
Change in Fair Value of Derivative Liabilities   805,590 
      
Balance at End of Period  $7,555,153 

 

On August 17, 2021, in connection with the amended and restated senior secured convertible credit facility (the Sixth Amendment”), the Company provided the note holders top-up and preemptive rights which were bifurcated from the related notes and classified as a derivative due to the variability of the number and price of shares issuable under these rights. See “Note 11 – Senior Secured Convertible Credit Facility” for further information.

 

The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at September 24, 2022:

 

     
   Top-Up
Provision
 
Average Stock Price  $0.04 
Weighted-Average Probability   50.00%
Term (in Years)   5.00 
Expected Stock Price Volatility   96.68%

 

The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities:

 

              
   Number of
Warrants
   Exercise
Price
   Expiration
Date
 
March 2021 Private Placement (1)   50,000,000   C$0.50   March 27, 2024  
              
   50,000,000          

 

 
(1) See “Note 12 – Shareholders’ Equity” for further information.

 

The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables:

 

     
Expected Stock Price Volatility   106.25%
Risk-Free Annual Interest Rate   2.51%
Expected Life (in Years)   0.50 
Share Price  $0.04 
Exercise Price  $0.37 

 

15

 

 

9. LEASES

 

The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates.

 

The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended September 24, 2022 and September 25, 2021:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Finance Lease Cost:          
Amortization of Finance Lease Right-of-Use Assets  $347,406   $283,406 
Interest on Lease Liabilities   1,804,507    1,784,541 
Operating Lease Cost   3,453,863    6,595,652 
Sublease Income (1)   (1,521,693)   - 
           
Total Lease Expenses  $5,605,776   $8,663,599 
           
Cash Paid for Amounts Included in the Measurement of Lease Liabilities:          
Financing Cash Flows from Finance Leases  $2,484   $959 
Operating Cash Flows from Operating Leases  $1,026,792   $3,478,891 

 

 
(1) See “Note 16 – Other Operating Income” for further information. 

 

The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of September 24, 2022 and June 25, 2022, is as follows:

 

   September 24,   June 25, 
   2022   2022 
Weighted-Average Remaining Lease Term (Years) - Finance Leases   47    46 
Weighted-Average Remaining Lease Term (Years) - Operating Leases   7    8 
Weighted-Average Discount Rate - Finance Leases   24.78%   24.33%
Weighted-Average Discount Rate - Operating Leases   15.96%   18.70%

 

16

 

 

Future lease payments under non-cancellable operating leases and finance leases as of September 24, 2022 are as follows:

 

           
Fiscal Year Ending  Operating
Leases
   Finance
Leases
 
July 1, 2023 (remaining)  $9,155,365   $4,387,279 
June 29, 2024   16,183,010    10,961,495 
June 28, 2025   25,224,922    14,020,131 
June 27, 2026   12,675,441    7,300,368 
June 26, 2027   12,716,234    7,519,379 
Thereafter   20,832,425    1,054,354,990 
           
Total Lease Payments   96,787,396    1,098,543,643 
Less Interest   (37,307,828)   (1,067,487,335)
           
Lease Liability Recognized  $59,479,568   $31,056,308 

 

The Company entered into a management agreement (the “Management Agreement”) with a third party to operate its cultivation facilities in California and Nevada (the “Cultivation Facilities”). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the “Purchase Option”). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of September 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three months ended September 24, 2022, the Company recorded sublease income under the Management Agreement. See “Note 16 – Other Operating Income” for further information.

 

17

 

 

10. NOTES PAYABLE

 

Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.

 

As of September 24, 2022 and June 25, 2022, notes payable consist of the following:

 

           
   September 24,   June 25, 
   2022   2022 
Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.  $72,300,000   $72,300,000 
           
Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum.   66,819,991    97,162,001 
           
Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471.   2,057,207    2,057,207 
           
Other   15,691    15,691 
           
Total Notes Payable   141,192,889    171,534,899 
Less Unamortized Debt Issuance Costs and Loan Origination Fees   -    (158,079)
           
Net Amount  $141,192,889   $171,376,820 
Less Current Portion of Notes Payable   (66,294,249)   (97,003,922)
           
Notes Payable, Net of Current Portion  $74,898,640   $74,372,898 

 

18

 

 

A reconciliation of the beginning and ending balances of notes payable for the three months ended September 24, 2022 is as follows:

 

      
   September 24, 
   2022 
Balance at Beginning of Period  $171,376,820 
      
Paid-In-Kind Interest Capitalized   1,257,988 
Cash Payments   (31,599,999)
Accretion of Debt Discount Included in Discontinued Operations   158,079 
      
Balance at End of Period   141,192,889 
      
Less Current Portion of Notes Payable   (66,294,249)
      
Notes Payable, Net of Current Portion  $74,898,640 

 

Non-Revolving Senior Secured Term Loan Facility

 

In February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification required that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposed covenants in regards to strategic actions the Company would have to implement if unable to pay the Term Loans by the extended stated maturity date.

 

During the three months ended September 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $31,599,999 with proceeds from the sale. An additional $8,500,000 principal repayment will be made in 2023 upon receipt of the final installment payment from the sale of the Company’s Florida-based operations. The Facility and Term Loans remain in default as of September 24, 2022 as the principal balance matured on July 31, 2022 and August 1, 2022, respectively. As of September 24, 2022, the Company is in ongoing discussions with the Lenders.

 

19

 

 

11. SENIOR SECURED CONVERTIBLE CREDIT FACILITY

 

Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.

 

As of September 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following:

 

              
      September 24,   June 25, 
   Tranche  2022   2022 
Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  1A  $23,376,684   $22,880,556 
              
Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  1B   100,679,152    98,542,422 
              
Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  2   32,738,817    32,043,996 
              
Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  3   12,677,140    12,408,091 
              
Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  4   14,911,453    14,594,985 
              
Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   23,932,224    23,424,438 
              
Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  IA-1   3,346,889    3,275,857 
              
Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  IA-2   6,472,344    6,334,980 
              
Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   10,103,343    9,888,919 
              
Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   2,237,875    2,190,380 
              
Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   12,587,295    12,320,154 
              
Total Drawn on Senior Secured Convertible Credit Facility      243,063,216    237,904,778 
              
Less Unamortized Debt Discount      (104,317,146)   (105,899,115)
              
Senior Secured Convertible Credit Facility, Net     $138,746,070   $132,005,663 

 

20

 

 

A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the three months ended September 24, 2022 is as follows:

 

                                                        
   Tranche 1   Tranche 2   Tranche 3   Tranche 4   Incremental Advance - 1   Incremental Advance - 2   3rd Advance   Amendment
Fee Notes
   Restatement Fee Notes   2nd Restatement Fee Notes   TOTAL 
Balance as of June 25, 2022  $80,178,586   $21,218,356   $8,217,079   $1,051,827   $224,585   $433,598   $842,981   $15,512,409   $2,211,711   $2,114,531   $132,005,663 
                                                        
Paid-In-Kind Interest Capitalized   2,632,858    694,821    269,049    316,468    71,032    137,364    267,141    507,786    214,424    47,495    5,158,438 
Accretion of Debt Discount   988,849    260,580    100,902    -    -    -    -    190,486    37,165    3,987    1,581,969 
                                                        
Balance as of September 24, 2022  $83,800,293   $22,173,757   $8,587,030   $1,368,295   $295,617   $570,962   $1,110,122   $16,210,681   $2,463,300   $2,166,013   $138,746,070 

 

21

 

 

12. SHAREHOLDERS’ EQUITY

 

Issued and Outstanding

 

A reconciliation of the beginning and ending issued and outstanding shares is as follows:

 

               
   Subordinate
Voting Shares
   MM CAN USA
Class B
Redeemable Units
   MM Enterprises USA
Common Units
 
Balance as of June 25, 2022   1,301,423,950    65,066,106    725,016 
Redemption of MedMen Corp Redeemable Shares   259,814    (259,814)   - 
                
Balance as of September 24, 2022   1,301,683,764    64,806,292    725,016 

 

Non-Controlling Interests

 

Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of September 24, 2022 and June 25, 2022, the holders of the MM CAN USA Redeemable Shares represent approximately 4.74% and 4.76%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately 0.05% of the Company.

 

Variable Interest Entities

 

The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of Venice Caregiver Foundation, Inc., LAX Fund II Group, LLC, and Natures Cure, Inc. This information represents amounts before intercompany eliminations.

 

As of and for the three months ended September 24, 2022, the balances and activities attributable to the VIEs consist of the following:

 

                     
   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   TOTAL 
Current Assets  $1,180,136   $-   $24,602,018   $25,782,154 
Non-Current Assets   8,763,511    3,233,062    4,891,725    16,888,298 
                     
Total Assets  $9,943,647   $3,233,062   $29,493,743   $42,670,452 
                     
Current Liabilities  $10,477,448   $16,016,119   $8,510,967   $35,004,534 
Non-Current Liabilities   7,004,484    2,004,062    1,342,632    10,351,178 
                     
Total Liabilities  $17,481,932   $18,020,181   $9,853,599   $45,355,712 
                     
Non-Controlling Interest  $(7,538,285)  $(14,787,119)  $19,640,163   $(2,685,241)
                     
Revenues  $1,959,080   $-   $3,317,299   $5,276,379 
Net (Loss) Income Attributable to Non-Controlling Interest  $(494,845)  $(810,965)  $885,605   $(420,205)

 

22

 

 

As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:

 

   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   TOTAL 
Current Assets  $1,735,304   $1,067,636   $23,557,168   $26,360,108 
Non-Current Assets   10,073,880    3,379,412    4,973,459    18,426,751 
                     
Total Assets  $11,809,184   $4,447,048   $28,530,627   $44,786,859 
                     
Current Liabilities  $9,238,460   $16,238,249   $8,433,436   $33,910,145 
Non-Current Liabilities   9,614,164    2,184,953    1,342,633    13,141,750 
                     
Total Liabilities  $18,852,624   $18,423,202   $9,776,069   $47,051,895 
                     
Non-Controlling Interest  $(7,043,440)  $(13,976,154)  $18,754,558   $(2,265,036)
                     
Revenues  $8,732,449   $1,857   $16,157,388   $24,891,694 
Net (Loss) Income Attributable to Non-Controlling Interest  $(1,384,751)  $(4,868,632)  $7,190,809   $937,426 

 

The net change in the consolidated VIEs and other non-controlling interest are as follows for the three months ended September 24, 2022:

 

                          
   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   Other Non- Controlling Interests   TOTAL 
Balance as of June 25, 2022  $(7,043,440)  $(13,976,154)  $18,754,558   $(471,717,698)  $(473,982,734)
                          
Net (Loss) Income   (494,845)   (810,965)   885,605    307,893    (112,312)
                          
Balance as of September 24, 2022  $(7,538,285)  $(14,787,119)  $19,640,163   $(471,409,805)  $(474,095,046)

 

Le Cirque Rouge, LP (the “OP”) is a Delaware limited partnership that holds substantially all of the real estate assets owned by the Treehouse Real Estate Investment Trust (the “REIT”), conducts the REIT’s operations and is financed by the REIT. Under Accounting Standards Codification (“ASC”) Topic 810, “Consolidation” (“ASC Topic 810”), the OP was determined to be a variable interest entity in which the Company has an implicit variable interest based on the leasing relationship and arrangement with the REIT. However, the Company is not the primary beneficiary under ASC Topic 810. Accordingly, Le Cirque Rouge, LP is not consolidated as a variable interest entity within the Consolidated Financial Statements. As of and during the three months ended September 24, 2022, the Company continues to have a variable interest in the OP and did not provide any financial or other support to the REIT other than the completion of the sale and leaseback transactions and the REIT being a lessor on various leases as described in “Note 9 – Leases”.

 

23

 

 

13. SHARE-BASED COMPENSATION

 

The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock units (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative expenses. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, cancelled, expire unexercised, are settled in cash or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of a Compensation Committee. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after 5 or 10 years.

 

A summary of share-based compensation expense for the three months ended September 24, 2022 and September 25, 2021 is as follows:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Stock Options  $863,685   $1,216,447 
Stock Grants for Compensation   -    333,333 
Restricted Stock Grants   -    1,554,297 
           
Total Share-Based Compensation  $863,685   $3,104,077 

 

Stock Options

 

A reconciliation of the beginning and ending balance of stock options outstanding is as follows:

 

           
   Number of
Stock Options
   Weighted-Average
Exercise Price
 
Balance as of June 25, 2022   8,649,673   $1.35 
           
Forfeited and Expired   (205,354)  $(3.39)
           
Balance as of September 24, 2022   8,444,319   $1.39 
           
Stock Options Exercisable as of September 24, 2022   8,037,095   $1.27 

 

24

 

 

Long-Term Incentive Plan (“LTIP”) Units and LLC Redeemable Units

 

A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows:

 

              
            Weighted  
    LTIP Units   LLC   Average  
    Issued and   Redeemable   Grant Date  
    Outstanding   Units   Fair Value  
Balance as of June 25, 2022 and September 24, 2022    19,323,878    725,016   $ 0.52  

 

Restricted Stock Units

 

A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows:

 

               
   Issued and
Outstanding
   Vested (1)   Weighted-Average
Fair Value
 
Balance as of June 25, 2022   10,998,483    4,030,460   $0.20 
                
Forfeiture of Restricted Stock (2)   (1,405,788)   -   $(0.22)
Vesting of Restricted Stock   -    1,117,081   $0.22 
                
Balance as of September 24, 2022   9,592,695    5,147,541   $0.20 

 

 
(1) Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date.
(2) Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022.

 

Warrants

 

A reconciliation of the beginning and ending balance of warrants outstanding is as follows:

 

                      
    Number of Warrants Outstanding     
    Subordinate
Voting Shares
   MM CAN USA
Redeemable Shares
   TOTAL   Weighted-Average
Exercise Price
 
Balance as of June 25, 2022    352,704,355    97,430,456    450,134,811   $0.25 
                      
Expired    (2,677,535)   -    (2,677,535)  $(3.27)
                      
Balance as of September 24, 2022    350,026,820    97,430,456    447,457,276   $0.23 

 

25

 

 

14. LOSS PER SHARE

 

The following is a reconciliation for the calculation of basic and diluted loss per share for the three months ended September 24, 2022 and September 25, 2021:

 

          
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.  $(20,146,436)  $(40,883,537)
Net Income (Loss) from Discontinued Operations   24,306,649    (14,446,491)
           
Total Net Income (Loss)  $4,160,213   $(55,330,028)
           
Weighted-Average Shares Outstanding - Basic and Diluted   1,301,659,701    942,696,052 
           
Earnings (Loss) Per Share - Basic and Diluted:          
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.  $(0.02)  $(0.04)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.  $0.02   $(0.02)

 

Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, LTIP share units, warrants and share options is anti-dilutive.

 

26

 

 

15. GENERAL AND ADMINISTRATIVE EXPENSES

 

During the three months ended September 24, 2022 and September 25, 2021, general and administrative expenses consisted of the following:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Salaries and Benefits  $6,858,048   $9,911,488 
Professional Fees   1,350,848    7,430,659 
Rent   3,627,925    4,754,883 
Licenses, Fees and Taxes   1,001,669    2,537,788 
Share-Based Compensation   863,685    1,642,853 
Deal Costs   429,272    1,637,587 
Other General and Administrative   3,714,670    4,733,976 
           
Total General and Administrative Expenses  $17,846,117   $32,649,234 

 

27

 

 

16. OTHER OPERATING (INCOME) EXPENSE

 

During the three months ended September 24, 2022 and September 25, 2021, other operating (income) expense consisted of the following:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Loss on Disposals of Assets  $205,595   $15,146 
Restructuring and Reorganization Expense   423,793    2,378,675 
Gain on Settlement of Accounts Payable   (74,637)   (177,990)
Gain on Lease Terminations   (1,587,650)   - 
Other Income   (1,522,219)   (16,803)
           
Total Other Operating (Income) Expense  $(2,555,118)  $2,199,028 

 

During the three months ended September 24, 2022, the Company recorded $1,521,650 of sublease income related to the cultivation facilities in California and Nevada as a component of Other Operating Income in the Consolidated Statements of Operations.

 

28

 

 

17. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES

 

The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended September 24, 2022 and September 25, 2021:

 

          
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Loss from Continuing Operations Before Provision for Income Taxes  $(18,065,206)  $(26,471,632)
Income Tax Expense   (2,193,542)   (19,691,908)
Effective Tax Rate   -12%   -74%

 

We have historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate (“AETR”) for the full fiscal year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. For the three months ended September 25, 2021, we determined we could no longer reliably estimate income taxes utilizing an AETR. The AETR estimate is highly sensitive to estimates of ordinary income (loss) and permanent differences such that minor fluctuations in these estimates could result in significant fluctuations of the Company’s AETR. Accordingly, we used our actual year-to-date effective tax rate to calculate income taxes for the three months ended September 25, 2022.

 

As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Massachusetts state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns.

 

The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized.

 

The effective tax rate for the three months ended September 24, 2022 is different from the three months ended September 25, 2021, respectively, primarily due to the Company’s income and related 280E expenditures. The Company’s non-deductible expenses related to IRC Section 280E limitations have remained relatively consistent.

 

The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and in Canada. The Company is generally subject to audit by taxing authorities in various U.S., state, and in foreign jurisdictions for fiscal years 2014 through the current fiscal year. As of September 24, 2022, the Company had $18,781,424 of unrecognized tax benefits, all of which would reduce income tax expense and the effective tax rate if recognized. During the three months ended September 24, 2022, the Company recognized a net discrete tax expense of $407,993 primarily related on interest of past liabilities. During the next twelve months, the Company does not estimate any material reduction in its unrecognized tax benefits.

 

29

 

 

18. COMMITMENTS AND CONTINGENCIES

 

Contingencies

 

The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of September 24, 2022 and June 25, 2022, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.

 

Claims and Litigation

 

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 24, 2022, there were no pending or threatening lawsuits that could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. As such, no accrual has been made in the Condensed Consolidated Financial Statements relating to claims and litigations. As of September 24, 2022, there are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest.

 

In March 2020, litigation was filed against the Company in the Superior Court of Arizona, Maricopa County, related to a purchase agreement for a previous acquisition. The Superior Court of Arizona, Maricopa County granted summary judgement in favor of the Company on all counts in July 2022. The Company is currently in process of recovering certain fees and costs associated with the lawsuit from the plaintiffs. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements.

 

In April 2020, a complaint was filed against the Company in Los Angeles Superior Court related to a contemplated acquisition in which the plaintiffs are seeking damages for alleged breach of contract and breach of implied covenant of good faith and fair dealing seeking declaratory relief and specific performance. The Company has filed counterclaims including for breach of contract, breach of promissory note, unjust enrichment and declaratory relief. The Company believes the likelihood of a loss contingency is remote. As such, no amount has been accrued in the financial statements.

 

In May 2020, litigation was filed against the Company related to a purchase agreement and secured promissory note for a previous acquisition. The Company is currently defending against this lawsuit, which claims for breach of contract, breach of implied covenant of good faith and fair dealing, common law fraud and securities fraud. The plaintiffs are seeking damages for such claims in which the amount is currently not reasonably estimable. In response, the Company filed a counterclaim and is seeking entitlement to proceeds of the sale, net of amounts owed under the secured promissory note. The plaintiffs filed an appeal to the ruling on the entitlement of proceeds in excess of the secured promissory note which was dismissed. The additionally claims and counterclaims are currently in dispute. Any loss recoveries related to the Company’s counterclaim have not been recorded. In addition, net proceeds resulting from the sale was not recognized as a receivable as the amount is not reasonably estimable.

 

In September 2020 and May 2020, legal disputes were filed against the Company related to the separation of former officers in which the severance issued is currently being disputed. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

30

 

 

In November 2020, entities affiliated with former officers of the Company initiated arbitration against a subsidiary of the Company in Los Angeles, California asserting breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and unjust enrichment. The claimants are generally seeking damages and compensatory damages according to proof, including lost earnings and other benefits, past and future, interest on lost earnings and benefits, reasonable attorney’s fees, and such other and further relief as the court deems proper. The Company asserted counterclaims, including for breach of the same management agreements. The arbitration is currently set for hearing in December 2022. The litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

In October 2021, a suit for premises liability and negligence seeking unspecified damages for pain and suffering, disability, mental and emotional distress, and loss of earnings was filed against the Company in Los Angeles Superior Court. The matter is in the process of being litigated. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

The Company is the defendant in several complaints filed by various of its landlords seeking rents and damages under leases. In 2020 a complaint was filed in Cook County Circuit Court, Illinois against the Company by a landlord claiming the Company had failed to meet its obligations to apply effort to obtain a retail cannabis license at a property and seeking rents and damages. The litigation is currently in the discovery phase. If the litigation is not settled or resolved, trial will likely take place During the fiscal year ended 2023. In July 2022, a complaint was filed against the Company in the United States District Court for the Southern District of New York by a landlord seeking damages under a lease on real estate located in Illinois. The Company is required to file an answer to the complaint by September 2022. Prior attempts to resolve the lease dispute with this landlord have failed. In June 2022, a complaint was filed against the Company by the Company’s landlord at its cultivation center in Utica, New York, related to an agreement to purchase land next to the cultivation center, which land was also owned by the landlord. Plaintiff seeks to enforce a land purchase agreement and seeks damages. In April 2022, the landlord at the Company’s dispensary location in Tampa, Florida, filed suit seeking damages under a lease, shortly after the Company announced its plans to sell its Florida business. The Company retained this lease and litigation following the sale of the Florida business and the litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

31

 

 

19. RELATED PARTY TRANSACTIONS

 

The Company’s Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.

 

32

 

 

20. SEGMENT INFORMATION

 

The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker manages the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.

 

33

 

 

21. REVENUE

 

While the Company operates in one segment as disclosed in “Note 20 – Segment Information”, the Company is disaggregating its revenue by geographical region in accordance with ASC 606, “Revenue from Contracts with Customers”. Revenue by state for the periods presented are as follows:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
California  $19,928,985   $24,626,555 
Nevada   2,997,469    4,079,151 
Illinois   3,542,071    4,328,602 
Arizona   2,794,648    3,701,596 
Massachusetts   780,875    - 
           
Revenue from Continuing Operations  $30,044,048   $36,735,904 
           
Revenue from Discontinued Operations   3,629,641    7,340,099 
           
Total Revenue  $33,673,689   $44,076,003 

 

34

 

 

22. DISCONTINUED OPERATIONS

 

On February 28, 2022, MME Florida LLC and its parent, MM Enterprises USA, LLC, a wholly-owned subsidiary of the Company entered into an Asset Purchase Agreement (the “Agreement”) with Green Sentry Holdings, LLC, (“Buyer”) for the sale of substantially all of the Company’s Florida-based assets, including its license, dispensaries, inventory and cultivation operations, and assumption of certain liabilities.

 

On August 22, 2022, the Company closed the transaction at the final sales price of $67,000,000, which comprised of $63,000,000 in cash and $4,000,000 in liabilities to be assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022 and is required to make one additional installment payment of $11,500,000 on or before March 15, 2023. During the three months ended September 24, 2022, $31,599,999 of the cash proceeds was used to repay the Senior Secured Term Loan Facility and the Company received net cash proceeds of $19,558,947. As of September 24, 2022, the final cash payment of $11,500,000 remains due and payable. Accordingly, the Company recognized a gain on sale of assets of $31,719,833 included in Net Income from Discontinued Operations for the three months ended September 24, 2022. All profit or loss relating to the Florida operations were eliminated from the Company’s continuing operations and are shown as a single line item in the Consolidated Statements of Operations.

 

The operating results of the discontinued operations are summarized as follows:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Revenue  $3,629,641   $7,340,099 
Cost of Goods Sold   2,103,298    5,227,553 
           
Gross Profit   1,526,343    2,112,546 
           
Expenses:          
General and Administrative   4,983,995    5,617,595 
Sales and Marketing   43,311    103,803 
Depreciation and Amortization   872,895    1,221,759 
Impairment Expense   (78,433)   - 
Gain on Disposal of Assets and Other Income   (35,659,761)   (597,591)
           
Total (Income) Expenses   (29,837,993)   6,345,566 
           
Income (Loss) from Discontinued Operations   31,364,336    (4,233,020)
           
Other Expense:          
Interest Expense   3,761,758    4,616,829 
Accretion of Debt Discount and Loan Origination Fees   158,079    3,540,908 
           
Total Other Expense   3,919,837    8,157,737 
           
Income (Loss) from Discontinued Operations Before Provision for Income Taxes   27,444,499    (12,390,757)
Provision for Income Tax Benefit (Expense)   (3,137,850)   (2,055,734)
           
Net Income (Loss) from Discontinued Operations  $24,306,649   $(14,446,491)

 

35

 

 

The carrying amounts of assets and liabilities in the disposal group are summarized as follows:

 

           
   September 24,   June 25, 
   2022   2022 
Carrying Amounts of the Assets Included in Discontinued Operations:          
           
Cash and Cash Equivalents  $355,378   $1,124,076 
Restricted Cash   5,280    5,280 
Accounts Receivable and Prepaid Expenses   95,048    334,621 
Inventory   2,915,345    6,866,833 
           
TOTAL CURRENT ASSETS (1)          
           
Property and Equipment, Net   9,713,565    41,273,597 
Operating Lease Right-of-Use Assets   19,780,991    31,543,058 
Intangible Assets, Net   10,582,559    40,799,146 
Other Assets   458,383    1,181,795 
           
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE  $43,906,549   $123,128,406 
           
Carrying Amounts of the Liabilities Included in Discontinued Operations:          
           
Accounts Payable and Accrued Liabilities  $2,640,664   $6,295,745 
Income Taxes Payable   (27,904)   1,671,380 
Other Current Liabilities   -    89,069 
Current Portion of Operating Lease Liabilities   2,605,317    4,209,512 
Current Portion of Finance Lease Liabilities   -    174,000 
           
TOTAL CURRENT LIABILITIES (1)          
           
Operating Lease Liabilities, Net of Current Portion   19,067,840    56,410,071 
Deferred Tax Liabilities   6,250,511    6,097,597 
Notes Payable   -    11,100,000 
           
TOTAL NON-CURRENT LIABILITIES (1)          
           
TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE  $30,536,428   $86,047,374 

 

36

 

 

23. SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date these Condensed Consolidated Financial Statements were issued and has concluded that no subsequent events have occurred that would require recognition in the Condensed Consolidated Financial Statements or disclosure in the Notes to the Condensed Consolidated Financial Statements.

 

37

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

 

This management’s discussion and analysis (“MD&A”) of the financial condition and results of operations of MedMen Enterprises Inc. (“MedMen Enterprises”, “MedMen”, the “Company”, “we” or “our”) is for the three months ended September 24, 2022. The following discussion should be read in conjunction with, and is qualified in its entirety by, the Condensed Consolidated Financial Statements and the accompanying notes presented in Item 1 of this Form 10-Q and those discussed in Item 8 of the Company’s Annual Report on Form 10-K (the “Form 10-K”) filed with the SEC on September 9, 2022. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties. Future results could differ materially from those discussed below for many reasons, including the risks described in “Disclosure Regarding Forward-Looking Statements,” Item 1A. “Risk Factors” and elsewhere in this Form 10-Q.

 

We are a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act. Accordingly, we have omitted certain information called for by this Item as permitted by applicable scaled disclosure rules.

 

All references to “$” and “dollars” refer to U.S. dollars. References to C$ refer to Canadian dollars. Certain totals, subtotals and percentages throughout this MD&A may not reconcile due to rounding.

 

Our fiscal year is a 52/53-week year ending on the last Saturday in June or first Saturday in July. For the current interim period, the three months ended September 24, 2022 and September 25, 2021 refer to the 13 weeks ended therein.

 

Overview

 

MedMen is a cannabis retailer based in the U.S. offering a robust selection of high-quality products, including MedMen-owned brands, LuxLyte, and MedMen Red through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. As of September 24, 2022, the Company operates 23 store locations across California (13), New York (4) Nevada (3), Illinois (1), Massachusetts (1) and Arizona (1).

 

On August 22, 2022, the Company completed the sale of its operations in the state of Florida, including its license, dispensaries, inventory and cultivation operations, to Green Sentry Holdings, LLC (“Buyer”) at the final sales price of $67,000,000 which comprised of $63,000,000 in cash and $4,000,000 in liabilities assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022, and is required to make one additional installment payments of $11,500,000 on or before March 15, 2023. As of September 24, 2022, net proceeds to the Company were $19,500,000 after $31,599,999 of the cash proceeds was used to repay the Senior Secured Term Loans with Hankey Capital. Proceeds of the transaction to the Company will be used to fund operations and pay interest to Hankey Capital while the Senior Secured Term Loans remain outstanding and in default. In addition, the Company licensed the tradename “MedMen” to the Buyer for use in Florida for a period of two years, subject to termination rights, for a quarterly revenue-based fee. All purchased assets and assumed liabilities related to Florida are excluded from our Consolidated Balance Sheets as of September 24, 2022 and all profits or losses from our Florida operations subsequent to August 22, 2022 are included in the Consolidated Statements of Operations. Refer to “Note 22 – Discontinued Operations” of the Consolidated Financial Statements in Item 1 for further information.

 

COVID-19 Pandemic

 

We continuously address the effects of the COVID-19 pandemic, a discussion of which is available in Item 1A “Risk Factors” of the 2022 Form 10-K. Our business and operating results for the three months ended September 24, 2022, continue to be impacted by the COVID-19 pandemic. The overall impact on our business continues to depend on the length of time that the pandemic continues, the impact on consumer purchasing behavior, inflation, and the extent to which it affects our ability to raise capital, and the effect of governmental regulations imposed in response to the pandemic, which all remain uncertain at this time. We continue to implement and evaluate actions to strengthen our financial position and support the continuity of our business and operations.

 

38

 

 

Results of Operations

 

Our consolidated results, in millions, except for per share and percentage data, for the three months ended September 24, 2022, compared to three months ended September 25, 2021, are as follows:

 

   Three Months Ended         
   September 24,   September 25,         
($ in Millions)  2022   2021   $ Change   % Change 
   (unaudited)   (unaudited)         
Revenue  $30.0   $36.7   $(6.7)   (18%)
Cost of Goods Sold   15.2    19.3    (4.1)   (21%)
                     
Gross Profit   14.9    17.4    (2.5)   (14%)
                     
Operating Expenses:                    
General and Administrative   17.8    32.6    (14.8)   (45%)
Sales and Marketing   0.4    0.6    (0.2)   (33%)
Depreciation and Amortization   3.9    5.8    (1.9)   (33%)
Unrealized Changes in Fair Value of Contingent Consideration   (0.9)   -    (0.9)   - 
Impairment Expense   1.7    0.4    1.3    325%
Other Operating (Income) Expense   (2.6)   2.2    (4.8)   (218%)
                     
Total Operating Expenses   20.5    41.7    (21.3)   (51%)
                     
Loss from Operations   (5.6)   (24.3)   18.7    (77%)
                     
Non-Operating Expense (Income):                    
Interest Expense   10.1    8.2    1.9    23%
Accretion of Debt Discount and Loan Origination Fees   1.6    6.3    (4.7)   (75%)
Change in Fair Value of Derivatives   0.8    (2.1)   2.9    (138%)
Gain on Extinguishment of Debt   -    (10.2)   10.2    (100%)
                     
Total Non-Operating Expense   12.4    2.2    10.2    464%
                     
Loss from Continuing Operations Before Provision for Income Taxes   (18.1)   (26.5)   8.4    (32%)
Provision for Income Tax Expense   (2.2)   (19.7)   17.5    (89%)
                     
Net Loss from Continuing Operations   (20.3)   (46.2)   25.9    (56%)
Net Income (Loss) from Discontinued Operations, Net of Taxes   24.3    (14.4)   38.7    (269%)
                     
Net Income (Loss)   4.0    (60.6)   64.6    (107%)
                     
Net Loss Attributable to Non-Controlling Interest   (0.1)   (5.3)   5.2    (98%)
                     
Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc.  $4.2   $(55.3)  $59.5    (108%)
                     
EBITDA from Continuing Operations (Non-GAAP)  $(2.5)  $(5.7)  $3.2    (56%)
Adjusted EBITDA from Continuing Operations (Non-GAAP)  $(2.0)  $(12.2)  $10.2    (84%)

 

39

 

 

Revenue

 

Revenue for the three months ended September 24, 2022 was $30.0 million, a decrease of $(6.7) million, or (18%), compared to revenue of $36.7 million for the three months ended September 25, 2021.

 

Revenue in various states in which we operate is as follows:

 

   Three Months Ended         
   September 24,   September 25,         
($ in Millions)  2022   2021   $ Change   % Change 
California  $19.9   $24.6   $(4.7)   (19%)
Nevada   3.0    4.1    (1.1)   (27%)
Illinois   3.5    4.3    (0.8)   (19%)
Arizona   2.8    3.7    (0.9)   (24%)
Massachusetts   0.8    -    0.8    - 
                     
Continuing Operations   30.0    36.7    (6.7)   (18%)
                     
Discontinued Operations   3.6    7.3    (3.7)   (51%)
                     
Total Revenue  $33.6   $44.0   $(10.4)   (24%)

 

Overall, across all markets, for the periods presented, we experienced declines in revenue across all markets.

 

In California, we experienced a decline of $(4.7) million or (19%) over the same prior year period primarily driven by lower basket size, inconsistent traffic to the stores which was slightly partially offset by flat conversion rates. We believe we were also affected by the status of the cannabis supply in this State. California is currently experiencing high levels of cannabis production which we believe has flooded the illegal market with quality cannabis flower that illicit operators are offering to cannabis consumers at lower selling prices. In addition, the increase in new dispensaries within key markets, especially West Hollywood, and the more aggressive promotional cadence these dispensaries are promoting, has resulted in a saturated market wherein the California cannabis consumer has an increased number of choices for cannabis products at discounted pricing. During this first fiscal quarter, we increased our focus on product portfolio and product selection, expanding vendor relationships, engaging in allowable marketing strategies, and continued efforts to develop our private label products.

 

In Nevada, revenue for the three months declined $(1.1) million or (27%). We experienced a decline in basket size as well as traffic and conversion rates. Nevada noted an overall decline in legal cannabis sales primarily related to a maturing industry, lower disposable income and a revenue base heavily reliant on tourism.

 

In Illinois, revenue declined $(0.8) million or (19%). We continue to face market pressure from additional licenses issued by surrounding municipalities as part of Illinois’ efforts to promote equality and accessible locations for the consumer. We have made great efforts in testing new promotional messaging that, if marketed properly, can increase foot traffic and revenue.

 

In Arizona, revenue for the period decreased $(0.9) million or (24%). This decrease resulted from a decline in medical-use sales because of a maturing recreational cannabis industry. Arizona is also experiencing an increase in new dispensary openings, that similar to California, has resulted in a saturated market. Exacerbating the increase in dispensary openings, is the increase in aggressive promotional cadences by these dispensaries. We continue our efforts to finding the optimal product selection that can meet the demands of both medical and recreational customers as well as planning for additional private label products from our own cultivation facility in Mesa.

 

40

 

 

In Massachusetts, our store near Fenway Park opened December 2021 with no comparable sales for this reporting period.

 

During our first fiscal quarter, we completed the sale of our Florida-based assets. We continue to hold for sale our New York-based assets which are presented as discontinued operations.

 

Cost of Goods Sold and Gross Profit

 

Cost of goods sold for the three months ended September 24, 2022 was $15.2 million compared to $19.3 million, a decrease of $(4.1) million, or (21%), for the three months ended September 25, 2021. Gross profit for the fiscal first quarter was $14.9 million, representing a gross margin of 50%, as compared to $17.4 million, representing a gross margin of 47%, for the same prior year period. The improvement in gross margin resulted from our continuous efforts to develop vendor programs that reduced our cost of goods sold, as well as our success in lowering costs of production at our cultivation centers.

 

Operating Expenses

 

Operating expenses for the three months ended September 24, 2022 were $20.5 million, a decrease of $(21.3) million, or (51%), compared to $41.7 million for the three months ended September 25, 2021. These changes were attributable to the factors discussed below.

 

General and administrative expenses (“G&A”) for the three months ended September 24, 2022 were $17.8 million, compared to $32.6 million for the same prior year period. The overall decrease in the three months period is primarily due to the Company’s corporate cost saving strategy. Key drivers of the decrease in G&A include reductions in professional fees ($6.1) million, payroll expenses ($3.0) million, licenses and fees ($1.5) million, deal costs ($1.2) million and rental payments ($1.1) million. Management continues to focus on reducing company-wide G&A. We expect G&A will continue to decrease in fiscal year 2023 as compared to prior year.

 

Sales and marketing expenses remained relatively consistent for the three months ended September 24, 2022 and September 25, 2021 in the amount of $0.4 million and $0.6 million, respectively.

 

Depreciation and amortization for the three months ended September 24, 2022 was $3.9 million, compared to $5.8 million for the same prior year period. The overall decrease is attributable to the impairment of assets recorded in Q4 2022 and delay in new capital projects. We are currently evaluating the long-term benefits of continuing to pursue the build out of some of our locations not yet opened or constructed. We are in negotiations with the landlords of our unfinished locations in California, Illinois and Massachusetts in an effort to reach the best outcome for all parties including the communities that live and work near these unfinished locations possibly deterring from market values.

 

Impairment expense for the three months ended September 24, 2022 was $1.7 million, compared to $0.4 million for the three months ended September 25, 2021. During the current period, the Company wrote off approximately $1.7 million of construction in progress.

 

Other operating (income) expense for the three months ended September 24, 2022 was $(2.6) million, compared to $2.2 million for the three months ended September 25, 2021. The decrease of $(4.8) million in other operating (income) expense was primarily due to a decrease of $(2.0) million in restructuring expenses coupled with a gain on lease termination of $1.6 million and sublease income of $1.5 million recognized during the fiscal first quarter of 2023, versus none in the comparative period.

 

41

 

 

Non-Operating Expense

 

Non-operating expense for the three months ended September 24, 2022, was $12.4 million, compared to $2.2 million in the prior year period. The increase in non-operating expense was primarily due a $10.2 million gain on extinguishment of debt recognized in prior fiscal first quarter versus none in the current period. This was offset by a $(4.7) million decrease in accretion of debt discount due to the principal repayment of $31.6 million on the Senior Secured Term Loan during the fiscal first quarter of 2023 and a $(2.9) million decrease in change in fair value of derivatives.

 

Provision for Income Taxes

 

MedMen is subject to income taxes in the jurisdictions in which it operates and, consequently, income tax expense is a function of the allocation of taxable income by jurisdiction and the various activities that impact the timing of taxable events. As we operate in the legal cannabis industry, we are subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which we are only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E and a higher effective tax rate than most industries. However California does not conform to IRC Section 280E and, accordingly, we deduct all operating expenses on MedMen’s California Franchise Tax Returns.

 

The provision for income taxes for the three months ended September 24, 2022 was $2.2 million, compared to the provision for income tax expense of $19.7 million for the three months ended September 25, 2021, primarily due to the Company’s forecasted income and related IRC Section 280E expenditures.

 

Net Loss

 

Net loss from continuing operations for the three months ended September 24, 2022 was $20.3 million, a decrease of $(25.9) million compared to $46.2 million for the three months ended September 25, 2021. For the fiscal first quarter of 2023, net loss from continuing operations was favorably impacted by the Company’s continued efforts to optimize selling, general and administrative costs and right-size the Company’s corporate infrastructure.

 

Non-GAAP Financial Measures

 

EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) transaction costs and restructuring costs; (ii) non-cash share-based compensation expense; (iii) fair value changes in derivative liabilities and contingent consideration; (iv) (gains) losses on disposal of assets, assets held for sale, extinguishment of debt and lease terminations; and (v) other one-time charges for non-cash operating costs. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.

 

42

 

 

Reconciliations of GAAP Measures to Non-GAAP Financial Measures

 

The table below reconciles Net Loss to EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations for the periods indicated.

 

   Three Months Ended 
   September 24,   September 25, 
($ in Millions)  2022   2021 
Net Income (Loss)  $4.0   $(60.6)
           
Less: Net (Income) Loss from Discontinued Operations, Net of Taxes   (24.3)   14.4 
Add (Deduct) Impact of:          
Net Interest and Other Financing Costs (1)   11.6    14.5 
Provision for Income Taxes   2.2    19.7 
Amortization and Depreciation   4.0    6.3 
           
Total Adjustments   17.8    40.5 
           
EBITDA from Continuing Operations  $(2.5)  $(5.7)
           
Add (Deduct) Impact of:          
Transaction Costs & Restructuring Costs  $0.9   $4.0 
Share-Based Compensation   0.9    1.6 
Change in Fair Value of Derivative Liabilities   0.8    (2.1)
Change in Fair Value of Contingent Consideration   (0.9)   - 
(Gain) Loss on Lease Termination   (1.6)   - 
(Gain) Loss on Extinguishment of Debt   -    (10.2)
(Gain) Loss from Disposal of Assets   0.2    - 
Sublease Income   (1.5)   - 
Impairment Expense   1.7    0.4 
Other Non-Cash Operating Costs   -    (0.2)
           
Total Adjustments  $0.5   $(6.5)
           
Adjusted EBITDA from Continuing Operations  $(2.0)  $(12.2)

 

 
(1)For the current period, net interest and other financing costs now include accretion of debt discount and loan origination fees of $1.6 million for the three months ended September 24, 2022. The prior year amount of $6.3 million for the three months ended September 25, 2021 have been reclassified for consistency with the current year presentation. Accretion of debt discount was previously excluded from the reconciliation of Net Loss to EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations.

 

43

 

 

EBITDA from Continuing Operations represents the Company’s current operating profitability and ability to generate cash flow and includes significant non-cash operating costs. Considering these adjustments, the Company had EBITDA from Continuing Operations of $(2.5) million for the three months ended September 24, 2022 compared to $(5.7) million for the comparative prior period. The change in EBITDA from Continuing Operations was primarily due to the Company’s continued cost-saving strategies and lower operating costs at the cultivation facilities of California and Nevada as a result of the licensing and management agreement which includes lower rents.

 

For the three months ended September 24, 2022, Adjusted EBITDA from Continuing Operations was $(2.0) million compared to $(12.2) million for the three months ended September 25, 2021. The improvement is primarily due to the decrease in general and administrative expenses. The financial performance of the Company is expected to further improve as the Company works towards profitability and coupled with significant deleveraging of its balance sheet, will reposition the Company for growth.

 

Refer to Item 2 “Liquidity and Capital Resources” for further discussion of management’s future outlook.

 

Cash Flows

 

The following table summarizes the Company’s consolidated cash flows for the three months ended September 24, 2022 and September 25, 2021:

 

   Three Months Ended         
   September 24,   September 25,         
($ in Millions)  2022   2021   $ Change   % Change 
Net Cash Used in Operating Activities  $(9.6)  $(23.0)  $13.4    (58%)
Net Cash Provided by (Used in) Investing Activities   51.5    (3.6)   55.1    (1,531%)
Net Cash (Used in) Provided by Financing Activities   (31.6)   93.2    (124.8)   (134%)
                     
Net Increase in Cash and Cash Equivalents   10.3    66.6    (56.3)   (85%)
Cash Included in Assets Held for Sale   -    (0.3)   0.3    100%
Cash and Cash Equivalents, Beginning of Period   10.8    11.6    (0.8)   (7%)
                     
Cash and Cash Equivalents, End of Period  $21.1   $77.9   $(56.8)   (73%)

 

Cash Flow from Operating Activities

 

Net cash used in operating activities was $9.6 million for the three months ended September 24, 2022, a decrease of $13.4 million, compared to $23.0 million for the three months ended September 25, 2021. The decrease was primarily driven by the decrease in general and administrative expenses as described in “Results of Operations” above.

 

Cash Flow from Investing Activities

 

Net cash provided by investing activities was $51.5 million for the three months ended September 24, 2022 compared to the $3.6 million of net cash used in investing activities in the prior year. This was primarily due to the $51.5 million in cash proceeds from the sale of the Company’s operations in the state of Florida during the current period.

 

44

 

 

Cash Flow from Financing Activities

 

Net cash used in financing activities was $31.6 million for the three months ended September 24, 2022 compared to $93.2 million net cash provided by financing activities for the three months ended September 25, 2021. During the current period, the Company used $31.6 million of the cash proceeds from the sale of its Florida-based operations to make principal repayments on the Senior Secured Term Loan. Whereas during the comparative prior period, the Company completed a private placement with Serruya Private Equity Inc. (“SPE”) resulting in an equity investment of $100.0 million.

 

Financial Condition and Going Concern

 

As of September 24, 2022, the Company had cash and cash equivalents of $21.1 million and working capital deficit of $134.9 million. The Company has incurred net losses from continuing operations of $20.3 million and $46.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.

 

The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with our master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. We also need to obtain an extension or a refinancing of our debt-in-default with the secured senior lender. Our annual operating plan for fiscal year 2023 estimates we will be able to manage our ongoing operations. However, our cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, we expect to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.

 

As of September 24, 2022, the accompanying Consolidated Financial Statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

 

The following table summarizes certain aspects of the Company’s financial condition as of September 24, 2022 and June 25, 2022:

 

   September 24,   June 25,         
($ in Millions)  2022   2022   $ Change   % Change 
Cash and Cash Equivalents  $21.1   $10.8   $10.3    95%
Total Current Assets  $98.7   $161.5   $(62.8)   (39%)
Total Assets  $251.1   $323.2   $(72.1)   (22%)
Total Current Liabilities  $233.6   $319.6   $(86.0)   (27%)
Notes Payable, Net of Current Portion  $74.9   $206.4   $(131.5)   (64%)
Total Liabilities  $564.7   $641.7   $(77.0)   (12%)
Total Shareholders’ Equity  $(313.6)  $(318.5)  $4.9    (2%)
Working Capital Deficit  $(134.9)  $(158.1)  $23.2    (15%)

 

45

 

 

In August 2022, the Company completed the sale of its operations in the state of Florida at the final sales price of $67,000,000 which comprised of $63,000,000 in cash and $4,000,000 in liabilities to be assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, $11,500,000 on September 15, 2023, and is required to make an additional installment payment of $11,500,000 on or before March 15, 2023. During the fiscal third quarter of 2022, net proceeds to the Company were $19,558,947 after a principal repayment of $31,599,999 on the Senior Secured Term Loans with Hankey Capital. The final cash payment of $11,500,000 remains due and receivable as of September 24, 2022. The Senior Secured Term Loans remains outstanding and in default as of September 24, 2022.

 

The $23.2 million improvement in working capital deficit was primarily related to the $31.6 million principal repayment on the Senior Secured Term Loans that matured on July 31, 2022 and August 1, 2022. The Company’s working capital will be significantly impacted by continued operations and growth in retail operations and the continued stewardship of the Company’s financial resources. The ability to fund working capital needs will also be dependent on the Company’s ability to raise additional debt and equity financing and execute cost savings plans.

 

Liquidity and Capital Resources

 

The primary need for liquidity is to fund working capital requirements of the business, including operationalizing existing licenses, capital expenditures, debt service and acquisitions. The primary source of liquidity has primarily been private and/or public financing and to a lesser extent by cash generated from sales. The ability to fund operations, to make planned capital expenditures, to execute on the growth/acquisition strategy, to make scheduled debt and rent payments and to repay or refinance indebtedness depends on the Company’s future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business and other factors, some of which are beyond its control. Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure.

 

Off-Balance Sheet Arrangements

 

The Company has no material undisclosed off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations, financial condition, revenues or expenses, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Policies, Significant Judgments and Estimates and Recent Accounting Pronouncements

 

There have been no changes in critical accounting policies, estimates and assumptions from the information provided in “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” included in the Form 10 for the fiscal year ended June 25, 2022 that have a significant effect on the amounts recognized in the Condensed Consolidated Financial Statements as of and for the fiscal quarter ended September 24, 2022. See “Note 2 – Summary of Significant Accounting Policies” in the Condensed Consolidated Financial Statements in Item 1 for recently adopted accounting standards. For more information on the Company’s critical accounting estimates, refer to the “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the Annual Report on Form 10-K for the fiscal year ended June 25, 2022. In addition, a detailed description of our critical accounting policies and recent accounting pronouncements are detailed in Part I, “Item 8. Financial Statements and Supplementary Data” of the Annual Report on Form 10-K for the fiscal year ended June 25, 2022.

 

46

 

 

Transactions with Related Parties

 

As of September 24, 2022 and June 25, 2022, there were no amounts due from or due to related parties that were recorded in the Consolidated Balance Sheets. Refer to “Note 19 – Related Party Transactions” of the Consolidated Financial Statements for the three months ended September 24, 2022 in Item 1.

 

The Company’s Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.

 

Senior Secured Convertible Credit Facility

 

As of September 24, 2022, the Company has drawn down a total of $165.0 million on the Convertible Facility, has accrued paid-in-kind interest of $45.2 million with an aggregate weighted average conversion price of approximately $0.24 per share, and an aggregate of 196,327,593 warrants with a weighted average exercise price of $0.17 per share.

 

Emerging Growth Company Status

 

The Company is an “emerging growth company” as defined in the Section 2(a) of the Exchange Act, as modified by the Jumpstart Our Business Start-ups Act of 2012, or the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act for complying with new or revised accounting standards applicable to public companies. The Company has elected to take advantage of this extended transition period and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Information not required to be filed by smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Pursuant to Rules 13a-15(b) and 15-d-15(b) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), as of September 24, 2022, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer of the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report.

 

The term “disclosure controls and procedures”, as defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

Based upon that evaluation and the identification of the material weakness described herein, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective, at the reasonable assurance level, as of the end of our last fiscal year end, June 25, 2022, and continues as such as of the end of the period covered by this report.

 

47

 

 

Changes in Internal Control Over Financial Reporting 

 

For fiscal year 2022, management identified a material weakness determining that the Company’s financial recordkeeping process was deficient and that it does not have effective controls over the period-end reconciliation process. The reconciliation process was not being performed in a manner that will detect and correct errors on a timely basis, including:

 

  general ledgers are not being reviewed regularly for assets that may not be recoverable or viable,
     
  review procedures for balance sheet account reconciliations and manual journal entries were not performed, and
     
 

some accounts and balances are not being reconciled regularly, and/or account reconciliations that are being completed do not properly address or adjust reconciling items.

 

Management plans to implement measures designed to improve its internal control over financial reporting to remediate material weaknesses described above by standardizing the monthly reconciliation process for material accounts and balances with formalized procedures. Material non-standard journal entries recorded in the accounting system will be reviewed for the various applicable accounting assertions including recoverability and validity. While the Company is actively engaged in the implementation of its remediation efforts to address this internal control weakness, the actions we have taken are subject to continued review, supported by confirmation and testing by management. Accordingly, the material weakness will not be considered fully remediated until the new control procedures are implemented for a sufficient period of time and management has concluded that these controls are operating effectively which we anticipate will occur in the ensuing months.

 

Except as noted above, there were no changes in our internal control over financial reporting during the three months ended September 24, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations on Effectiveness of Controls

 

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements attributable to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Assessments of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements as a result of error or fraud may occur and not be detected.

 

48

 

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Other than noted below, there have been no material developments during the fiscal quarter covered by this Report for our legal proceedings that were disclosed in our Annual Report on Form 10-K filed on September 9, 2022.

 

On October 6, 2022 the Company entered into a Settlement and Mutual Release Agreement with Charles Coburn, Daryll DeSantis, Unisys Technical Solutions, LLC and Delsantro Investments LLC in connection with a complaint filed by these parties on May 26, 2020 and counterclaim by the Company (the “Unisys Litigation”). The agreement resolved the Unisys Litigation and preserved the Company’s right to a pro rata distribution from plaintiff and cross defendant Charles Coburn’s bankruptcy estate as may be ordered by the bankruptcy court.

 

On July 11, 2022 Thor 952 Fulton Street, LLC, an affiliate of Thor Equities Group, filed a complaint in the United States District Court for the Southern District of New York against Future Transactions Holdings, LLC, an affiliate of the Company, MM Enterprises USA, LLC, and the Company seeking approximately $950,960 in damages relating to a lease of commercial property located in Illinois, which lease specified use as a cannabis dispensary, claiming diversity jurisdiction. On September 16, 2022 the Company moved to dismiss the case on the basis that the subject matter of the contract was illegal under federal law, and plaintiffs thereafter moved for a voluntary dismissal. On October 17, 2022 the United States District court granted plaintiff’s motion for voluntary dismissal of the complaint without prejudice. On October 19, 2022 Future Transactions Holdings, LLC, MM Enterprises USA, LLC, and the Company filed a complaint under the federal Declaratory Judgment Act against Thor 942 Fulton Street, LLC.

 

ITEM 1A. RISK FACTORS.

 

Smaller reporting companies are not required to provide the information required by this Item.

 

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

See discussion of Senior Secured Term Loan in “Note 10 – Notes Payable” under Part I, “Item 1. Notes to Condensed Consolidated Financial Statements”, which is incorporated in this item by reference.

 

ITEM 4. MINE SAFETY DISCLOSURE

 

Not applicable.

 

49

 

 

ITEM 5. OTHER INFORMATION

 

By resolution dated as of September 21, 2022, as consideration for Mr. Record’s service to the Company since April 24, 2022, when he was appointed as Chief Executive Officer, including successfully guiding the Company through the sale of its Florida assets, the Board effectively approved a cash bonus of $171,429. This payment represents the amount already due to Mr. Record pursuant to the terms of his employment entered at the time of his appointment; except that he shall now receive cash in lieu of RSUs for the period beginning on the date of his appointment through and until the date of the Board resolution. The Board also approved the grant to Mr. Record under the Company’s 2018 Stock and Incentive Plan of $3,000,000 worth of options with a term of five years to purchase Subordinate Voting Shares at an exercise price per share of $0.051968 and with one-third vesting on the date of grant and one-third vesting on each of April 24, 2023 and April 24, 2024. The resolution directs the Company to determine the number of options to be issued through the application of the Black Scholes option pricing model. The options will vest automatically upon a change of control or Mr. Record’s termination as CEO, unless the Board determines that Mr. Record is terminated based on his conduct or performance. A change of control generally includes the acquisition of 50% of the voting securities of the Company, a merger, or sale of all or substantially all of the Company’s assets. Pursuant to his employment terms, Mr. Record will continue to receive an annual salary of $416,000 and is eligible to receive up to an additional $8,000 per week during his service as CEO (the “Bonus”), one half of which will be paid in cash and one half will be paid in RSUs. The Bonus will be paid quarterly at the approval of the Board and not contingent on any specific requirements unless the Board determines reasonably that Mr. Record’s performance did not meet minimal acceptable standards or Mr. Record is terminated based on conduct or performance. The number of RSUs granted will be based on the trailing 10-day volume weighted average price of the Subordinate Voting Shares trading on the Canadian Securities Exchange or any National Securities Exchange prior to the date of grant.

 

On October 18, 2022, the Company’s Board of Directors approved a change to director compensation with regards to calculating the number of Subordinate Voting Shares issued to non-employee directors. The Company’s non-employee directors will continue to receive an annual fee of $250,000, of which one-third is paid in cash on a quarterly basis and two-thirds is paid in Subordinate Voting Shares. Each director will now receive on an annual basis 3,453,802 Subordinate Voting Shares, of which 864,200 Subordinate Voting Shares will vest quarterly, with retroactive effect to April 21, 2022.

 

In February 2022, the Company executed the Sixth Modification extending the maturity date of senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification makes no modification to the current interest rate. The Sixth Modification provides that the definitive documentation with respect to the conditional purchase of the Term Loans by Superhero Acquisition, L.P., an existing lender under the Company’s Senior Secured Convertible Purchase Agreement dated August 7, 2021, must be entered within 45 days or the stated maturity date of the Term Loans become due. The Sixth Modification requires that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposes covenants in regards strategic actions the Company must implement if it is unable to pay the Term Loans by the extended stated maturity date. During the three months ended September 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $31,599,999 with proceeds from the sale. The Facility remains in default as of September 24, 2022 and the Company is in ongoing discussions with the Lenders.

 

50

 

 

ITEM 6. EXHIBITS

 

        Incorporated by Reference  
Exhibit No.   Exhibit Description   Form   File No.   Exhibit   Filing Date   Filed/
Furnished
Herewith
 
10.1   First Amendment to Asset Purchase Agreement dated July 31, 2022 among MME Florida, LLC, MM Enterprises USA, LLC, and Green Sentry Holdings, LLC.   8-K   000-56199   10.1   8/26/22      
10.2   Second Amendment to Asset Purchase Agreement dated August 22, 2022 among MME Florida, LLC, MM Enterprises USA, LLC, and Green Sentry Holdings, LLC.   8-K   000-56199   10.2   8/26/22      
10.3   Compensation Terms for CEO (Ed Record) approved by Board on September 22, 2022                    
31.1   Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.                    
31.2   Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.                    
32.1*   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                    
101.INS   XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.                      
101.SCH   XBRL Taxonomy Extension Schema Document.                    
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.                    
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.                    
101.LAB   XBRL Taxonomy Extension Label Linkbase Document.                    
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.                    
104   Cover Page Interactive Data File. (Formatted as Inline XBRL and contained in Exhibit 101.)                    

 

 
* This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

 

51

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 3, 2022 MEDMEN ENTERPRISES INC
   
  /s/ Ana Bowman
  By: Ana Bowman
  Its: Chief Financial Officer

 

52

EX-10.3 2 medmenenter_ex10-3.htm EXHIBIT 10.3

 

Exhibit 10.3

 

CEO Compensation Terms

(as approved by the Board of Directors on September 21, 2022)

 

1. As compensation for his services, Ed Record (“Record) will be paid US$416,000 per annum which he will receive in the amount of US$16,000 per pay period, subject to all withholdings and deductions as required by law and paid on a bi-weekly basis.

 

2. Record shall be eligible for up to US$8,000.00 each week he is employed as Chief Executive Officer (the “Bonus”), one half of which shall be paid in cash and one half of which shall be paid in restricted stock units exchangeable for Class B Subordinate Voting Shares (“RSUs”), to be granted at the end of each fiscal year.

 

a. As consideration for Record’s service as Chief Executive Officer from the Start Date (April 24, 2022) until the date hereof, the number of RSU’s that would have been granted to Record under this provision shall be paid to Record at their equivalent cash value and the full amount of the Bonus for that period shall be paid immediately in exchange, in part, for Record having successfully guided the Corporation through the sale of its Florida assets.

 

b. As consideration for Record’s service as Chief Executive Officer from the date hereof going forward, the Bonus shall be paid quarterly at the approval of the Board, which approval shall not be contingent on Record meeting any specific requirements and which amount shall be earned and paid quarterly unless the Board determines reasonably that Record’s performance did not meet minimal acceptable standards or the Board terminated Record’s employment during the prior quarter based on conduct or performance.

 

3. As a long term equity incentive, the Board hereby grants Record US$3,000,000.00 in stock options to acquire Shares (“Options”), with such Options having a strike price of CAD$0.07, which price the Board finds is above the recent closing price of Shares on the Canadian Securities Exchange on either of the last two trading days. Such Options shall vest as follows: US$1,000,000.00 immediately, US$1,000,000.00 on the one year anniversary of the Start Date, and $1,000,000.000 on the second year anniversary of the Start Date. For purposes of this issuance of Options, the Board finds the current CAD/USD exchange rate is equal to 0.7424. The issue price of the Options shall be determined using the Black Scholes option pricing model, the strike price of the Options shall be CAD$0.07 and the Options shall expire five (5) years from the date of grant. The unvested portion of the Options shall vest automatically upon a Change of Control or termination of Record as Chief Executive Officer, unless the Board reasonably determines that it terminated Record’s employment based on his conduct or performance.

 

 

 

 

4. Definition of Change of Control. "Change in Control" for purposes of this Agreement, shall mean the occurrence of any of the following events occurring after the date of this Agreement (each, a "Fundamental Change"): (a) the acquisition by one person, or a group of persons acting jointly or in concert, of more than 50% of the voting rights attached to the outstanding voting and equity securities of Corporation on a fully diluted basis in a single transaction or in a series of transactions occurring during a period of not more than twelve months; (b) the Corporation is merged, amalgamated or consolidated with another corporation; or (c) a sale of substantially all of the assets of the Corporation (held directly or indirectly) to another entity, unless, following any of the foregoing Fundamental Changes in (a) through (c) above, all or substantially all of the individuals and entities that were the beneficial owners of the Corporation's outstanding voting securities immediately prior to such Fundamental Change beneficially own immediately after the transaction or transactions, directly or indirectly, 50% or more of the combined voting power of the then outstanding voting securities (or comparable interests) of the entity resulting from such Fundamental Change (including an entity that, as a result of such transaction, owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more affiliates) insubstantially the same proportions as their ownership of the Corporation's voting securities immediately prior to such Fundamental Change.

 

5. Other than as provided for specifically herein, the number of RSUs granted by the Board shall be calculated based upon the dollar value of the award divided by the trailing 10-day volume weighted average price of the Company’s shares trading on the Canadian Securities Exchange or any National Securities Exchange prior to the date of grant (the “Issue Price”).

 

6. Record shall receive no other compensation other than as set forth herein or as otherwise agreed by the Board.

 

7. All equity granted hereunder is issued pursuant to the terms of the 2018 Stock and Incentive Plan of the Corporation.

 

 

 

EX-31.1 3 medmenenter_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CEO Certification

 

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Ed Record, certify that:

 

  1. I have reviewed this report on Form 10-Q of MedMen Enterprises Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 3, 2022 By: /s/ Edward J. Record
    Edward J. Record
    Chief Executive Officer

 

 

EX-31.2 4 medmenenter_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

CFO Certification

 

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Ana Bowman, certify that:

 

  1. I have reviewed this report on Form 10-Q of MedMen Enterprises Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 3, 2022 By: /s/ Ana Bowman
    Ana Bowman
    Chief Financial Officer

 

 

EX-32.1 5 medmenenter_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q for the period ended September 24, 2022 of MedMen Enterprises Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

  1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.

 

By: /s/ Edward J. Record  
  Edward J. Record  
  Chief Executive Officer  
     
  November 3, 2022  
     
By: /s/ Ana Bowman  
  Ana Bowman  
  Chief Financial Officer  
     
  November 3, 2022  

 

 

EX-101.SCH 6 mmen-20220924.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - ASSETS HELD FOR SALE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - OTHER OPERATING (INCOME) EXPENSE link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - ASSETS HELD FOR SALE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SHAREHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - OTHER OPERATING (INCOME) EXPENSE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - INVENTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - ASSETS HELD FOR SALE (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - DERIVATIVE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - DERIVATIVE LIABILITIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - DERIVATIVE LIABILITIES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - DERIVATIVE LIABILITIES (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - LEASES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - NOTES PAYABLE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - SHAREHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - SHAREHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - SHAREHOLDERS' EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - SHAREHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - SHARE-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - SHARE-BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - SHARE-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - SHARE-BASED COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - SHARE-BASED COMPENSATION (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000077 - Disclosure - SHARE-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000078 - Disclosure - LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000079 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000080 - Disclosure - OTHER OPERATING EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000081 - Disclosure - OTHER OPERATING (INCOME) EXPENSE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000082 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000083 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000084 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000085 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000086 - Disclosure - DISCONTINUED OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000087 - Disclosure - DISCONTINUED OPERATIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000088 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mmen-20220924_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 mmen-20220924_def.xml XBRL DEFINITION FILE EX-101.LAB 9 mmen-20220924_lab.xml XBRL LABEL FILE Class of Warrant or Right [Axis] Subordinate Voting Shares [Member] Equity Components [Axis] Subordinate Voting [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Equity Attributable To Shareholders Of Medmen [Member] Noncontrolling Interest [Member] Sale of Stock [Axis] Discontinued Operations [Member] Other Asset [Member] Total [Member] Product and Service [Axis] Dispensary License [Member] Finite-Lived Intangible Assets by Major Class [Axis] Customer Relationship [Member] Long-Lived Assets Held-for-sale by Asset Type [Axis] Capitalized Software [Member] Intellectual Property [Member] Extinguishment of Debt [Axis] Accounts Payable and Accrued Liabilities [Member] Financial Instrument [Axis] Derivative Liabilities One [Member] Top Up Provision [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] Notes Payable [Member] Secured Convertible Note [Member] Secured Convertible Note 1 [Member] Secured Convertible Note 2 [Member] Secured Convertible Note 3 [Member] Secured Convertible Note 4 [Member] Secured Convertible Note 5 [Member] Secured Convertible Note 6 [Member] Secured Convertible Note 7 [Member] Secured Convertible Note 8 [Member] Secured Convertible Note 9 [Member] Secured Convertible Note 10 [Member] Vesting [Axis] Tranche One [Member] Tranche Two [Member] Tranche Three [Member] Tranche Four [Member] Incremental Advance One [Member] Incremental Advance Two [Member] Advance 3rd [Member] Amendment Fee Notes [Member] Restatement Fee Notes [Member] Second Restatement Fee Notes [Member] Investment Secondary Categorization [Axis] Senior Secured Convertible Total [Member] Related Party Transaction [Axis] Mm Can Usa Class B Redeemable Units [Member] Mm Enterprises Usa Common Units [Member] Ownership [Axis] MM CAN USA [Member] MM Enterprises USA [Member] Venice Caregivers Foundation Inc [Member] L A X Fund Two Group L L C [Member] Natures Cure Inc [Member] Vies Total [Member] Non Controlling Interests [Member] Other Non Controlling Interests [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Award Type [Axis] Equity Option [Member] Stock Grants [Member] Restricted Stock Grants [Member] Warrant [Member] [Subordinate Voting Shares [Member]] Title of Individual [Axis] Board of Directors Chairman [Member] Geographic Distribution [Axis] CALIFORNIA NEVADA ILLINOIS ARIZONA MASSACHUSETTS Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and Cash Equivalents Accounts Receivable and Prepaid Expenses Inventory Assets Held for Sale Receivable for Assets Held for Sale Other Assets Total Current Assets Operating Lease Right-of-Use Assets Property and Equipment, Net Intangible Assets, Net Goodwill Other Non-Current Assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS’ EQUITY LIABILITIES: Current Liabilities: Accounts Payable and Accrued Liabilities Income Taxes Payable Other Liabilities Derivative Liabilities Current Portion of Operating Lease Liabilities Current Portion of Finance Lease Liabilities Current Portion of Notes Payable Liabilities Held for Sale Total Current Liabilities Operating Lease Liabilities Finance Lease Liabilities Other Non-Current Liabilities Deferred Tax Liability Senior Secured Convertible Credit Facility Notes Payable TOTAL LIABILITIES SHAREHOLDERS’ EQUITY: Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding) Subordinate Voting Shares (no par value, unlimited shares authorized, 1,301,683,764 and 1,301,423,950 shares issued and outstanding as of September 24, 2022 and June 26, 2022, respectively) Additional Paid-In Capital Accumulated Deficit Total Equity Attributable to Shareholders of MedMen Enterprises Inc. Non-Controlling Interest TOTAL SHAREHOLDERS’ EQUITY TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Preferred Stock, Par Value Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Subordinate voting, shares issued Subordinate voting, shares outstanding Income Statement [Abstract] Revenue Cost of Goods Sold Gross Profit Operating Expenses: General and Administrative Sales and Marketing Depreciation and Amortization Realized and Unrealized Changes in Fair Value of Contingent Consideration Impairment Expense Other Operating (Income) Expense Total Operating Expenses Loss from Operations Non-Operating (Income) Expenses: Interest Expense Interest Income Accretion of Debt Discount and Loan Origination Fees Change in Fair Value of Derivatives Gain on Extinguishment of Debt Total Non-Operating Expenses Loss from Continuing Operations Before Provision for Income Taxes Provision for Income Tax Expense Net Loss from Continuing Operations Net Income (Loss) from Discontinued Operations, Net of Taxes Net Income (Loss) Net Loss Attributable to Non-Controlling Interest Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc. Earnings (Loss) Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. Weighted-Average Shares Outstanding - Basic and Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Net Loss Net Income (Loss) Controlling Interest Equity Transactions Shares Issued for Cash, Net of Fees Shares Issued for Cash, Net of Fees, Shares Shares Issued to Settle Debt and Accrued Interest Shares Issued to Settle Debt and Accrued Interest, Shares Shares Issued to Settle Accounts Payable and Liabilities Shares Issued to Settle Accounts Payable and Liabilities, Shares Equity Component of Debt - New and Amended Partner Contributions Redemption of MedMen Corp Redeemable Shares Redemption of MedMen Corp Redeemable Shares, Shares Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options, Shares Shares Issued for Exercise of Warrants Shares Issued for Exercise of Warrants, Shares Shares Issued for Conversion of Debt Shares Issued for Conversion of Debt, Shares Stock Grants for Compensation Stock Grants for Compensation, Shares Deferred Tax Impact On Conversion Feature Share-Based Compensation Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Loss from Continuing Operations Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: Deferred Tax Expense Depreciation and Amortization Non-Cash Operating Lease Costs Accretion of Debt Discount and Loan Origination Fees Loss on Disposals of Assets Gain on Lease Terminations Accretion of Deferred Gain on Sale of Property Impairment of Assets Realized and Unrealized Changes in Fair Value of Contingent Consideration Change in Fair Value of Derivative Liabilities Gain on Extinguishment of Debt Share-Based Compensation Interest Capitalized to Senior Secured Convertible Debt and Notes Payable Interest Capitalized to Finance Lease Liabilities Changes in Operating Assets and Liabilities: Accounts Receivable and Prepaid Expenses Inventory Other Current Assets Other Assets Accounts Payable and Accrued Liabilities Interest Payments on Finance Leases Cash Payments - Operating Lease Liabilities Income Taxes Payable Other Current Liabilities Other Non-Current Liabilities NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES Net Cash Used in Discontinued Operating Activities NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of Property and Equipment Additions to Intangible Assets Proceeds from the Sale of Assets Held for Sale Restricted Cash NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES Net Cash Used in Discontinued Investing Activities NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Issuance of Subordinate Voting Shares for Cash Payment of Stock Issuance Costs Relating to Private Placement Exercise of Warrants for Cash Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility Proceeds from Issuance of Notes Payable Principal Repayments of Notes Payable Principal Repayments of Finance Lease Liability Distributions - Non-Controlling Interest NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES NET INCREASE IN CASH AND CASH EQUIVALENTS Cash Included in Assets Held for Sale Cash and Cash Equivalents, Beginning of Period CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION Cash Paid for Interest Non-Cash Investing and Financing Activities: Net Assets Transferred to Held for Sale Redemption of MedMen Corp Redeemable Shares Derivative Liability Incurred on Convertible Facility and Equity Financing Conversion of Convertible Debentures Shares Issued to Settle Debt and Lender Fees Shares Issued to Settle Accounts Payable and Liabilities Equity Component of Debt - New and Amended Deferred Tax Impact on Conversion Feature Accounting Policies [Abstract] NATURE OF OPERATIONS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Inventory Disclosure [Abstract] INVENTORY Assets Held For Sale ASSETS HELD FOR SALE Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Derivative Liabilities DERIVATIVE LIABILITIES Leases [Abstract] LEASES Notes Payable NOTES PAYABLE Debt Disclosure [Abstract] SENIOR SECURED CONVERTIBLE CREDIT FACILITY Equity [Abstract] SHAREHOLDERS’ EQUITY Share-Based Payment Arrangement [Abstract] SHARE-BASED COMPENSATION Earnings Per Share [Abstract] LOSS PER SHARE General And Administrative Expenses GENERAL AND ADMINISTRATIVE EXPENSES Other Operating Income Expense OTHER OPERATING (INCOME) EXPENSE Income Tax Disclosure [Abstract] PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Segment Reporting [Abstract] SEGMENT INFORMATION Revenue from Contract with Customer [Abstract] REVENUE Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Preparation Going Concern COVID-19 Basis of Consolidation Significant Accounting Policies Earnings (Loss) per Share Reclassifications Recently Adopted Accounting Standards Recently Issued Accounting Standards Schedule of inventories Schedule of asset held for sale Schedule of property and equipment Schedule of Intangible assets Schedule of accounts payable and accrued liabilities Schedule of reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities Schedule of assumptions to measure fair value Schedule of warrant issued Schedule of assumptions to measure fair value Schedule of lease cost Schedule of future leases payments Schedule of notes payable Schedule of Reconciliation of Notes payable Schedule of senior secured convertible credit facility Schedule of Shares issued and outstanding Schedule of VIE Schedule of other non-controlling interest Schedule of share-based compensation expense Schedule of stock options Schedule of LTIP Units and LLC Redeemable Units Schedule of Restricted Stock Grants Schedule of Warrants Schedule of basic and diluted loss per share Schedule of general and administrative expenses Schedule of other operating expenses Schedule of income tax expense and effective tax rates Schedule of Disaggregation of revenue Schedule of net operating loss of discontinued operation Schedule of assets included in discontinued operation Cash and cash equivalents Net working capital deficit Losses from continuing operations Reclassifications impacted leasehold improvements and furniture and fixtures Reclassifications impacted customer relationships and accumulated amortization Reclassifications impacted accumulated amortization Reclassifications impacted Non-controlling interest and accumulated deficit Reclassifications impacted Short-term and long-term operating lease liabilities Raw Materials Work-in-Process Finished Goods Total Inventory Other Asset Impairment Charges Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Balance at Beginning of Period Ongoing Activities Proceeds from Sale Gain on Sale of Assets Held for Sale Balance at End of Period Land and Buildings Capital Leases Furniture and Fixtures Leasehold Improvements Equipment and Software Construction in Progress Total Property and Equipment Less Accumulated Depreciation Property and Equipment, Net Other Depreciation and Amortization Cost of Goods and Services Sold Depreciation recognized for capital leases Borrowing costs Average capitalization rate Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Total Intangible Assets Less Accumulated Amortization Intangible Assets, Net Depreciation, Depletion and Amortization, Nonproduction Schedule of Extinguishment of Debt [Table] Extinguishment of Debt [Line Items] Accounts Payable Accrued Liabilities Accrued Inventory Accrued Payroll Local & State Taxes Payable Total Accounts Payable and Accrued Liabilities Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Balance at Beginning of Period Balance at End of Period Share Price Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate March 2021 Private Placement Total Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets Interest on Lease Liabilities Operating Lease Cost Sublease Income Total Lease Expenses Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases Operating Cash Flows from Operating Leases Finance Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent July 1, 2023 (remaining) July 1, 2023 (remaining) June 29, 2024 June 29, 2024 June 28, 2025 June 28, 2025 June 27, 2026 June 27, 2026 June 26, 2027 June 26, 2027 Thereafter Thereafter Total lease payment Total lease payment Less Interest Less Interest Lease Liability Recognized Lease Liability Recognized Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Finance liabilities Notes Payable, Current Promissory notes Other Total notes Payables Less. Unamortization Debt Issuance Cost an Loan Origination Fess Net Amount Less Current Portion of Notes Payable Notes Payables, net of Current Portion Balance at beginning of period Paid in kind interest Capitalized Cash payments Accretion of Debt Discount included in Discontinued Operations Balance at End of period Less Current portion of notes payables Notes payable, Net of Current portion Proceeds from Sale of Other Assets Proceeds from (Repayments of) Debt Total Drawn On Senior Secured Convertible Credit Facility Less Unamortize Debt Discount Senior Secured Convertible Credit Facility Net Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Balance at beginning of period Paid-In-Kind Interest Capitalized Accretion of Debt Discount Balance at end of period Redemption of MedMen Corp Redeemable Shares Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Current Assets Non-Current Assets Total Assets Current Liabilities Non-Current Liabilities Total Liabilities Non-Controlling Interest Revenues Net (Loss) Income Attributable to Non-Controlling Interest Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Balance at beginning Net (Loss) Income Balance at ending Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Total Share-Based Compensation Number of Stock Options, Beginning Balance Weighted Average Exercise Price, Beginning Balance Number of Stock Options, Forfeited Weighted Average Exercise Price, Forfeited Number of Stock Options, Ending Balance Weighted Average Exercise Price, Ending Balance Number of Stock Options, Stock Options Exercisable Weighted Average Exercise Price, Stock Options Exercisable LTIP Issued And Outstanding LLC Redeemable Units Weighted Average grant date fair Value Issued And Outstanding, Beginning Balance Vested, Beginning Balance Weighted average fair value at beginning Issued And Outstanding, Forfeiture of Restricted Stock Vested, Forfeiture of Restricted Stock Weighted Average fair Value, Forfeiture of Restricted Stock Vesting of Restricted Stock Vested, Vesting of Restricted Stock WeightedAverage Fair Value, Vesting of Restricted Stock Issued And Outstanding, Ending Balance Vested, Ending Balance Weighted average fair value at ending Beginning Balance Weighted Average Exercise Price, Beginning balance Expired Weighted Average Exercise Price, Expired Ending Balance Weighted Average Exercise Price, Ending Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. Net Income (Loss) from Discontinued Operations Total Net Income (Loss) Weighted-Average Shares Outstanding - Basic and Diluted Earnings (Loss) Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. Salaries and Benefits Professional Fees Rent Licenses, Fees and Taxes Share-Based Compensation Deal Costs Other General and Administrative Total General and Administrative Expenses Other Operating Expense Loss on Disposals of Assets Restructuring and Reorganization Expense Gain on Settlement of Accounts Payable Gain on Lease Terminations Other Income Total Other Operating (Income) Expense Sublease income Income Tax Expense Effective Tax Rate Provision for income taxes and deferred income taxes description Gross unrecognized tax benefits Net discrete tax expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Debt Instrument, Periodic Payment Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Line Items] Total Revenue Revenue from Continuing Operations Revenue from Discontinued Operations Revenue Cost of Goods Sold Gross Profit Expenses: General and Administrative Sales and Marketing Depreciation and Amortization Impairment Expense Gain on Disposal of Assets and Other Income Total (Income) Expenses Income (Loss) from Discontinued Operations Other Expense: Interest Expense Accretion of Debt Discount and Loan Origination Fees Total Other Expense Income (Loss) from Discontinued Operations Before Provision for Income Taxes Provision for Income Tax Benefit (Expense) Net Income (Loss) from Discontinued Operations Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents Restricted Cash Accounts Receivable and Prepaid Expenses Inventory TOTAL CURRENT ASSETS (1) Property and Equipment, Net Operating Lease Right-of-Use Assets Intangible Assets, Net Other Assets TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities Income Taxes Payable Other Current Liabilities Current Portion of Operating Lease Liabilities Current Portion of Finance Lease Liabilities TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion Deferred Tax Liabilities Notes Payable TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE Sales Price Sales in cash Liabilities assumed by buyer Buyer cash payment description Proceeds from Other Debt Proceeds from Issuance of Debt Remains due and payable Gain (Loss) on Disposition of Assets for Financial Service Operations Amount of cash paid for interest capitalized, classified as investing activity. The cash outflow for a borrowing supported by a written promise to pay an obligation. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit [Default Label] Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income Tax Expense (Benefit) Shares, Outstanding DeferredTaxImpactOnConversionFeature Depreciation, Depletion and Amortization AccretionOfDebtDiscountsAndLoanOriginationFees Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain (Loss) on Termination of Lease Gain (Loss) on Disposition of Oil and Gas and Timber Property Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Extinguishment of Debt, Gain (Loss), Net of Tax Share-Based Payment Arrangement, Noncash Expense InterestCapitalizedToSeniorSecuredConvertibleDebtAndNotesPayable InterestCapitalizedToFinanceLeaseLiabilities Increase (Decrease) in Accounts Receivable and Other Operating Assets Increase (Decrease) in Inventories Increase (Decrease) in Other Current Assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Finance Lease, Interest Payment on Liability Increase (Decrease) in Income Taxes Increase (Decrease) in Other Noncurrent Liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Operating Activities PaymentsToAcquirePropertyPlantAndEquipments PaymentsToAcquireIntangibleAsset Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Provided by (Used in) Investing Activities PaymentOfStockIssuanceCostsRelatingToPrivatePlacement PrincipalRepaymentsOfFinanceLeaseLiability Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect CashIncludedInAssetsHeldForSale Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock Redeemed or Called During Period, Value ShareIssuedToSettleAccountsPayableAndLiabilities EquityComponentsOfDebtNewAndAmended Defined Benefit Plan, Assumptions [Table Text Block] Inventory, Gross Property, Plant and Equipment, Other, Accumulated Depreciation Property, Plant and Equipment, Other, Net Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment IntangibleAssetNetExcludingGoodwill Derivative Liability Sublease Income Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, to be Paid, Year Three Finance Lease, Liability, to be Paid, Year Four Finance Lease, Liability, to be Paid, Year Five Finance Lease, Liability, to be Paid, after Year Five Finance Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Notes Payable, Related Parties, Noncurrent Repayments of Debt Debt Instrument, Unamortized Discount Other Notes Payable, Current Redemption of MedMen Corp Redemable Shares Noncontrolling Interest in Variable Interest Entity Redeemable Noncontrolling Interest, Equity, Carrying Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price WeightedaverageNumberOfSharesOutstandingBasicAndDiluted Income (Loss) from Continuing Operations, Per Diluted Share Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Employee Benefit and Share-Based Payment Arrangement, Noncash Restructuring Charges GainLossOnSettlementOfAccountsPayable Revenue [Default Label] CostOfGoodsSold GeneralAndAdministrative SalesAndMarketing DepreciationAndAmortizations ImpairmentExpense InterestExpenses AccretionOfDebtDiscountAndLoansOriginationFees ProvisionForIncomeTaxExpenseBenefit Income (Loss) on Discontinued Operations CashAndCashEquivalents RestrictedsCash AccountsReceivableAndPrepaidExpenses Inventory [Default Label] PropertyAndEquipmentNet OperatingLeaseRightofuseAssets IntangibleAssetsNet OtherAsset AccountsPayableAndAccruedLiabilities IncomeTaxesPayable OtherCurrentLiabilities CurrentPortionOfOperatingLeaseLiabilities CurrentPortionOfFinanceLeaseLiabilities NotesPayableNetOfCurrentPortion EX-101.PRE 10 mmen-20220924_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
3 Months Ended
Sep. 24, 2022
Oct. 31, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 24, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --06-30  
Entity File Number 000-56199  
Entity Registrant Name MEDMEN ENTERPRISES INC.  
Entity Central Index Key 0001776932  
Entity Tax Identification Number 98-1431779  
Entity Incorporation, State or Country Code A1  
Entity Address, Address Line One 8740 S Sepulveda Blvd  
Entity Address, Address Line Two Suite 105  
Entity Address, City or Town Los Angeles  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90045  
City Area Code (424)  
Local Phone Number 330-2082  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,301,683,764
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Current Assets:    
Cash and Cash Equivalents $ 21,097,057 $ 10,795,999
Accounts Receivable and Prepaid Expenses 5,376,069 7,539,767
Inventory 9,117,809 10,010,731
Assets Held for Sale 44,185,218 123,158,751
Receivable for Assets Held for Sale 11,500,000
Other Assets 7,403,829 9,990,992
Total Current Assets 98,679,982 161,496,240
Operating Lease Right-of-Use Assets 44,461,062 47,649,270
Property and Equipment, Net 59,965,935 64,107,792
Intangible Assets, Net 34,057,051 35,746,114
Goodwill 9,810,049 9,810,049
Other Non-Current Assets 4,157,513 4,414,219
TOTAL ASSETS 251,131,592 323,223,684
Current Liabilities:    
Accounts Payable and Accrued Liabilities 35,355,136 38,905,818
Income Taxes Payable 64,710,033 58,646,291
Other Liabilities 17,121,093 16,704,283
Derivative Liabilities 7,555,153 6,749,563
Current Portion of Operating Lease Liabilities 12,199,351 10,925,128
Current Portion of Finance Lease Liabilities 4,150,484 4,061,273
Current Portion of Notes Payable 66,294,249 97,003,922
Liabilities Held for Sale 26,195,800 86,595,102
Total Current Liabilities 233,581,299 319,591,380
Operating Lease Liabilities 47,280,217 50,917,244
Finance Lease Liabilities 26,905,824 26,553,287
Other Non-Current Liabilities 2,987,812 3,082,277
Deferred Tax Liability 40,295,319 35,213,671
Senior Secured Convertible Credit Facility 138,746,070 132,005,663
Notes Payable 74,898,640 74,372,898
TOTAL LIABILITIES 564,695,181 641,736,420
SHAREHOLDERS’ EQUITY:    
Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding)
Subordinate Voting Shares (no par value, unlimited shares authorized, 1,301,683,764 and 1,301,423,950 shares issued and outstanding as of September 24, 2022 and June 26, 2022, respectively)
Additional Paid-In Capital 1,058,145,437 1,057,228,873
Accumulated Deficit (897,613,980) (901,758,875)
Total Equity Attributable to Shareholders of MedMen Enterprises Inc. 160,531,457 155,469,998
Non-Controlling Interest (474,095,046) (473,982,734)
TOTAL SHAREHOLDERS’ EQUITY (313,563,589) (318,512,736)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 251,131,592 $ 323,223,684
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 24, 2022
Jun. 25, 2022
Class of Warrant or Right [Line Items]    
Preferred Stock, Par Value $ 0 $ 0
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Subordinate Voting Shares [Member]    
Class of Warrant or Right [Line Items]    
Subordinate voting, shares issued 1,301,683,764 1,301,423,950
Subordinate voting, shares outstanding 1,301,683,764 1,301,423,950
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Income Statement [Abstract]    
Revenue $ 30,044,048 $ 36,735,904
Cost of Goods Sold 15,187,672 19,349,990
Gross Profit 14,856,376 17,385,914
Operating Expenses:    
General and Administrative 17,846,117 32,649,234
Sales and Marketing 443,790 593,224
Depreciation and Amortization 3,946,523 5,823,617
Realized and Unrealized Changes in Fair Value of Contingent Consideration (863,856)
Impairment Expense 1,663,911 435,241
Other Operating (Income) Expense (2,555,118) 2,199,028
Total Operating Expenses 20,481,367 41,700,344
Loss from Operations (5,624,991) (24,314,430)
Non-Operating (Income) Expenses:    
Interest Expense 10,052,691 8,171,764
Interest Income (33) (23,008)
Accretion of Debt Discount and Loan Origination Fees 1,581,967 6,347,471
Change in Fair Value of Derivatives 805,590 (2,105,415)
Gain on Extinguishment of Debt (10,233,610)
Total Non-Operating Expenses 12,440,215 2,157,202
Loss from Continuing Operations Before Provision for Income Taxes (18,065,206) (26,471,632)
Provision for Income Tax Expense (2,193,542) (19,691,908)
Net Loss from Continuing Operations (20,258,748) (46,163,540)
Net Income (Loss) from Discontinued Operations, Net of Taxes 24,306,649 (14,446,491)
Net Income (Loss) 4,047,901 (60,610,031)
Net Loss Attributable to Non-Controlling Interest (112,312) (5,280,003)
Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc. $ 4,160,213 $ (55,330,028)
Earnings (Loss) Per Share - Basic and Diluted:    
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.02) $ (0.04)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. $ 0.02 $ (0.02)
Weighted-Average Shares Outstanding - Basic and Diluted 1,301,659,701 942,696,052
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
Subordinate Voting [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total Equity Attributable To Shareholders Of Medmen [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 27, 2021 $ 908,992,686 $ (717,232,706) $ 191,759,980 $ (445,393,599) $ (253,633,619)
Beginning balance, shares at Jun. 27, 2021 726,866,374          
Net Loss (55,330,028) (55,330,028) (5,280,003) (60,610,031)
Controlling Interest Equity Transactions            
Shares Issued for Cash, Net of Fees 73,393,745 73,393,745 73,393,745
Shares Issued for Cash, Net of Fees, Shares 406,249,973          
Shares Issued to Settle Debt and Accrued Interest 4,030,000 4,030,000 4,030,000
Shares Issued to Settle Debt and Accrued Interest, Shares 20,833,333          
Shares Issued to Settle Accounts Payable and Liabilities 700,000 700,000 700,000
Shares Issued to Settle Accounts Payable and Liabilities, Shares 4,182,730          
Equity Component of Debt - New and Amended 41,388,048 41,388,048 41,388,048
Redemption of MedMen Corp Redeemable Shares 1,121,441 374,701 1,496,142 (1,496,142)
Redemption of MedMen Corp Redeemable Shares, Shares 4,054,278          
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options, Shares 8,473,868          
Shares Issued for Exercise of Warrants 1,273,679 1,273,679 1,273,679
Shares Issued for Exercise of Warrants, Shares 8,807,605          
Shares Issued for Conversion of Debt 2,371,100 2,371,100 2,371,100
Shares Issued for Conversion of Debt, Shares 16,014,665          
Stock Grants for Compensation 1,421,400 1,421,400 1,421,400
Stock Grants for Compensation, Shares 1,455,415          
Deferred Tax Impact On Conversion Feature (13,057,730) (13,057,730) (13,057,730)
Share-Based Compensation 1,682,677 1,682,677 1,682,677
Ending balance, value at Sep. 25, 2021 1,023,317,046 (772,188,033) 251,129,013 (452,169,744) (201,040,731)
Ending balance, shares at Sep. 25, 2021 1,196,938,241          
Beginning balance, value at Jun. 26, 2022 1,057,228,873 (901,758,875) 155,469,998 (473,982,734) (318,512,736)
Beginning balance, shares at Jun. 26, 2022 1,301,423,950          
Net Income (Loss) 4,160,213 4,160,213 (112,312) 4,047,901
Controlling Interest Equity Transactions            
Partner Contributions 37,561 37,561 37,561
Redemption of MedMen Corp Redeemable Shares 15,318 (15,318)
Redemption of MedMen Corp Redeemable Shares, Shares 259,814          
Share-Based Compensation 863,685 863,685 863,685
Ending balance, value at Sep. 24, 2022 $ 1,058,145,437 $ (897,613,980) $ 160,531,457 $ (474,095,046) $ (313,563,589)
Ending balance, shares at Sep. 24, 2022 1,301,683,764          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net Loss from Continuing Operations $ (20,258,748) $ (46,163,540)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:    
Deferred Tax Expense (4,497,141)
Depreciation and Amortization 3,971,473 6,256,917
Non-Cash Operating Lease Costs 3,453,863 4,442,077
Accretion of Debt Discount and Loan Origination Fees 1,581,970 6,347,471
Loss on Disposals of Assets 205,595
Gain on Lease Terminations (1,587,670)
Accretion of Deferred Gain on Sale of Property (141,657) (141,657)
Impairment of Assets 1,663,911 435,241
Realized and Unrealized Changes in Fair Value of Contingent Consideration 863,856
Change in Fair Value of Derivative Liabilities 805,590 (2,105,415)
Gain on Extinguishment of Debt (10,233,610)
Share-Based Compensation 863,685 3,104,077
Interest Capitalized to Senior Secured Convertible Debt and Notes Payable 6,416,426 7,837,693
Interest Capitalized to Finance Lease Liabilities 444,232 377,885
Changes in Operating Assets and Liabilities:    
Accounts Receivable and Prepaid Expenses 2,163,698 617,325
Inventory 892,922 (1,710,735)
Other Current Assets 2,587,163 282,230
Other Assets 256,706
Accounts Payable and Accrued Liabilities (1,746,175) 4,827,997
Interest Payments on Finance Leases (1,804,507) (1,784,541)
Cash Payments - Operating Lease Liabilities (1,026,792) (3,478,891)
Income Taxes Payable 11,145,390 21,707,961
Other Current Liabilities (447,046) (2,413,113)
Other Non-Current Liabilities 47,192
NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES 10,351,077 (16,291,769)
Net Cash Used in Discontinued Operating Activities (19,961,041) (6,684,431)
NET CASH USED IN OPERATING ACTIVITIES (9,609,964) (22,976,200)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of Property and Equipment (391,730)
Additions to Intangible Assets (24,056) (461,456)
Proceeds from the Sale of Assets Held for Sale 51,500,000
Restricted Cash 730
NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES 51,475,944 (852,456)
Net Cash Used in Discontinued Investing Activities (2,764,417)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 51,475,944 (3,616,873)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance of Subordinate Voting Shares for Cash 95,000,000
Payment of Stock Issuance Costs Relating to Private Placement (5,352,505)
Exercise of Warrants for Cash 1,273,679
Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility (2,608,964)
Proceeds from Issuance of Notes Payable 5,000,000
Principal Repayments of Notes Payable (31,599,999) (75,605)
Principal Repayments of Finance Lease Liability (2,484) (959)
Distributions - Non-Controlling Interest 37,561
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (31,564,922) 93,235,646
NET INCREASE IN CASH AND CASH EQUIVALENTS 10,301,058 66,642,573
Cash Included in Assets Held for Sale (275,178)
Cash and Cash Equivalents, Beginning of Period 10,795,999 11,575,138
CASH AND CASH EQUIVALENTS, END OF PERIOD 21,097,057 77,942,533
SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION    
Cash Paid for Interest 1,260,562 2,336,120
Non-Cash Investing and Financing Activities:    
Net Assets Transferred to Held for Sale 4,476,993
Redemption of MedMen Corp Redeemable Shares 1,496,142
Derivative Liability Incurred on Convertible Facility and Equity Financing 30,500,000
Conversion of Convertible Debentures 2,371,100
Shares Issued to Settle Debt and Lender Fees 4,030,000
Shares Issued to Settle Accounts Payable and Liabilities 700,000
Equity Component of Debt - New and Amended 41,388,047
Deferred Tax Impact on Conversion Feature $ 13,057,730
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
NATURE OF OPERATIONS
3 Months Ended
Sep. 24, 2022
Accounting Policies [Abstract]  
NATURE OF OPERATIONS

 

1. NATURE OF OPERATIONS

 

MedMen Enterprises Inc. and its subsidiaries over which the company has control (collectively, “MedMen”, the “Company”, “we” or “us”) is a premier cannabis retailer based in the U.S. with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands – MedMen Red and LuxLyte – through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. MedMen Buds provides exclusive access to promotions, product drops and content.

 

As of September 24, 2022, the Company owns 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4). The Company continues to market its assets in New York and thus classifies all assets and liabilities and profit or loss allocable to its operations in the state of New York as discontinued operations. In August 2022, the Company completed the sale of its operations in the state of Florida of which all assets and liabilities and profit or loss allocable to Florida are classified as discontinued operations until the day of sale, or August 22, 2022. As of September 24, 2022, the remaining post-acquisition assets and liabilities and profit or loss allocable to Florida have been reclassified as continuing operations.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Sep. 24, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Preparation

 

The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.

 

In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

 

The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”).

 

Going Concern

 

As of September 24, 2022, the Company had cash and cash equivalents of $21.1 million and working capital deficit of $134.9 million. The Company has incurred net losses from continuing operations of $20.3 million and $46.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.

 

The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.

 

COVID-19

 

In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. During the current reporting period, aspects of the Company’s business continue to be affected by impacts of the COVID-19 pandemic, as the Company’s retail stores strive to operate within the local rules and regulations of the states and localities in which the Company operates. While the Company saw continued recovery from the impacts of the COVID 19-pandemic during the first quarter of 2023, the Company continues to closely monitor the potential impact that a resurgence of the COVID-19 virus, including as a result of the emergence of new variants and strains, could have on the Company’s operations. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liabilities. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.

 

Basis of Consolidation

 

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of September 24, 2022.

 

Significant Accounting Policies

 

The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended September 24, 2022.

 

Earnings (Loss) per Share

 

The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.

 

Reclassifications

 

Certain amounts reported in the Notes to the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. These non-material corrections and reclassifications impacted leasehold improvements and furniture and fixtures in the amount of approximately $940,000 between the categories. Customer relationships and accumulated amortization of customer relationships in the amount of $1,440,000 between the categories were reclassed between the two categories. Fully amortized management agreements and its related accumulated amortization in the amount of $964,000 were also reclassed. Non-controlling interest and accumulated deficit in the amount of approximately $3,662,000 have been reclassed between the two categories. In addition, the Company reclassified short-term and long-term operating lease liabilities between the two categories in the amount of approximately $6,825,000. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections.

 

Recently Adopted Accounting Standards

 

In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.

 

Recently Issued Accounting Standards

 

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

 

In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50)” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVENTORY
3 Months Ended
Sep. 24, 2022
Inventory Disclosure [Abstract]  
INVENTORY

 

3. INVENTORY

 

Inventory consists of the following:

 

           
   September 24,   June 25, 
   2022   2022 
Raw Materials  $612,901   $521,777 
Work-in-Process   1,142,397    671,541 
Finished Goods   7,362,511    8,817,413 
           
Total Inventory  $9,117,809   $10,010,731 

 

During the three months ended September 24, 2022 and September 25, 2021, the Company recognized impairment of nil and $864,314, respectively, to write down inventory to its net realizable value.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
ASSETS HELD FOR SALE
3 Months Ended
Sep. 24, 2022
Assets Held For Sale  
ASSETS HELD FOR SALE

 

4. ASSETS HELD FOR SALE

 

A reconciliation of our assets held for sale is as follows:

 

               
   Discontinued
Operations (1)
   Other
Assets
   TOTAL 
Balance as of June 25, 2022  $123,128,406   $30,345   $123,158,751 
Ongoing Activities   (47,881,618)   248,324    (47,633,294)
Proceeds from Sale   (67,000,000)   -    (67,000,000)
Gain on Sale of Assets Held for Sale   35,659,761    -    35,659,761 
                
Balance as of September 24, 2022  $43,906,549   $278,669   $44,185,218 

 

 
(1) See “Note 22 – Discontinued Operations” for further information.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT
3 Months Ended
Sep. 24, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

 

5. PROPERTY AND EQUIPMENT

 

As of September 24, 2022 and June 25, 2022, property and equipment consists of the following:

 

          
   September 24,   June 25, 
   2022   2022 
Land and Buildings  $29,933,999   $29,933,999 
Capital Leases   5,318,516    5,315,625 
Furniture and Fixtures   8,325,228    8,776,994 
Leasehold Improvements   33,625,893    33,069,524 
Equipment and Software   16,316,334    16,897,649 
Construction in Progress   4,528,762    6,828,923 
           
Total Property and Equipment   98,048,732    100,822,714 
           
Less Accumulated Depreciation   (38,082,797)   (36,714,922)
           
Property and Equipment, Net  $59,965,935   $64,107,792 

 

Depreciation expense related to continuing operations of $2,258,354 and $3,031,080 was recorded for the three months ended September 24, 2022 and September 25, 2021, respectively, of which $24,950 and $433,300, respectively, is included in cost of goods sold. The amount of depreciation recognized for the capital leases during the three months ended September 24, 2022 and September 25, 2021 was $347,406 and $283,406, respectively, see “Note 9 – Leases” for further information.

 

Borrowing costs were not capitalized as there were no active construction projects in progress during the three months ended September 24, 2022. During the three months ended September 25, 2021, borrowing costs totaling $375,241 were capitalized using an average capitalization rate of 11.95%.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS
3 Months Ended
Sep. 24, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

 

6. INTANGIBLE ASSETS

 

As of September 24, 2022 and June 25, 2022, intangible assets consist of the following:

 

           
   September 24,   June 25, 
   2022   2022 
Dispensary Licenses  $49,253,452   $49,253,452 
Customer Relationships   16,409,600    16,409,600 
Capitalized Software   7,413,470    7,413,470 
Intellectual Property   4,016,597    4,016,597 
           
Total Intangible Assets   77,093,119    77,093,119 
           
Dispensary Licenses   (17,477,268)   (16,876,912)
Customer Relationships   (16,589,651)   (15,870,284)
Capitalized Software   (4,681,748)   (4,413,974)
Intellectual Property   (4,287,401)   (4,185,835)
           
Less Accumulated Amortization   (43,036,068)   (41,347,005)
           
Intangible Assets, Net  $34,057,051   $35,746,114 

 

The Company recorded amortization expense related to continuing operations of $1,713,119 and $3,225,837 for the three months ended September 24, 2022 and September 25, 2021, respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
3 Months Ended
Sep. 24, 2022
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

As of September 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following:

 

          
   September 24,   June 25, 
   2022   2022 
Accounts Payable  $19,078,177   $14,627,746 
Accrued Liabilities   7,784,119    10,031,194 
Accrued Inventory   3,129,868    5,868,831 
Accrued Payroll   2,081,284    1,682,517 
Local & State Taxes Payable   3,281,687    6,695,532 
           
Total Accounts Payable and Accrued Liabilities  $35,355,136   $38,905,818 

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES
3 Months Ended
Sep. 24, 2022
Disclosure Derivative Liabilities Abstract  
DERIVATIVE LIABILITIES

 

8. DERIVATIVE LIABILITIES

 

A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three months ended September 24, 2022 is as follows:

 

      
   September 24, 
   2022 
Balance at Beginning of Period  $6,749,563 
      
Change in Fair Value of Derivative Liabilities   805,590 
      
Balance at End of Period  $7,555,153 

 

On August 17, 2021, in connection with the amended and restated senior secured convertible credit facility (the Sixth Amendment”), the Company provided the note holders top-up and preemptive rights which were bifurcated from the related notes and classified as a derivative due to the variability of the number and price of shares issuable under these rights. See “Note 11 – Senior Secured Convertible Credit Facility” for further information.

 

The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at September 24, 2022:

 

     
   Top-Up
Provision
 
Average Stock Price  $0.04 
Weighted-Average Probability   50.00%
Term (in Years)   5.00 
Expected Stock Price Volatility   96.68%

 

The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities:

 

              
   Number of
Warrants
   Exercise
Price
   Expiration
Date
 
March 2021 Private Placement (1)   50,000,000   C$0.50   March 27, 2024  
              
   50,000,000          

 

 
(1) See “Note 12 – Shareholders’ Equity” for further information.

 

The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables:

 

     
Expected Stock Price Volatility   106.25%
Risk-Free Annual Interest Rate   2.51%
Expected Life (in Years)   0.50 
Share Price  $0.04 
Exercise Price  $0.37 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES
3 Months Ended
Sep. 24, 2022
Leases [Abstract]  
LEASES

 

9. LEASES

 

The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates.

 

The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended September 24, 2022 and September 25, 2021:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Finance Lease Cost:          
Amortization of Finance Lease Right-of-Use Assets  $347,406   $283,406 
Interest on Lease Liabilities   1,804,507    1,784,541 
Operating Lease Cost   3,453,863    6,595,652 
Sublease Income (1)   (1,521,693)   - 
           
Total Lease Expenses  $5,605,776   $8,663,599 
           
Cash Paid for Amounts Included in the Measurement of Lease Liabilities:          
Financing Cash Flows from Finance Leases  $2,484   $959 
Operating Cash Flows from Operating Leases  $1,026,792   $3,478,891 

 

 
(1) See “Note 16 – Other Operating Income” for further information. 

 

The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of September 24, 2022 and June 25, 2022, is as follows:

 

   September 24,   June 25, 
   2022   2022 
Weighted-Average Remaining Lease Term (Years) - Finance Leases   47    46 
Weighted-Average Remaining Lease Term (Years) - Operating Leases   7    8 
Weighted-Average Discount Rate - Finance Leases   24.78%   24.33%
Weighted-Average Discount Rate - Operating Leases   15.96%   18.70%

 

Future lease payments under non-cancellable operating leases and finance leases as of September 24, 2022 are as follows:

 

           
Fiscal Year Ending  Operating
Leases
   Finance
Leases
 
July 1, 2023 (remaining)  $9,155,365   $4,387,279 
June 29, 2024   16,183,010    10,961,495 
June 28, 2025   25,224,922    14,020,131 
June 27, 2026   12,675,441    7,300,368 
June 26, 2027   12,716,234    7,519,379 
Thereafter   20,832,425    1,054,354,990 
           
Total Lease Payments   96,787,396    1,098,543,643 
Less Interest   (37,307,828)   (1,067,487,335)
           
Lease Liability Recognized  $59,479,568   $31,056,308 

 

The Company entered into a management agreement (the “Management Agreement”) with a third party to operate its cultivation facilities in California and Nevada (the “Cultivation Facilities”). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the “Purchase Option”). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of September 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three months ended September 24, 2022, the Company recorded sublease income under the Management Agreement. See “Note 16 – Other Operating Income” for further information.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE
3 Months Ended
Sep. 24, 2022
Disclosure Notes Payable Abstract  
NOTES PAYABLE

 

10. NOTES PAYABLE

 

Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.

 

As of September 24, 2022 and June 25, 2022, notes payable consist of the following:

 

           
   September 24,   June 25, 
   2022   2022 
Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.  $72,300,000   $72,300,000 
           
Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum.   66,819,991    97,162,001 
           
Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471.   2,057,207    2,057,207 
           
Other   15,691    15,691 
           
Total Notes Payable   141,192,889    171,534,899 
Less Unamortized Debt Issuance Costs and Loan Origination Fees   -    (158,079)
           
Net Amount  $141,192,889   $171,376,820 
Less Current Portion of Notes Payable   (66,294,249)   (97,003,922)
           
Notes Payable, Net of Current Portion  $74,898,640   $74,372,898 

 

A reconciliation of the beginning and ending balances of notes payable for the three months ended September 24, 2022 is as follows:

 

      
   September 24, 
   2022 
Balance at Beginning of Period  $171,376,820 
      
Paid-In-Kind Interest Capitalized   1,257,988 
Cash Payments   (31,599,999)
Accretion of Debt Discount Included in Discontinued Operations   158,079 
      
Balance at End of Period   141,192,889 
      
Less Current Portion of Notes Payable   (66,294,249)
      
Notes Payable, Net of Current Portion  $74,898,640 

 

Non-Revolving Senior Secured Term Loan Facility

 

In February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification required that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposed covenants in regards to strategic actions the Company would have to implement if unable to pay the Term Loans by the extended stated maturity date.

 

During the three months ended September 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $31,599,999 with proceeds from the sale. An additional $8,500,000 principal repayment will be made in 2023 upon receipt of the final installment payment from the sale of the Company’s Florida-based operations. The Facility and Term Loans remain in default as of September 24, 2022 as the principal balance matured on July 31, 2022 and August 1, 2022, respectively. As of September 24, 2022, the Company is in ongoing discussions with the Lenders.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
SENIOR SECURED CONVERTIBLE CREDIT FACILITY
3 Months Ended
Sep. 24, 2022
Debt Disclosure [Abstract]  
SENIOR SECURED CONVERTIBLE CREDIT FACILITY

 

11. SENIOR SECURED CONVERTIBLE CREDIT FACILITY

 

Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.

 

As of September 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following:

 

              
      September 24,   June 25, 
   Tranche  2022   2022 
Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  1A  $23,376,684   $22,880,556 
              
Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  1B   100,679,152    98,542,422 
              
Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  2   32,738,817    32,043,996 
              
Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  3   12,677,140    12,408,091 
              
Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  4   14,911,453    14,594,985 
              
Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   23,932,224    23,424,438 
              
Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  IA-1   3,346,889    3,275,857 
              
Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  IA-2   6,472,344    6,334,980 
              
Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   10,103,343    9,888,919 
              
Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   2,237,875    2,190,380 
              
Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   12,587,295    12,320,154 
              
Total Drawn on Senior Secured Convertible Credit Facility      243,063,216    237,904,778 
              
Less Unamortized Debt Discount      (104,317,146)   (105,899,115)
              
Senior Secured Convertible Credit Facility, Net     $138,746,070   $132,005,663 

 

A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the three months ended September 24, 2022 is as follows:

 

                                                        
   Tranche 1   Tranche 2   Tranche 3   Tranche 4   Incremental Advance - 1   Incremental Advance - 2   3rd Advance   Amendment
Fee Notes
   Restatement Fee Notes   2nd Restatement Fee Notes   TOTAL 
Balance as of June 25, 2022  $80,178,586   $21,218,356   $8,217,079   $1,051,827   $224,585   $433,598   $842,981   $15,512,409   $2,211,711   $2,114,531   $132,005,663 
                                                        
Paid-In-Kind Interest Capitalized   2,632,858    694,821    269,049    316,468    71,032    137,364    267,141    507,786    214,424    47,495    5,158,438 
Accretion of Debt Discount   988,849    260,580    100,902    -    -    -    -    190,486    37,165    3,987    1,581,969 
                                                        
Balance as of September 24, 2022  $83,800,293   $22,173,757   $8,587,030   $1,368,295   $295,617   $570,962   $1,110,122   $16,210,681   $2,463,300   $2,166,013   $138,746,070 

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS’ EQUITY
3 Months Ended
Sep. 24, 2022
Equity [Abstract]  
SHAREHOLDERS’ EQUITY

 

12. SHAREHOLDERS’ EQUITY

 

Issued and Outstanding

 

A reconciliation of the beginning and ending issued and outstanding shares is as follows:

 

               
   Subordinate
Voting Shares
   MM CAN USA
Class B
Redeemable Units
   MM Enterprises USA
Common Units
 
Balance as of June 25, 2022   1,301,423,950    65,066,106    725,016 
Redemption of MedMen Corp Redeemable Shares   259,814    (259,814)   - 
                
Balance as of September 24, 2022   1,301,683,764    64,806,292    725,016 

 

Non-Controlling Interests

 

Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of September 24, 2022 and June 25, 2022, the holders of the MM CAN USA Redeemable Shares represent approximately 4.74% and 4.76%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately 0.05% of the Company.

 

Variable Interest Entities

 

The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of Venice Caregiver Foundation, Inc., LAX Fund II Group, LLC, and Natures Cure, Inc. This information represents amounts before intercompany eliminations.

 

As of and for the three months ended September 24, 2022, the balances and activities attributable to the VIEs consist of the following:

 

                     
   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   TOTAL 
Current Assets  $1,180,136   $-   $24,602,018   $25,782,154 
Non-Current Assets   8,763,511    3,233,062    4,891,725    16,888,298 
                     
Total Assets  $9,943,647   $3,233,062   $29,493,743   $42,670,452 
                     
Current Liabilities  $10,477,448   $16,016,119   $8,510,967   $35,004,534 
Non-Current Liabilities   7,004,484    2,004,062    1,342,632    10,351,178 
                     
Total Liabilities  $17,481,932   $18,020,181   $9,853,599   $45,355,712 
                     
Non-Controlling Interest  $(7,538,285)  $(14,787,119)  $19,640,163   $(2,685,241)
                     
Revenues  $1,959,080   $-   $3,317,299   $5,276,379 
Net (Loss) Income Attributable to Non-Controlling Interest  $(494,845)  $(810,965)  $885,605   $(420,205)

 

As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:

 

   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   TOTAL 
Current Assets  $1,735,304   $1,067,636   $23,557,168   $26,360,108 
Non-Current Assets   10,073,880    3,379,412    4,973,459    18,426,751 
                     
Total Assets  $11,809,184   $4,447,048   $28,530,627   $44,786,859 
                     
Current Liabilities  $9,238,460   $16,238,249   $8,433,436   $33,910,145 
Non-Current Liabilities   9,614,164    2,184,953    1,342,633    13,141,750 
                     
Total Liabilities  $18,852,624   $18,423,202   $9,776,069   $47,051,895 
                     
Non-Controlling Interest  $(7,043,440)  $(13,976,154)  $18,754,558   $(2,265,036)
                     
Revenues  $8,732,449   $1,857   $16,157,388   $24,891,694 
Net (Loss) Income Attributable to Non-Controlling Interest  $(1,384,751)  $(4,868,632)  $7,190,809   $937,426 

 

The net change in the consolidated VIEs and other non-controlling interest are as follows for the three months ended September 24, 2022:

 

                          
   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   Other Non- Controlling Interests   TOTAL 
Balance as of June 25, 2022  $(7,043,440)  $(13,976,154)  $18,754,558   $(471,717,698)  $(473,982,734)
                          
Net (Loss) Income   (494,845)   (810,965)   885,605    307,893    (112,312)
                          
Balance as of September 24, 2022  $(7,538,285)  $(14,787,119)  $19,640,163   $(471,409,805)  $(474,095,046)

 

Le Cirque Rouge, LP (the “OP”) is a Delaware limited partnership that holds substantially all of the real estate assets owned by the Treehouse Real Estate Investment Trust (the “REIT”), conducts the REIT’s operations and is financed by the REIT. Under Accounting Standards Codification (“ASC”) Topic 810, “Consolidation” (“ASC Topic 810”), the OP was determined to be a variable interest entity in which the Company has an implicit variable interest based on the leasing relationship and arrangement with the REIT. However, the Company is not the primary beneficiary under ASC Topic 810. Accordingly, Le Cirque Rouge, LP is not consolidated as a variable interest entity within the Consolidated Financial Statements. As of and during the three months ended September 24, 2022, the Company continues to have a variable interest in the OP and did not provide any financial or other support to the REIT other than the completion of the sale and leaseback transactions and the REIT being a lessor on various leases as described in “Note 9 – Leases”.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION
3 Months Ended
Sep. 24, 2022
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION

 

13. SHARE-BASED COMPENSATION

 

The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock units (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative expenses. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, cancelled, expire unexercised, are settled in cash or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of a Compensation Committee. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after 5 or 10 years.

 

A summary of share-based compensation expense for the three months ended September 24, 2022 and September 25, 2021 is as follows:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Stock Options  $863,685   $1,216,447 
Stock Grants for Compensation   -    333,333 
Restricted Stock Grants   -    1,554,297 
           
Total Share-Based Compensation  $863,685   $3,104,077 

 

Stock Options

 

A reconciliation of the beginning and ending balance of stock options outstanding is as follows:

 

           
   Number of
Stock Options
   Weighted-Average
Exercise Price
 
Balance as of June 25, 2022   8,649,673   $1.35 
           
Forfeited and Expired   (205,354)  $(3.39)
           
Balance as of September 24, 2022   8,444,319   $1.39 
           
Stock Options Exercisable as of September 24, 2022   8,037,095   $1.27 

 

Long-Term Incentive Plan (“LTIP”) Units and LLC Redeemable Units

 

A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows:

 

              
            Weighted  
    LTIP Units   LLC   Average  
    Issued and   Redeemable   Grant Date  
    Outstanding   Units   Fair Value  
Balance as of June 25, 2022 and September 24, 2022    19,323,878    725,016   $ 0.52  

 

Restricted Stock Units

 

A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows:

 

               
   Issued and
Outstanding
   Vested (1)   Weighted-Average
Fair Value
 
Balance as of June 25, 2022   10,998,483    4,030,460   $0.20 
                
Forfeiture of Restricted Stock (2)   (1,405,788)   -   $(0.22)
Vesting of Restricted Stock   -    1,117,081   $0.22 
                
Balance as of September 24, 2022   9,592,695    5,147,541   $0.20 

 

 
(1) Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date.
(2) Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022.

 

Warrants

 

A reconciliation of the beginning and ending balance of warrants outstanding is as follows:

 

                      
    Number of Warrants Outstanding     
    Subordinate
Voting Shares
   MM CAN USA
Redeemable Shares
   TOTAL   Weighted-Average
Exercise Price
 
Balance as of June 25, 2022    352,704,355    97,430,456    450,134,811   $0.25 
                      
Expired    (2,677,535)   -    (2,677,535)  $(3.27)
                      
Balance as of September 24, 2022    350,026,820    97,430,456    447,457,276   $0.23 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOSS PER SHARE
3 Months Ended
Sep. 24, 2022
Earnings Per Share [Abstract]  
LOSS PER SHARE

 

14. LOSS PER SHARE

 

The following is a reconciliation for the calculation of basic and diluted loss per share for the three months ended September 24, 2022 and September 25, 2021:

 

          
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.  $(20,146,436)  $(40,883,537)
Net Income (Loss) from Discontinued Operations   24,306,649    (14,446,491)
           
Total Net Income (Loss)  $4,160,213   $(55,330,028)
           
Weighted-Average Shares Outstanding - Basic and Diluted   1,301,659,701    942,696,052 
           
Earnings (Loss) Per Share - Basic and Diluted:          
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.  $(0.02)  $(0.04)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.  $0.02   $(0.02)

 

Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, LTIP share units, warrants and share options is anti-dilutive.

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
GENERAL AND ADMINISTRATIVE EXPENSES
3 Months Ended
Sep. 24, 2022
General And Administrative Expenses  
GENERAL AND ADMINISTRATIVE EXPENSES

 

15. GENERAL AND ADMINISTRATIVE EXPENSES

 

During the three months ended September 24, 2022 and September 25, 2021, general and administrative expenses consisted of the following:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Salaries and Benefits  $6,858,048   $9,911,488 
Professional Fees   1,350,848    7,430,659 
Rent   3,627,925    4,754,883 
Licenses, Fees and Taxes   1,001,669    2,537,788 
Share-Based Compensation   863,685    1,642,853 
Deal Costs   429,272    1,637,587 
Other General and Administrative   3,714,670    4,733,976 
           
Total General and Administrative Expenses  $17,846,117   $32,649,234 

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
OTHER OPERATING (INCOME) EXPENSE
3 Months Ended
Sep. 24, 2022
Other Operating Income Expense  
OTHER OPERATING (INCOME) EXPENSE

 

16. OTHER OPERATING (INCOME) EXPENSE

 

During the three months ended September 24, 2022 and September 25, 2021, other operating (income) expense consisted of the following:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Loss on Disposals of Assets  $205,595   $15,146 
Restructuring and Reorganization Expense   423,793    2,378,675 
Gain on Settlement of Accounts Payable   (74,637)   (177,990)
Gain on Lease Terminations   (1,587,650)   - 
Other Income   (1,522,219)   (16,803)
           
Total Other Operating (Income) Expense  $(2,555,118)  $2,199,028 

 

During the three months ended September 24, 2022, the Company recorded $1,521,650 of sublease income related to the cultivation facilities in California and Nevada as a component of Other Operating Income in the Consolidated Statements of Operations.

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES
3 Months Ended
Sep. 24, 2022
Income Tax Disclosure [Abstract]  
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES

 

17. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES

 

The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended September 24, 2022 and September 25, 2021:

 

          
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Loss from Continuing Operations Before Provision for Income Taxes  $(18,065,206)  $(26,471,632)
Income Tax Expense   (2,193,542)   (19,691,908)
Effective Tax Rate   -12%   -74%

 

We have historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate (“AETR”) for the full fiscal year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. For the three months ended September 25, 2021, we determined we could no longer reliably estimate income taxes utilizing an AETR. The AETR estimate is highly sensitive to estimates of ordinary income (loss) and permanent differences such that minor fluctuations in these estimates could result in significant fluctuations of the Company’s AETR. Accordingly, we used our actual year-to-date effective tax rate to calculate income taxes for the three months ended September 25, 2022.

 

As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Massachusetts state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns.

 

The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized.

 

The effective tax rate for the three months ended September 24, 2022 is different from the three months ended September 25, 2021, respectively, primarily due to the Company’s income and related 280E expenditures. The Company’s non-deductible expenses related to IRC Section 280E limitations have remained relatively consistent.

 

The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and in Canada. The Company is generally subject to audit by taxing authorities in various U.S., state, and in foreign jurisdictions for fiscal years 2014 through the current fiscal year. As of September 24, 2022, the Company had $18,781,424 of unrecognized tax benefits, all of which would reduce income tax expense and the effective tax rate if recognized. During the three months ended September 24, 2022, the Company recognized a net discrete tax expense of $407,993 primarily related on interest of past liabilities. During the next twelve months, the Company does not estimate any material reduction in its unrecognized tax benefits.

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Sep. 24, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

 

18. COMMITMENTS AND CONTINGENCIES

 

Contingencies

 

The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of September 24, 2022 and June 25, 2022, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.

 

Claims and Litigation

 

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 24, 2022, there were no pending or threatening lawsuits that could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. As such, no accrual has been made in the Condensed Consolidated Financial Statements relating to claims and litigations. As of September 24, 2022, there are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest.

 

In March 2020, litigation was filed against the Company in the Superior Court of Arizona, Maricopa County, related to a purchase agreement for a previous acquisition. The Superior Court of Arizona, Maricopa County granted summary judgement in favor of the Company on all counts in July 2022. The Company is currently in process of recovering certain fees and costs associated with the lawsuit from the plaintiffs. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements.

 

In April 2020, a complaint was filed against the Company in Los Angeles Superior Court related to a contemplated acquisition in which the plaintiffs are seeking damages for alleged breach of contract and breach of implied covenant of good faith and fair dealing seeking declaratory relief and specific performance. The Company has filed counterclaims including for breach of contract, breach of promissory note, unjust enrichment and declaratory relief. The Company believes the likelihood of a loss contingency is remote. As such, no amount has been accrued in the financial statements.

 

In May 2020, litigation was filed against the Company related to a purchase agreement and secured promissory note for a previous acquisition. The Company is currently defending against this lawsuit, which claims for breach of contract, breach of implied covenant of good faith and fair dealing, common law fraud and securities fraud. The plaintiffs are seeking damages for such claims in which the amount is currently not reasonably estimable. In response, the Company filed a counterclaim and is seeking entitlement to proceeds of the sale, net of amounts owed under the secured promissory note. The plaintiffs filed an appeal to the ruling on the entitlement of proceeds in excess of the secured promissory note which was dismissed. The additionally claims and counterclaims are currently in dispute. Any loss recoveries related to the Company’s counterclaim have not been recorded. In addition, net proceeds resulting from the sale was not recognized as a receivable as the amount is not reasonably estimable.

 

In September 2020 and May 2020, legal disputes were filed against the Company related to the separation of former officers in which the severance issued is currently being disputed. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

In November 2020, entities affiliated with former officers of the Company initiated arbitration against a subsidiary of the Company in Los Angeles, California asserting breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and unjust enrichment. The claimants are generally seeking damages and compensatory damages according to proof, including lost earnings and other benefits, past and future, interest on lost earnings and benefits, reasonable attorney’s fees, and such other and further relief as the court deems proper. The Company asserted counterclaims, including for breach of the same management agreements. The arbitration is currently set for hearing in December 2022. The litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

In October 2021, a suit for premises liability and negligence seeking unspecified damages for pain and suffering, disability, mental and emotional distress, and loss of earnings was filed against the Company in Los Angeles Superior Court. The matter is in the process of being litigated. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

The Company is the defendant in several complaints filed by various of its landlords seeking rents and damages under leases. In 2020 a complaint was filed in Cook County Circuit Court, Illinois against the Company by a landlord claiming the Company had failed to meet its obligations to apply effort to obtain a retail cannabis license at a property and seeking rents and damages. The litigation is currently in the discovery phase. If the litigation is not settled or resolved, trial will likely take place During the fiscal year ended 2023. In July 2022, a complaint was filed against the Company in the United States District Court for the Southern District of New York by a landlord seeking damages under a lease on real estate located in Illinois. The Company is required to file an answer to the complaint by September 2022. Prior attempts to resolve the lease dispute with this landlord have failed. In June 2022, a complaint was filed against the Company by the Company’s landlord at its cultivation center in Utica, New York, related to an agreement to purchase land next to the cultivation center, which land was also owned by the landlord. Plaintiff seeks to enforce a land purchase agreement and seeks damages. In April 2022, the landlord at the Company’s dispensary location in Tampa, Florida, filed suit seeking damages under a lease, shortly after the Company announced its plans to sell its Florida business. The Company retained this lease and litigation following the sale of the Florida business and the litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS
3 Months Ended
Sep. 24, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

 

19. RELATED PARTY TRANSACTIONS

 

The Company’s Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.

 

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
SEGMENT INFORMATION
3 Months Ended
Sep. 24, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION

 

20. SEGMENT INFORMATION

 

The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker manages the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUE
3 Months Ended
Sep. 24, 2022
Revenue from Contract with Customer [Abstract]  
REVENUE

 

21. REVENUE

 

While the Company operates in one segment as disclosed in “Note 20 – Segment Information”, the Company is disaggregating its revenue by geographical region in accordance with ASC 606, “Revenue from Contracts with Customers”. Revenue by state for the periods presented are as follows:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
California  $19,928,985   $24,626,555 
Nevada   2,997,469    4,079,151 
Illinois   3,542,071    4,328,602 
Arizona   2,794,648    3,701,596 
Massachusetts   780,875    - 
           
Revenue from Continuing Operations  $30,044,048   $36,735,904 
           
Revenue from Discontinued Operations   3,629,641    7,340,099 
           
Total Revenue  $33,673,689   $44,076,003 

 

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISCONTINUED OPERATIONS
3 Months Ended
Sep. 24, 2022
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS

 

22. DISCONTINUED OPERATIONS

 

On February 28, 2022, MME Florida LLC and its parent, MM Enterprises USA, LLC, a wholly-owned subsidiary of the Company entered into an Asset Purchase Agreement (the “Agreement”) with Green Sentry Holdings, LLC, (“Buyer”) for the sale of substantially all of the Company’s Florida-based assets, including its license, dispensaries, inventory and cultivation operations, and assumption of certain liabilities.

 

On August 22, 2022, the Company closed the transaction at the final sales price of $67,000,000, which comprised of $63,000,000 in cash and $4,000,000 in liabilities to be assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022 and is required to make one additional installment payment of $11,500,000 on or before March 15, 2023. During the three months ended September 24, 2022, $31,599,999 of the cash proceeds was used to repay the Senior Secured Term Loan Facility and the Company received net cash proceeds of $19,558,947. As of September 24, 2022, the final cash payment of $11,500,000 remains due and payable. Accordingly, the Company recognized a gain on sale of assets of $31,719,833 included in Net Income from Discontinued Operations for the three months ended September 24, 2022. All profit or loss relating to the Florida operations were eliminated from the Company’s continuing operations and are shown as a single line item in the Consolidated Statements of Operations.

 

The operating results of the discontinued operations are summarized as follows:

 

           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Revenue  $3,629,641   $7,340,099 
Cost of Goods Sold   2,103,298    5,227,553 
           
Gross Profit   1,526,343    2,112,546 
           
Expenses:          
General and Administrative   4,983,995    5,617,595 
Sales and Marketing   43,311    103,803 
Depreciation and Amortization   872,895    1,221,759 
Impairment Expense   (78,433)   - 
Gain on Disposal of Assets and Other Income   (35,659,761)   (597,591)
           
Total (Income) Expenses   (29,837,993)   6,345,566 
           
Income (Loss) from Discontinued Operations   31,364,336    (4,233,020)
           
Other Expense:          
Interest Expense   3,761,758    4,616,829 
Accretion of Debt Discount and Loan Origination Fees   158,079    3,540,908 
           
Total Other Expense   3,919,837    8,157,737 
           
Income (Loss) from Discontinued Operations Before Provision for Income Taxes   27,444,499    (12,390,757)
Provision for Income Tax Benefit (Expense)   (3,137,850)   (2,055,734)
           
Net Income (Loss) from Discontinued Operations  $24,306,649   $(14,446,491)

 

The carrying amounts of assets and liabilities in the disposal group are summarized as follows:

 

           
   September 24,   June 25, 
   2022   2022 
Carrying Amounts of the Assets Included in Discontinued Operations:          
           
Cash and Cash Equivalents  $355,378   $1,124,076 
Restricted Cash   5,280    5,280 
Accounts Receivable and Prepaid Expenses   95,048    334,621 
Inventory   2,915,345    6,866,833 
           
TOTAL CURRENT ASSETS (1)          
           
Property and Equipment, Net   9,713,565    41,273,597 
Operating Lease Right-of-Use Assets   19,780,991    31,543,058 
Intangible Assets, Net   10,582,559    40,799,146 
Other Assets   458,383    1,181,795 
           
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE  $43,906,549   $123,128,406 
           
Carrying Amounts of the Liabilities Included in Discontinued Operations:          
           
Accounts Payable and Accrued Liabilities  $2,640,664   $6,295,745 
Income Taxes Payable   (27,904)   1,671,380 
Other Current Liabilities   -    89,069 
Current Portion of Operating Lease Liabilities   2,605,317    4,209,512 
Current Portion of Finance Lease Liabilities   -    174,000 
           
TOTAL CURRENT LIABILITIES (1)          
           
Operating Lease Liabilities, Net of Current Portion   19,067,840    56,410,071 
Deferred Tax Liabilities   6,250,511    6,097,597 
Notes Payable   -    11,100,000 
           
TOTAL NON-CURRENT LIABILITIES (1)          
           
TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE  $30,536,428   $86,047,374 

 

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS
3 Months Ended
Sep. 24, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

 

23. SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date these Condensed Consolidated Financial Statements were issued and has concluded that no subsequent events have occurred that would require recognition in the Condensed Consolidated Financial Statements or disclosure in the Notes to the Condensed Consolidated Financial Statements.

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Sep. 24, 2022
Accounting Policies [Abstract]  
Basis of Preparation

Basis of Preparation

 

The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.

 

In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

 

The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”).

 

Going Concern

Going Concern

 

As of September 24, 2022, the Company had cash and cash equivalents of $21.1 million and working capital deficit of $134.9 million. The Company has incurred net losses from continuing operations of $20.3 million and $46.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.

 

The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.

 

COVID-19

COVID-19

 

In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. During the current reporting period, aspects of the Company’s business continue to be affected by impacts of the COVID-19 pandemic, as the Company’s retail stores strive to operate within the local rules and regulations of the states and localities in which the Company operates. While the Company saw continued recovery from the impacts of the COVID 19-pandemic during the first quarter of 2023, the Company continues to closely monitor the potential impact that a resurgence of the COVID-19 virus, including as a result of the emergence of new variants and strains, could have on the Company’s operations. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liabilities. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.

 

Basis of Consolidation

Basis of Consolidation

 

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of September 24, 2022.

 

Significant Accounting Policies

Significant Accounting Policies

 

The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended September 24, 2022.

 

Earnings (Loss) per Share

Earnings (Loss) per Share

 

The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.

 

Reclassifications

Reclassifications

 

Certain amounts reported in the Notes to the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. These non-material corrections and reclassifications impacted leasehold improvements and furniture and fixtures in the amount of approximately $940,000 between the categories. Customer relationships and accumulated amortization of customer relationships in the amount of $1,440,000 between the categories were reclassed between the two categories. Fully amortized management agreements and its related accumulated amortization in the amount of $964,000 were also reclassed. Non-controlling interest and accumulated deficit in the amount of approximately $3,662,000 have been reclassed between the two categories. In addition, the Company reclassified short-term and long-term operating lease liabilities between the two categories in the amount of approximately $6,825,000. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections.

 

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.

 

Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

 

In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50)” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

 

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVENTORY (Tables)
3 Months Ended
Sep. 24, 2022
Inventory Disclosure [Abstract]  
Schedule of inventories
           
   September 24,   June 25, 
   2022   2022 
Raw Materials  $612,901   $521,777 
Work-in-Process   1,142,397    671,541 
Finished Goods   7,362,511    8,817,413 
           
Total Inventory  $9,117,809   $10,010,731 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
ASSETS HELD FOR SALE (Tables)
3 Months Ended
Sep. 24, 2022
Assets Held For Sale  
Schedule of asset held for sale
               
   Discontinued
Operations (1)
   Other
Assets
   TOTAL 
Balance as of June 25, 2022  $123,128,406   $30,345   $123,158,751 
Ongoing Activities   (47,881,618)   248,324    (47,633,294)
Proceeds from Sale   (67,000,000)   -    (67,000,000)
Gain on Sale of Assets Held for Sale   35,659,761    -    35,659,761 
                
Balance as of September 24, 2022  $43,906,549   $278,669   $44,185,218 

 

 
(1) See “Note 22 – Discontinued Operations” for further information.
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Tables)
3 Months Ended
Sep. 24, 2022
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
          
   September 24,   June 25, 
   2022   2022 
Land and Buildings  $29,933,999   $29,933,999 
Capital Leases   5,318,516    5,315,625 
Furniture and Fixtures   8,325,228    8,776,994 
Leasehold Improvements   33,625,893    33,069,524 
Equipment and Software   16,316,334    16,897,649 
Construction in Progress   4,528,762    6,828,923 
           
Total Property and Equipment   98,048,732    100,822,714 
           
Less Accumulated Depreciation   (38,082,797)   (36,714,922)
           
Property and Equipment, Net  $59,965,935   $64,107,792 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS (Tables)
3 Months Ended
Sep. 24, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible assets
           
   September 24,   June 25, 
   2022   2022 
Dispensary Licenses  $49,253,452   $49,253,452 
Customer Relationships   16,409,600    16,409,600 
Capitalized Software   7,413,470    7,413,470 
Intellectual Property   4,016,597    4,016,597 
           
Total Intangible Assets   77,093,119    77,093,119 
           
Dispensary Licenses   (17,477,268)   (16,876,912)
Customer Relationships   (16,589,651)   (15,870,284)
Capitalized Software   (4,681,748)   (4,413,974)
Intellectual Property   (4,287,401)   (4,185,835)
           
Less Accumulated Amortization   (43,036,068)   (41,347,005)
           
Intangible Assets, Net  $34,057,051   $35,746,114 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
3 Months Ended
Sep. 24, 2022
Payables and Accruals [Abstract]  
Schedule of accounts payable and accrued liabilities
          
   September 24,   June 25, 
   2022   2022 
Accounts Payable  $19,078,177   $14,627,746 
Accrued Liabilities   7,784,119    10,031,194 
Accrued Inventory   3,129,868    5,868,831 
Accrued Payroll   2,081,284    1,682,517 
Local & State Taxes Payable   3,281,687    6,695,532 
           
Total Accounts Payable and Accrued Liabilities  $35,355,136   $38,905,818 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Tables)
3 Months Ended
Sep. 24, 2022
Disclosure Derivative Liabilities Abstract  
Schedule of reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities
      
   September 24, 
   2022 
Balance at Beginning of Period  $6,749,563 
      
Change in Fair Value of Derivative Liabilities   805,590 
      
Balance at End of Period  $7,555,153 
Schedule of assumptions to measure fair value
     
   Top-Up
Provision
 
Average Stock Price  $0.04 
Weighted-Average Probability   50.00%
Term (in Years)   5.00 
Expected Stock Price Volatility   96.68%
Schedule of warrant issued
              
   Number of
Warrants
   Exercise
Price
   Expiration
Date
 
March 2021 Private Placement (1)   50,000,000   C$0.50   March 27, 2024  
              
   50,000,000          

 

 
(1) See “Note 12 – Shareholders’ Equity” for further information.
Schedule of assumptions to measure fair value
     
Expected Stock Price Volatility   106.25%
Risk-Free Annual Interest Rate   2.51%
Expected Life (in Years)   0.50 
Share Price  $0.04 
Exercise Price  $0.37 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES (Tables)
3 Months Ended
Sep. 24, 2022
Leases [Abstract]  
Schedule of lease cost
           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Finance Lease Cost:          
Amortization of Finance Lease Right-of-Use Assets  $347,406   $283,406 
Interest on Lease Liabilities   1,804,507    1,784,541 
Operating Lease Cost   3,453,863    6,595,652 
Sublease Income (1)   (1,521,693)   - 
           
Total Lease Expenses  $5,605,776   $8,663,599 
           
Cash Paid for Amounts Included in the Measurement of Lease Liabilities:          
Financing Cash Flows from Finance Leases  $2,484   $959 
Operating Cash Flows from Operating Leases  $1,026,792   $3,478,891 

 

 
(1) See “Note 16 – Other Operating Income” for further information. 

 

The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of September 24, 2022 and June 25, 2022, is as follows:

 

   September 24,   June 25, 
   2022   2022 
Weighted-Average Remaining Lease Term (Years) - Finance Leases   47    46 
Weighted-Average Remaining Lease Term (Years) - Operating Leases   7    8 
Weighted-Average Discount Rate - Finance Leases   24.78%   24.33%
Weighted-Average Discount Rate - Operating Leases   15.96%   18.70%
Schedule of future leases payments
           
Fiscal Year Ending  Operating
Leases
   Finance
Leases
 
July 1, 2023 (remaining)  $9,155,365   $4,387,279 
June 29, 2024   16,183,010    10,961,495 
June 28, 2025   25,224,922    14,020,131 
June 27, 2026   12,675,441    7,300,368 
June 26, 2027   12,716,234    7,519,379 
Thereafter   20,832,425    1,054,354,990 
           
Total Lease Payments   96,787,396    1,098,543,643 
Less Interest   (37,307,828)   (1,067,487,335)
           
Lease Liability Recognized  $59,479,568   $31,056,308 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE (Tables)
3 Months Ended
Sep. 24, 2022
Disclosure Notes Payable Abstract  
Schedule of notes payable
           
   September 24,   June 25, 
   2022   2022 
Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.  $72,300,000   $72,300,000 
           
Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum.   66,819,991    97,162,001 
           
Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471.   2,057,207    2,057,207 
           
Other   15,691    15,691 
           
Total Notes Payable   141,192,889    171,534,899 
Less Unamortized Debt Issuance Costs and Loan Origination Fees   -    (158,079)
           
Net Amount  $141,192,889   $171,376,820 
Less Current Portion of Notes Payable   (66,294,249)   (97,003,922)
           
Notes Payable, Net of Current Portion  $74,898,640   $74,372,898 
Schedule of Reconciliation of Notes payable
      
   September 24, 
   2022 
Balance at Beginning of Period  $171,376,820 
      
Paid-In-Kind Interest Capitalized   1,257,988 
Cash Payments   (31,599,999)
Accretion of Debt Discount Included in Discontinued Operations   158,079 
      
Balance at End of Period   141,192,889 
      
Less Current Portion of Notes Payable   (66,294,249)
      
Notes Payable, Net of Current Portion  $74,898,640 
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables)
3 Months Ended
Sep. 24, 2022
Debt Disclosure [Abstract]  
Schedule of senior secured convertible credit facility
              
      September 24,   June 25, 
   Tranche  2022   2022 
Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  1A  $23,376,684   $22,880,556 
              
Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  1B   100,679,152    98,542,422 
              
Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  2   32,738,817    32,043,996 
              
Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  3   12,677,140    12,408,091 
              
Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  4   14,911,453    14,594,985 
              
Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   23,932,224    23,424,438 
              
Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  IA-1   3,346,889    3,275,857 
              
Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  IA-2   6,472,344    6,334,980 
              
Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   10,103,343    9,888,919 
              
Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   2,237,875    2,190,380 
              
Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.  -   12,587,295    12,320,154 
              
Total Drawn on Senior Secured Convertible Credit Facility      243,063,216    237,904,778 
              
Less Unamortized Debt Discount      (104,317,146)   (105,899,115)
              
Senior Secured Convertible Credit Facility, Net     $138,746,070   $132,005,663 
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS’ EQUITY (Tables)
3 Months Ended
Sep. 24, 2022
Equity [Abstract]  
Schedule of Shares issued and outstanding
               
   Subordinate
Voting Shares
   MM CAN USA
Class B
Redeemable Units
   MM Enterprises USA
Common Units
 
Balance as of June 25, 2022   1,301,423,950    65,066,106    725,016 
Redemption of MedMen Corp Redeemable Shares   259,814    (259,814)   - 
                
Balance as of September 24, 2022   1,301,683,764    64,806,292    725,016 
Schedule of VIE
                     
   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   TOTAL 
Current Assets  $1,180,136   $-   $24,602,018   $25,782,154 
Non-Current Assets   8,763,511    3,233,062    4,891,725    16,888,298 
                     
Total Assets  $9,943,647   $3,233,062   $29,493,743   $42,670,452 
                     
Current Liabilities  $10,477,448   $16,016,119   $8,510,967   $35,004,534 
Non-Current Liabilities   7,004,484    2,004,062    1,342,632    10,351,178 
                     
Total Liabilities  $17,481,932   $18,020,181   $9,853,599   $45,355,712 
                     
Non-Controlling Interest  $(7,538,285)  $(14,787,119)  $19,640,163   $(2,685,241)
                     
Revenues  $1,959,080   $-   $3,317,299   $5,276,379 
Net (Loss) Income Attributable to Non-Controlling Interest  $(494,845)  $(810,965)  $885,605   $(420,205)

 

As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:

 

   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   TOTAL 
Current Assets  $1,735,304   $1,067,636   $23,557,168   $26,360,108 
Non-Current Assets   10,073,880    3,379,412    4,973,459    18,426,751 
                     
Total Assets  $11,809,184   $4,447,048   $28,530,627   $44,786,859 
                     
Current Liabilities  $9,238,460   $16,238,249   $8,433,436   $33,910,145 
Non-Current Liabilities   9,614,164    2,184,953    1,342,633    13,141,750 
                     
Total Liabilities  $18,852,624   $18,423,202   $9,776,069   $47,051,895 
                     
Non-Controlling Interest  $(7,043,440)  $(13,976,154)  $18,754,558   $(2,265,036)
                     
Revenues  $8,732,449   $1,857   $16,157,388   $24,891,694 
Net (Loss) Income Attributable to Non-Controlling Interest  $(1,384,751)  $(4,868,632)  $7,190,809   $937,426 
Schedule of other non-controlling interest
                          
   Venice Caregivers Foundation, Inc.   LAX Fund II Group, LLC   Natures Cure, Inc.   Other Non- Controlling Interests   TOTAL 
Balance as of June 25, 2022  $(7,043,440)  $(13,976,154)  $18,754,558   $(471,717,698)  $(473,982,734)
                          
Net (Loss) Income   (494,845)   (810,965)   885,605    307,893    (112,312)
                          
Balance as of September 24, 2022  $(7,538,285)  $(14,787,119)  $19,640,163   $(471,409,805)  $(474,095,046)
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Tables)
3 Months Ended
Sep. 24, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based compensation expense
           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Stock Options  $863,685   $1,216,447 
Stock Grants for Compensation   -    333,333 
Restricted Stock Grants   -    1,554,297 
           
Total Share-Based Compensation  $863,685   $3,104,077 
Schedule of stock options
           
   Number of
Stock Options
   Weighted-Average
Exercise Price
 
Balance as of June 25, 2022   8,649,673   $1.35 
           
Forfeited and Expired   (205,354)  $(3.39)
           
Balance as of September 24, 2022   8,444,319   $1.39 
           
Stock Options Exercisable as of September 24, 2022   8,037,095   $1.27 
Schedule of LTIP Units and LLC Redeemable Units
              
            Weighted  
    LTIP Units   LLC   Average  
    Issued and   Redeemable   Grant Date  
    Outstanding   Units   Fair Value  
Balance as of June 25, 2022 and September 24, 2022    19,323,878    725,016   $ 0.52  
Schedule of Restricted Stock Grants
               
   Issued and
Outstanding
   Vested (1)   Weighted-Average
Fair Value
 
Balance as of June 25, 2022   10,998,483    4,030,460   $0.20 
                
Forfeiture of Restricted Stock (2)   (1,405,788)   -   $(0.22)
Vesting of Restricted Stock   -    1,117,081   $0.22 
                
Balance as of September 24, 2022   9,592,695    5,147,541   $0.20 

 

 
(1) Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date.
(2) Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022.
Schedule of Warrants
                      
    Number of Warrants Outstanding     
    Subordinate
Voting Shares
   MM CAN USA
Redeemable Shares
   TOTAL   Weighted-Average
Exercise Price
 
Balance as of June 25, 2022    352,704,355    97,430,456    450,134,811   $0.25 
                      
Expired    (2,677,535)   -    (2,677,535)  $(3.27)
                      
Balance as of September 24, 2022    350,026,820    97,430,456    447,457,276   $0.23 
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOSS PER SHARE (Tables)
3 Months Ended
Sep. 24, 2022
Earnings Per Share [Abstract]  
Schedule of basic and diluted loss per share
          
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.  $(20,146,436)  $(40,883,537)
Net Income (Loss) from Discontinued Operations   24,306,649    (14,446,491)
           
Total Net Income (Loss)  $4,160,213   $(55,330,028)
           
Weighted-Average Shares Outstanding - Basic and Diluted   1,301,659,701    942,696,052 
           
Earnings (Loss) Per Share - Basic and Diluted:          
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.  $(0.02)  $(0.04)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.  $0.02   $(0.02)
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
GENERAL AND ADMINISTRATIVE EXPENSES (Tables)
3 Months Ended
Sep. 24, 2022
General And Administrative Expenses  
Schedule of general and administrative expenses
           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Salaries and Benefits  $6,858,048   $9,911,488 
Professional Fees   1,350,848    7,430,659 
Rent   3,627,925    4,754,883 
Licenses, Fees and Taxes   1,001,669    2,537,788 
Share-Based Compensation   863,685    1,642,853 
Deal Costs   429,272    1,637,587 
Other General and Administrative   3,714,670    4,733,976 
           
Total General and Administrative Expenses  $17,846,117   $32,649,234 
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
OTHER OPERATING (INCOME) EXPENSE (Tables)
3 Months Ended
Sep. 24, 2022
Other Operating Income Expense  
Schedule of other operating expenses
           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Loss on Disposals of Assets  $205,595   $15,146 
Restructuring and Reorganization Expense   423,793    2,378,675 
Gain on Settlement of Accounts Payable   (74,637)   (177,990)
Gain on Lease Terminations   (1,587,650)   - 
Other Income   (1,522,219)   (16,803)
           
Total Other Operating (Income) Expense  $(2,555,118)  $2,199,028 
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables)
3 Months Ended
Sep. 24, 2022
Income Tax Disclosure [Abstract]  
Schedule of income tax expense and effective tax rates
          
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Loss from Continuing Operations Before Provision for Income Taxes  $(18,065,206)  $(26,471,632)
Income Tax Expense   (2,193,542)   (19,691,908)
Effective Tax Rate   -12%   -74%
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUE (Tables)
3 Months Ended
Sep. 24, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of revenue
           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
California  $19,928,985   $24,626,555 
Nevada   2,997,469    4,079,151 
Illinois   3,542,071    4,328,602 
Arizona   2,794,648    3,701,596 
Massachusetts   780,875    - 
           
Revenue from Continuing Operations  $30,044,048   $36,735,904 
           
Revenue from Discontinued Operations   3,629,641    7,340,099 
           
Total Revenue  $33,673,689   $44,076,003 

 

XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISCONTINUED OPERATIONS (Tables)
3 Months Ended
Sep. 24, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of net operating loss of discontinued operation
           
   Three Months Ended 
   September 24,   September 25, 
   2022   2021 
Revenue  $3,629,641   $7,340,099 
Cost of Goods Sold   2,103,298    5,227,553 
           
Gross Profit   1,526,343    2,112,546 
           
Expenses:          
General and Administrative   4,983,995    5,617,595 
Sales and Marketing   43,311    103,803 
Depreciation and Amortization   872,895    1,221,759 
Impairment Expense   (78,433)   - 
Gain on Disposal of Assets and Other Income   (35,659,761)   (597,591)
           
Total (Income) Expenses   (29,837,993)   6,345,566 
           
Income (Loss) from Discontinued Operations   31,364,336    (4,233,020)
           
Other Expense:          
Interest Expense   3,761,758    4,616,829 
Accretion of Debt Discount and Loan Origination Fees   158,079    3,540,908 
           
Total Other Expense   3,919,837    8,157,737 
           
Income (Loss) from Discontinued Operations Before Provision for Income Taxes   27,444,499    (12,390,757)
Provision for Income Tax Benefit (Expense)   (3,137,850)   (2,055,734)
           
Net Income (Loss) from Discontinued Operations  $24,306,649   $(14,446,491)
Schedule of assets included in discontinued operation
           
   September 24,   June 25, 
   2022   2022 
Carrying Amounts of the Assets Included in Discontinued Operations:          
           
Cash and Cash Equivalents  $355,378   $1,124,076 
Restricted Cash   5,280    5,280 
Accounts Receivable and Prepaid Expenses   95,048    334,621 
Inventory   2,915,345    6,866,833 
           
TOTAL CURRENT ASSETS (1)          
           
Property and Equipment, Net   9,713,565    41,273,597 
Operating Lease Right-of-Use Assets   19,780,991    31,543,058 
Intangible Assets, Net   10,582,559    40,799,146 
Other Assets   458,383    1,181,795 
           
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE  $43,906,549   $123,128,406 
           
Carrying Amounts of the Liabilities Included in Discontinued Operations:          
           
Accounts Payable and Accrued Liabilities  $2,640,664   $6,295,745 
Income Taxes Payable   (27,904)   1,671,380 
Other Current Liabilities   -    89,069 
Current Portion of Operating Lease Liabilities   2,605,317    4,209,512 
Current Portion of Finance Lease Liabilities   -    174,000 
           
TOTAL CURRENT LIABILITIES (1)          
           
Operating Lease Liabilities, Net of Current Portion   19,067,840    56,410,071 
Deferred Tax Liabilities   6,250,511    6,097,597 
Notes Payable   -    11,100,000 
           
TOTAL NON-CURRENT LIABILITIES (1)          
           
TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE  $30,536,428   $86,047,374 
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jun. 25, 2022
Sep. 24, 2022
Sep. 25, 2021
Accounting Policies [Abstract]      
Cash and cash equivalents   $ 21,100,000  
Net working capital deficit   134,900,000  
Losses from continuing operations   $ 20,300,000 $ 46,200,000
Reclassifications impacted leasehold improvements and furniture and fixtures $ 940,000    
Reclassifications impacted customer relationships and accumulated amortization 1,440,000    
Reclassifications impacted accumulated amortization 964,000    
Reclassifications impacted Non-controlling interest and accumulated deficit 3,662,000    
Reclassifications impacted Short-term and long-term operating lease liabilities $ 6,825,000    
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVENTORY (Details) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Inventory Disclosure [Abstract]    
Raw Materials $ 612,901 $ 521,777
Work-in-Process 1,142,397 671,541
Finished Goods 7,362,511 8,817,413
Total Inventory $ 9,117,809 $ 10,010,731
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVENTORY (Details Narrative)
3 Months Ended
Sep. 25, 2021
USD ($)
Inventory Disclosure [Abstract]  
Other Asset Impairment Charges $ 864,314
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
ASSETS HELD FOR SALE (Details)
3 Months Ended
Sep. 24, 2022
USD ($)
Subsidiary, Sale of Stock [Line Items]  
Balance at Beginning of Period $ 123,158,751
Balance at End of Period 44,185,218
Discontinued Operations [Member]  
Subsidiary, Sale of Stock [Line Items]  
Balance at Beginning of Period 123,128,406 [1]
Ongoing Activities (47,881,618) [1]
Proceeds from Sale (67,000,000) [1]
Gain on Sale of Assets Held for Sale 35,659,761 [1]
Balance at End of Period 43,906,549 [1]
Other Asset [Member]  
Subsidiary, Sale of Stock [Line Items]  
Balance at Beginning of Period 30,345
Ongoing Activities 248,324
Proceeds from Sale
Gain on Sale of Assets Held for Sale
Balance at End of Period 278,669
Total [Member]  
Subsidiary, Sale of Stock [Line Items]  
Balance at Beginning of Period 123,158,751
Ongoing Activities (47,633,294)
Proceeds from Sale (67,000,000)
Gain on Sale of Assets Held for Sale 35,659,761
Balance at End of Period $ 44,185,218
[1] See “Note 22 – Discontinued Operations” for further information.
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Property, Plant and Equipment [Abstract]    
Land and Buildings $ 29,933,999 $ 29,933,999
Capital Leases 5,318,516 5,315,625
Furniture and Fixtures 8,325,228 8,776,994
Leasehold Improvements 33,625,893 33,069,524
Equipment and Software 16,316,334 16,897,649
Construction in Progress 4,528,762 6,828,923
Total Property and Equipment 98,048,732 100,822,714
Less Accumulated Depreciation (38,082,797) (36,714,922)
Property and Equipment, Net $ 59,965,935 $ 64,107,792
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Property, Plant and Equipment [Abstract]    
Other Depreciation and Amortization $ 2,258,354 $ 3,031,080
Cost of Goods and Services Sold 24,950 433,300
Depreciation recognized for capital leases 347,406 $ 283,406
Borrowing costs $ 375,241  
Average capitalization rate 11.95%  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS (Details) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Finite-Lived Intangible Assets [Line Items]    
Total Intangible Assets $ 77,093,119 $ 77,093,119
Less Accumulated Amortization (43,036,068) (41,347,005)
Intangible Assets, Net 34,057,051 35,746,114
Capitalized Software [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total Intangible Assets 7,413,470 7,413,470
Less Accumulated Amortization (4,681,748) (4,413,974)
Customer Relationship [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total Intangible Assets 16,409,600 16,409,600
Less Accumulated Amortization (16,589,651) (15,870,284)
Intellectual Property [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total Intangible Assets 4,016,597 4,016,597
Less Accumulated Amortization (4,287,401) (4,185,835)
Dispensary License [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total Intangible Assets 49,253,452 49,253,452
Less Accumulated Amortization $ (17,477,268) $ (16,876,912)
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS (Details Narrative) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Depreciation, Depletion and Amortization, Nonproduction $ 1,713,119 $ 3,225,837
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Extinguishment of Debt [Line Items]    
Total Accounts Payable and Accrued Liabilities $ 35,355,136 $ 38,905,818
Accounts Payable and Accrued Liabilities [Member]    
Extinguishment of Debt [Line Items]    
Accounts Payable 19,078,177 14,627,746
Accrued Liabilities 7,784,119 10,031,194
Accrued Inventory 3,129,868 5,868,831
Accrued Payroll 2,081,284 1,682,517
Local & State Taxes Payable 3,281,687 6,695,532
Total Accounts Payable and Accrued Liabilities $ 35,355,136 $ 38,905,818
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Change in Fair Value of Derivative Liabilities $ 805,590 $ (2,105,415)
Derivative Liabilities One [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Balance at Beginning of Period 6,749,563  
Change in Fair Value of Derivative Liabilities 805,590  
Balance at End of Period $ 7,555,153  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Details 1)
3 Months Ended
Sep. 24, 2022
$ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Share Price $ 0.04
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 106.25%
Top Up Provision [Member]  
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Share Price $ 0.04
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 50.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 96.68%
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Details 2)
Sep. 24, 2022
shares
Disclosure Derivative Liabilities Abstract  
March 2021 Private Placement 50,000,000 [1]
Total 50,000,000
[1] See “Note 12 – Shareholders’ Equity” for further information.
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Details 3)
3 Months Ended
Sep. 24, 2022
$ / shares
Disclosure Derivative Liabilities Abstract  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 106.25%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 2.51%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 6 months
Share Price $ 0.04
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 0.37
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Jun. 25, 2022
Finance Lease Cost:      
Amortization of Finance Lease Right-of-Use Assets $ 347,406 $ 283,406  
Interest on Lease Liabilities 1,804,507 1,784,541  
Operating Lease Cost 3,453,863 6,595,652  
Sublease Income [1] (1,521,693)  
Total Lease Expenses 5,605,776 8,663,599  
Cash Paid for Amounts Included in the Measurement of Lease Liabilities:      
Financing Cash Flows from Finance Leases 2,484 959  
Operating Cash Flows from Operating Leases $ 1,026,792 $ 3,478,891  
Finance Lease, Weighted Average Remaining Lease Term 47 years   46 years
Operating Lease, Weighted Average Remaining Lease Term 7 years   8 years
Finance Lease, Weighted Average Discount Rate, Percent 24.78%   24.33%
Operating Lease, Weighted Average Discount Rate, Percent 15.96%   18.70%
[1] See “Note 16 – Other Operating Income” for further information. 
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES (Details 1)
Sep. 24, 2022
USD ($)
Leases [Abstract]  
July 1, 2023 (remaining) $ 9,155,365
July 1, 2023 (remaining) 4,387,279
June 29, 2024 16,183,010
June 29, 2024 10,961,495
June 28, 2025 25,224,922
June 28, 2025 14,020,131
June 27, 2026 12,675,441
June 27, 2026 7,300,368
June 26, 2027 12,716,234
June 26, 2027 7,519,379
Thereafter 20,832,425
Thereafter 1,054,354,990
Total lease payment 96,787,396
Total lease payment 1,098,543,643
Less Interest (37,307,828)
Less Interest (1,067,487,335)
Lease Liability Recognized 59,479,568
Lease Liability Recognized $ 31,056,308
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE (Details) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Short-Term Debt [Line Items]    
Finance liabilities $ 4,150,484 $ 4,061,273
Total notes Payables 74,898,640 74,372,898
Convertible Notes Payable [Member]    
Short-Term Debt [Line Items]    
Finance liabilities 72,300,000 72,300,000
Notes Payable, Current 66,819,991 97,162,001
Promissory notes 2,057,207 2,057,207
Other 15,691 15,691
Total notes Payables 141,192,889 171,534,899
Less. Unamortization Debt Issuance Cost an Loan Origination Fess (158,079)
Net Amount 141,192,889 171,376,820
Less Current Portion of Notes Payable (66,294,249) (97,003,922)
Notes Payables, net of Current Portion $ 74,898,640 $ 74,372,898
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE (Details 1) - Notes Payable [Member]
3 Months Ended
Sep. 24, 2022
USD ($)
Short-Term Debt [Line Items]  
Balance at beginning of period $ 171,376,820
Paid in kind interest Capitalized 1,257,988
Cash payments (31,599,999)
Accretion of Debt Discount included in Discontinued Operations 158,079
Balance at End of period 141,192,889
Less Current portion of notes payables (66,294,249)
Notes payable, Net of Current portion $ 74,898,640
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE (Details Narrative) - USD ($)
3 Months Ended
Feb. 02, 2022
Sep. 24, 2022
Disclosure Notes Payable Abstract    
Proceeds from Sale of Other Assets $ 37,500,000  
Proceeds from (Repayments of) Debt   $ 31,599,999
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility $ 243,063,216 $ 237,904,778
Less Unamortize Debt Discount (104,317,146) (105,899,115)
Senior Secured Convertible Credit Facility Net 138,746,070 132,005,663
Secured Convertible Note [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 23,376,684 22,880,556
Secured Convertible Note 1 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 100,679,152 98,542,422
Secured Convertible Note 2 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 32,738,817 32,043,996
Secured Convertible Note 3 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 12,677,140 12,408,091
Secured Convertible Note 4 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 14,911,453 14,594,985
Secured Convertible Note 5 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 23,932,224 23,424,438
Secured Convertible Note 6 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 3,346,889 3,275,857
Secured Convertible Note 7 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 6,472,344 6,334,980
Secured Convertible Note 8 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 10,103,343 9,888,919
Secured Convertible Note 9 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility 2,237,875 2,190,380
Secured Convertible Note 10 [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total Drawn On Senior Secured Convertible Credit Facility $ 12,587,295 $ 12,320,154
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative)
3 Months Ended
Sep. 24, 2022
USD ($)
Senior Secured Convertible Total [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period $ 132,005,663
Paid-In-Kind Interest Capitalized 5,158,438
Accretion of Debt Discount 1,581,969
Balance at end of period 138,746,070
Tranche One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 80,178,586
Paid-In-Kind Interest Capitalized 2,632,858
Accretion of Debt Discount 988,849
Balance at end of period 83,800,293
Tranche Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 21,218,356
Paid-In-Kind Interest Capitalized 694,821
Accretion of Debt Discount 260,580
Balance at end of period 22,173,757
Tranche Three [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 8,217,079
Paid-In-Kind Interest Capitalized 269,049
Accretion of Debt Discount 100,902
Balance at end of period 8,587,030
Tranche Four [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 1,051,827
Paid-In-Kind Interest Capitalized 316,468
Accretion of Debt Discount
Balance at end of period 1,368,295
Incremental Advance One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 224,585
Paid-In-Kind Interest Capitalized 71,032
Accretion of Debt Discount
Balance at end of period 295,617
Incremental Advance Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 433,598
Paid-In-Kind Interest Capitalized 137,364
Accretion of Debt Discount
Balance at end of period 570,962
Advance 3rd [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 842,981
Paid-In-Kind Interest Capitalized 267,141
Accretion of Debt Discount
Balance at end of period 1,110,122
Amendment Fee Notes [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 15,512,409
Paid-In-Kind Interest Capitalized 507,786
Accretion of Debt Discount 190,486
Balance at end of period 16,210,681
Restatement Fee Notes [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 2,211,711
Paid-In-Kind Interest Capitalized 214,424
Accretion of Debt Discount 37,165
Balance at end of period 2,463,300
Second Restatement Fee Notes [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Balance at beginning of period 2,114,531
Paid-In-Kind Interest Capitalized 47,495
Accretion of Debt Discount 3,987
Balance at end of period $ 2,166,013
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS' EQUITY (Details)
3 Months Ended
Sep. 24, 2022
shares
Mm Can Usa Class B Redeemable Units [Member]  
Class of Warrant or Right [Line Items]  
Beginning balance, shares 65,066,106
Redemption of MedMen Corp Redeemable Shares (259,814)
Ending balance, shares 64,806,292
Mm Enterprises Usa Common Units [Member]  
Class of Warrant or Right [Line Items]  
Beginning balance, shares 725,016
Redemption of MedMen Corp Redeemable Shares
Ending balance, shares 725,016
Subordinate Voting Shares [Member]  
Class of Warrant or Right [Line Items]  
Beginning balance, shares 1,301,423,950
Redemption of MedMen Corp Redeemable Shares 259,814
Ending balance, shares 1,301,683,764
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS' EQUITY (Details 1) - USD ($)
3 Months Ended 12 Months Ended
Sep. 24, 2022
Jun. 25, 2022
Venice Caregivers Foundation Inc [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Current Assets $ 1,180,136 $ 1,735,304
Non-Current Assets 8,763,511 10,073,880
Total Assets 9,943,647 11,809,184
Current Liabilities 10,477,448 9,238,460
Non-Current Liabilities 7,004,484 9,614,164
Total Liabilities 17,481,932 18,852,624
Non-Controlling Interest (7,538,285) (7,043,440)
Revenues 1,959,080 8,732,449
Net (Loss) Income Attributable to Non-Controlling Interest (494,845) (1,384,751)
L A X Fund Two Group L L C [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Current Assets 1,067,636
Non-Current Assets 3,233,062 3,379,412
Total Assets 3,233,062 4,447,048
Current Liabilities 16,016,119 16,238,249
Non-Current Liabilities 2,004,062 2,184,953
Total Liabilities 18,020,181 18,423,202
Non-Controlling Interest (14,787,119) (13,976,154)
Revenues 1,857
Net (Loss) Income Attributable to Non-Controlling Interest (810,965) (4,868,632)
Natures Cure Inc [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Current Assets 24,602,018 23,557,168
Non-Current Assets 4,891,725 4,973,459
Total Assets 29,493,743 28,530,627
Current Liabilities 8,510,967 8,433,436
Non-Current Liabilities 1,342,632 1,342,633
Total Liabilities 9,853,599 9,776,069
Non-Controlling Interest 19,640,163 18,754,558
Revenues 3,317,299 16,157,388
Net (Loss) Income Attributable to Non-Controlling Interest 885,605 7,190,809
Vies Total [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Current Assets 25,782,154 26,360,108
Non-Current Assets 16,888,298 18,426,751
Total Assets 42,670,452 44,786,859
Current Liabilities 35,004,534 33,910,145
Non-Current Liabilities 10,351,178 13,141,750
Total Liabilities 45,355,712 47,051,895
Non-Controlling Interest (2,685,241) (2,265,036)
Revenues 5,276,379 24,891,694
Net (Loss) Income Attributable to Non-Controlling Interest $ (420,205) $ 937,426
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS' EQUITY (Details 2) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net (Loss) Income $ 4,047,901 $ (60,610,031)
Venice Caregivers Foundation Inc [Member] | Non Controlling Interests [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Balance at beginning (7,043,440)  
Net (Loss) Income (494,845)  
Balance at ending (7,538,285)  
L A X Fund Two Group L L C [Member] | Non Controlling Interests [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Balance at beginning (13,976,154)  
Net (Loss) Income (810,965)  
Balance at ending (14,787,119)  
Natures Cure Inc [Member] | Non Controlling Interests [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Balance at beginning 18,754,558  
Net (Loss) Income 885,605  
Balance at ending 19,640,163  
Other Non Controlling Interests [Member] | Non Controlling Interests [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Balance at beginning (471,717,698)  
Net (Loss) Income 307,893  
Balance at ending (471,409,805)  
Total [Member] | Non Controlling Interests [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Balance at beginning (473,982,734)  
Net (Loss) Income (112,312)  
Balance at ending $ (474,095,046)  
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS’ EQUITY (Details Narrative)
Sep. 24, 2022
Jun. 25, 2022
MM CAN USA [Member]    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 4.74% 4.76%
MM Enterprises USA [Member]    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   0.05%
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total Share-Based Compensation $ 863,685 $ 3,104,077
Equity Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total Share-Based Compensation 863,685 1,216,447
Stock Grants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total Share-Based Compensation 333,333
Restricted Stock Grants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total Share-Based Compensation $ 1,554,297
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Details 1)
3 Months Ended
Sep. 24, 2022
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Stock Options, Beginning Balance | shares 8,649,673
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 1.35
Number of Stock Options, Forfeited | shares (205,354)
Weighted Average Exercise Price, Forfeited | $ / shares $ (3.39)
Number of Stock Options, Ending Balance | shares 8,444,319
Weighted Average Exercise Price, Ending Balance | $ / shares $ 1.39
Number of Stock Options, Stock Options Exercisable | shares 8,037,095
Weighted Average Exercise Price, Stock Options Exercisable | $ / shares $ 1.27
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Details 2)
Sep. 24, 2022
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
LTIP Issued And Outstanding 19,323,878
LLC Redeemable Units 725,016
Weighted Average grant date fair Value | $ / shares $ 0.52
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Details 3)
3 Months Ended
Sep. 24, 2022
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Issued And Outstanding, Beginning Balance 10,998,483
Vested, Beginning Balance 4,030,460 [1]
Weighted average fair value at beginning | $ / shares $ 0.20
Issued And Outstanding, Forfeiture of Restricted Stock (1,405,788) [2]
Vested, Forfeiture of Restricted Stock [1],[2]
Weighted Average fair Value, Forfeiture of Restricted Stock | $ / shares $ (0.22) [2]
Vesting of Restricted Stock
Vested, Vesting of Restricted Stock 1,117,081 [1]
WeightedAverage Fair Value, Vesting of Restricted Stock | $ / shares $ 0.22
Issued And Outstanding, Ending Balance 9,592,695
Vested, Ending Balance 5,147,541 [1]
Weighted average fair value at ending | $ / shares $ 0.20
[1] Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date.
[2] Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022.
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Details 4) - Warrant [Member]
3 Months Ended
Sep. 24, 2022
$ / shares
shares
Class of Warrant or Right [Line Items]  
Beginning Balance 450,134,811
Weighted Average Exercise Price, Beginning balance | $ / shares $ 0.25
Expired (2,677,535)
Weighted Average Exercise Price, Expired | $ / shares $ (3.27)
Ending Balance 447,457,276
Weighted Average Exercise Price, Ending | $ / shares $ 0.23
[Subordinate Voting Shares [Member]]  
Class of Warrant or Right [Line Items]  
Beginning Balance 352,704,355
Expired (2,677,535)
Ending Balance 350,026,820
Mm Can Usa Class B Redeemable Units [Member]  
Class of Warrant or Right [Line Items]  
Beginning Balance 97,430,456
Expired
Ending Balance 97,430,456
XML 87 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE-BASED COMPENSATION (Details Narrative)
3 Months Ended
Sep. 24, 2022
Minimum [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period 5 years
Maximum [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period 10 years
XML 88 R78.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOSS PER SHARE (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Earnings Per Share [Abstract]    
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (20,146,436) $ (40,883,537)
Net Income (Loss) from Discontinued Operations 24,306,649 (14,446,491)
Total Net Income (Loss) $ 4,160,213 $ (55,330,028)
Weighted-Average Shares Outstanding - Basic and Diluted 1,301,659,701 942,696,052
Earnings (Loss) Per Share - Basic and Diluted:    
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.02) $ (0.04)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. $ 0.02 $ (0.02)
XML 89 R79.htm IDEA: XBRL DOCUMENT v3.22.2.2
GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
General And Administrative Expenses    
Salaries and Benefits $ 6,858,048 $ 9,911,488
Professional Fees 1,350,848 7,430,659
Rent 3,627,925 4,754,883
Licenses, Fees and Taxes 1,001,669 2,537,788
Share-Based Compensation 863,685 1,642,853
Deal Costs 429,272 1,637,587
Other General and Administrative 3,714,670 4,733,976
Total General and Administrative Expenses $ 17,846,117 $ 32,649,234
XML 90 R80.htm IDEA: XBRL DOCUMENT v3.22.2.2
OTHER OPERATING EXPENSE (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Other Operating Income Expense    
Loss on Disposals of Assets $ 205,595 $ 15,146
Restructuring and Reorganization Expense 423,793 2,378,675
Gain on Settlement of Accounts Payable (74,637) (177,990)
Gain on Lease Terminations (1,587,650)
Other Income (1,522,219) (16,803)
Total Other Operating (Income) Expense $ (2,555,118) $ 2,199,028
XML 91 R81.htm IDEA: XBRL DOCUMENT v3.22.2.2
OTHER OPERATING (INCOME) EXPENSE (Details Narrative)
3 Months Ended
Sep. 24, 2022
USD ($)
Other Operating Income Expense  
Sublease income $ 1,521,650
XML 92 R82.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Income Tax Disclosure [Abstract]    
Loss from Continuing Operations Before Provision for Income Taxes $ (18,065,206) $ (26,471,632)
Income Tax Expense $ (2,193,542) $ (19,691,908)
Effective Tax Rate (12.00%) (74.00%)
XML 93 R83.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative)
3 Months Ended
Sep. 24, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Provision for income taxes and deferred income taxes description The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized.
Gross unrecognized tax benefits $ 18,781,424
Net discrete tax expense $ 407,993
XML 94 R84.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS (Details Narrative)
3 Months Ended
Sep. 24, 2022
USD ($)
Board of Directors Chairman [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Debt Instrument, Periodic Payment $ 200,000
XML 95 R85.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUE (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Financing Receivable, Past Due [Line Items]    
Total Revenue $ 33,673,689 $ 44,076,003
Revenue from Continuing Operations 30,044,048 36,735,904
Revenue from Discontinued Operations 3,629,641 7,340,099
CALIFORNIA    
Financing Receivable, Past Due [Line Items]    
Total Revenue 19,928,985 24,626,555
NEVADA    
Financing Receivable, Past Due [Line Items]    
Total Revenue 2,997,469 4,079,151
ILLINOIS    
Financing Receivable, Past Due [Line Items]    
Total Revenue 3,542,071 4,328,602
ARIZONA    
Financing Receivable, Past Due [Line Items]    
Total Revenue 2,794,648 3,701,596
MASSACHUSETTS    
Financing Receivable, Past Due [Line Items]    
Total Revenue $ 780,875
XML 96 R86.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISCONTINUED OPERATIONS (Details) - USD ($)
3 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Discontinued Operations and Disposal Groups [Abstract]    
Revenue $ 3,629,641 $ 7,340,099
Cost of Goods Sold 2,103,298 5,227,553
Gross Profit 1,526,343 2,112,546
Expenses:    
General and Administrative 4,983,995 5,617,595
Sales and Marketing 43,311 103,803
Depreciation and Amortization 872,895 1,221,759
Impairment Expense (78,433)
Gain on Disposal of Assets and Other Income (35,659,761) (597,591)
Total (Income) Expenses (29,837,993) 6,345,566
Income (Loss) from Discontinued Operations 31,364,336 (4,233,020)
Other Expense:    
Interest Expense 3,761,758 4,616,829
Accretion of Debt Discount and Loan Origination Fees 158,079 3,540,908
Total Other Expense 3,919,837 8,157,737
Income (Loss) from Discontinued Operations Before Provision for Income Taxes 27,444,499 (12,390,757)
Provision for Income Tax Benefit (Expense) (3,137,850) (2,055,734)
Net Income (Loss) from Discontinued Operations $ 24,306,649 $ (14,446,491)
XML 97 R87.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISCONTINUED OPERATIONS (Details 1) - USD ($)
Sep. 24, 2022
Jun. 25, 2022
Carrying Amounts of the Assets Included in Discontinued Operations:    
Cash and Cash Equivalents $ 355,378 $ 1,124,076
Restricted Cash 5,280 5,280
Accounts Receivable and Prepaid Expenses 95,048 334,621
Inventory 2,915,345 6,866,833
TOTAL CURRENT ASSETS (1)    
Property and Equipment, Net 9,713,565 41,273,597
Operating Lease Right-of-Use Assets 19,780,991 31,543,058
Intangible Assets, Net 10,582,559 40,799,146
Other Assets 458,383 1,181,795
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE 43,906,549 123,128,406
Carrying Amounts of the Liabilities Included in Discontinued Operations:    
Accounts Payable and Accrued Liabilities 2,640,664 6,295,745
Income Taxes Payable (27,904) 1,671,380
Other Current Liabilities 89,069
Current Portion of Operating Lease Liabilities 2,605,317 4,209,512
Current Portion of Finance Lease Liabilities 174,000
TOTAL CURRENT LIABILITIES (1)    
Operating Lease Liabilities, Net of Current Portion 19,067,840 56,410,071
Deferred Tax Liabilities 6,250,511 6,097,597
Notes Payable 11,100,000
TOTAL NON-CURRENT LIABILITIES (1)    
TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 30,536,428 $ 86,047,374
XML 98 R88.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISCONTINUED OPERATIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Sep. 15, 2022
Aug. 22, 2022
Sep. 24, 2022
Discontinued Operations and Disposal Groups [Abstract]      
Sales Price   $ 67,000,000  
Sales in cash   63,000,000  
Liabilities assumed by buyer   4,000,000  
Buyer cash payment description The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022 and is required to make one additional installment payment of $11,500,000 on or before March 15, 2023.    
Proceeds from Other Debt     $ 31,599,999
Proceeds from Issuance of Debt     19,558,947
Remains due and payable     $ 11,500,000
Gain (Loss) on Disposition of Assets for Financial Service Operations   $ 31,719,833  
XML 99 medmenenter_10q_htm.xml IDEA: XBRL DOCUMENT 0001776932 2022-06-26 2022-09-24 0001776932 2022-10-31 0001776932 2022-09-24 0001776932 2022-06-25 0001776932 mmen:SubordinateVotingStockMember 2022-09-24 0001776932 mmen:SubordinateVotingStockMember 2022-06-25 0001776932 2021-06-27 2021-09-25 0001776932 mmen:SubordinateVotingMember 2022-06-26 0001776932 us-gaap:AdditionalPaidInCapitalMember 2022-06-26 0001776932 us-gaap:RetainedEarningsMember 2022-06-26 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2022-06-26 0001776932 us-gaap:NoncontrollingInterestMember 2022-06-26 0001776932 2022-06-26 0001776932 mmen:SubordinateVotingMember 2021-06-27 0001776932 us-gaap:AdditionalPaidInCapitalMember 2021-06-27 0001776932 us-gaap:RetainedEarningsMember 2021-06-27 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2021-06-27 0001776932 us-gaap:NoncontrollingInterestMember 2021-06-27 0001776932 2021-06-27 0001776932 mmen:SubordinateVotingMember 2022-06-27 2022-09-24 0001776932 us-gaap:AdditionalPaidInCapitalMember 2022-06-27 2022-09-24 0001776932 us-gaap:RetainedEarningsMember 2022-06-27 2022-09-24 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2022-06-27 2022-09-24 0001776932 us-gaap:NoncontrollingInterestMember 2022-06-27 2022-09-24 0001776932 2022-06-27 2022-09-24 0001776932 mmen:SubordinateVotingMember 2021-06-28 2021-09-25 0001776932 us-gaap:AdditionalPaidInCapitalMember 2021-06-28 2021-09-25 0001776932 us-gaap:RetainedEarningsMember 2021-06-28 2021-09-25 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2021-06-28 2021-09-25 0001776932 us-gaap:NoncontrollingInterestMember 2021-06-28 2021-09-25 0001776932 2021-06-28 2021-09-25 0001776932 mmen:SubordinateVotingMember 2022-09-24 0001776932 us-gaap:AdditionalPaidInCapitalMember 2022-09-24 0001776932 us-gaap:RetainedEarningsMember 2022-09-24 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2022-09-24 0001776932 us-gaap:NoncontrollingInterestMember 2022-09-24 0001776932 mmen:SubordinateVotingMember 2021-09-25 0001776932 us-gaap:AdditionalPaidInCapitalMember 2021-09-25 0001776932 us-gaap:RetainedEarningsMember 2021-09-25 0001776932 mmen:TotalEquityAttributableToShareholdersOfMedmenMember 2021-09-25 0001776932 us-gaap:NoncontrollingInterestMember 2021-09-25 0001776932 2021-09-25 0001776932 2021-06-26 0001776932 2022-06-01 2022-06-25 0001776932 mmen:DiscontinuedOperationsMember 2022-06-25 0001776932 mmen:OtherAssetMember 2022-06-25 0001776932 mmen:TotalMember 2022-06-25 0001776932 mmen:DiscontinuedOperationsMember 2022-06-26 2022-09-24 0001776932 mmen:OtherAssetMember 2022-06-26 2022-09-24 0001776932 mmen:TotalMember 2022-06-26 2022-09-24 0001776932 mmen:DiscontinuedOperationsMember 2022-09-24 0001776932 mmen:OtherAssetMember 2022-09-24 0001776932 mmen:TotalMember 2022-09-24 0001776932 mmen:DispensaryLicenseMember 2022-09-24 0001776932 mmen:DispensaryLicenseMember 2022-06-25 0001776932 mmen:CustomerRelationshipMember 2022-09-24 0001776932 mmen:CustomerRelationshipMember 2022-06-25 0001776932 mmen:CapitalizedSoftwareMember 2022-09-24 0001776932 mmen:CapitalizedSoftwareMember 2022-06-25 0001776932 us-gaap:IntellectualPropertyMember 2022-09-24 0001776932 us-gaap:IntellectualPropertyMember 2022-06-25 0001776932 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2022-09-24 0001776932 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2022-06-25 0001776932 mmen:DerivativeLiabilitiesOneMember 2022-06-25 0001776932 mmen:DerivativeLiabilitiesOneMember 2022-06-26 2022-09-24 0001776932 mmen:DerivativeLiabilitiesOneMember 2022-09-24 0001776932 mmen:TopUpProvisionMember 2022-09-24 0001776932 mmen:TopUpProvisionMember 2022-06-26 2022-09-24 0001776932 us-gaap:ConvertibleNotesPayableMember 2022-09-24 0001776932 us-gaap:ConvertibleNotesPayableMember 2022-06-25 0001776932 mmen:NotesPayableMember 2022-06-25 0001776932 mmen:NotesPayableMember 2022-06-26 2022-09-24 0001776932 mmen:NotesPayableMember 2022-09-24 0001776932 2022-01-29 2022-02-02 0001776932 mmen:SecuredConvertibleNoteMember 2022-09-24 0001776932 mmen:SecuredConvertibleNoteMember 2022-06-25 0001776932 mmen:SecuredConvertibleNote1Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote1Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote2Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote2Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote3Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote3Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote4Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote4Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote5Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote5Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote6Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote6Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote7Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote7Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote8Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote8Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote9Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote9Member 2022-06-25 0001776932 mmen:SecuredConvertibleNote10Member 2022-09-24 0001776932 mmen:SecuredConvertibleNote10Member 2022-06-25 0001776932 mmen:TrancheOneMember 2022-06-25 0001776932 mmen:TrancheTwoMember 2022-06-25 0001776932 mmen:TrancheThreeMember 2022-06-25 0001776932 mmen:TrancheFourMember 2022-06-25 0001776932 mmen:IncrementalAdvanceOneMember 2022-06-25 0001776932 mmen:IncrementalAdvanceTwoMember 2022-06-25 0001776932 mmen:Advance3rdMember 2022-06-25 0001776932 mmen:AmendmentFeeNotesMember 2022-06-25 0001776932 mmen:RestatementFeeNotesMember 2022-06-25 0001776932 mmen:SecondRestatementFeeNotesMember 2022-06-25 0001776932 mmen:SeniorSecuredConvertibleTotalMember 2022-06-25 0001776932 mmen:TrancheOneMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheTwoMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheThreeMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheFourMember 2022-06-26 2022-09-24 0001776932 mmen:IncrementalAdvanceOneMember 2022-06-26 2022-09-24 0001776932 mmen:IncrementalAdvanceTwoMember 2022-06-26 2022-09-24 0001776932 mmen:Advance3rdMember 2022-06-26 2022-09-24 0001776932 mmen:AmendmentFeeNotesMember 2022-06-26 2022-09-24 0001776932 mmen:RestatementFeeNotesMember 2022-06-26 2022-09-24 0001776932 mmen:SecondRestatementFeeNotesMember 2022-06-26 2022-09-24 0001776932 mmen:SeniorSecuredConvertibleTotalMember 2022-06-26 2022-09-24 0001776932 mmen:TrancheOneMember 2022-09-24 0001776932 mmen:TrancheTwoMember 2022-09-24 0001776932 mmen:TrancheThreeMember 2022-09-24 0001776932 mmen:TrancheFourMember 2022-09-24 0001776932 mmen:IncrementalAdvanceOneMember 2022-09-24 0001776932 mmen:IncrementalAdvanceTwoMember 2022-09-24 0001776932 mmen:Advance3rdMember 2022-09-24 0001776932 mmen:AmendmentFeeNotesMember 2022-09-24 0001776932 mmen:RestatementFeeNotesMember 2022-09-24 0001776932 mmen:SecondRestatementFeeNotesMember 2022-09-24 0001776932 mmen:SeniorSecuredConvertibleTotalMember 2022-09-24 0001776932 mmen:MmCanUsaClassBRedeemableUnitsMember 2022-06-25 0001776932 mmen:MmEnterprisesUsaCommonUnitsMember 2022-06-25 0001776932 mmen:SubordinateVotingStockMember 2022-06-26 2022-09-24 0001776932 mmen:MmCanUsaClassBRedeemableUnitsMember 2022-06-26 2022-09-24 0001776932 mmen:MmEnterprisesUsaCommonUnitsMember 2022-06-26 2022-09-24 0001776932 mmen:MmCanUsaClassBRedeemableUnitsMember 2022-09-24 0001776932 mmen:MmEnterprisesUsaCommonUnitsMember 2022-09-24 0001776932 mmen:MMCANUSAMember 2022-09-24 0001776932 mmen:MMCANUSAMember 2022-06-25 0001776932 mmen:MMEnterprisesUSAMember 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember 2022-09-24 0001776932 mmen:NaturesCureIncMember 2022-09-24 0001776932 mmen:ViesTotalMember 2022-09-24 0001776932 mmen:VeniceCaregiversFoundationIncMember 2022-06-26 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember 2022-06-26 2022-09-24 0001776932 mmen:NaturesCureIncMember 2022-06-26 2022-09-24 0001776932 mmen:ViesTotalMember 2022-06-26 2022-09-24 0001776932 mmen:VeniceCaregiversFoundationIncMember 2022-06-25 0001776932 mmen:LAXFundTwoGroupLLCMember 2022-06-25 0001776932 mmen:NaturesCureIncMember 2022-06-25 0001776932 mmen:ViesTotalMember 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember 2021-06-27 2022-06-25 0001776932 mmen:LAXFundTwoGroupLLCMember 2021-06-27 2022-06-25 0001776932 mmen:NaturesCureIncMember 2021-06-27 2022-06-25 0001776932 mmen:ViesTotalMember 2021-06-27 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:LAXFundTwoGroupLLCMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:NaturesCureIncMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:OtherNonControllingInterestsMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:TotalMember mmen:NonControllingInterestsMember 2022-06-25 0001776932 mmen:VeniceCaregiversFoundationIncMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:NaturesCureIncMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:OtherNonControllingInterestsMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:TotalMember mmen:NonControllingInterestsMember 2022-06-26 2022-09-24 0001776932 mmen:VeniceCaregiversFoundationIncMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:LAXFundTwoGroupLLCMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:NaturesCureIncMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:OtherNonControllingInterestsMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 mmen:TotalMember mmen:NonControllingInterestsMember 2022-09-24 0001776932 srt:MinimumMember 2022-06-26 2022-09-24 0001776932 srt:MaximumMember 2022-06-26 2022-09-24 0001776932 us-gaap:StockOptionMember 2022-06-26 2022-09-24 0001776932 us-gaap:StockOptionMember 2021-06-27 2021-09-25 0001776932 mmen:StockGrantsMember 2022-06-26 2022-09-24 0001776932 mmen:StockGrantsMember 2021-06-27 2021-09-25 0001776932 mmen:RestrictedStockGrantsMember 2022-06-26 2022-09-24 0001776932 mmen:RestrictedStockGrantsMember 2021-06-27 2021-09-25 0001776932 us-gaap:WarrantMember mmen:SubordinateVotingsSharesMember 2022-06-26 2022-09-24 0001776932 us-gaap:WarrantMember mmen:MmCanUsaClassBRedeemableUnitsMember 2022-06-26 2022-09-24 0001776932 us-gaap:WarrantMember 2022-06-26 2022-09-24 0001776932 srt:BoardOfDirectorsChairmanMember 2022-06-26 2022-09-24 0001776932 stpr:CA 2022-06-26 2022-09-24 0001776932 stpr:CA 2021-06-27 2021-09-25 0001776932 stpr:NV 2022-06-26 2022-09-24 0001776932 stpr:NV 2021-06-27 2021-09-25 0001776932 stpr:IL 2022-06-26 2022-09-24 0001776932 stpr:IL 2021-06-27 2021-09-25 0001776932 stpr:AZ 2022-06-26 2022-09-24 0001776932 stpr:AZ 2021-06-27 2021-09-25 0001776932 stpr:MA 2022-06-26 2022-09-24 0001776932 stpr:MA 2021-06-27 2021-09-25 0001776932 2022-08-01 2022-08-22 0001776932 2022-09-01 2022-09-15 iso4217:USD shares iso4217:USD shares pure 0001776932 false --06-30 2023 Q1 10-Q true 2022-09-24 false 000-56199 MEDMEN ENTERPRISES INC. A1 98-1431779 8740 S Sepulveda Blvd Suite 105 Los Angeles CA 90045 (424) 330-2082 No Yes Accelerated Filer true true false false 1301683764 21097057 10795999 5376069 7539767 9117809 10010731 44185218 123158751 11500000 7403829 9990992 98679982 161496240 44461062 47649270 59965935 64107792 34057051 35746114 9810049 9810049 4157513 4414219 251131592 323223684 35355136 38905818 64710033 58646291 17121093 16704283 7555153 6749563 12199351 10925128 4150484 4061273 66294249 97003922 26195800 86595102 233581299 319591380 47280217 50917244 26905824 26553287 2987812 3082277 40295319 35213671 138746070 132005663 74898640 74372898 564695181 641736420 0 0 0 0 0 0 1301683764 1301683764 1301423950 1301423950 1058145437 1057228873 -897613980 -901758875 160531457 155469998 -474095046 -473982734 -313563589 -318512736 251131592 323223684 30044048 36735904 15187672 19349990 14856376 17385914 17846117 32649234 443790 593224 3946523 5823617 -863856 1663911 435241 -2555118 2199028 20481367 41700344 -5624991 -24314430 10052691 8171764 -33 -23008 1581967 6347471 805590 -2105415 -10233610 12440215 2157202 -18065206 -26471632 2193542 19691908 -20258748 -46163540 24306649 -14446491 4047901 -60610031 -112312 -5280003 4160213 -55330028 -0.02 -0.04 0.02 -0.02 1301659701 942696052 1301423950 1057228873 -901758875 155469998 -473982734 -318512736 4160213 4160213 -112312 4047901 37561 37561 37561 259814 15318 -15318 863685 863685 863685 1301683764 1058145437 -897613980 160531457 -474095046 -313563589 726866374 908992686 -717232706 191759980 -445393599 -253633619 -55330028 -55330028 -5280003 -60610031 406249973 73393745 73393745 73393745 20833333 4030000 4030000 4030000 4182730 700000 700000 700000 41388048 41388048 41388048 4054278 1121441 374701 1496142 -1496142 8473868 8807605 1273679 1273679 1273679 16014665 2371100 2371100 2371100 1455415 1421400 1421400 1421400 13057730 13057730 13057730 1682677 1682677 1682677 1196938241 1023317046 -772188033 251129013 -452169744 -201040731 -20258748 -46163540 -4497141 3971473 6256917 3453863 4442077 -1581970 -6347471 -205595 1587670 141657 141657 1663911 435241 -863856 805590 -2105415 10233610 863685 3104077 -6416426 -7837693 -444232 -377885 -2163698 -617325 -892922 1710735 -2587163 -282230 -256706 -1746175 4827997 1804507 1784541 -1026792 -3478891 11145390 21707961 -447046 -2413113 47192 10351077 -16291769 -19961041 -6684431 -9609964 -22976200 391730 24056 461456 51500000 730 51475944 -852456 -2764417 51475944 -3616873 95000000 5352505 1273679 -2608964 5000000 -31599999 -75605 2484 959 37561 -31564922 93235646 10301058 66642573 275178 10795999 11575138 21097057 77942533 1260562 2336120 4476993 1496142 30500000 2371100 4030000 700000 41388047 13057730 <p id="xdx_802_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z2g9Y2Q1UjAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0in; text-align: justify"/> <td style="border-bottom: Black 1pt solid; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="border-bottom: Black 1pt solid; text-align: justify"><span id="xdx_828_zkG6d6lBgS9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NATURE OF OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MedMen Enterprises Inc. and its subsidiaries over which the company has control (collectively, “MedMen”, the “Company”, “we” or “us”) is a premier cannabis retailer based in the U.S. with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands – MedMen Red and LuxLyte – through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. MedMen Buds provides exclusive access to promotions, product drops and content.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022, the Company owns 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4). The Company continues to market its assets in New York and thus classifies all assets and liabilities and profit or loss allocable to its operations in the state of New York as discontinued operations. In August 2022, the Company completed the sale of its operations in the state of Florida of which all assets and liabilities and profit or loss allocable to Florida are classified as discontinued operations until the day of sale, or August 22, 2022. As of September 24, 2022, the remaining post-acquisition assets and liabilities and profit or loss allocable to Florida have been reclassified as continuing operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_z6uSNyggdnFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1pt solid; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td> <td style="border-bottom: Black 1pt solid; text-align: justify"><span id="xdx_827_zQyN2q8ycVB6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNhFOiIVcLN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_ziZpays76Bhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Preparation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--GoingConcernPolicyTextBlock_zl2Smm4hKmBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86A_zFsCL0B5tgfe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022, the Company had cash and cash equivalents of $<span id="xdx_903_ecustom--CashAndCashEquivalent_iI_pn5n6_c20220924_zORSmwZX1s1h">21.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and working capital deficit of $<span id="xdx_909_ecustom--WorkingCapitalDeficit_iI_pn5n6_c20220924_zrRIIpviKyq5">134.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company has incurred net losses from continuing operations of $<span id="xdx_908_ecustom--LossesFromContinuingOperations_pn5n6_c20220626__20220924_zwLecByDo9sd">20.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90E_ecustom--LossesFromContinuingOperations_pn5n6_c20210627__20210925_zbZKwzCwG5b7">46.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_ecustom--COVID19PolicyTextBlock_ztCu9OkYbXla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zkB5QSVEE4w8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. During the current reporting period, aspects of the Company’s business continue to be affected by impacts of the COVID-19 pandemic, as the Company’s retail stores strive to operate within the local rules and regulations of the states and localities in which the Company operates. While the Company saw continued recovery from the impacts of the COVID 19-pandemic during the first quarter of 2023, the Company continues to closely monitor the potential impact that a resurgence of the COVID-19 virus, including as a result of the emergence of new variants and strains, could have on the Company’s operations. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liabilities. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zDesChQ4PcY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zxsrkwtrk2Wd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Consolidation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of September 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--SignificantAccountingPolicyTextBlock_ziTsi4K951gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_zCQgAfzCdsA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant Accounting Policies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended September 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zeBYAwmSm2L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zR0SSLbofXze" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings (Loss) per Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwLUMlYBno6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_ziZtvCerzzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts reported in the Notes to the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. These non-material corrections and reclassifications impacted leasehold improvements and furniture and fixtures in the amount of approximately $<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentTransfersAndChanges_pp0p0_c20220601__20220625_zKulvDt7P00k" title="Reclassifications impacted leasehold improvements and furniture and fixtures">940,000</span> between the categories. Customer relationships and accumulated amortization of customer relationships in the amount of $<span id="xdx_90C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1_pp0p0_c20220601__20220625_z1wf9qsYPNYi" title="Reclassifications impacted customer relationships and accumulated amortization">1,440,000</span> between the categories were reclassed between the two categories. Fully amortized management agreements and its related accumulated amortization in the amount of $<span id="xdx_909_ecustom--ReclassificationsImpactedAccumulatedAmortization_pp0p0_c20220601__20220625_zulcdNUqlhB5" title="Reclassifications impacted accumulated amortization">964,000</span> were also reclassed. Non-controlling interest and accumulated deficit in the amount of approximately $<span id="xdx_902_ecustom--ReclassificationsImpactedNoncontrollingInterestAndAccumulatedDeficit_pp0p0_c20220601__20220625_z7Pkla3oLPWj" title="Reclassifications impacted Non-controlling interest and accumulated deficit">3,662,000</span> have been reclassed between the two categories. In addition, the Company reclassified short-term and long-term operating lease liabilities between the two categories in the amount of approximately $<span id="xdx_904_ecustom--ReclassificationsImpactedShorttermAndLongtermOperatingLeaseLiabilities_pp0p0_c20220601__20220625_zmbh8oSbaH5j" title="Reclassifications impacted Short-term and long-term operating lease liabilities">6,825,000</span>. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEr6wnytPpMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zpfOBpLomeU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Adopted Accounting Standards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “<i>Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</i>” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyIssuedAccountingStandardspolicytextblock_z67hiw4WxvR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zRoISJAYSeAk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Issued Accounting Standards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU 2020-04, “<i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the FASB issued ASU 2022-04, “<i>Liabilities – Supplier Finance Programs (Subtopic 405-50)</i>” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNhFOiIVcLN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_ziZpays76Bhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Preparation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--GoingConcernPolicyTextBlock_zl2Smm4hKmBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86A_zFsCL0B5tgfe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022, the Company had cash and cash equivalents of $<span id="xdx_903_ecustom--CashAndCashEquivalent_iI_pn5n6_c20220924_zORSmwZX1s1h">21.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and working capital deficit of $<span id="xdx_909_ecustom--WorkingCapitalDeficit_iI_pn5n6_c20220924_zrRIIpviKyq5">134.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company has incurred net losses from continuing operations of $<span id="xdx_908_ecustom--LossesFromContinuingOperations_pn5n6_c20220626__20220924_zwLecByDo9sd">20.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90E_ecustom--LossesFromContinuingOperations_pn5n6_c20210627__20210925_zbZKwzCwG5b7">46.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 21100000 134900000 20300000 46200000 <p id="xdx_84F_ecustom--COVID19PolicyTextBlock_ztCu9OkYbXla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zkB5QSVEE4w8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. During the current reporting period, aspects of the Company’s business continue to be affected by impacts of the COVID-19 pandemic, as the Company’s retail stores strive to operate within the local rules and regulations of the states and localities in which the Company operates. While the Company saw continued recovery from the impacts of the COVID 19-pandemic during the first quarter of 2023, the Company continues to closely monitor the potential impact that a resurgence of the COVID-19 virus, including as a result of the emergence of new variants and strains, could have on the Company’s operations. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liabilities. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zDesChQ4PcY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zxsrkwtrk2Wd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Consolidation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of September 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--SignificantAccountingPolicyTextBlock_ziTsi4K951gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_zCQgAfzCdsA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant Accounting Policies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended September 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zeBYAwmSm2L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zR0SSLbofXze" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings (Loss) per Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwLUMlYBno6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_ziZtvCerzzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts reported in the Notes to the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. These non-material corrections and reclassifications impacted leasehold improvements and furniture and fixtures in the amount of approximately $<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentTransfersAndChanges_pp0p0_c20220601__20220625_zKulvDt7P00k" title="Reclassifications impacted leasehold improvements and furniture and fixtures">940,000</span> between the categories. Customer relationships and accumulated amortization of customer relationships in the amount of $<span id="xdx_90C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1_pp0p0_c20220601__20220625_z1wf9qsYPNYi" title="Reclassifications impacted customer relationships and accumulated amortization">1,440,000</span> between the categories were reclassed between the two categories. Fully amortized management agreements and its related accumulated amortization in the amount of $<span id="xdx_909_ecustom--ReclassificationsImpactedAccumulatedAmortization_pp0p0_c20220601__20220625_zulcdNUqlhB5" title="Reclassifications impacted accumulated amortization">964,000</span> were also reclassed. Non-controlling interest and accumulated deficit in the amount of approximately $<span id="xdx_902_ecustom--ReclassificationsImpactedNoncontrollingInterestAndAccumulatedDeficit_pp0p0_c20220601__20220625_z7Pkla3oLPWj" title="Reclassifications impacted Non-controlling interest and accumulated deficit">3,662,000</span> have been reclassed between the two categories. In addition, the Company reclassified short-term and long-term operating lease liabilities between the two categories in the amount of approximately $<span id="xdx_904_ecustom--ReclassificationsImpactedShorttermAndLongtermOperatingLeaseLiabilities_pp0p0_c20220601__20220625_zmbh8oSbaH5j" title="Reclassifications impacted Short-term and long-term operating lease liabilities">6,825,000</span>. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 940000 1440000 964000 3662000 6825000 <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEr6wnytPpMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zpfOBpLomeU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Adopted Accounting Standards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “<i>Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</i>” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyIssuedAccountingStandardspolicytextblock_z67hiw4WxvR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zRoISJAYSeAk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Issued Accounting Standards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU 2020-04, “<i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the FASB issued ASU 2022-04, “<i>Liabilities – Supplier Finance Programs (Subtopic 405-50)</i>” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_z45XPhPmCme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td> <td style="text-align: justify"><span id="xdx_820_zXai8ZFc19tg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zmYCMqcoYoxi" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INVENTORY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8BE_zAGS1I0NLJIl" style="display: none">Schedule of inventories</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_495_20220924_zflnJV5buzD3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49E_20220625_zHsTHPWu7oE2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maCz8NO_z2cRN2Mkoxy5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw Materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">612,901</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">521,777</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_maCz8NO_ztZOjVz8CVl4" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work-in-Process</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,142,397</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">671,541</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoods_iI_maCz8NO_z5wnj2jRHTkf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Finished Goods</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,362,511</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,817,413</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryGross_iTI_mtCz8NO_zbvWpVWYrnZ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Inventory</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,117,809</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,010,731</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 24, 2022 and September 25, 2021, the Company recognized impairment of nil and $<span id="xdx_905_eus-gaap--OtherAssetImpairmentCharges_pp0p0_c20210627__20210925_zd2HJUin9Npi">864,314</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, to write down inventory to its net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zmYCMqcoYoxi" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INVENTORY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8BE_zAGS1I0NLJIl" style="display: none">Schedule of inventories</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_495_20220924_zflnJV5buzD3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49E_20220625_zHsTHPWu7oE2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maCz8NO_z2cRN2Mkoxy5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw Materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">612,901</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">521,777</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_maCz8NO_ztZOjVz8CVl4" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work-in-Process</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,142,397</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">671,541</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoods_iI_maCz8NO_z5wnj2jRHTkf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Finished Goods</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,362,511</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,817,413</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryGross_iTI_mtCz8NO_zbvWpVWYrnZ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Inventory</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,117,809</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,010,731</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 612901 521777 1142397 671541 7362511 8817413 9117809 10010731 864314 <p id="xdx_805_ecustom--AssetsHeldForSaleTextBlock_z1XtAPHghgY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td> <td style="text-align: justify"><span id="xdx_82D_zToKhweMQZZe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSETS HELD FOR SALE</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of our assets held for sale is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAssetsHeldForSaleTableTextBlock_zUPBOQgE5Ii5" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - ASSETS HELD FOR SALE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_zhr1lRTYVhN" style="display: none">Schedule of asset held for sale</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Discontinued<br/> Operations <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other<br/> Assets</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iS_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zFvuJAPcNoA6" style="width: 9%; font-weight: bold; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">123,128,406</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iS_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_zhJhSnDokEWh" style="width: 9%; font-weight: bold; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">30,345</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iS_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_zOtnOD3owVmj" style="width: 9%; font-weight: bold; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">123,158,751</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Ongoing Activities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--OngoingActivityFromDiscontinuedOperations_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_z5MI98P5unF3" style="text-align: right" title="Ongoing Activities"><span style="font-family: Times New Roman, Times, Serif">(47,881,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--OngoingActivityFromDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_pp0p0" style="text-align: right" title="Ongoing Activities"><span style="font-family: Times New Roman, Times, Serif">248,324</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--OngoingActivityFromDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_pp0p0" style="text-align: right" title="Ongoing Activities"><span style="font-family: Times New Roman, Times, Serif">(47,633,294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from Sale</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ProceedsFromSaleDiscontinuedOperations_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zca3wicLOTcc" style="text-align: right" title="Proceeds from Sale"><span style="font-family: Times New Roman, Times, Serif">(67,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ProceedsFromSaleDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_pp0p0" style="text-align: right" title="Proceeds from Sale"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ProceedsFromSaleDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_pp0p0" style="text-align: right" title="Proceeds from Sale"><span style="font-family: Times New Roman, Times, Serif">(67,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Gain on Sale of Assets Held for Sale</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zccP2tobiOvg" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on Sale of Assets Held for Sale"><span style="font-family: Times New Roman, Times, Serif">35,659,761</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on Sale of Assets Held for Sale"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on Sale of Assets Held for Sale"><span style="font-family: Times New Roman, Times, Serif">35,659,761</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iE_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zRlN9vxuoewe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">43,906,549</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iE_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_zPasGI243J72" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">278,669</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iE_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_zNolXIGg8Xh8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">44,185,218</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F0E_zXXC0iMYmtwe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F10_zcMKByuTzMlk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See “Note 22 – Discontinued Operations” for further information.</i></span></td></tr> </table> <p id="xdx_8A5_zQACJgOtH8Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAssetsHeldForSaleTableTextBlock_zUPBOQgE5Ii5" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - ASSETS HELD FOR SALE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_zhr1lRTYVhN" style="display: none">Schedule of asset held for sale</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Discontinued<br/> Operations <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other<br/> Assets</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iS_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zFvuJAPcNoA6" style="width: 9%; font-weight: bold; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">123,128,406</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iS_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_zhJhSnDokEWh" style="width: 9%; font-weight: bold; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">30,345</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iS_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_zOtnOD3owVmj" style="width: 9%; font-weight: bold; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">123,158,751</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Ongoing Activities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--OngoingActivityFromDiscontinuedOperations_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_z5MI98P5unF3" style="text-align: right" title="Ongoing Activities"><span style="font-family: Times New Roman, Times, Serif">(47,881,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--OngoingActivityFromDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_pp0p0" style="text-align: right" title="Ongoing Activities"><span style="font-family: Times New Roman, Times, Serif">248,324</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--OngoingActivityFromDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_pp0p0" style="text-align: right" title="Ongoing Activities"><span style="font-family: Times New Roman, Times, Serif">(47,633,294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from Sale</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ProceedsFromSaleDiscontinuedOperations_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zca3wicLOTcc" style="text-align: right" title="Proceeds from Sale"><span style="font-family: Times New Roman, Times, Serif">(67,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ProceedsFromSaleDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_pp0p0" style="text-align: right" title="Proceeds from Sale"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ProceedsFromSaleDiscontinuedOperations_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_pp0p0" style="text-align: right" title="Proceeds from Sale"><span style="font-family: Times New Roman, Times, Serif">(67,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Gain on Sale of Assets Held for Sale</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zccP2tobiOvg" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on Sale of Assets Held for Sale"><span style="font-family: Times New Roman, Times, Serif">35,659,761</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on Sale of Assets Held for Sale"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on Sale of Assets Held for Sale"><span style="font-family: Times New Roman, Times, Serif">35,659,761</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iE_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--DiscontinuedOperationsMember_fKDEp_zRlN9vxuoewe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">43,906,549</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iE_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--OtherAssetMember_zPasGI243J72" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">278,669</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iE_pp0p0_c20220626__20220924__us-gaap--SubsidiarySaleOfStockAxis__custom--TotalMember_zNolXIGg8Xh8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">44,185,218</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F0E_zXXC0iMYmtwe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F10_zcMKByuTzMlk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See “Note 22 – Discontinued Operations” for further information.</i></span></td></tr> </table> 123128406 30345 123158751 -47881618 248324 -47633294 -67000000 -67000000 35659761 35659761 43906549 278669 44185218 <p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlMpSxwLRuel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td> <td style="text-align: justify"><span id="xdx_827_zGpObVQIPM3d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022 and June 25, 2022, property and equipment consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5APe4bz3SZf" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B4_z8sZgqUTkEzf" style="display: none">Schedule of property and equipment</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220924" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49D_20220625" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--Land_iI_zhmq8zoSmL77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Land and Buildings</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,933,999</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,933,999</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--CapitalLeasesLiabilities_iI_z35ui6T0yInb" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,318,516</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,315,625</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--FurnitureAndFixturesGross_iI_zj7Zdw7qUtli" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and Fixtures</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,325,228</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,776,994</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LeaseholdImprovementsGross_iI_zsiliSvxkODk" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,625,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,069,524</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOther_iI_z2AO7i4iIqD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equipment and Software</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,316,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,897,649</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_zwnFG7xRD7m6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Construction in Progress</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,528,762</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,828,923</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_zxloHqeDEP1l" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Property and Equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">98,048,732</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,822,714</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_di_zcXYyGxgRUVh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Accumulated Depreciation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(38,082,797</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(36,714,922</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_z1TElx1eJote" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment, Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59,965,935</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,107,792</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense related to continuing operations of $<span id="xdx_900_eus-gaap--OtherDepreciationAndAmortization_c20220626__20220924_pp0p0">2,258,354 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--OtherDepreciationAndAmortization_c20210627__20210925_pp0p0">3,031,080 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded for the three months ended September 24, 2022 and September 25, 2021, respectively, of which $<span id="xdx_902_eus-gaap--CostOfGoodsAndServicesSold_c20220626__20220924_pp0p0">24,950 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_902_eus-gaap--CostOfGoodsAndServicesSold_c20210627__20210925_pp0p0">433,300</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, is included in cost of goods sold. The amount of depreciation recognized for the capital leases during the three months ended September 24, 2022 and September 25, 2021 was $<span id="xdx_900_ecustom--DepreciationRecognizedForCapitalLeases_pp0p0_c20220626__20220924_zn9E24bD4Gd5" title="Depreciation recognized for capital leases">347,406 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_901_ecustom--DepreciationRecognizedForCapitalLeases_c20210627__20210925_pp0p0">283,406</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, see <i>“Note 9 – Leases” </i>for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowing costs were not capitalized as there were no active construction projects in progress during the three months ended September 24, 2022. During the three months ended September 25, 2021, borrowing costs totaling $<span id="xdx_90E_ecustom--BorrowingCosts_c20220626__20220924_pp0p0">375,241 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were capitalized using an average capitalization rate of <span id="xdx_903_ecustom--AverageCapitalizationRate_dp_c20220626__20220924_zXuWkoKgSiLh">11.95</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5APe4bz3SZf" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B4_z8sZgqUTkEzf" style="display: none">Schedule of property and equipment</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220924" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49D_20220625" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--Land_iI_zhmq8zoSmL77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Land and Buildings</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,933,999</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,933,999</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--CapitalLeasesLiabilities_iI_z35ui6T0yInb" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,318,516</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,315,625</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--FurnitureAndFixturesGross_iI_zj7Zdw7qUtli" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and Fixtures</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,325,228</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,776,994</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LeaseholdImprovementsGross_iI_zsiliSvxkODk" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,625,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,069,524</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOther_iI_z2AO7i4iIqD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equipment and Software</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,316,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,897,649</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_zwnFG7xRD7m6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Construction in Progress</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,528,762</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,828,923</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_zxloHqeDEP1l" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Property and Equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">98,048,732</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,822,714</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_di_zcXYyGxgRUVh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Accumulated Depreciation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(38,082,797</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(36,714,922</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_z1TElx1eJote" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment, Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59,965,935</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,107,792</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 29933999 29933999 5318516 5315625 8325228 8776994 33625893 33069524 16316334 16897649 4528762 6828923 98048732 100822714 38082797 36714922 59965935 64107792 2258354 3031080 24950 433300 347406 283406 375241 0.1195 <p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zt4BwJGTf9j7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td> <td style="text-align: justify"><span id="xdx_82C_zMd0KInGukgj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSETS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022 and June 25, 2022, intangible assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ztQkHFEIyGmh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B7_z5JnoIJY3uT8" style="display: none">Schedule of Intangible assets</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dispensary Licenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_pp0p0" style="width: 9%; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">49,253,452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_pp0p0" style="width: 9%; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">49,253,452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer Relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">16,409,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">16,409,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized Software</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">7,413,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">7,413,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Intellectual Property</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">4,016,597</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">4,016,597</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Intangible Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">77,093,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">77,093,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dispensary Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_zogQGMCoVCj6" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(17,477,268</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_zuNNfGbHRIja" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(16,876,912</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer Relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_zlqlnQx6kcm2" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(16,589,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_zHF54HQx48yd" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(15,870,284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized Software</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_z0IhU5jwEZrd" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,681,748</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_zUxIioaH3fKh" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,413,974</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Intellectual Property</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zHigaxwXshvl" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,287,401</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zRuD5oJyJyQa" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,185,835</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Accumulated Amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924_zz4HyIJ6IF39" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(43,036,068</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625_ztOFnVtqHYY8" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(41,347,005</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Intangible Assets, Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--IntangibleAssetNetExcludingGoodwill_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Intangible Assets, Net"><span style="font-family: Times New Roman, Times, Serif">34,057,051</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--IntangibleAssetNetExcludingGoodwill_c20220625_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Intangible Assets, Net"><span style="font-family: Times New Roman, Times, Serif">35,746,114</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded amortization expense related to continuing operations of $<span id="xdx_900_eus-gaap--DepreciationAndAmortization_c20220626__20220924_pp0p0">1,713,119 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--DepreciationAndAmortization_c20210627__20210925_pp0p0">3,225,837 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the three months ended September 24, 2022 and September 25, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ztQkHFEIyGmh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B7_z5JnoIJY3uT8" style="display: none">Schedule of Intangible assets</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dispensary Licenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_pp0p0" style="width: 9%; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">49,253,452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_pp0p0" style="width: 9%; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">49,253,452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer Relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">16,409,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">16,409,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized Software</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">7,413,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">7,413,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Intellectual Property</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">4,016,597</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">4,016,597</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Intangible Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220924_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">77,093,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_c20220625_pp0p0" style="text-align: right" title="Total Intangible Assets"><span style="font-family: Times New Roman, Times, Serif">77,093,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dispensary Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_zogQGMCoVCj6" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(17,477,268</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__srt--ProductOrServiceAxis__custom--DispensaryLicenseMember_zuNNfGbHRIja" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(16,876,912</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer Relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_zlqlnQx6kcm2" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(16,589,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipMember_zHF54HQx48yd" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(15,870,284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized Software</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_z0IhU5jwEZrd" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,681,748</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CapitalizedSoftwareMember_zUxIioaH3fKh" style="text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,413,974</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Intellectual Property</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zHigaxwXshvl" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,287,401</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zRuD5oJyJyQa" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(4,185,835</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Accumulated Amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220924_zz4HyIJ6IF39" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(43,036,068</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220625_ztOFnVtqHYY8" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">(41,347,005</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Intangible Assets, Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--IntangibleAssetNetExcludingGoodwill_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Intangible Assets, Net"><span style="font-family: Times New Roman, Times, Serif">34,057,051</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--IntangibleAssetNetExcludingGoodwill_c20220625_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Intangible Assets, Net"><span style="font-family: Times New Roman, Times, Serif">35,746,114</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 49253452 49253452 16409600 16409600 7413470 7413470 4016597 4016597 77093119 77093119 17477268 16876912 16589651 15870284 4681748 4413974 4287401 4185835 43036068 41347005 34057051 35746114 1713119 3225837 <p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zqWcGpcskEv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td> <td style="text-align: justify"><span id="xdx_82C_zJum7M1Ec7va" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxeQOizEWeth" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B0_zYH6SfZul4A5" style="display: none">Schedule of accounts payable and accrued liabilities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220924_us-gaap--ExtinguishmentOfDebtAxis_us-gaap--AccountsPayableAndAccruedLiabilitiesMember" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220625_us-gaap--ExtinguishmentOfDebtAxis_us-gaap--AccountsPayableAndAccruedLiabilitiesMember" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_iI_zxZunwDGA1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,078,177</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,627,746</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iI_zNl7aS6XwYu8" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,784,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,031,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--AccruedInventory_iI_z50AUOBZ5sTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,129,868</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,868,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AccruedPayrollTaxesCurrent_iI_z4bTHRi33EHi" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Payroll</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,081,284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,682,517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_zjBStemL1p62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Local &amp; State Taxes Payable</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,281,687</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,695,532</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zsgj9XpL3A6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Accounts Payable and Accrued Liabilities</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,355,136</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,905,818</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxeQOizEWeth" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B0_zYH6SfZul4A5" style="display: none">Schedule of accounts payable and accrued liabilities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220924_us-gaap--ExtinguishmentOfDebtAxis_us-gaap--AccountsPayableAndAccruedLiabilitiesMember" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220625_us-gaap--ExtinguishmentOfDebtAxis_us-gaap--AccountsPayableAndAccruedLiabilitiesMember" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_iI_zxZunwDGA1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,078,177</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,627,746</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iI_zNl7aS6XwYu8" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,784,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,031,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--AccruedInventory_iI_z50AUOBZ5sTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,129,868</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,868,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AccruedPayrollTaxesCurrent_iI_z4bTHRi33EHi" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Payroll</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,081,284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,682,517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_zjBStemL1p62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Local &amp; State Taxes Payable</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,281,687</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,695,532</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zsgj9XpL3A6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Accounts Payable and Accrued Liabilities</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,355,136</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,905,818</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 19078177 14627746 7784119 10031194 3129868 5868831 2081284 1682517 3281687 6695532 35355136 38905818 <p id="xdx_801_ecustom--DerivativeLiabilitiesTextBlock_zLJg7eden042" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td> <td style="text-align: justify"><span id="xdx_824_zABWHXdeiYck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DERIVATIVE LIABILITIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three months ended September 24, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock_zr1dDb1QANd9" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B1_zIfWJtEkTfrj" style="display: none">Schedule of reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at Beginning of Period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesOneMember_zIAzFNU89lMc" style="width: 9%; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">6,749,563</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Change in Fair Value of Derivative Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pp0p0_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesOneMember_zCeemWv9njs4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in Fair Value of Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif">805,590</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at End of Period</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesOneMember_zoF8BYZfxy9e" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">7,555,153</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zvLUqe4zoIH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2021, in connection with the amended and restated senior secured convertible credit facility (the Sixth Amendment”), the Company provided the note holders top-up and preemptive rights which were bifurcated from the related notes and classified as a derivative due to the variability of the number and price of shares issuable under these rights. See “<i>Note 11 – Senior Secured Convertible Credit Facility” </i>for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at September 24, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zlfmi9frGWf5" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zQmOsNEtGmP8" style="display: none">Schedule of assumptions to measure fair value</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Top-Up<br/> Provision</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Average Stock Price</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_c20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_pdd" style="font-family: Times New Roman, Times, Serif">0.04</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Probability</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_zYrO9WAoJIgb" style="font-family: Times New Roman, Times, Serif">50.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Term (in Years)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_z5a2FkdWfQ2f" style="font-family: Times New Roman, Times, Serif">5.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Stock Price Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_z3pU8YucyVd2" style="font-family: Times New Roman, Times, Serif">96.68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8A1_zRQPhrSnXyL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfWarrantsIssuedTableTextBlock_zQgt6iMgU6mj" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BA_zU17paSJocCk" style="display: none">Schedule of warrant issued</span><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"/> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Warrants</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/> Price</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration<br/> Date</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 62%; padding-bottom: 1pt; font-weight: 400; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">March 2021 Private Placement <span style="font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400"><sup>(1)</sup></span></span></td><td style="width: 1%; padding-bottom: 1pt; font-weight: 400; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><span id="xdx_90E_ecustom--March2021PrivatePlacement_iI_c20220924_fKDEp_zZnoqz5N5uJc" style="font-family: Times New Roman, Times, Serif">50,000,000</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 10%; padding-bottom: 1pt; text-align: center">C$<span style="font-family: Times New Roman, Times, Serif">0.50</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; width: 12%; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">March 27, 2024</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"/> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"/> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--Total_c20220924_pdd" style="font-family: Times New Roman, Times, Serif">50,000,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; padding-bottom: 2.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F09_zAo4iBWMt7Vk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F1F_zRalA0n0zUt8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See “Note 12 – Shareholders’ Equity” for further information.</i></span></td></tr> </table> <p id="xdx_8AD_zUdC15wmDnn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zQBMSxXBdlj9" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zULi1MMArgrj" style="display: none">Schedule of assumptions to measure fair value</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Stock Price Volatility</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220626__20220924_zzBF5bQ6V98e" style="font-family: Times New Roman, Times, Serif">106.25</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-Free Annual Interest Rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220626__20220924_zJIIOVvEgDQf" style="font-family: Times New Roman, Times, Serif">2.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Life (in Years)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220626__20220924_zdKOo66495S6" style="font-family: Times New Roman, Times, Serif">0.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share Price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharePrice_c20220924_pdd" style="font-family: Times New Roman, Times, Serif">0.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220924_pdd" style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zcxMRazhzwt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock_zr1dDb1QANd9" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B1_zIfWJtEkTfrj" style="display: none">Schedule of reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at Beginning of Period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesOneMember_zIAzFNU89lMc" style="width: 9%; text-align: right" title="Balance at Beginning of Period"><span style="font-family: Times New Roman, Times, Serif">6,749,563</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Change in Fair Value of Derivative Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pp0p0_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesOneMember_zCeemWv9njs4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in Fair Value of Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif">805,590</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at End of Period</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesOneMember_zoF8BYZfxy9e" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at End of Period"><span style="font-family: Times New Roman, Times, Serif">7,555,153</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 6749563 805590 7555153 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zlfmi9frGWf5" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zQmOsNEtGmP8" style="display: none">Schedule of assumptions to measure fair value</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Top-Up<br/> Provision</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Average Stock Price</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_c20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_pdd" style="font-family: Times New Roman, Times, Serif">0.04</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Probability</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_zYrO9WAoJIgb" style="font-family: Times New Roman, Times, Serif">50.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Term (in Years)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_z5a2FkdWfQ2f" style="font-family: Times New Roman, Times, Serif">5.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Stock Price Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220626__20220924__us-gaap--FinancialInstrumentAxis__custom--TopUpProvisionMember_z3pU8YucyVd2" style="font-family: Times New Roman, Times, Serif">96.68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 0.04 0.5000 P5Y 0.9668 <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfWarrantsIssuedTableTextBlock_zQgt6iMgU6mj" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BA_zU17paSJocCk" style="display: none">Schedule of warrant issued</span><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"/> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Warrants</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/> Price</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration<br/> Date</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 62%; padding-bottom: 1pt; font-weight: 400; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">March 2021 Private Placement <span style="font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400"><sup>(1)</sup></span></span></td><td style="width: 1%; padding-bottom: 1pt; font-weight: 400; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><span id="xdx_90E_ecustom--March2021PrivatePlacement_iI_c20220924_fKDEp_zZnoqz5N5uJc" style="font-family: Times New Roman, Times, Serif">50,000,000</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 10%; padding-bottom: 1pt; text-align: center">C$<span style="font-family: Times New Roman, Times, Serif">0.50</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; width: 12%; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">March 27, 2024</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"/> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"/> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--Total_c20220924_pdd" style="font-family: Times New Roman, Times, Serif">50,000,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; padding-bottom: 2.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F09_zAo4iBWMt7Vk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F1F_zRalA0n0zUt8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See “Note 12 – Shareholders’ Equity” for further information.</i></span></td></tr> </table> 50000000 50000000 <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zQBMSxXBdlj9" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zULi1MMArgrj" style="display: none">Schedule of assumptions to measure fair value</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Stock Price Volatility</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220626__20220924_zzBF5bQ6V98e" style="font-family: Times New Roman, Times, Serif">106.25</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-Free Annual Interest Rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220626__20220924_zJIIOVvEgDQf" style="font-family: Times New Roman, Times, Serif">2.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Life (in Years)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220626__20220924_zdKOo66495S6" style="font-family: Times New Roman, Times, Serif">0.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share Price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharePrice_c20220924_pdd" style="font-family: Times New Roman, Times, Serif">0.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220924_pdd" style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1.0625 0.0251 P0Y6M 0.04 0.37 <p id="xdx_803_eus-gaap--LeasesOfLesseeDisclosureTextBlock_z5IU8zhfx5yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td> <td style="text-align: justify"><span id="xdx_822_zYxro8F1R7ll" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended September 24, 2022 and September 25, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfLeaseCostTableTextblock_z2i5BMW6JgLl" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - LEASES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B0_zHkrhlNkVB2a" style="display: none">Schedule of lease cost</span></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49C_20220626__20220924_zvp7X0wWWaQ7" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_498_20210627__20210925_zFhjeIgawLH" style="padding-bottom: 1pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--FinanceLeaseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance Lease Cost:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of Finance Lease Right-of-Use Assets</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">347,406</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,406</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--InterestOnLeaseLiabilities_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest on Lease Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,804,507</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,784,541</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,453,863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,595,652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--SubleaseIncome_iN_pp0p0_di_zAWKIXwLFZr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Sublease Income <span id="xdx_F4F_zXyN5JmLYAa2" style="font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400"><sup>(1)</sup></span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,521,693</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseExpense_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Lease Expenses</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,605,776</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,663,599</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--CashFlowInvestingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Paid for Amounts Included in the Measurement of Lease Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--FinancingCashFlowsFromFinanceLeases_zdUgMUaUV7y2" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing Cash Flows from Finance Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,484</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">959</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--OperatingCashFlowFromOperatingLeases_zsuIt4bbLj9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Cash Flows from Operating Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,026,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,478,891</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F04_zXo4Iz4rYjC7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F13_zLnk2GkAYdGh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See “Note 16 – Other Operating Income” for further information. </i></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of September 24, 2022 and June 25, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Remaining Lease Term (Years) - Finance Leases</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220924_zpG9LeyCWhlg" style="font-family: Times New Roman, Times, Serif">47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220625_zDvMKwBhdlhi" style="font-family: Times New Roman, Times, Serif">46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Remaining Lease Term (Years) - Operating Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220924_zcpHTXtZ5fLc" style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220625_zQxYuSC1mui7" style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Discount Rate - Finance Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_906_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220924_zpHQ5nHg1cb2" style="font-family: Times New Roman, Times, Serif">24.78</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220625_z4UJfsMPUGhc" style="font-family: Times New Roman, Times, Serif">24.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Discount Rate - Operating Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220924_zkRLybBXA3od" style="font-family: Times New Roman, Times, Serif">15.96</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220625_zAk8XFXh5q13" style="font-family: Times New Roman, Times, Serif">18.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8A6_zUQzlj0s2sp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future lease payments under non-cancellable operating leases and finance leases as of September 24, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_zJnQheIsbGWl" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - LEASES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B3_zDDEnXMHhTM6" style="display: none">Schedule of future leases payments</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal Year Ending</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating<br/> Leases</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance<br/> Leases</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">July 1, 2023 (remaining)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_c20220924_pp0p0" style="width: 9%; text-align: right" title="July 1, 2023 (remaining)"><span style="font-family: Times New Roman, Times, Serif">9,155,365</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20220924_pp0p0" style="width: 9%; text-align: right" title="July 1, 2023 (remaining)"><span style="font-family: Times New Roman, Times, Serif">4,387,279</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 29, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--CapitalLeasesFutureMinimumPaymentsDueInTwoYears_c20220924_pp0p0" style="text-align: right" title="June 29, 2024"><span style="font-family: Times New Roman, Times, Serif">16,183,010</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20220924_pp0p0" style="text-align: right" title="June 29, 2024"><span style="font-family: Times New Roman, Times, Serif">10,961,495</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 28, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c20220924_pp0p0" style="text-align: right" title="June 28, 2025"><span style="font-family: Times New Roman, Times, Serif">25,224,922</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20220924_pp0p0" style="text-align: right" title="June 28, 2025"><span style="font-family: Times New Roman, Times, Serif">14,020,131</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 27, 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_c20220924_pp0p0" style="text-align: right" title="June 27, 2026"><span style="font-family: Times New Roman, Times, Serif">12,675,441</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20220924_pp0p0" style="text-align: right" title="June 27, 2026"><span style="font-family: Times New Roman, Times, Serif">7,300,368</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 26, 2027</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c20220924_pp0p0" style="text-align: right" title="June 26, 2027"><span style="font-family: Times New Roman, Times, Serif">12,716,234</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20220924_pp0p0" style="text-align: right" title="June 26, 2027"><span style="font-family: Times New Roman, Times, Serif">7,519,379</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueThereafter_c20220924_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif">20,832,425</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20220924_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif">1,054,354,990</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Lease Payments</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_c20220924_pp0p0" style="text-align: right" title="Total lease payment"><span style="font-family: Times New Roman, Times, Serif">96,787,396</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_c20220924_pp0p0" style="text-align: right" title="Total lease payment"><span style="font-family: Times New Roman, Times, Serif">1,098,543,643</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Interest</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20220924_zNE5uGnifdhc" style="border-bottom: Black 1pt solid; text-align: right" title="Less Interest"><span style="font-family: Times New Roman, Times, Serif">(37,307,828</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20220924_z4maxiBW2p41" style="border-bottom: Black 1pt solid; text-align: right" title="Less Interest"><span style="font-family: Times New Roman, Times, Serif">(1,067,487,335</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease Liability Recognized</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Lease Liability Recognized"><span style="font-family: Times New Roman, Times, Serif">59,479,568</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Lease Liability Recognized"><span style="font-family: Times New Roman, Times, Serif">31,056,308</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zZFwy17Ukxe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into a management agreement (the “Management Agreement”) with a third party to operate its cultivation facilities in California and Nevada (the “Cultivation Facilities”). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the “Purchase Option”). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of September 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three months ended September 24, 2022, the Company recorded sublease income under the Management Agreement. See “<i>Note 16 – Other Operating Income</i>” for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfLeaseCostTableTextblock_z2i5BMW6JgLl" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - LEASES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B0_zHkrhlNkVB2a" style="display: none">Schedule of lease cost</span></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49C_20220626__20220924_zvp7X0wWWaQ7" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_498_20210627__20210925_zFhjeIgawLH" style="padding-bottom: 1pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--FinanceLeaseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance Lease Cost:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of Finance Lease Right-of-Use Assets</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">347,406</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,406</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--InterestOnLeaseLiabilities_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest on Lease Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,804,507</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,784,541</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,453,863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,595,652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--SubleaseIncome_iN_pp0p0_di_zAWKIXwLFZr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Sublease Income <span id="xdx_F4F_zXyN5JmLYAa2" style="font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400"><sup>(1)</sup></span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,521,693</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseExpense_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Lease Expenses</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,605,776</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,663,599</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--CashFlowInvestingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Paid for Amounts Included in the Measurement of Lease Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--FinancingCashFlowsFromFinanceLeases_zdUgMUaUV7y2" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing Cash Flows from Finance Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,484</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">959</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--OperatingCashFlowFromOperatingLeases_zsuIt4bbLj9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Cash Flows from Operating Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,026,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,478,891</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F04_zXo4Iz4rYjC7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F13_zLnk2GkAYdGh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See “Note 16 – Other Operating Income” for further information. </i></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of September 24, 2022 and June 25, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Remaining Lease Term (Years) - Finance Leases</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220924_zpG9LeyCWhlg" style="font-family: Times New Roman, Times, Serif">47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220625_zDvMKwBhdlhi" style="font-family: Times New Roman, Times, Serif">46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Remaining Lease Term (Years) - Operating Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220924_zcpHTXtZ5fLc" style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220625_zQxYuSC1mui7" style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Discount Rate - Finance Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_906_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220924_zpHQ5nHg1cb2" style="font-family: Times New Roman, Times, Serif">24.78</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220625_z4UJfsMPUGhc" style="font-family: Times New Roman, Times, Serif">24.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Discount Rate - Operating Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220924_zkRLybBXA3od" style="font-family: Times New Roman, Times, Serif">15.96</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220625_zAk8XFXh5q13" style="font-family: Times New Roman, Times, Serif">18.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 347406 283406 1804507 1784541 3453863 6595652 1521693 5605776 8663599 2484 959 1026792 3478891 P47Y P46Y P7Y P8Y 0.2478 0.2433 0.1596 0.1870 <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_zJnQheIsbGWl" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - LEASES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B3_zDDEnXMHhTM6" style="display: none">Schedule of future leases payments</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal Year Ending</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating<br/> Leases</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance<br/> Leases</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">July 1, 2023 (remaining)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_c20220924_pp0p0" style="width: 9%; text-align: right" title="July 1, 2023 (remaining)"><span style="font-family: Times New Roman, Times, Serif">9,155,365</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20220924_pp0p0" style="width: 9%; text-align: right" title="July 1, 2023 (remaining)"><span style="font-family: Times New Roman, Times, Serif">4,387,279</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 29, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--CapitalLeasesFutureMinimumPaymentsDueInTwoYears_c20220924_pp0p0" style="text-align: right" title="June 29, 2024"><span style="font-family: Times New Roman, Times, Serif">16,183,010</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20220924_pp0p0" style="text-align: right" title="June 29, 2024"><span style="font-family: Times New Roman, Times, Serif">10,961,495</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 28, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c20220924_pp0p0" style="text-align: right" title="June 28, 2025"><span style="font-family: Times New Roman, Times, Serif">25,224,922</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20220924_pp0p0" style="text-align: right" title="June 28, 2025"><span style="font-family: Times New Roman, Times, Serif">14,020,131</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 27, 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_c20220924_pp0p0" style="text-align: right" title="June 27, 2026"><span style="font-family: Times New Roman, Times, Serif">12,675,441</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20220924_pp0p0" style="text-align: right" title="June 27, 2026"><span style="font-family: Times New Roman, Times, Serif">7,300,368</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 26, 2027</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c20220924_pp0p0" style="text-align: right" title="June 26, 2027"><span style="font-family: Times New Roman, Times, Serif">12,716,234</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20220924_pp0p0" style="text-align: right" title="June 26, 2027"><span style="font-family: Times New Roman, Times, Serif">7,519,379</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueThereafter_c20220924_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif">20,832,425</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20220924_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif">1,054,354,990</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Lease Payments</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_c20220924_pp0p0" style="text-align: right" title="Total lease payment"><span style="font-family: Times New Roman, Times, Serif">96,787,396</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_c20220924_pp0p0" style="text-align: right" title="Total lease payment"><span style="font-family: Times New Roman, Times, Serif">1,098,543,643</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Interest</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20220924_zNE5uGnifdhc" style="border-bottom: Black 1pt solid; text-align: right" title="Less Interest"><span style="font-family: Times New Roman, Times, Serif">(37,307,828</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20220924_z4maxiBW2p41" style="border-bottom: Black 1pt solid; text-align: right" title="Less Interest"><span style="font-family: Times New Roman, Times, Serif">(1,067,487,335</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease Liability Recognized</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Lease Liability Recognized"><span style="font-family: Times New Roman, Times, Serif">59,479,568</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Lease Liability Recognized"><span style="font-family: Times New Roman, Times, Serif">31,056,308</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 9155365 4387279 16183010 10961495 25224922 14020131 12675441 7300368 12716234 7519379 20832425 1054354990 96787396 1098543643 37307828 1067487335 59479568 31056308 <p id="xdx_80E_ecustom--NotesPayableTextBlock_zRHjTFcZGgtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td> <td style="text-align: justify"><span id="xdx_825_zQ6o9o90dRE3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES PAYABLE</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022 and June 25, 2022, notes payable consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zktxZZMoB9r2" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B0_zmOt1zGHybil" style="display: none">Schedule of notes payable</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityCurrent_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="width: 9%; text-align: right" title="Finance liabilities"><span style="font-family: Times New Roman, Times, Serif">72,300,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityCurrent_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="width: 9%; text-align: right" title="Finance liabilities"><span style="font-family: Times New Roman, Times, Serif">72,300,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum.</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--NotesPayableCurrent_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Notes Payable, Current"><span style="font-family: Times New Roman, Times, Serif">66,819,991</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Notes Payable, Current"><span style="font-family: Times New Roman, Times, Serif">97,162,001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471.</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--DebtInstrumentFairValue_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Promissory notes"><span style="font-family: Times New Roman, Times, Serif">2,057,207</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--DebtInstrumentFairValue_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Promissory notes"><span style="font-family: Times New Roman, Times, Serif">2,057,207</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--OtherNotesPayable_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">15,691</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--OtherNotesPayable_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">15,691</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Notes Payable</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--NotesPayable_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Total notes Payables"><span style="font-family: Times New Roman, Times, Serif">141,192,889</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--NotesPayable_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Total notes Payables"><span style="font-family: Times New Roman, Times, Serif">171,534,899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Unamortized Debt Issuance Costs and Loan Origination Fees</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less. Unamortization Debt Issuance Cost an Loan Origination Fess"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less. Unamortization Debt Issuance Cost an Loan Origination Fess"><span style="font-family: Times New Roman, Times, Serif">(158,079</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Amount</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Net Amount"><span style="font-family: Times New Roman, Times, Serif">141,192,889</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Net Amount"><span style="font-family: Times New Roman, Times, Serif">171,376,820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Current Portion of Notes Payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesNoncurrent_iNI_pp0p0_di_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zO2fsP7U9K9" style="border-bottom: Black 1pt solid; text-align: right" title="Less Current Portion of Notes Payable"><span style="font-family: Times New Roman, Times, Serif">(66,294,249</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesNoncurrent_iNI_pp0p0_di_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zqwQJDmqOm25" style="border-bottom: Black 1pt solid; text-align: right" title="Less Current Portion of Notes Payable"><span style="font-family: Times New Roman, Times, Serif">(97,003,922</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Notes Payable, Net of Current Portion</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NotesAndLoansPayableCurrent_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payables, net of Current Portion"><span style="font-family: Times New Roman, Times, Serif">74,898,640</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--NotesAndLoansPayableCurrent_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payables, net of Current Portion"><span style="font-family: Times New Roman, Times, Serif">74,372,898</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zEGaJX7YSJd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balances of notes payable for the three months ended September 24, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfReconciliationOfNotesPayable_zzFbwNYFvlX8" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B8_zUbAsuvmFhMc" style="display: none">Schedule of Reconciliation of Notes payable</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at Beginning of Period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_zHfdnkto3q52" style="width: 9%; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif">171,376,820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paid-In-Kind Interest Capitalized</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--PaidInKindInterestCapitalized_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="text-align: right" title="Paid in kind interest Capitalized"><span style="font-family: Times New Roman, Times, Serif">1,257,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Payments</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_zHLw2hmAtjFk" style="text-align: right" title="Cash payments"><span style="font-family: Times New Roman, Times, Serif">(31,599,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accretion of Debt Discount Included in Discontinued Operations</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--AccretionOfDebtDiscountIncludedInDiscontinuedOperations_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of Debt Discount included in Discontinued Operations"><span style="font-family: Times New Roman, Times, Serif">158,079</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at End of Period</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--NotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_z5yshL7mUC2g" style="font-weight: bold; text-align: right" title="Balance at End of period"><span style="font-family: Times New Roman, Times, Serif">141,192,889</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Current Portion of Notes Payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--LessCurrentPortionOfNotesPayables_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less Current portion of notes payables"><span style="font-family: Times New Roman, Times, Serif">(66,294,249</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Notes Payable, Net of Current Portion</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NotesIssued1_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes payable, Net of Current portion"><span style="font-family: Times New Roman, Times, Serif">74,898,640</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zU2Nr9i1dG5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Revolving Senior Secured Term Loan Facility</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification required that the Company make a mandatory prepayment of at least $<span id="xdx_908_eus-gaap--ProceedsFromSaleOfOtherAssets1_c20220129__20220202_pp0p0">37,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event the sale of certain assets and imposed covenants in regards to strategic actions the Company would have to implement if unable to pay the Term Loans by the extended stated maturity date.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $<span id="xdx_90E_eus-gaap--ProceedsFromRepaymentsOfDebt_c20220626__20220924_pp0p0">31,599,999</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with proceeds from the sale. An additional $8,500,000 principal repayment will be made in 2023 upon receipt of the final installment payment from the sale of the Company’s Florida-based operations. The Facility and Term Loans remain in default as of September 24, 2022 as the principal balance matured on July 31, 2022 and August 1, 2022, respectively. As of September 24, 2022, the Company is in ongoing discussions with the Lenders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zktxZZMoB9r2" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B0_zmOt1zGHybil" style="display: none">Schedule of notes payable</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityCurrent_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="width: 9%; text-align: right" title="Finance liabilities"><span style="font-family: Times New Roman, Times, Serif">72,300,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityCurrent_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="width: 9%; text-align: right" title="Finance liabilities"><span style="font-family: Times New Roman, Times, Serif">72,300,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum.</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--NotesPayableCurrent_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Notes Payable, Current"><span style="font-family: Times New Roman, Times, Serif">66,819,991</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Notes Payable, Current"><span style="font-family: Times New Roman, Times, Serif">97,162,001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471.</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--DebtInstrumentFairValue_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Promissory notes"><span style="font-family: Times New Roman, Times, Serif">2,057,207</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--DebtInstrumentFairValue_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Promissory notes"><span style="font-family: Times New Roman, Times, Serif">2,057,207</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--OtherNotesPayable_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">15,691</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--OtherNotesPayable_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">15,691</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Notes Payable</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--NotesPayable_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Total notes Payables"><span style="font-family: Times New Roman, Times, Serif">141,192,889</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--NotesPayable_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Total notes Payables"><span style="font-family: Times New Roman, Times, Serif">171,534,899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Unamortized Debt Issuance Costs and Loan Origination Fees</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less. Unamortization Debt Issuance Cost an Loan Origination Fess"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less. Unamortization Debt Issuance Cost an Loan Origination Fess"><span style="font-family: Times New Roman, Times, Serif">(158,079</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Amount</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Net Amount"><span style="font-family: Times New Roman, Times, Serif">141,192,889</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="text-align: right" title="Net Amount"><span style="font-family: Times New Roman, Times, Serif">171,376,820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Current Portion of Notes Payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesNoncurrent_iNI_pp0p0_di_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zO2fsP7U9K9" style="border-bottom: Black 1pt solid; text-align: right" title="Less Current Portion of Notes Payable"><span style="font-family: Times New Roman, Times, Serif">(66,294,249</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesNoncurrent_iNI_pp0p0_di_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zqwQJDmqOm25" style="border-bottom: Black 1pt solid; text-align: right" title="Less Current Portion of Notes Payable"><span style="font-family: Times New Roman, Times, Serif">(97,003,922</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Notes Payable, Net of Current Portion</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NotesAndLoansPayableCurrent_c20220924__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payables, net of Current Portion"><span style="font-family: Times New Roman, Times, Serif">74,898,640</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--NotesAndLoansPayableCurrent_c20220625__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payables, net of Current Portion"><span style="font-family: Times New Roman, Times, Serif">74,372,898</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 72300000 72300000 66819991 97162001 2057207 2057207 15691 15691 141192889 171534899 -158079 141192889 171376820 66294249 97003922 74898640 74372898 <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfReconciliationOfNotesPayable_zzFbwNYFvlX8" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B8_zUbAsuvmFhMc" style="display: none">Schedule of Reconciliation of Notes payable</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at Beginning of Period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_zHfdnkto3q52" style="width: 9%; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif">171,376,820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paid-In-Kind Interest Capitalized</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--PaidInKindInterestCapitalized_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="text-align: right" title="Paid in kind interest Capitalized"><span style="font-family: Times New Roman, Times, Serif">1,257,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Payments</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_zHLw2hmAtjFk" style="text-align: right" title="Cash payments"><span style="font-family: Times New Roman, Times, Serif">(31,599,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accretion of Debt Discount Included in Discontinued Operations</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--AccretionOfDebtDiscountIncludedInDiscontinuedOperations_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of Debt Discount included in Discontinued Operations"><span style="font-family: Times New Roman, Times, Serif">158,079</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Balance at End of Period</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--NotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_z5yshL7mUC2g" style="font-weight: bold; text-align: right" title="Balance at End of period"><span style="font-family: Times New Roman, Times, Serif">141,192,889</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less Current Portion of Notes Payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--LessCurrentPortionOfNotesPayables_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less Current portion of notes payables"><span style="font-family: Times New Roman, Times, Serif">(66,294,249</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Notes Payable, Net of Current Portion</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NotesIssued1_c20220626__20220924__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes payable, Net of Current portion"><span style="font-family: Times New Roman, Times, Serif">74,898,640</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 171376820 1257988 31599999 158079 141192889 -66294249 74898640 37500000 31599999 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zNbBze0qpsWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td> <td style="text-align: justify"><span id="xdx_820_zNgf11Lkhlfa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SENIOR SECURED CONVERTIBLE CREDIT FACILITY</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zshomhOJBeo" style="width: 100%" summary="xdx: Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B9_zpLng35Dxzhk" style="display: none">Schedule of senior secured convertible credit facility</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Tranche</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1A</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNoteMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">23,376,684</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNoteMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">22,880,556</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; width: 65%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1B</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote1Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">100,679,152</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote1Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">98,542,422</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote2Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">32,738,817</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote2Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">32,043,996</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,677,140</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,408,091</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote4Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">14,911,453</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote4Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">14,594,985</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote5Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">23,932,224</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote5Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">23,424,438</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">IA-1</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote6Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">3,346,889</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote6Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">3,275,857</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">IA-2</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote7Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">6,472,344</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote7Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">6,334,980</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote8Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">10,103,343</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote8Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">9,888,919</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote9Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">2,237,875</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote9Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">2,190,380</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote10Member_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,587,295</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote10Member_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,320,154</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Total Drawn on Senior Secured Convertible Credit Facility</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayable_c20220924_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">243,063,216</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ConvertibleNotesPayable_c20220625_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">237,904,778</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Less Unamortized Debt Discount</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20220924_znb1pfr2OEPa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less Unamortize Debt Discount"><span style="font-family: Times New Roman, Times, Serif">(104,317,146</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20220625_zoBJL9EMxnO9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less Unamortize Debt Discount"><span style="font-family: Times New Roman, Times, Serif">(105,899,115</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior Secured Convertible Credit Facility, Net</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ConvertibleDebtCurrent_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Senior Secured Convertible Credit Facility Net"><span style="font-family: Times New Roman, Times, Serif">138,746,070</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ConvertibleDebtCurrent_c20220625_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Senior Secured Convertible Credit Facility Net"><span style="font-family: Times New Roman, Times, Serif">132,005,663</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_zq2bsoRK3hjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the three months ended September 24, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> <span id="xdx_8BD_zpeyHO1FvhHf" style="display: none">Schedule of reconciliation senior secured convertible credit facility</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tranche 1</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tranche 2</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tranche 3</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tranche 4</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Incremental Advance - 1</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Incremental Advance - 2</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3rd Advance</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amendment <br/> Fee Notes</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Restatement Fee Notes</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2nd Restatement Fee Notes</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_981_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheOneMember_zn7okpF691Sj" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">80,178,586</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_983_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheTwoMember_zaIUqrX06Tb5" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21,218,356</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98E_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheThreeMember_zK5aq04pxchh" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,217,079</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_980_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheFourMember_zf5fWLgcBKKi" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,051,827</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_988_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceOneMember_zBIEjLi5oV1h" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">224,585</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_980_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceTwoMember_zRkmfR5qbn98" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">433,598</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98F_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--Advance3rdMember_zi3kfv7AUeA9" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">842,981</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--AmendmentFeeNotesMember_zfy880ECX6o5" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,512,409</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_988_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--RestatementFeeNotesMember_zMPJklNtux2b" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,211,711</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_989_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--SecondRestatementFeeNotesMember_zpbxAZZDJQy" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,114,531</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_980_eus-gaap--OtherNotesPayableCurrent_iS_pp0p0_c20220626__20220924__us-gaap--InvestmentSecondaryCategorizationAxis__custom--SeniorSecuredConvertibleTotalMember_zx0oBrRsT66f" style="width: 5%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">132,005,663</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Paid-In-Kind Interest Capitalized</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98B_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheOneMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,632,858</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_981_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheTwoMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">694,821</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_981_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheThreeMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">269,049</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_988_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheFourMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">316,468</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_988_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceOneMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">71,032</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98F_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceTwoMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">137,364</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_982_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--Advance3rdMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">267,141</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_988_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--AmendmentFeeNotesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">507,786</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98D_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--RestatementFeeNotesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">214,424</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_985_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--VestingAxis__custom--SecondRestatementFeeNotesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">47,495</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98F_eus-gaap--InterestPaidCapitalized_c20220626__20220924__us-gaap--InvestmentSecondaryCategorizationAxis__custom--SeniorSecuredConvertibleTotalMember_pp0p0" style="font-size: 10pt; text-align: right" title="Paid-In-Kind Interest Capitalized"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,158,438</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accretion of Debt Discount</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_988_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheOneMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">988,849</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_981_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheTwoMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">260,580</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_984_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheThreeMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100,902</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98A_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheFourMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_988_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceOneMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_981_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceTwoMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_989_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--Advance3rdMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98C_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--AmendmentFeeNotesMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">190,486</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_982_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--RestatementFeeNotesMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">37,165</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_989_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--VestingAxis__custom--SecondRestatementFeeNotesMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,987</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98E_eus-gaap--AccretionExpense_c20220626__20220924__us-gaap--InvestmentSecondaryCategorizationAxis__custom--SeniorSecuredConvertibleTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accretion of Debt Discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,581,969</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheOneMember_zjkstHXus8L" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">83,800,293</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_984_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheTwoMember_zfV0m5RgOYJ8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">22,173,757</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_980_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheThreeMember_zeKRTpP8HoT5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,587,030</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98C_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--TrancheFourMember_zMda7oY7D61i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,368,295</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98A_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceOneMember_zDuzYGkirAdj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">295,617</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_981_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--IncrementalAdvanceTwoMember_zCiHs7DpopO4" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">570,962</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_983_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--Advance3rdMember_zPHhISGSEKak" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,110,122</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_980_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--AmendmentFeeNotesMember_zYxd8XJRzUx2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">16,210,681</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98D_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--RestatementFeeNotesMember_z9bFBTsqmZR1" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,463,300</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98A_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--VestingAxis__custom--SecondRestatementFeeNotesMember_zi8AgN5gK7Y1" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,166,013</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td id="xdx_98A_eus-gaap--OtherNotesPayableCurrent_iE_pp0p0_c20220626__20220924__us-gaap--InvestmentSecondaryCategorizationAxis__custom--SeniorSecuredConvertibleTotalMember_zrqnPv228osb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">138,746,070</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> </table> <p id="xdx_8A1_zqG73AHbtQ7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zshomhOJBeo" style="width: 100%" summary="xdx: Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B9_zpLng35Dxzhk" style="display: none">Schedule of senior secured convertible credit facility</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Tranche</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1A</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNoteMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">23,376,684</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNoteMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">22,880,556</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; width: 65%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1B</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote1Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">100,679,152</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote1Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">98,542,422</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote2Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">32,738,817</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote2Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">32,043,996</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,677,140</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,408,091</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote4Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">14,911,453</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote4Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">14,594,985</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote5Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">23,932,224</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote5Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">23,424,438</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">IA-1</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote6Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">3,346,889</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote6Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">3,275,857</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">IA-2</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote7Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">6,472,344</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote7Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">6,334,980</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote8Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">10,103,343</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote8Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">9,888,919</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote9Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">2,237,875</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote9Member_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">2,190,380</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum.</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ConvertibleNotesPayable_c20220924__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote10Member_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,587,295</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_c20220625__us-gaap--FinancialInstrumentAxis__custom--SecuredConvertibleNote10Member_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">12,320,154</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Total Drawn on Senior Secured Convertible Credit Facility</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayable_c20220924_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">243,063,216</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ConvertibleNotesPayable_c20220625_pp0p0" style="font-size: 10pt; text-align: right" title="Total Drawn On Senior Secured Convertible Credit Facility"><span style="font-family: Times New Roman, Times, Serif">237,904,778</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Less Unamortized Debt Discount</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20220924_znb1pfr2OEPa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less Unamortize Debt Discount"><span style="font-family: Times New Roman, Times, Serif">(104,317,146</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20220625_zoBJL9EMxnO9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less Unamortize Debt Discount"><span style="font-family: Times New Roman, Times, Serif">(105,899,115</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Senior Secured Convertible Credit Facility, Net</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ConvertibleDebtCurrent_c20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Senior Secured Convertible Credit Facility Net"><span style="font-family: Times New Roman, Times, Serif">138,746,070</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ConvertibleDebtCurrent_c20220625_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Senior Secured Convertible Credit Facility Net"><span style="font-family: Times New Roman, Times, Serif">132,005,663</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 23376684 22880556 100679152 98542422 32738817 32043996 12677140 12408091 14911453 14594985 23932224 23424438 3346889 3275857 6472344 6334980 10103343 9888919 2237875 2190380 12587295 12320154 243063216 237904778 104317146 105899115 138746070 132005663 80178586 21218356 8217079 1051827 224585 433598 842981 15512409 2211711 2114531 132005663 2632858 694821 269049 316468 71032 137364 267141 507786 214424 47495 5158438 988849 260580 100902 190486 37165 3987 1581969 83800293 22173757 8587030 1368295 295617 570962 1110122 16210681 2463300 2166013 138746070 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zGMdfRtyckI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td> <td style="text-align: justify"><span id="xdx_823_zWkAf8TtyAk5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHAREHOLDERS’ EQUITY</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issued and Outstanding</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending issued and outstanding shares is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfSharesIssuedAndOutstanding_zPdojluWLTc6" style="width: 100%" summary="xdx: Disclosure - SHAREHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span id="xdx_8B3_zbwO1zzLE5we" style="display: none">Schedule of Shares issued and outstanding</span></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Subordinate<br/> Voting Shares</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">MM CAN USA <br/> Class B<br/> Redeemable Units</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">MM Enterprises USA <br/> Common Units</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__custom--SubordinateVotingStockMember_zHTlzFoNpbV4" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,301,423,950</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_zTZiU9NKkhge" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">65,066,106</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmEnterprisesUsaCommonUnitsMember_zD63AiFW1Dzg" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">725,016</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Redemption of MedMen Corp Redeemable Shares</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--RedemptionOfMedmenCorpRedemableShares_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__custom--SubordinateVotingStockMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Redemption of MedMen Corp Redeemable Shares"><span style="font-family: Times New Roman, Times, Serif">259,814</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--RedemptionOfMedmenCorpRedemableShares_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Redemption of MedMen Corp Redeemable Shares"><span style="font-family: Times New Roman, Times, Serif">(259,814</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--RedemptionOfMedmenCorpRedemableShares_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmEnterprisesUsaCommonUnitsMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Redemption of MedMen Corp Redeemable Shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__custom--SubordinateVotingStockMember_zFvKnZl8Cj3k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,301,683,764</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_zE4RYODgLyb9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">64,806,292</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmEnterprisesUsaCommonUnitsMember_zsR3KoAARUs" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">725,016</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AD_zERLY8AjWwx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Controlling Interests</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of September 24, 2022 and June 25, 2022, the holders of the MM CAN USA Redeemable Shares represent approximately <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20220924__srt--OwnershipAxis__custom--MMCANUSAMember_z1hFfK15Iusj">4.74</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20220625__srt--OwnershipAxis__custom--MMCANUSAMember_zIoraA4hkde">4.76</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately <span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20220625__srt--OwnershipAxis__custom--MMEnterprisesUSAMember_zC2TMyXP4orl">0.05</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Variable Interest Entities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of Venice Caregiver Foundation, Inc., LAX Fund II Group, LLC, and Natures Cure, Inc. This information represents amounts before intercompany eliminations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the three months ended September 24, 2022, the balances and activities attributable to the VIEs consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfVies_zNjPUHrONrfl" style="width: 100%" summary="xdx: Disclosure - SHAREHOLDERS' EQUITY (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B4_ztJ7ASyl7gjk" style="display: none">Schedule of VIE</span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Venice Caregivers Foundation, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LAX Fund II Group, LLC</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Natures Cure, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Assets</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">1,180,136</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">24,602,018</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">25,782,154</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">8,763,511</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">3,233,062</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">4,891,725</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">16,888,298</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">9,943,647</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">3,233,062</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">29,493,743</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">42,670,452</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">10,477,448</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">16,016,119</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">8,510,967</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">35,004,534</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">7,004,484</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">2,004,062</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">1,342,632</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">10,351,178</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">17,481,932</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">18,020,181</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,853,599</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">45,355,712</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(7,538,285</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(14,787,119</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">19,640,163</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(2,685,241</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">1,959,080</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">3,317,299</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">5,276,379</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net (Loss) Income Attributable to Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(494,845</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(810,965</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">885,605</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(420,205</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Venice Caregivers Foundation, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LAX Fund II Group, LLC</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Natures Cure, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Assets</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">1,735,304</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">1,067,636</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">23,557,168</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">26,360,108</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">10,073,880</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">3,379,412</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">4,973,459</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">18,426,751</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">11,809,184</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">4,447,048</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">28,530,627</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">44,786,859</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,238,460</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">16,238,249</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">8,433,436</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">33,910,145</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,614,164</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">2,184,953</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">1,342,633</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">13,141,750</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">18,852,624</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">18,423,202</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,776,069</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">47,051,895</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(7,043,440</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(13,976,154</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">18,754,558</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(2,265,036</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">8,732,449</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">1,857</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">16,157,388</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">24,891,694</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net (Loss) Income Attributable to Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(1,384,751</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(4,868,632</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">7,190,809</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">937,426</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_zLknVH5q3Hd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net change in the consolidated VIEs and other non-controlling interest are as follows for the three months ended September 24, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zhlRdlhjhO8b" style="width: 100%" summary="xdx: Disclosure - SHAREHOLDERS' EQUITY (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B4_zHlPD0hUoS1f" style="display: none">Schedule of other non-controlling interest</span></span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Venice Caregivers Foundation, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LAX Fund II Group, LLC</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Natures Cure, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Other Non- Controlling Interests</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zF2jLIMTaS6f" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(7,043,440</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zF9IudHJ2Ike" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(13,976,154</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zNWLun4Za6E6" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">18,754,558</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--OtherNonControllingInterestsMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zhU20qqWfOY3" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(471,717,698</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--TotalMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zZ7Zh2Uclg2f" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(473,982,734</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net (Loss) Income</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">(494,845</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">(810,965</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">885,605</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--OtherNonControllingInterestsMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">307,893</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--TotalMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">(112,312</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zJ1INIedrHA2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(7,538,285</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_z1mt8fgFPBM9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(14,787,119</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zE5KzOQVCQb8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">19,640,163</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--OtherNonControllingInterestsMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zoGfxts0HUX9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(471,409,805</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--TotalMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zFc5KUZivfr5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(474,095,046</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8A4_zGNQdIWTIel7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Le Cirque Rouge, LP (the “OP”) is a Delaware limited partnership that holds substantially all of the real estate assets owned by the Treehouse Real Estate Investment Trust (the “REIT”), conducts the REIT’s operations and is financed by the REIT. Under Accounting Standards Codification (“ASC”) Topic 810, “<i>Consolidation</i>” (“ASC Topic 810”), the OP was determined to be a variable interest entity in which the Company has an implicit variable interest based on the leasing relationship and arrangement with the REIT. However, the Company is not the primary beneficiary under ASC Topic 810. Accordingly, Le Cirque Rouge, LP is not consolidated as a variable interest entity within the Consolidated Financial Statements. As of and during the three months ended September 24, 2022, the Company continues to have a variable interest in the OP and did not provide any financial or other support to the REIT other than the completion of the sale and leaseback transactions and the REIT being a lessor on various leases as described in “<i>Note 9 – Leases</i>”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfSharesIssuedAndOutstanding_zPdojluWLTc6" style="width: 100%" summary="xdx: Disclosure - SHAREHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span id="xdx_8B3_zbwO1zzLE5we" style="display: none">Schedule of Shares issued and outstanding</span></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Subordinate<br/> Voting Shares</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">MM CAN USA <br/> Class B<br/> Redeemable Units</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">MM Enterprises USA <br/> Common Units</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__custom--SubordinateVotingStockMember_zHTlzFoNpbV4" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,301,423,950</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_zTZiU9NKkhge" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">65,066,106</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmEnterprisesUsaCommonUnitsMember_zD63AiFW1Dzg" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">725,016</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Redemption of MedMen Corp Redeemable Shares</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--RedemptionOfMedmenCorpRedemableShares_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__custom--SubordinateVotingStockMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Redemption of MedMen Corp Redeemable Shares"><span style="font-family: Times New Roman, Times, Serif">259,814</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--RedemptionOfMedmenCorpRedemableShares_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Redemption of MedMen Corp Redeemable Shares"><span style="font-family: Times New Roman, Times, Serif">(259,814</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--RedemptionOfMedmenCorpRedemableShares_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmEnterprisesUsaCommonUnitsMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Redemption of MedMen Corp Redeemable Shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__custom--SubordinateVotingStockMember_zFvKnZl8Cj3k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,301,683,764</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_zE4RYODgLyb9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">64,806,292</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--MmEnterprisesUsaCommonUnitsMember_zsR3KoAARUs" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">725,016</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1301423950 65066106 725016 259814 -259814 1301683764 64806292 725016 0.0474 0.0476 0.0005 <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfVies_zNjPUHrONrfl" style="width: 100%" summary="xdx: Disclosure - SHAREHOLDERS' EQUITY (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B4_ztJ7ASyl7gjk" style="display: none">Schedule of VIE</span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Venice Caregivers Foundation, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LAX Fund II Group, LLC</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Natures Cure, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Assets</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">1,180,136</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">24,602,018</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--CurrentAssets_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">25,782,154</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">8,763,511</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">3,233,062</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">4,891,725</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">16,888,298</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">9,943,647</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">3,233,062</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">29,493,743</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsNet_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">42,670,452</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">10,477,448</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">16,016,119</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">8,510,967</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--CurrentLiabilities_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">35,004,534</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">7,004,484</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">2,004,062</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">1,342,632</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--LiabilitiesNoncurrent_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">10,351,178</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">17,481,932</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">18,020,181</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,853,599</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--Liability_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">45,355,712</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(7,538,285</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(14,787,119</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">19,640,163</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(2,685,241</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">1,959,080</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">3,317,299</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenuesNetOfInterestExpense_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">5,276,379</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net (Loss) Income Attributable to Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(494,845</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(810,965</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">885,605</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(420,205</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Venice Caregivers Foundation, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LAX Fund II Group, LLC</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Natures Cure, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Assets</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">1,735,304</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">1,067,636</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">23,557,168</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CurrentAssets_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Current Assets"><span style="font-family: Times New Roman, Times, Serif">26,360,108</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">10,073,880</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">3,379,412</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">4,973,459</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AssetsNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Assets"><span style="font-family: Times New Roman, Times, Serif">18,426,751</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">11,809,184</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">4,447,048</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">28,530,627</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsNet_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Assets"><span style="font-family: Times New Roman, Times, Serif">44,786,859</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,238,460</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">16,238,249</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">8,433,436</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--CurrentLiabilities_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; text-align: right" title="Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">33,910,145</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Current Liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,614,164</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">2,184,953</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">1,342,633</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--LiabilitiesNoncurrent_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-Current Liabilities"><span style="font-family: Times New Roman, Times, Serif">13,141,750</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">18,852,624</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">18,423,202</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">9,776,069</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--Liability_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total Liabilities"><span style="font-family: Times New Roman, Times, Serif">47,051,895</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(7,043,440</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(13,976,154</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">18,754,558</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--NoncontrollingInterestInVariableInterestEntity_c20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(2,265,036</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">8,732,449</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">1,857</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">16,157,388</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenuesNetOfInterestExpense_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif">24,891,694</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net (Loss) Income Attributable to Non-Controlling Interest</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(1,384,751</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">(4,868,632</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">7,190,809</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_c20210627__20220625__us-gaap--RelatedPartyTransactionAxis__custom--ViesTotalMember_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net (Loss) Income Attributable to Non-Controlling Interest"><span style="font-family: Times New Roman, Times, Serif">937,426</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1180136 24602018 25782154 8763511 3233062 4891725 16888298 9943647 3233062 29493743 42670452 10477448 16016119 8510967 35004534 7004484 2004062 1342632 10351178 17481932 18020181 9853599 45355712 -7538285 -14787119 19640163 -2685241 1959080 3317299 5276379 -494845 -810965 885605 -420205 1735304 1067636 23557168 26360108 10073880 3379412 4973459 18426751 11809184 4447048 28530627 44786859 9238460 16238249 8433436 33910145 9614164 2184953 1342633 13141750 18852624 18423202 9776069 47051895 -7043440 -13976154 18754558 -2265036 8732449 1857 16157388 24891694 -1384751 -4868632 7190809 937426 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zhlRdlhjhO8b" style="width: 100%" summary="xdx: Disclosure - SHAREHOLDERS' EQUITY (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B4_zHlPD0hUoS1f" style="display: none">Schedule of other non-controlling interest</span></span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Venice Caregivers Foundation, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LAX Fund II Group, LLC</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Natures Cure, Inc.</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Other Non- Controlling Interests</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zF2jLIMTaS6f" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(7,043,440</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zF9IudHJ2Ike" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(13,976,154</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zNWLun4Za6E6" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">18,754,558</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--OtherNonControllingInterestsMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zhU20qqWfOY3" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(471,717,698</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--TotalMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zZ7Zh2Uclg2f" style="width: 9%; font-size: 10pt; text-align: right" title="Balance at beginning"><span style="font-family: Times New Roman, Times, Serif">(473,982,734</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net (Loss) Income</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">(494,845</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">(810,965</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">885,605</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--OtherNonControllingInterestsMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">307,893</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ProfitLoss_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--TotalMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (Loss) Income"><span style="font-family: Times New Roman, Times, Serif">(112,312</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--VeniceCaregiversFoundationIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zJ1INIedrHA2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(7,538,285</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--LAXFundTwoGroupLLCMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_z1mt8fgFPBM9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(14,787,119</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--NaturesCureIncMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zE5KzOQVCQb8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">19,640,163</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--OtherNonControllingInterestsMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zoGfxts0HUX9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(471,409,805</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_pp0p0_c20220626__20220924__us-gaap--RelatedPartyTransactionAxis__custom--TotalMember__us-gaap--StatementEquityComponentsAxis__custom--NonControllingInterestsMember_zFc5KUZivfr5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance at ending"><span style="font-family: Times New Roman, Times, Serif">(474,095,046</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> -7043440 -13976154 18754558 -471717698 -473982734 -494845 -810965 885605 307893 -112312 -7538285 -14787119 19640163 -471409805 -474095046 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z6Kk9cqVN7o5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td> <td style="text-align: justify"><span id="xdx_82C_z6DC8723bSG8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED COMPENSATION</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock units (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative expenses. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, cancelled, expire unexercised, are settled in cash or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of a Compensation Committee. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220626__20220924__srt--RangeAxis__srt--MinimumMember_zjh9Ux81tfQf">5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220626__20220924__srt--RangeAxis__srt--MaximumMember_zE91FFxEl852">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of share-based compensation expense for the three months ended September 24, 2022 and September 25, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zhatiEpKIprl" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8BA_z5Vf4m8Ai8p1" style="display: none">Schedule of share-based compensation expense</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--TotalSharebasedCompensation_c20220626__20220924__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">863,685</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--TotalSharebasedCompensation_c20210627__20210925__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">1,216,447</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock Grants for Compensation</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--TotalSharebasedCompensation_c20220626__20220924__us-gaap--AwardTypeAxis__custom--StockGrantsMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--TotalSharebasedCompensation_c20210627__20210925__us-gaap--AwardTypeAxis__custom--StockGrantsMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">333,333</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Grants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--TotalSharebasedCompensation_c20220626__20220924__us-gaap--AwardTypeAxis__custom--RestrictedStockGrantsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--TotalSharebasedCompensation_c20210627__20210925__us-gaap--AwardTypeAxis__custom--RestrictedStockGrantsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">1,554,297</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Share-Based Compensation</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--TotalSharebasedCompensation_pp0p0_c20220626__20220924_zQW9smhix4F5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">863,685</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--TotalSharebasedCompensation_pp0p0_c20210627__20210925_zFBGvNIUSbC7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">3,104,077</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_z2p2ZAYmG6R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balance of stock options outstanding is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ztJGiPtXN50i" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B0_zkHRJqwkbXA1" style="display: none">Schedule of stock options</span></span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Stock Options</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average<br/> Exercise Price</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220626__20220924_zzdAqzopMg6j" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Number of Stock Options, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">8,649,673</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220626__20220924_zam7o11VfVll" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">1.35</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Forfeited and Expired</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_iN_di_c20220626__20220924_zGgbvpzzc4Gk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Stock Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(205,354</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_iN_di_c20220626__20220924_zRmnOHVmto5i" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(3.39</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220626__20220924_z3MGfwt6eAoh" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Number of Stock Options, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">8,444,319</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220626__20220924_zpCV7bQP7y0b" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">1.39</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock Options Exercisable as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Number of Stock Options, Stock Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">8,037,095</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220924_pdd" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Stock Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">1.27</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zLKTlShoxDCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Long-Term Incentive Plan (“LTIP”) Units and LLC Redeemable Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfLTIPUnitsAndLLCRedeemableUnitsTableTextBlock_zSJnYzahcKu" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8BE_zlSLbn6Yi9C6"><span id="xdx_8B7_zI3D9fSEzm56" style="display: none">Schedule of LTIP Units and LLC Redeemable Units</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LTIP Units</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LLC</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Average</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Issued and</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Redeemable</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Units</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Fair Value</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 63%; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022 and September 24, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--LtipIssuedAndOutstanding_c20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right; width: 9%" title="LTIP Issued And Outstanding"><span style="font-family: Times New Roman, Times, Serif">19,323,878</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--LlcRedeemableUnits_c20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right; width: 9%" title="LLC Redeemable Units"><span style="font-family: Times New Roman, Times, Serif">725,016</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_98A_ecustom--WeightedAverageGrantDateFairValue_c20220924_pdd" style="font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 2.5pt; width: 9%; vertical-align: bottom" title="Weighted Average grant date fair Value"><span style="font-family: Times New Roman, Times, Serif">0.52</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zZlBGKguXdd7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z1B8Ozlc4LL1" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8B0_zX8ojXbmD1V7"/><span id="xdx_8B3_z81KSFHTxVMc" style="display: none; font-family: Times New Roman, Times, Serif">Schedule of Restricted Stock Grants</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b>Issued and<br/> Outstanding</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-size: 10pt; font-weight: 400; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: 400; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b>Vested <span style="font-size: 10pt"><i><sup>(1)</sup></i></span></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: 400; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted-Average<br/> Fair Value</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--IssuedAndOutstandingBegningBalances_c20220626__20220924_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Issued And Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">10,998,483</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--VestedBegningBalance_c20220626__20220924_fKDEp_z8v3bFn5eho3" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Vested, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">4,030,460</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220626__20220924_zKSp1oDk0JC2" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average fair value at beginning"><span style="font-family: Times New Roman, Times, Serif">0.20</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Forfeiture of Restricted Stock <span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(2)</sup></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--IssuedAndOutstandingForfeitureOfRestrictedStock_c20220626__20220924_fKDIp_zEUNhHTuYAfa" style="font-size: 10pt; text-align: right" title="Issued And Outstanding, Forfeiture of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">(1,405,788</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--VestedForfeitureOfRestrictedStock_c20220626__20220924_fKDEpKDIp_zOZQQs5GhUB6" style="font-size: 10pt; text-align: right" title="Vested, Forfeiture of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WeightedAverageFairValueForfeitureOfRestrictedStock_c20220626__20220924_fKDIp_zVCzLpe4jTfi" style="font-size: 10pt; text-align: right" title="Weighted Average fair Value, Forfeiture of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">(0.22</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Vesting of Restricted Stock</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--VestingOfRestrictedStock_c20220626__20220924_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vesting of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1430">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--VestedVestingOfRestrictedStock_c20220626__20220924_fKDEp_zdJE7fLI72i4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vested, Vesting of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">1,117,081</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WeightedaverageFairValueVestingOfRestrictedStock_c20220626__20220924_pdd" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="WeightedAverage Fair Value, Vesting of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">0.22</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--IssuedAndOutstandingEndingBalances_c20220626__20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Issued And Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">9,592,695</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--VestedEndingBalance_c20220626__20220924_fKDEp_zy5oUG7DYvZ" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Vested, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">5,147,541</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220626__20220924_zTGpDd5XXkhi" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average fair value at ending"><span style="font-family: Times New Roman, Times, Serif">0.20</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F09_zXPQZuWtTZg3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F1A_zKteunasGyq4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date.</i></span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0px; text-align: justify"/> <td style="width: 0.25in; text-align: justify"><span id="xdx_F09_zhWjeNdVkmhl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(2)</i></span></td> <td style="text-align: justify"><span id="xdx_F17_z909CqnVECQ7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022.</i></span></td></tr> </table> <p id="xdx_8A7_ztKROJ5uDMC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending balance of warrants outstanding is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_zzwEIzdTZAe8" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B3_zq92dWemmkw7" style="display: none">Schedule of Warrants</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Number of Warrants Outstanding</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Subordinate<br/> Voting Shares</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">MM CAN USA<br/> Redeemable Shares</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom">Weighted-Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 51%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--BegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--SubordinateVotingsSharesMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">352,704,355</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--BegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">97,430,456</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--BegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">450,134,811</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--WeightedAverageExercisePriceBegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">0.25</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--SubordinateVotingsSharesMember_zwRRLJaYcu02" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired"><span style="font-family: Times New Roman, Times, Serif">(2,677,535</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_zFbXbSqWkmj6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1456">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5eOOyyS4bUh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired"><span style="font-family: Times New Roman, Times, Serif">(2,677,535</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaIg6k1lKF33" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">(3.27</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--EndingBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--SubordinateVotingsSharesMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">350,026,820</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--EndingBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">97,430,456</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--EndingBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">447,457,276</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--WeightedAverageExercisePriceEnding_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Ending"><span style="font-family: Times New Roman, Times, Serif">0.23</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A9_zkTqDwWajVZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y P10Y <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zhatiEpKIprl" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8BA_z5Vf4m8Ai8p1" style="display: none">Schedule of share-based compensation expense</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--TotalSharebasedCompensation_c20220626__20220924__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">863,685</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--TotalSharebasedCompensation_c20210627__20210925__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">1,216,447</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock Grants for Compensation</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--TotalSharebasedCompensation_c20220626__20220924__us-gaap--AwardTypeAxis__custom--StockGrantsMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--TotalSharebasedCompensation_c20210627__20210925__us-gaap--AwardTypeAxis__custom--StockGrantsMember_pp0p0" style="font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">333,333</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Grants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--TotalSharebasedCompensation_c20220626__20220924__us-gaap--AwardTypeAxis__custom--RestrictedStockGrantsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--TotalSharebasedCompensation_c20210627__20210925__us-gaap--AwardTypeAxis__custom--RestrictedStockGrantsMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">1,554,297</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Share-Based Compensation</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--TotalSharebasedCompensation_pp0p0_c20220626__20220924_zQW9smhix4F5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">863,685</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--TotalSharebasedCompensation_pp0p0_c20210627__20210925_zFBGvNIUSbC7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Share-Based Compensation"><span style="font-family: Times New Roman, Times, Serif">3,104,077</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 863685 1216447 333333 1554297 863685 3104077 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ztJGiPtXN50i" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B0_zkHRJqwkbXA1" style="display: none">Schedule of stock options</span></span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Stock Options</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average<br/> Exercise Price</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220626__20220924_zzdAqzopMg6j" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Number of Stock Options, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">8,649,673</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220626__20220924_zam7o11VfVll" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">1.35</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Forfeited and Expired</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_iN_di_c20220626__20220924_zGgbvpzzc4Gk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Stock Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(205,354</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_iN_di_c20220626__20220924_zRmnOHVmto5i" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(3.39</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220626__20220924_z3MGfwt6eAoh" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Number of Stock Options, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">8,444,319</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220626__20220924_zpCV7bQP7y0b" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">1.39</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock Options Exercisable as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Number of Stock Options, Stock Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">8,037,095</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220924_pdd" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Stock Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">1.27</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 8649673 1.35 205354 3.39 8444319 1.39 8037095 1.27 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfLTIPUnitsAndLLCRedeemableUnitsTableTextBlock_zSJnYzahcKu" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8BE_zlSLbn6Yi9C6"><span id="xdx_8B7_zI3D9fSEzm56" style="display: none">Schedule of LTIP Units and LLC Redeemable Units</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LTIP Units</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">LLC</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Average</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Issued and</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Redeemable</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Units</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Fair Value</span></td> <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 63%; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022 and September 24, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--LtipIssuedAndOutstanding_c20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right; width: 9%" title="LTIP Issued And Outstanding"><span style="font-family: Times New Roman, Times, Serif">19,323,878</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--LlcRedeemableUnits_c20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right; width: 9%" title="LLC Redeemable Units"><span style="font-family: Times New Roman, Times, Serif">725,016</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_98A_ecustom--WeightedAverageGrantDateFairValue_c20220924_pdd" style="font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 2.5pt; width: 9%; vertical-align: bottom" title="Weighted Average grant date fair Value"><span style="font-family: Times New Roman, Times, Serif">0.52</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 19323878 725016 0.52 <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z1B8Ozlc4LL1" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8B0_zX8ojXbmD1V7"/><span id="xdx_8B3_z81KSFHTxVMc" style="display: none; font-family: Times New Roman, Times, Serif">Schedule of Restricted Stock Grants</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b>Issued and<br/> Outstanding</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-size: 10pt; font-weight: 400; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: 400; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b>Vested <span style="font-size: 10pt"><i><sup>(1)</sup></i></span></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: 400; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted-Average<br/> Fair Value</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--IssuedAndOutstandingBegningBalances_c20220626__20220924_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Issued And Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">10,998,483</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--VestedBegningBalance_c20220626__20220924_fKDEp_z8v3bFn5eho3" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Vested, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">4,030,460</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220626__20220924_zKSp1oDk0JC2" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average fair value at beginning"><span style="font-family: Times New Roman, Times, Serif">0.20</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Forfeiture of Restricted Stock <span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(2)</sup></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--IssuedAndOutstandingForfeitureOfRestrictedStock_c20220626__20220924_fKDIp_zEUNhHTuYAfa" style="font-size: 10pt; text-align: right" title="Issued And Outstanding, Forfeiture of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">(1,405,788</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--VestedForfeitureOfRestrictedStock_c20220626__20220924_fKDEpKDIp_zOZQQs5GhUB6" style="font-size: 10pt; text-align: right" title="Vested, Forfeiture of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WeightedAverageFairValueForfeitureOfRestrictedStock_c20220626__20220924_fKDIp_zVCzLpe4jTfi" style="font-size: 10pt; text-align: right" title="Weighted Average fair Value, Forfeiture of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">(0.22</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Vesting of Restricted Stock</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--VestingOfRestrictedStock_c20220626__20220924_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vesting of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1430">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--VestedVestingOfRestrictedStock_c20220626__20220924_fKDEp_zdJE7fLI72i4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vested, Vesting of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">1,117,081</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WeightedaverageFairValueVestingOfRestrictedStock_c20220626__20220924_pdd" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="WeightedAverage Fair Value, Vesting of Restricted Stock"><span style="font-family: Times New Roman, Times, Serif">0.22</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--IssuedAndOutstandingEndingBalances_c20220626__20220924_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Issued And Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">9,592,695</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--VestedEndingBalance_c20220626__20220924_fKDEp_zy5oUG7DYvZ" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Vested, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">5,147,541</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220626__20220924_zTGpDd5XXkhi" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average fair value at ending"><span style="font-family: Times New Roman, Times, Serif">0.20</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span id="xdx_F09_zXPQZuWtTZg3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td> <td style="text-align: justify"><span id="xdx_F1A_zKteunasGyq4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date.</i></span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0px; text-align: justify"/> <td style="width: 0.25in; text-align: justify"><span id="xdx_F09_zhWjeNdVkmhl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(2)</i></span></td> <td style="text-align: justify"><span id="xdx_F17_z909CqnVECQ7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022.</i></span></td></tr> </table> 10998483 4030460 0.20 -1405788 -0.22 1117081 0.22 9592695 5147541 0.20 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_zzwEIzdTZAe8" style="width: 100%" summary="xdx: Disclosure - SHARE-BASED COMPENSATION (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B3_zq92dWemmkw7" style="display: none">Schedule of Warrants</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Number of Warrants Outstanding</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Subordinate<br/> Voting Shares</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">MM CAN USA<br/> Redeemable Shares</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom">Weighted-Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 51%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 25, 2022</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--BegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--SubordinateVotingsSharesMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">352,704,355</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--BegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">97,430,456</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--BegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">450,134,811</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--WeightedAverageExercisePriceBegningBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">0.25</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--SubordinateVotingsSharesMember_zwRRLJaYcu02" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired"><span style="font-family: Times New Roman, Times, Serif">(2,677,535</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_zFbXbSqWkmj6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1456">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5eOOyyS4bUh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired"><span style="font-family: Times New Roman, Times, Serif">(2,677,535</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_iN_di_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaIg6k1lKF33" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">(3.27</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 24, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--EndingBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--SubordinateVotingsSharesMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">350,026,820</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--EndingBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--MmCanUsaClassBRedeemableUnitsMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">97,430,456</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--EndingBalance_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">447,457,276</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--WeightedAverageExercisePriceEnding_c20220626__20220924__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted Average Exercise Price, Ending"><span style="font-family: Times New Roman, Times, Serif">0.23</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 352704355 97430456 450134811 0.25 2677535 2677535 3.27 350026820 97430456 447457276 0.23 <p id="xdx_807_eus-gaap--EarningsPerShareTextBlock_zvexoQJXJqSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td> <td style="text-align: justify"><span id="xdx_821_zwucpGlw2rA" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation for the calculation of basic and diluted loss per share for the three months ended September 24, 2022 and September 25, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zInkt1KFgYBg" style="width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8BD_zAIIkErlLky9" style="display: none">Schedule of basic and diluted loss per share</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_498_20220626__20220924_zf7NQQE9G8ue" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49D_20210627__20210925_zRVJFh7HfBPa" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossAttributableToParent_ztFxXi2fqzr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,146,436</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,883,537</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net Income (Loss) from Discontinued Operations</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,306,649</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,446,491</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zhEE6kYh8WD1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Net Income (Loss)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,160,213</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55,330,028</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--WeightedaverageNumberOfSharesOutstandingBasicAndDiluted_zQV2bSZJiEt1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Shares Outstanding - Basic and Diluted</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,301,659,701</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">942,696,052</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--LossPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Earnings (Loss) Per Share - Basic and Diluted:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zN1ksyj9hu01" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.02</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.04</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_i01_z49RzW8QQwC8" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.02</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.02</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8AD_zEuwuh43AaRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, LTIP share units, warrants and share options is anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zInkt1KFgYBg" style="width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8BD_zAIIkErlLky9" style="display: none">Schedule of basic and diluted loss per share</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_498_20220626__20220924_zf7NQQE9G8ue" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49D_20210627__20210925_zRVJFh7HfBPa" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossAttributableToParent_ztFxXi2fqzr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,146,436</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,883,537</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net Income (Loss) from Discontinued Operations</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,306,649</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,446,491</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zhEE6kYh8WD1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Net Income (Loss)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,160,213</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55,330,028</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--WeightedaverageNumberOfSharesOutstandingBasicAndDiluted_zQV2bSZJiEt1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Weighted-Average Shares Outstanding - Basic and Diluted</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,301,659,701</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">942,696,052</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--LossPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Earnings (Loss) Per Share - Basic and Diluted:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zN1ksyj9hu01" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.02</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.04</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_i01_z49RzW8QQwC8" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.02</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.02</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> -20146436 -40883537 24306649 -14446491 4160213 -55330028 1301659701 942696052 -0.02 -0.04 0.02 -0.02 <p id="xdx_806_ecustom--GeneralAndAdministrativeExpensesTextBlock_zM0AaydpP7Gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span></td> <td style="text-align: justify"><span id="xdx_822_z4STyac715Nb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL AND ADMINISTRATIVE EXPENSES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 24, 2022 and September 25, 2021, general and administrative expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_zXBdlKDDUJdc" style="width: 100%" summary="xdx: Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8BD_zTldOSsLs2W4" style="display: none">Schedule of general and administrative expenses</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49E_20220626__20220924_zQ0rstxuQdNd" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_498_20210627__20210925_zouSKaOAb2og" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--SalariesAndWages_zxFtnKbr0169" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Salaries and Benefits</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,858,048</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,911,488</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--ProfessionalFees_zWM57CGoOStj" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Professional Fees</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,350,848</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,430,659</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LeaseAndRentalExpense_zPDUu5cfNMId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Rent</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,627,925</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,754,883</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--LicensesFeesAndTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Licenses, Fees and Taxes</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,001,669</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,537,788</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_z1xWaPDBuGrb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Share-Based Compensation</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">863,685</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,642,853</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--DealCost_zCh4jdMYpV3b" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deal Costs</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">429,272</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,637,587</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--OtherGeneralAndAdministrative_za3UZZbtj1bf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other General and Administrative</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,714,670</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,733,976</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--OtherGeneralAndAdministrativeExpense_zZXZhgEUbige" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total General and Administrative Expenses</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,846,117</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,649,234</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_zXBdlKDDUJdc" style="width: 100%" summary="xdx: Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8BD_zTldOSsLs2W4" style="display: none">Schedule of general and administrative expenses</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49E_20220626__20220924_zQ0rstxuQdNd" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_498_20210627__20210925_zouSKaOAb2og" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--SalariesAndWages_zxFtnKbr0169" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Salaries and Benefits</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,858,048</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,911,488</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--ProfessionalFees_zWM57CGoOStj" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Professional Fees</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,350,848</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,430,659</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LeaseAndRentalExpense_zPDUu5cfNMId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Rent</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,627,925</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,754,883</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--LicensesFeesAndTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Licenses, Fees and Taxes</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,001,669</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,537,788</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_z1xWaPDBuGrb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Share-Based Compensation</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">863,685</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,642,853</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--DealCost_zCh4jdMYpV3b" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deal Costs</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">429,272</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,637,587</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--OtherGeneralAndAdministrative_za3UZZbtj1bf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other General and Administrative</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,714,670</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,733,976</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--OtherGeneralAndAdministrativeExpense_zZXZhgEUbige" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total General and Administrative Expenses</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,846,117</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,649,234</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 6858048 9911488 1350848 7430659 3627925 4754883 1001669 2537788 863685 1642853 429272 1637587 3714670 4733976 17846117 32649234 <p id="xdx_803_ecustom--OtherOperatingExpenseDisclosureTextBlock_z6HV7hEMZjK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span></td> <td style="text-align: justify"><span id="xdx_821_zuzCRB0MsKeh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER OPERATING (INCOME) EXPENSE</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 24, 2022 and September 25, 2021, other operating (income) expense consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfOtherOperatingExpensesTableTextBlock_zDSnhJrk1eWe" style="width: 100%" summary="xdx: Disclosure - OTHER OPERATING EXPENSE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B6_z2HoV5rBRoJl" style="display: none">Schedule of other operating expenses</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49C_20220626__20220924_zErL8H2Hw21e" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49D_20210627__20210925_zFShzPsLHFG7" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--GainLossOnDispositionOfAssets1_zPMw2nAN0dC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss on Disposals of Assets</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205,595</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,146</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RestructuringCharges_iN_di_zkNS6fgEuzO4" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Restructuring and Reorganization Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423,793</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,378,675</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--GainLossOnSettlementOfAccountsPayable_iN_di_z9spEDTzJr63" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gain on Settlement of Accounts Payable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(74,637</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(177,990</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--GainLossOnContractTermination_zBtDdINBXoZc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gain on Lease Terminations</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,587,650</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1537">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--OtherOperatingIncomeExpenseNet_zA2hLEwOyL96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Income</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,522,219</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,803</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--TotalOtherOperatingExpenseIncome_zeba39Kamep8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Other Operating (Income) Expense</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,555,118</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,199,028</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 24, 2022, the Company recorded $<span id="xdx_90E_ecustom--SubleasesIncome_c20220626__20220924_zaRoMGkqyZU5" title="Sublease income">1,521,650 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of sublease income related to the cultivation facilities in California and Nevada as a component of Other Operating Income in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfOtherOperatingExpensesTableTextBlock_zDSnhJrk1eWe" style="width: 100%" summary="xdx: Disclosure - OTHER OPERATING EXPENSE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B6_z2HoV5rBRoJl" style="display: none">Schedule of other operating expenses</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49C_20220626__20220924_zErL8H2Hw21e" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49D_20210627__20210925_zFShzPsLHFG7" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--GainLossOnDispositionOfAssets1_zPMw2nAN0dC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss on Disposals of Assets</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205,595</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,146</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RestructuringCharges_iN_di_zkNS6fgEuzO4" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Restructuring and Reorganization Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423,793</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,378,675</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--GainLossOnSettlementOfAccountsPayable_iN_di_z9spEDTzJr63" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gain on Settlement of Accounts Payable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(74,637</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(177,990</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--GainLossOnContractTermination_zBtDdINBXoZc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gain on Lease Terminations</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,587,650</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1537">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--OtherOperatingIncomeExpenseNet_zA2hLEwOyL96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Income</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,522,219</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,803</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--TotalOtherOperatingExpenseIncome_zeba39Kamep8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Other Operating (Income) Expense</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,555,118</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,199,028</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 205595 15146 -423793 -2378675 74637 177990 -1587650 -1522219 -16803 -2555118 2199028 1521650 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_z5dPvtZFV6Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span></td> <td style="text-align: justify"><span id="xdx_82A_zaztsjYweKXk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended September 24, 2022 and September 25, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znFuhx919GY8" style="width: 100%" summary="xdx: Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8BB_zyNFF13podMc" style="display: none">Schedule of income tax expense and effective tax rates</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_493_20220626__20220924_zYKxCK1djqu3" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49F_20210627__20210925_zrh2mEmOwcwb" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zNevAt7APVnc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss from Continuing Operations Before Provision for Income Taxes</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,065,206</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,471,632</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_zbTBxuP2RhBi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income Tax Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,193,542</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,691,908</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zS2qvtd7aQm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Effective Tax Rate</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-12</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-74</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate (“AETR”) for the full fiscal year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. For the three months ended September 25, 2021, we determined we could no longer reliably estimate income taxes utilizing an AETR. The AETR estimate is highly sensitive to estimates of ordinary income (loss) and permanent differences such that minor fluctuations in these estimates could result in significant fluctuations of the Company’s AETR. Accordingly, we used our actual year-to-date effective tax rate to calculate income taxes for the three months ended September 25, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Massachusetts state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_901_ecustom--ProvisionForIncomeTaxesAndDeferredIncomeTaxesDescription_c20220626__20220924" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective tax rate for the three months ended September 24, 2022 is different from the three months ended September 25, 2021, respectively, primarily due to the Company’s income and related 280E expenditures. The Company’s non-deductible expenses related to IRC Section 280E limitations have remained relatively consistent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and in Canada. The Company is generally subject to audit by taxing authorities in various U.S., state, and in foreign jurisdictions for fiscal years 2014 through the current fiscal year. As of September 24, 2022, the Company had $<span id="xdx_907_ecustom--GrossUnrecognizedTaxBenefits_c20220924_pp0p0">18,781,424 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized tax benefits, all of which would reduce income tax expense and the effective tax rate if recognized. During the three months ended September 24, 2022, the Company recognized a net discrete tax expense of $<span id="xdx_908_ecustom--NetDiscreteTaxExpense_c20220626__20220924_pp0p0">407,993</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">primarily related on interest of past liabilities. During the next twelve months, the Company does not estimate any material reduction in its unrecognized tax benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znFuhx919GY8" style="width: 100%" summary="xdx: Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8BB_zyNFF13podMc" style="display: none">Schedule of income tax expense and effective tax rates</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_493_20220626__20220924_zYKxCK1djqu3" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49F_20210627__20210925_zrh2mEmOwcwb" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zNevAt7APVnc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss from Continuing Operations Before Provision for Income Taxes</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,065,206</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,471,632</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_zbTBxuP2RhBi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income Tax Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,193,542</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,691,908</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zS2qvtd7aQm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Effective Tax Rate</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-12</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-74</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> -18065206 -26471632 -2193542 -19691908 -0.12 -0.74 The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized. 18781424 407993 <p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zb42X7Bvvxlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span></td> <td style="text-align: justify"><span id="xdx_82B_zFLxDutS2SM" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMITMENTS AND CONTINGENCIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingencies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of September 24, 2022 and June 25, 2022, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Claims and Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 24, 2022, there were no pending or threatening lawsuits that could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. As such, no accrual has been made in the Condensed Consolidated Financial Statements relating to claims and litigations. As of September 24, 2022, there are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, litigation was filed against the Company in the Superior Court of Arizona, Maricopa County, related to a purchase agreement for a previous acquisition. The Superior Court of Arizona, Maricopa County granted summary judgement in favor of the Company on all counts in July 2022. The Company is currently in process of recovering certain fees and costs associated with the lawsuit from the plaintiffs. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2020, a complaint was filed against the Company in Los Angeles Superior Court related to a contemplated acquisition in which the plaintiffs are seeking damages for alleged breach of contract and breach of implied covenant of good faith and fair dealing seeking declaratory relief and specific performance. The Company has filed counterclaims including for breach of contract, breach of promissory note, unjust enrichment and declaratory relief. The Company believes the likelihood of a loss contingency is remote. As such, no amount has been accrued in the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2020, litigation was filed against the Company related to a purchase agreement and secured promissory note for a previous acquisition. The Company is currently defending against this lawsuit, which claims for breach of contract, breach of implied covenant of good faith and fair dealing, common law fraud and securities fraud. The plaintiffs are seeking damages for such claims in which the amount is currently not reasonably estimable. In response, the Company filed a counterclaim and is seeking entitlement to proceeds of the sale, net of amounts owed under the secured promissory note. The plaintiffs filed an appeal to the ruling on the entitlement of proceeds in excess of the secured promissory note which was dismissed. The additionally claims and counterclaims are currently in dispute. Any loss recoveries related to the Company’s counterclaim have not been recorded. In addition, net proceeds resulting from the sale was not recognized as a receivable as the amount is not reasonably estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2020 and May 2020, legal disputes were filed against the Company related to the separation of former officers in which the severance issued is currently being disputed. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In November 2020, entities affiliated with former officers of the Company initiated arbitration against a subsidiary of the Company in Los Angeles, California asserting breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and unjust enrichment. The claimants are generally seeking damages and compensatory damages according to proof, including lost earnings and other benefits, past and future, interest on lost earnings and benefits, reasonable attorney’s fees, and such other and further relief as the court deems proper. The Company asserted counterclaims, including for breach of the same management agreements. The arbitration is currently set for hearing in December 2022. The litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, a suit for premises liability and negligence seeking unspecified damages for pain and suffering, disability, mental and emotional distress, and loss of earnings was filed against the Company in Los Angeles Superior Court. The matter is in the process of being litigated. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is the defendant in several complaints filed by various of its landlords seeking rents and damages under leases. In 2020 a complaint was filed in Cook County Circuit Court, Illinois against the Company by a landlord claiming the Company had failed to meet its obligations to apply effort to obtain a retail cannabis license at a property and seeking rents and damages. The litigation is currently in the discovery phase. If the litigation is not settled or resolved, trial will likely take place During the fiscal year ended 2023. In July 2022, a complaint was filed against the Company in the United States District Court for the Southern District of New York by a landlord seeking damages under a lease on real estate located in Illinois. The Company is required to file an answer to the complaint by September 2022. Prior attempts to resolve the lease dispute with this landlord have failed. In June 2022, a complaint was filed against the Company by the Company’s landlord at its cultivation center in Utica, New York, related to an agreement to purchase land next to the cultivation center, which land was also owned by the landlord. Plaintiff seeks to enforce a land purchase agreement and seeks damages. In April 2022, the landlord at the Company’s dispensary location in Tampa, Florida, filed suit seeking damages under a lease, shortly after the Company announced its plans to sell its Florida business. The Company retained this lease and litigation following the sale of the Florida business and the litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOCMP3MwWuug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.</b></span></td> <td style="text-align: justify"><span id="xdx_827_z2SxwUjmfP3i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RELATED PARTY TRANSACTIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Board of Directors each receive quarterly fees of $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20220626__20220924__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_pp0p0">200,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 200000 <p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zwxLXVbiQzM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.</b></span></td> <td style="text-align: justify"><span id="xdx_825_z5GMJnfzp9ce" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEGMENT INFORMATION</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker manages the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_801_eus-gaap--RevenueFromContractWithCustomerTextBlock_z3j2s7BzhjUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.</b></span></td> <td style="text-align: justify"><span id="xdx_82D_zykp14boCAhd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUE</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company operates in one segment as disclosed in “<i>Note 20 – Segment Information</i>”, the Company is disaggregating its revenue by geographical region in accordance with ASC 606, “<i>Revenue from Contracts with Customers</i>”. Revenue by state for the periods presented are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0GBsOyrtdf5" style="width: 100%" summary="xdx: Disclosure - REVENUE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B3_zxbH5h9A4s8h" style="display: none">Schedule of Disaggregation of revenue</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">California</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--CA_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">19,928,985</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--CA_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">24,626,555</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Nevada</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--NV_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">2,997,469</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--NV_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">4,079,151</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Illinois</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--IL_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">3,542,071</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--IL_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">4,328,602</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Arizona</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--AZ_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">2,794,648</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--AZ_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">3,701,596</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Massachusetts</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--MA_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">780,875</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--MA_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1593">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenue from Continuing Operations</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--RevenueFromContinuingOperations_c20220626__20220924_pp0p0" style="font-size: 10pt; text-align: right" title="Revenue from Continuing Operations"><span style="font-family: Times New Roman, Times, Serif">30,044,048</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--RevenueFromContinuingOperations_c20210627__20210925_pp0p0" style="font-size: 10pt; text-align: right" title="Revenue from Continuing Operations"><span style="font-family: Times New Roman, Times, Serif">36,735,904</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenue from Discontinued Operations</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--RevenueFromDiscontinuedOperations_c20220626__20220924_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue from Discontinued Operations"><span style="font-family: Times New Roman, Times, Serif">3,629,641</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--RevenueFromDiscontinuedOperations_c20210627__20210925_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue from Discontinued Operations"><span style="font-family: Times New Roman, Times, Serif">7,340,099</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Revenue</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">33,673,689</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">44,076,003</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0GBsOyrtdf5" style="width: 100%" summary="xdx: Disclosure - REVENUE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B3_zxbH5h9A4s8h" style="display: none">Schedule of Disaggregation of revenue</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">California</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--CA_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">19,928,985</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--CA_pp0p0" style="width: 9%; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">24,626,555</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Nevada</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--NV_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">2,997,469</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--NV_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">4,079,151</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Illinois</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--IL_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">3,542,071</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--IL_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">4,328,602</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Arizona</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--AZ_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">2,794,648</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--AZ_pp0p0" style="font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">3,701,596</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Massachusetts</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924__us-gaap--GeographicDistributionAxis__stpr--MA_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">780,875</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925__us-gaap--GeographicDistributionAxis__stpr--MA_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1593">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenue from Continuing Operations</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--RevenueFromContinuingOperations_c20220626__20220924_pp0p0" style="font-size: 10pt; text-align: right" title="Revenue from Continuing Operations"><span style="font-family: Times New Roman, Times, Serif">30,044,048</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--RevenueFromContinuingOperations_c20210627__20210925_pp0p0" style="font-size: 10pt; text-align: right" title="Revenue from Continuing Operations"><span style="font-family: Times New Roman, Times, Serif">36,735,904</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenue from Discontinued Operations</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--RevenueFromDiscontinuedOperations_c20220626__20220924_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue from Discontinued Operations"><span style="font-family: Times New Roman, Times, Serif">3,629,641</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--RevenueFromDiscontinuedOperations_c20210627__20210925_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue from Discontinued Operations"><span style="font-family: Times New Roman, Times, Serif">7,340,099</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Revenue</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220626__20220924_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">33,673,689</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210627__20210925_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Total Revenue"><span style="font-family: Times New Roman, Times, Serif">44,076,003</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 19928985 24626555 2997469 4079151 3542071 4328602 2794648 3701596 780875 30044048 36735904 3629641 7340099 33673689 44076003 <p id="xdx_80F_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zLhvepmuaNZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.</b></span></td> <td style="text-align: justify"><span id="xdx_82A_zwdLpvaxX2m4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DISCONTINUED OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 28, 2022, MME Florida LLC and its parent, MM Enterprises USA, LLC, a wholly-owned subsidiary of the Company entered into an Asset Purchase Agreement (the “Agreement”) with Green Sentry Holdings, LLC, (“Buyer”) for the sale of substantially all of the Company’s Florida-based assets, including its license, dispensaries, inventory and cultivation operations, and assumption of certain liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 22, 2022, the Company closed the transaction at the final sales price of $<span id="xdx_901_ecustom--SalesPrice_c20220801__20220822_pp0p0">67,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which comprised of $<span id="xdx_907_ecustom--SalesInCash_pp0p0_c20220801__20220822_z5Esz62cAYl2" title="Sales in cash">63,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash and $<span id="xdx_90D_ecustom--LiabilitiesAssumedByBuyer_pp0p0_c20220801__20220822_zS8trJKqox6k" title="Liabilities assumed by buyer">4,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in liabilities to be assumed by the Buyer. <span id="xdx_90C_ecustom--BuyerCashPaymentDescription_c20220901__20220915_zug69DI40nN9" title="Buyer cash payment description">The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022 and is required to make one additional installment payment of $11,500,000 on or before March 15, 2023.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 24, 2022, $<span id="xdx_905_eus-gaap--ProceedsFromOtherDebt_pp0p0_c20220626__20220924_zqH3VxeXthc5">31,599,999 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the cash proceeds was used to repay the Senior Secured Term Loan Facility and the Company received net cash proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfDebt_c20220626__20220924_pp0p0">19,558,947</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. As of September 24, 2022, the final cash payment of $<span id="xdx_905_ecustom--RemainsDueAndPayable_iI_pp0p0_c20220924_zJghmXmmExc1" title="Remains due and payable">11,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remains due and payable. Accordingly, the Company recognized a gain on sale of assets of $<span id="xdx_90D_eus-gaap--GainsLossesOnSalesOfAssets_c20220801__20220822_pp0p0">31,719,833 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in Net Income from Discontinued Operations for the three months ended September 24, 2022. All profit or loss relating to the Florida operations were eliminated from the Company’s continuing operations and are shown as a single line item in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating results of the discontinued operations are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock_z8n8oEacCtYj" style="width: 100%" summary="xdx: Disclosure - DISCONTINUED OPERATIONS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B4_zCipzJJYl8Q4" style="display: none">Schedule of net operating loss of discontinued operation</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_493_20220626__20220924_zv9ZDz1QVBYf" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_497_20210627__20210925_zIhUrxPhOQT" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--Revenue_zSB3ZIVuE7Gg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,629,641</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,340,099</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--CostOfGoodsSold_zACESA2jJmDc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Cost of Goods Sold</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,103,298</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,227,553</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--GrossProfits_zurggDJdeWUc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gross Profit</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,526,343</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,112,546</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zoxsouLh32Z9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Expenses:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--GeneralAndAdministrative_i01_zDoSRn1HEhhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">General and Administrative</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,983,995</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,617,595</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--SalesAndMarketing_i01_zM1YxZsX1DF9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Sales and Marketing</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,311</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">103,803</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--DepreciationAndAmortizations_i01_z1jTUQ0AIRP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Depreciation and Amortization</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">872,895</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,221,759</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--ImpairmentExpense_i01_zSObCqhHQdG" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Impairment Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(78,433</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1645">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--GainOnDisposalOfAssetsAndOtherIncome_i01_zvm5C9dGOEva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gain on Disposal of Assets and Other Income</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(35,659,761</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(597,591</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--Expenses_i01_zTdiPUBEOQs6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total (Income) Expenses</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(29,837,993</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,345,566</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_i01_zs24A5k78PB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income (Loss) from Discontinued Operations</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,364,336</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,233,020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--OtherIncomeAndExpensesAbstract_iB_zY46YNct4aQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Expense:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--InterestExpenses_i01_znVZy54yfre3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Interest Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,761,758</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,616,829</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--AccretionOfDebtDiscountAndLoansOriginationFees_i01_zF6IGnIX0wx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Accretion of Debt Discount and Loan Origination Fees</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">158,079</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,540,908</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--TotalOtherExpense_zJl4yxowMLe1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Other Expense</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,919,837</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,157,737</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--IncomeLossOnDiscontinuedOperationsBeforeProvisionForIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income (Loss) from Discontinued Operations Before Provision for Income Taxes</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,444,499</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,390,757</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_ecustom--ProvisionForIncomeTaxExpenseBenefit_iN_di_zJAbUHXONBj3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Provision for Income Tax Benefit (Expense)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,137,850</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,055,734</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--IncomeLossOnDiscontinuedOperations_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net Income (Loss) from Discontinued Operations</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,306,649</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,446,491</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8AE_zETwJSJeqzt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of assets and liabilities in the disposal group are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAssetsIncludedInDiscontinuedOperationTableTextBlock_zf80H0sshzmd" style="width: 100%" summary="xdx: Disclosure - DISCONTINUED OPERATIONS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B5_zkTuhXbGjfag" style="display: none">Schedule of assets included in discontinued operation</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49C_20220924_zVTn0aKB8a03" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49A_20220625_zjT4sCe6ilP2" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--CarryingAmountsOfAssetsIncludedInDiscontinuedOperationsAbstract_iB_zcyF6ja4y0I4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Carrying Amounts of the Assets Included in Discontinued Operations:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--CashAndCashEquivalents_i01I_zdB7ji7kUxxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">355,378</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,124,076</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--RestrictedsCash_i01I_zohaIRcuBHS" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Restricted Cash</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,280</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,280</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--AccountsReceivableAndPrepaidExpenses_i01I_zxrWKt1iH3vd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Accounts Receivable and Prepaid Expenses</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,048</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">334,621</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--Inventory_i01I_zv4xu8OiGG4a" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,915,345</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,866,833</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--TotalCurrentAssetsAbstract_i01B_zpKkZvT8yIHf" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL CURRENT ASSETS <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--PropertyAndEquipmentNet_i01I_zKw11ZDcltC9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment, Net</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,713,565</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,273,597</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--OperatingLeaseRightofuseAssets_i01I_zfqBueED0SD6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Right-of-Use Assets</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,780,991</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,543,058</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--IntangibleAssetsNet_i01I_z6oYTDbNJ5v6" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Intangible Assets, Net</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,582,559</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,799,146</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--OtherAsset_i01I_z8mSM3XSgzn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">458,383</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,181,795</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--TotalAssetsOfDisposalGroupClassifiedAsHeldForSale_i01I_z1IMdKcikaNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,906,549</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">123,128,406</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_iB_zuFY5umWerLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Carrying Amounts of the Liabilities Included in Discontinued Operations:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zcbLEoqip7T7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,640,664</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,295,745</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--IncomeTaxesPayable_i01I_zy9TaEBUSMzd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income Taxes Payable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,904</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,671,380</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--OtherCurrentLiabilities_i01I_zDF9rQZ4p3Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">89,069</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--CurrentPortionOfOperatingLeaseLiabilities_i01I_zn5aZhfExlHe" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Portion of Operating Lease Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,605,317</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,209,512</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--CurrentPortionOfFinanceLeaseLiabilities_i01I_zfXqTjPEG53g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Portion of Finance Lease Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1728">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">174,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--TotalCurrentLiabilitiesAbstract_i01B_zWF9oib3JuMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL CURRENT LIABILITIES <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--OperatingLeaseLiabilitiesNetOfCurrentPortionDiscontinuedOperation_i01I_zx6mS6ob8TF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Liabilities, Net of Current Portion</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,067,840</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,410,071</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--DeferredTaxLiability_i01I_zRRatQgpBAQ4" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deferred Tax Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,250,511</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,097,597</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--NotesPayableNetOfCurrentPortion_i01I_z2QXWdWNqhlk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Notes Payable</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,100,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--TotalNoncurrentLiabilitiesAbstract_i01B_zd7WYitKVvDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL NON-CURRENT LIABILITIES <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_i01I_zq9p6ugxvTAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,536,428</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,047,374</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A1_zCWsyjmxW10a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 67000000 63000000 4000000 The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022 and is required to make one additional installment payment of $11,500,000 on or before March 15, 2023. 31599999 19558947 11500000 31719833 <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock_z8n8oEacCtYj" style="width: 100%" summary="xdx: Disclosure - DISCONTINUED OPERATIONS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B4_zCipzJJYl8Q4" style="display: none">Schedule of net operating loss of discontinued operation</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_493_20220626__20220924_zv9ZDz1QVBYf" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_497_20210627__20210925_zIhUrxPhOQT" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--Revenue_zSB3ZIVuE7Gg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,629,641</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,340,099</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--CostOfGoodsSold_zACESA2jJmDc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Cost of Goods Sold</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,103,298</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,227,553</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--GrossProfits_zurggDJdeWUc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gross Profit</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,526,343</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,112,546</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zoxsouLh32Z9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Expenses:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--GeneralAndAdministrative_i01_zDoSRn1HEhhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">General and Administrative</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,983,995</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,617,595</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--SalesAndMarketing_i01_zM1YxZsX1DF9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Sales and Marketing</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,311</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">103,803</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--DepreciationAndAmortizations_i01_z1jTUQ0AIRP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Depreciation and Amortization</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">872,895</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,221,759</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--ImpairmentExpense_i01_zSObCqhHQdG" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Impairment Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(78,433</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1645">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--GainOnDisposalOfAssetsAndOtherIncome_i01_zvm5C9dGOEva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Gain on Disposal of Assets and Other Income</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(35,659,761</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(597,591</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--Expenses_i01_zTdiPUBEOQs6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total (Income) Expenses</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(29,837,993</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,345,566</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_i01_zs24A5k78PB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income (Loss) from Discontinued Operations</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,364,336</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,233,020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--OtherIncomeAndExpensesAbstract_iB_zY46YNct4aQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Expense:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--InterestExpenses_i01_znVZy54yfre3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Interest Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,761,758</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,616,829</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--AccretionOfDebtDiscountAndLoansOriginationFees_i01_zF6IGnIX0wx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Accretion of Debt Discount and Loan Origination Fees</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">158,079</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,540,908</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--TotalOtherExpense_zJl4yxowMLe1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Other Expense</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,919,837</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,157,737</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--IncomeLossOnDiscontinuedOperationsBeforeProvisionForIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income (Loss) from Discontinued Operations Before Provision for Income Taxes</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,444,499</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,390,757</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_ecustom--ProvisionForIncomeTaxExpenseBenefit_iN_di_zJAbUHXONBj3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Provision for Income Tax Benefit (Expense)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,137,850</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,055,734</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--IncomeLossOnDiscontinuedOperations_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Net Income (Loss) from Discontinued Operations</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,306,649</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,446,491</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> 3629641 7340099 2103298 5227553 1526343 2112546 4983995 5617595 43311 103803 872895 1221759 -78433 -35659761 -597591 -29837993 6345566 31364336 -4233020 3761758 4616829 158079 3540908 3919837 8157737 27444499 -12390757 3137850 2055734 24306649 -14446491 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAssetsIncludedInDiscontinuedOperationTableTextBlock_zf80H0sshzmd" style="width: 100%" summary="xdx: Disclosure - DISCONTINUED OPERATIONS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> <span id="xdx_8B5_zkTuhXbGjfag" style="display: none">Schedule of assets included in discontinued operation</span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49C_20220924_zVTn0aKB8a03" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_49A_20220625_zjT4sCe6ilP2" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">September 24,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">June 25,</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--CarryingAmountsOfAssetsIncludedInDiscontinuedOperationsAbstract_iB_zcyF6ja4y0I4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Carrying Amounts of the Assets Included in Discontinued Operations:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--CashAndCashEquivalents_i01I_zdB7ji7kUxxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">355,378</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,124,076</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--RestrictedsCash_i01I_zohaIRcuBHS" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Restricted Cash</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,280</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,280</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--AccountsReceivableAndPrepaidExpenses_i01I_zxrWKt1iH3vd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Accounts Receivable and Prepaid Expenses</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,048</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">334,621</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--Inventory_i01I_zv4xu8OiGG4a" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,915,345</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,866,833</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--TotalCurrentAssetsAbstract_i01B_zpKkZvT8yIHf" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL CURRENT ASSETS <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--PropertyAndEquipmentNet_i01I_zKw11ZDcltC9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment, Net</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,713,565</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,273,597</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--OperatingLeaseRightofuseAssets_i01I_zfqBueED0SD6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Right-of-Use Assets</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,780,991</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,543,058</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--IntangibleAssetsNet_i01I_z6oYTDbNJ5v6" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Intangible Assets, Net</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,582,559</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,799,146</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--OtherAsset_i01I_z8mSM3XSgzn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">458,383</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,181,795</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--TotalAssetsOfDisposalGroupClassifiedAsHeldForSale_i01I_z1IMdKcikaNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,906,549</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">123,128,406</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_iB_zuFY5umWerLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Carrying Amounts of the Liabilities Included in Discontinued Operations:</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zcbLEoqip7T7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,640,664</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,295,745</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--IncomeTaxesPayable_i01I_zy9TaEBUSMzd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Income Taxes Payable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,904</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,671,380</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--OtherCurrentLiabilities_i01I_zDF9rQZ4p3Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Other Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">89,069</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_ecustom--CurrentPortionOfOperatingLeaseLiabilities_i01I_zn5aZhfExlHe" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Portion of Operating Lease Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,605,317</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,209,512</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--CurrentPortionOfFinanceLeaseLiabilities_i01I_zfXqTjPEG53g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Current Portion of Finance Lease Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1728">-</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">174,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--TotalCurrentLiabilitiesAbstract_i01B_zWF9oib3JuMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL CURRENT LIABILITIES <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--OperatingLeaseLiabilitiesNetOfCurrentPortionDiscontinuedOperation_i01I_zx6mS6ob8TF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Liabilities, Net of Current Portion</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,067,840</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,410,071</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--DeferredTaxLiability_i01I_zRRatQgpBAQ4" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deferred Tax Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,250,511</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,097,597</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--NotesPayableNetOfCurrentPortion_i01I_z2QXWdWNqhlk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Notes Payable</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,100,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--TotalNoncurrentLiabilitiesAbstract_i01B_zd7WYitKVvDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL NON-CURRENT LIABILITIES <span style="font-size: 10pt; font-weight: 700"><i><sup>(1)</sup></i></span></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_i01I_zq9p6ugxvTAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,536,428</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,047,374</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 355378 1124076 5280 5280 95048 334621 2915345 6866833 9713565 41273597 19780991 31543058 10582559 40799146 458383 1181795 43906549 123128406 2640664 6295745 -27904 1671380 89069 2605317 4209512 174000 19067840 56410071 6250511 6097597 11100000 30536428 86047374 <p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zeVM00uqx1P3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td> <td style="text-align: justify"><span id="xdx_82E_zXdFp4h2Nsk8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBSEQUENT EVENTS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date these Condensed Consolidated Financial Statements were issued and has concluded that no subsequent events have occurred that would require recognition in the Condensed Consolidated Financial Statements or disclosure in the Notes to the Condensed Consolidated Financial Statements.</span></p> See “Note 22 – Discontinued Operations” for further information. See “Note 12 – Shareholders’ Equity” for further information. See “Note 16 – Other Operating Income” for further information.  Restricted stock units were issued on September 24, 2021 and vests 37.5% on the first anniversary, 12.5% on the second anniversary, 37.5% on the third anniversary, and 12.5% on the fourth anniversary of the grant date. Restricted stock units were forfeited upon resignation of certain employees prior to their vesting during the three months ended September 24, 2022. EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

    M@5281"DL4&H;"VZ2JC1"L2C29KNHO4MWF:YCCY],=^LD8$+?=U%>XGS]:B2%(.F;%PJH0VH,Q$"Q0XY-29!&/"Q'6(J? MA 8P(TE$4>_##0588>@QD /%$P4X]9"DD0_+E.437J^GV68;I>: (A/VS18U MX"%?1$E0C%'"4W*&::!*!0YM9L^T=TZZ29;.=N1#DD> K>-/(PR60D.$EBQB M:HCJ!6+2#\&8B!8HP8,4PE*F+_A*+>C2TQOCEW_"KTB]!SB\G%##[I!@( 6*%')F"%I4P M8M*(B ;*+\=9FL#$V%*.B7&BJ@?6X,I0"10P%-P8Y*&BWGTY MR5WT M,H\)49.'9,46G0TL4) M8_*ABNI?ETF*WRG]E\KZ99<&;I]3$D% 3%*C4_"GDCRI_T!4AU[R#(0T[QU< M?1^>-.]M2?,>-&G>CR'-W9<,"&D^.+CZ(3QI/MB2Y@-HTGP811I2\$%CS93\ MNB3! ^>P)%_)=S)2C.8X4$:'_V%LA2T U M9=QY!J.(14!"";-Z361"5.3+C.Z1>LI2]08!4<172:O U:4]? ZBQ!6@A,N^ M,K;7C,H%FHU_*7%:R,-WYYFWEGT(IVG(ZP<@2G>(1FBFZ^>>2_/G/"G)F^E% MQ+NT6N61[1M4R/DJ92W,NL2E0B!*7X=,2)?+95%?V#,MEMDZ624T >L5&7SF M223S2B;DBQ!J@#4;1 D05%#"$C*N-X*HEO1,@IL<4Q)B4A#L$"!.8YPO'AZD MK;U.V! M021!'B*=5""-I.**(;FUQ*L=:1]?W[V_9QF@90%6$/'6)BG -2W2X#D(;BA M*?-MOWO_]?TWJ-;R7/S7V5T>Q:1)7+YN[K.U(ON45,H7"300:QY(1$!008U+ MO%845:*(RX;(3M4#*W%G\-P7 :2PZJ+O/011Z#)$0N7OE76@D#][63W1JRH5 M!Q+D8KY#OPSD,/QW94!00 -,&)14HJB6#7$@H6VR'LV=@,=@G8!'0R?@$6(G MX-&V$_ 8K!-0OY:G""%Q:7&_3AXC17)"K;1O4F@@#_DA$05%%34^9-(4,'IQS\>UM: 'I[:ELH XHP6H.L-=Y?QH^\9< M*] 1RQ+3^R*29WP>E5&%3>FO2MSWH4H=Z.%I2IDL( II 2K/3S8Z-%5,5',J M6,J8?$JZ6H^99I?X0,I_XA@!HI@[IA$!1 \9+DT&F1S5LD&XL-Q$Z_79KDA2 M7*@;HH&47RY((?:YT!,!Q 49+@47F"BJ98-P8;;!^2-IWC[FV9?RJV7&UK(?8Y(10%Q18=/P9E:!7&=.J5N&/*\M G%>99%M:<24<^T48(=<$:0 M@T08%3B!+6N\HO,MUUF)[C+TJ<"H?,*(;6>-R>^=3/#<3JB;1E8K>B""]\K3 M.,IE%-()>[]U1 E8N'M$D 1!)",\]3TDC0:J53RS9D$XG'?'<0S$O,0;Y6D' MLXHO!MF"KWEDD@?!)DN00TXQM?[@FBDBJADRFU$WN;VZB]<3\MPSE@ <=(P[ M$B XHH2EZA9W[PH(DSMO=[].5A?K+%+/LO1D/&?,$^$-DN6U H 8(*)2IU X[.BS0*(X[/76_R 7_X0%??, MSUUQ^AA%6\Y,O"Z+^I>6HM4/OS:[1Q8/S9:2FXQ/;"ANM'=3]4'0,GNMJ%Z_PE.&.F4?$T26/Z MK]G?=\ESM*:M\:2<1GG^2GJ!GZ/U;GBNPE'7)Z.T M0K-9Z:)6B5'S)L?;*(G1[&6+TP*'I^8\I1?(9ODK<4GQ'?HB/HDF ]?E4_6O^$U_%%EB])N+S.RILH)T.*\Z389D6T_IAGNZVV?V"A M[;_O9>V2V!LSJH*AFAM>(48Q;435T4.6(VI@7T+25!J,9=_]^/Y[QC3ZRZ]M M%"1 !=0#[ZPT?##* 3IED85X<.;88QRRI=.04;(<@SQ[1S/63/<&+8J*(Q/T M&:/40+OA2)0*SA\C-/GV!"X9G!\VU C("B,APG&AS,IH?6D[5: Z7$^-H/Y$ M07!.++:8WLN4/E[BJ,"WR>,3:3X_%9C!4[%?K^,UDMC [P45G0*<^&*!4@@U MM0YB2HAIG68/IW3+)A"VW>0905F^WA#D)1E8TEF*+9V(5P^_]"H^N68#ODLU MG3P8IEF %+/&<14VHF_D3Q#1"$ZP>5H2J GIIG'&$TRSE]5Z1Q>^/V99_"59 MJP>N-JI^Q__VSO3G!+@FFR_B(4Z&$ZZ8U;N M':E,L&FFRDB7N<&)>Q>]X-I//4&EDCZ)J(':)9Q$# RQU-C$::%5ML&(*=0D M"DX6-A"UCFA*:>_3!7:12B$*ACQZ?/)) TBAYASGR7-$$X!94TBOXI-'-N"[ M9-+)@V&4!4CA3%2C HI;_;7&&MFK(4 9E,*M :L<4"\"#S7 <,P*IJJ/?T./ M%V$T7!F&Q#Y^^@J[<$^OXI-Y-N"[O-/)@V&=!4@+SE56 #+N,HM2NVZ[ M5-+KC(4::F^J0A0#PR8U-@L27617?6O'/"K =@N&'846%2 A/';)&:MI]"8IZT2VODG5$K^%!# MSSF#"AC&V>$<\@WN &,XV6BW-4RA$'+"UV*3F%0:#+.,$,W;Q2 1ZYRF3LIQ M?!>]='N;%+-REE*CX7<.V B]/P6L% =#+C-&<0*8:]"EJ898>Q^"5IPY7>(T MR7)V-2..IUGZC,FPF@["R7\FY46T8B\?^.:DZ>T,JILKS5E4.[7@?'+'*MZ_ M2951I8TZZHCKH]I \!#&9G2J"1U%O>J+^ Q2,G#=J-1]'IPV&E#B9>Y I]', M8]U@4P6&.0*PDP/:+=&=?83!:>"\$QK*WF>WW)/1F5OYCUF8U_N98W>C=?9:3%T0E_IRQ MFRD8"FD?3B7JKZ.L!]OVC.5RP6EE 4Z(1:TTXN+N!#M![TX^?/?NY(<_?SCY MTP_?,VKQ7[Y__^'DQS]^IZ<>B@JZ6+DD)8/I=2/H_?(F-EB=I7C^G5OSNZ_]SJ.6<;;:'T3)?$\G4;;A/0U%+5=*>UU3[4>!;E*;W>8+):[3:[-4WY?8X? MDE6BZM/9*/HDE[TC79Z9M"T$SNNUCWRM:6^K%@_.$+$^ M-#M]JCUL7>[?973UJ?7#P*M#&0\;YO;Y(/K0.,8R]'"ZAT_R^;XW M/-.I4(.4!L$PB2S5@4522[3&Z6;HF0^FZZ@H%@\_1WD>I>4B9\GS[C2K5#H% MKQ/U*5+,@RC=]2J M%L%,2L%))CA@)%JC 9ML0Y@.A*.J[.;A(CSK^G/S-U&^R-F]5S&;IK_!.1N) M64WLJY7#K9>8'%(OH:@TP;#2":YFH87? $GT$5,$QD@^33]G4^I6'Z*O$(YY M,N!JMG6E@3), M'(JFJ1A2N!9);Z*EMKK= <4UQF:ZD"FFWFZVQ5E#O@5;9N M:[[24&6C$'K]5PQ59NG@Y+&&J%L1?F9*)_WU6[^L48),4>!R_H:5:4BX<*C6IZI"_C M=%<5-GCTH=^KT)+Q> M7"!"Z]U=T#Z&M7(B A.N,: 2B(L$9T!S?+N^FM70@]#(!SF,KX(M/80_% 83 M/DP(U8?N:X7P._ _XI2 6M/,K_$F21/J -WO6B%451>3EM>88^="+P[I5< P MS ZG$*JX%D_%V],+3KU;X+C8+7W3)&X+T=,$II,-0R M0A2&UM&:[L,GG&H4@M/I'&]SO$I8:B:%GWT1OZ?H17#]8_/M[DSE:T\,?A*Z?TKSZC^D3@86+>7H1)3E;-%L\3%G*KDV233+M;]/COB(-^;HF1NS6,*LLH21&U MS==IZ=BP-8]Z]H/'1Q+1UQG',KDGWF0IF_!*X_EF2SR@_Z%O?ET,^(RM[HYU M(Z^]=G">CX8L3&,VS4R :GBR5 M>2:E=GSZ-9?^YE!4.?R$A^V0// $A]7$!JRI,!4\^;DA<4X##E^Y M :T=$O($&C6#MW.CX,K.JJG;/ "3L_6QH9Y3G?OKA75ME;CG>]"UH =WGTME MP?#+ %!RQSD3!]-OFJ?/! [M]7,/=.212/KEC1)JGS*"&""VJ+ IB<(%CS04 MH_?P8=K$+A[.\7W),MKOV*B17O2PR)-'NE.*/+_ \B0YC@:\#==&.=8,X)RT M@Y-K-&1)4@AN@TY942NH-L,FNJ@AU+&$J*G@ >QCE*2TS[A(VPNYYBEIUG>T MFA6DAMT0IZ(7U0*:M;K7%4M'IWI+EY:ZP7D[$K"P_X9-NHISKJTQ&"0MJ(^8 M>#E[H=W)75(\4?]X?=5\&H.>;UI:N3'DHU8)%!%MD K+Z40/D7C85ZF#:'#R M*4<_BL^@D?>;OM< NY_+5R$,:QK$!%,^A=8?AH*91FNG /8P# M[5GL[Y&L)E6!_&OZEF]XE>J^J%.I3A"5)V-+&%T(?MY%LX3>%?";@&$(K)]K MH7X**QP+N(QD"VD8"''*TMU PE5C@KT2EBEMB":64+PC8A MTR"/.,!PZY((.EN!-5J7NN@V=.^9",[E_7 +%S"K)S+?:LY_EX&;>P5PL@=U M>.]8*1R, :T>[AY(*XIB< ZLJ_(SIGEL<1P]$X"/6,B1-6CT9&VELPEO79:1 MSC7=%D?]X'S> _20PK65TPDW(\G%*.O(! _H38HM72KWH9#?*S-D /M77W0E M@I-*"TLXX-]F. .2BKU!=&E(ORX3#$(, :B4')?@4JLKH6E(EH(T!>(1T0*VG)UV+8);XP5Z6E9$;.]C&F[U):A<+[6P )*E% MG+0Q\-9(ZA!#+4@:(*(2"+2:%3?1*YWOHD?JVVMT;;^-P4A0NEHYJ.6KU@)< MPMK MF5L;0M5QGC*A-8<%,*Z!5DK4W#)ZQ!R+>R\42*/"L F.A\Y#O/Q_#3; M;+.T.7Y_C;_0YH4\CW&L[M':Z_K;7NGH3KNWTE(1!C4=T0J[*ODD3J/?I*$Y M)6.J+U4F<6;F2*R[B?(RQ3F;8:++6Y+3BAHY;VS2P6R8(Q."P1(-,N&T*Q=% M/=FC99"/\6;+4RA=X9C\-,WR+?T5;V@$5#>L\&[N-+)^6ZC!H-$3EC% M_.VUE'%#B[46_MT?"0U'1X]#W(LL_D\$VCF_)/_-D M55:7/7]*D[(@K3F=Z%SCHIB]X'R5%'CQL-@J6\L#&0XUU[W?AU!-AX^S"H/V MAW3%/*G.S:/6/K] '+$WL$YA_0Y4OX16I>HUD"N+]=K/?N;?5L6Q6TW:Q_8_ M4"5R7)_:KRKY;7]:7W^.\CPR+U[)=4*17PE?Q6A! 21-52C-W.L2JM(-Q23[ MP*M6!<,KRX"ITGL;+',-=#*R'2I\'>#0 HFY'.SY+J>;JMEN69:X=IJESS@O MV(B"_UTF=""!5T22SKNRK0F3^+]W/(VX^KS#0=_A]ZC$$3Z/L'7_4"\(7G^. MZ97%CI?&,IATMXH/P;$;OX3;U[4V"J ".7X BQIC:1%Z%7%S8TR=.';/F?KU MD35R= -;MJ&9(/E-@.IM7T8=?ST<2_AMU\:@$)QP+BC%\W-T1,;U*CJUFMX) MI.DI&W4 $$C5-S8H0">0OC>L(]"1(]$Y?L!YCN.[Z(5>)[HJ%VD;#2]P5.Z$ MY!H.>MX(Y>)&0RH;)2BYAUT!BS=\9@KHT7:;?DJ_>"]P4ZG]BZ;Q'%" M:T&TOHF2>)Y.HVU21FM6)]2D;K437U=8O_ODN*I"3=@?PY66'><;C% MJ^PQ331WRWM[N\_^I>=/VNV(>GIU\/@?QE]IU_:4F;;NA1Q[7 /Y,/^' &>L M9ZDVN?R!/1-V;/%<,?;G^(])#]:Q<3X6'R(#@ZG0E"!-W[^ ,L-9Y0 A0^FH M>+I89U]4YW/M5(*D:M& ER9MDOT>:>4,[ M5;]\LW>FSSJSGE?N/>/\/BNP;OSM@%DD8JM:'5AK=8(SLHG%ES@J<,&;B&:< M-Z>3@='Z/"$>E-.L4&XNRRUM4&F.@Y$KC0UZ9W\]!6O&V]F4'$ ME(ZT>$A3/6!^F(9NFF IUND19'J:.8O219X\)BFK2*I<6ZX6O"THCG.M65IT M4P>UR#@*NM#SK(TT)X)K._Q8.C&$.I8.DLMK[V!+;X6GO>)%2L!NLR+A7V%2 M%%@960TZ/L.H%?QNS-0J0.&D"UCI?<^$75PC6K,+';@&(++=X7Q3U8/% PO: MQD\@4PE#-35X.=-$>;A$4V(=\HRJ4)[Q%K>C!HEFRVB-%P\W>48Z",K[<=7B M8>@E!RVG5E\6+JVD. T-:#58KHE&3= 'M9'@-&-!E6XK2G+:;9T^1?FC3?ODYW&3K6%K00N:J2U@_Q9)'&U2A6\ALQ3TAB0KL4YYO^>I^L MSFSHK.WYRCL7EP;+IS:J8"*T&UYA^9NQ521K:^.0.0OWINKLA5:A75(\;9I\ M8G4MKN_L4WPG.U6?)'5QILM0&SUHP=?1-C[=4%* MP,+F2$$2VNJ,%N4AMC#O,85=;YBMMF;3#@)-T9DF6IKD/Y7XS\;VO02AA\9#."*.P^@Z4CEV>R)5:1I5IU+'=9M=F MYNL4KS[KQ$62TAW+;(K+D$W;33\LUPUNZ7FM4(;/83UP6[Y65JII3TB]4+'+ MW2R+5CX8]NJY& @[;#(YIA\YJ;0!#YX,D.7CIV*PL8W-? TS9(??Y"9Z6V?U MOL4K3,9[/%4XVVG5;@?4K4_N93$LLYU=UU/=VAR4\'TX5R2+"SQ5?&N U86; M'&^C)*[WXT&,XW/2)TK)BURFNWHZ83DM@:]G;44X0.L94F6K@;H'2&4.'0-"#3SLEYB'[F""J)*$L?RG\H>=ZQW-1U 9 M1Y5+%HP=HX;-?IU%F"-EV[EQ?* MKF;W5J+ZBCA(4P;=*9%ZPH-@9HLA:0U4M6W*5MDGK=T_%9XAFJF0GH3>2J2.N@#F=*2NV4YH]57?@L36E+$PGP6/>31L/14 M..\!*:;*1HCT>,M=].(T?._HA!Z^"_!-P_=& 7XS+X(5PR250$SD4(M01Q[) MC^FC*O4!#*+4;MD/[-_&+BD]8OW8'G84'(P-1U-480( 2[7..8WWW]1 R8A= MSEIV>!,@<^US^.A2WPR^VKY&869QLLW]LY]%KS6@S,IHK>/_07P1#C+/[A!+ M^71SN_@\/Y^=H[._H:\_+__D3^2Y8'"FJ-88=?V2? \=@* MHK(!H#[HW;.@O]P F+[)&-2R9%B]-#M=;6G.':ADEM3OO0,$"!IK'!L7PM]J MN#:%YBH:OZD03%>>BT.DF-0: L!B"TZ MP?ZUSA:^^OLNR7%]IO>&0*0;BFD2Z*WLYC!W=8_WW3L[U>RT=="%L@0Q$O>0 MAC<$TA-=:N@>[68+9HVJ+Q+.TY(@HUO/V:JTE;^"3CBZ*>"K.390@$TL.5@Q M^2._?( E>6Q5H&PS(/Q>81RSK+(\(P*;"^'H)"%QS2EE@0\1;^%.": M:#=X'IP@&E#B&?[FXFLJ%CQJV7LWS<@CW>\E>]C$8//0?T@NW&=;&^AN88;7O_KH8@-E, M[-XN MNV%9O?#-.EJQ!/":"4%70[ZG8\)VE ?"+!BWQ0C,K@MO*,WL MH=H@G>RM3*+&9O ^0G=SUYPODH*JXE=4274)*X*O&K"=B@?/)HZ M@!2N+JV>4PY6*H>+F0>E6*>UX+F4:/HDBP^AT M%-JT;*L9)E4#23H=4$_Y8 M*BQ-]--DT9J2'Y(2740K=L(&*&>O",C=AF:19\F^G+ZDH!N>NPIWS/P=* +G ML!RM?C&KVRWUD=B-= S(0&T;K6_QMEI47CR8LAE:*/GK6=HZT/8B31K!:>4$ M4^13I8=:Q:!LDF66&QY(==8.RR^M2WJB255AC5%<8=LR4)X<<.\V5\'%\X2N M$]_OV/H /8"3I27Q?\TRQ?.CW3+OK=2\L<_!B89V%CHP(IP]4.&&QJXF.N6G MI5IM5*L'[\[9SX_N/<$*=>9[OQGO-[&:H\:M7,UI5W"ZZSJR6>_@'*8>T__1 M':?/T1JS+(/=G3J3-.[_T)&\P7F2Q<-CD;.7U7H7DP]&_F#).&])BS1[>,#* ME2#?('QO"/#_@8<["/PA@%6G@_@NBPOSZ^GM;+*;30K*L:] - M^Z,C?X+.\&.2IG3\0 _;,(BZ.O(_AQKO Y!CENHOACN(0])=*+)F]P3-R*^+ M"W0SNYTOSH.'SN5NNUVSA=QH39V[6&=?YBF)[!NV']*PKX\ MLE,-/NLQ#J]P'=*GFYO+V16AY>02G<^7T\O%\M/M#%TL;E&SC8IT(LE_7TWN MYHOKX&QMX0M=?W.CWFZE9O=LQ6&0P%71$+PU\Z?\O'+/66?-I%:VQT M-N@?:Q,HJ3E\D'271VG!+]>^RPQC8 LE;Z-@:P>:<;!1(SB_G&#*#G]4X]Z. M)MT/ FL8S#;OW>(8DQY!O,BGT7J-X_-=3GC/!R'L@E=55\)2V6M/SLFA7D?. M2A-:TC\GU.)QUAAOMK3;1T>=5SB^PBF:9OD6<8LL0SK?C7RLA5+AZN'7.4]7 M&"_2SEZI>H]4E;>B?&W"LW1Q[P!6_2VS'NP3M*NP>YN$$7T/YH>PABO>5OV* M:M,TUWIWFUYMO4E]0OYL7G"L.7'V_H+4S,5#_U)/,G#;Y?*++BV4_,V+VSK0 MSHR;-&!PTA:F, 9J]&BL'5RF6JD>B4P\@M/=??S"V+)LKH>]Q&F,\PLL[6': MZ7FCE(L;#:MLE& 0RP&I])+J G%=ONF8:K?7]'(#B%@X*L?ZX,5K6@P7];K; M\,N]$>[U>>A@ $H_ZIZE?*,AK2_7^ N]4&A# M:TPL^QA6:MZ(Z>!$PT4+'5#TL\<(FE4AX/HN*A,3K&_+UZ(HC_?4.OY1G!,-OB@\S MQI!/)HYWM,M0=RM@F#L:NC!)/KFC:\>+BSIS]^(Z_([C9?*8)@_)BB;)%:JH MB;NVREYGQ)TI7 #-/&.)T\9(Z9XAG-S79]M[C]V_%..-9L'^X+5P0C>S6? M)QQMG>B><#3I!.>-(U!AI-'9L']QW$36 C15I#%*>R.-&7+#%;4H#(H8\0G, M6"YG=TOTT^SRG&WY7$XN9\';*^7%%H9>D86>YW0E=FX,4I7HE8(3S16I)$4) MTSM!3+-__PBD;I/20?MNE)L)$.2T[&:YZ,.GK'TW[.:63FW<_8T=[*!G.F[H MWOG@7/V89?&79+TF3@UN;RFL!Y6.-GRR=91[7;HZ&0##US&HAX2M;; X*US3 M W;$JO+6/'"UT/1\%L36E<'Y$),:&)K:8Q4'M7>3ZX_SL\L9XCW1X,RK=BP4 M="5ZMYN MM[$/=Z.M!5CJ'>NR9!W8U1080N^'7QB]\\6,);J9_&W"@BCIE)(?;^EM/9?S MR=G\\B!9?XQ3AN*^;O5&!#?5 %.'5LY(I@^U>J#V7[EAMMAK?[P]?5* VCE% MDT; 1S!ZCP)?9[?SSY&[^>7;(F+1W0\P21YHZ=T,AG\VF'&"W M->Q+!*>(%M:0%5P(4L^,(UH\7&(RBL'V?3 +/?^TL7!#9))&"1BYS$@%OM%L M:,?O"75S*MMU@.0: ?H].NB2[HY,'&@O1P-53!YP_,3673C:KHQ"T%\6 !W0 M]N2_3"IXO#!"$TI^<3=K1E+!&R-ZJ,%ZYEXE[+/9T0/NMC5RR>"$L8(GCH7N M2Z!SZ'T_3)T8I70X#FD[+ I1H"PR;E:=7<_I[HO9]-/M[)Q>N?QY=GO'YL6G MY(?Y';J83.G :>_=7WO3BI_ ,@2DH9!/$LD!=KG3EP!#&2DLQ0$X0'&&)2QY MRM8QS@N.CK:Z]I''0=][WAD7MX34,S;*8,CGBEB(8#]-;F<_+2[/9[?+?_ZG M/[]_]Z>_LNT1 ")6ZP1-\+#9XK1@IUG8I5XX9C=\L9/,]V1D&5UD$0_J#N"$]%']Z1C50?:WRL!5A5< M792L--B:",ZZ_7 +.W>Y.IK0G6P] ZBV<"2"FH!K%RTG8[N>0;R7Y-AZ>R;.MX%'TAPZM]%+P[9 M030:?L^^&*'WS[PHQ8-3S1ZCF!V$A2Z:20[F0K'$)?,I*YU*8(H9SE6IY2&3 MS.)0Q#=Y/_F"U97^Y\=C&[O667!+=/@C-OFFTV2\>@%I.K-S;X_8I=*T#CJ)7? MILCJ:@0ZBI!BI\HY^\#I9 $" M*2U#IH,Z>*K:!\O;V>7DCG17;R8TU\K=[>1Z.9D"R2>+'VE+<(NW64B!;^B+P[Y)&\V0'+/=*VE6 \L\ MEQW>'VG7#]1-RK?X&:<[?$%*D?9I:87X.2F?IKNBS#8X-W;]++7]-K9.+O4; M6BM5,%QTPRMV"YDVHI\/U?KH"S& :@N0PJ3!67/GT%8=$%D-W4([W;="5W.' M\//L^E/XU1@:\=GX?X?C:M&)CL'2F#S89D6T_IAGNZW-[G$G*[ZWQ(YP<;@% MUL$$&)*.PRT<"NQ80:T9-I%9&T+<$J08V_=QGJ[6N[CJXXC?Q.%DX=YF/9/_ M(!]A4!OVL@FI>AS"$:&^S)=\,I2FK8)T<\SNOL!_WY$._^S9XDB06MSK*,P MNC?T4LB"(9P!H##(:L01EX<47H>^&,?W:OF0?-*/Y57"8!EEOD;H;#G[]T]T MZ$Y[H RE%;W<@UN1'KE_S3>Q6:I[/7^-2>'>G>N66F"X9X3W"$1F3*][O0F MQ]N(M[''VOZ=$6Q36G!YJJ>56=S?%F\SZ'93MUHV.%DL 8IIONG$=J5R)%Y, M%Y_GY^]^M*"$2M(;&_10&R+(Q6!P0(M-W%Q A$_?_1B\=2(,+ CBF,4GNS9) MK^)W@XL9?'\[BUH^.(D<0"K;FI[ND:**^I9'?8RQT_,6<5S<:.*/C5)P(KDB M%;K0K2J2W'DH&NW0Y_N]=P;89=FYB5GP6=S-^;Y<:YV3_ABDW M&V 8.Q*XN$+;UPT?**_QET[LS[.4_+EB26T*ESD(=S,^J3O6R2YU76V H>Y( MX!+J$I7U*YK$V99N/NTT^\LR2N,HCX]U=KU^][PH=CAN7]R\=\M<*(D+]ZJN MI;L-;]W,L>XU74Y7 \&YN0]J)3&YG:/P[O*<_'6G MRQCMKNYU&<'1J=ZJ@J5N<*J.!"P,F"IU.@)/*@/'NV&E!2O>'FS,4.Z@[&\D M[NI0.QRWU0S.M%%P=3R+J 7T1&\(?\AR5!S@AO ##)44U[6:0J"-(HC+=K5A MSZP5G(;.4'44W%9&V#XI7%L(SL*VEETD:5+BR^09"]>Q.K;,#I;"--+.KLK; M:VLS8)@\'KN.VIU[=UF@A=3)M+F2T)'>8TR&X?EXY^6$=[<'D/FCG=!V,"JC M:,NMLB@?<;MH??1[!%OOR!B0,(2\CB?0R@*2><_)*S@X0#>M]!% ME;P'C_Y2/F%T7R/D74F&$=USD%0F;F\P[40>)KQB2,FP&ST0K.B9@E6K!&_& MFP]ZC2OU97Z]P1'=AQXN4%.8NSUF!%4GQ*[LE_6 M5FV^Q_?[["!X_ZS=WH2WEP>/-:$\-DR$[#9;?F"GS-"&O[83#8[>0?DYHK=% ME 6?HW;I0.@U S3P-JY(&F"=6G#2NF/5T>T+5T<)4P_>GO2F%.MZ\*DPT-!9 M.]!@S\8EQ;A.IPKEUM-QL&$'0W;=+[UJI,&N7+6U4 H0 @T.2**?0@-:X-/# MU+%J3371BJ@"BG<7NY)0^RI)D\UNPWRK;[2YR/)IM$W*:,WOGG:=ZQUM.-#4 M[YX?0C$3/-)J<-8?W!5=S7A@IGD%83-ES"R@6D*O-77DOTPE#+/5X.6<%>4! MLE$)4L>SE-UROCWJ+>?J.:3NK=QNLT]]30 SEC)7+&84NVK!.>6.54>M6V%& M[OJ09#M@++M,4GJS78[CI+R(5O44I'5@,^J'B7*6;LE#GD$Y.%?'(M8QML!I M0K>\T&DE')-^:4K&6"5;K%TQLV2\P^R^'CU2LB,*U53")(T7N[*@VQ*3]%%? M9W5Z :*DV0U)C%0K!6>=*U(=V[AR-=_#EARR5O_H!/M,ZH;>.2X1@#1=:!)Z MT,?0B-#!I"ORS_/P>O,9ZLRN29-.J.C'804V5C,F(1M2;Y T#1_9K.410E MCF_)/_-D1?YB%99_D'&!?93-,#%]#_?EX7R$P>#UX9!>Z"=T:V.(64,?V7X7 M0+7A)L_BW:JL=N*\-EO&'"N K9DPG'=S4DYS.QL F>T$7$?F>K<6(/8.$]S0 M78TKEG)\O2N=-UXY6@O#Y5$NRRGM9 H@L\?@UQ'\GNJS+DS,+:!U5A0L_U%Q MB/Q'QE[X1YSB/%K30T/Q)DD3FGZ9[N:M9IF<^N&NM@+TQ,>Y*^F+NQD*SN1# MH-?Q^)$;Y*?$>B;KR9;C#RBE-\L[$=C.0@#:NK@F(:N-.C2*.F VSWHW4^@' M8^,!>Q1T'B=+Z%\ MT&>EH790&;W4_.\(K%:/J$5! U>(\*:+'QQP_5MN9JGNHK"J I:[G M^VGLW1E<0F-6!$-?%[0ZHO;M\!.CS-+1.P_7N&P:&YJ#=/$@O2:G]>C2V)L8 M:3) ]V(OYR7]C5'V@I/Y@$YH-_/BLM,?8<,]>F"Y>PE95AOWE$.,7PU%$Z<8 M7#1WH4<9#)9K;)3CROQC3M:@T7V\"\8\907M@#"S]*"^5Z9/H^*))C0@_Z)) MKIZC->E9R3Z$0M#?#1@ZH.T%&#(I&$S201.NOR!"/'T#_0,WXL>:(_@YRW^C M-[3PPS[GI ^]2J0L4 AZ8X$6:,,"J10,%NB@#5E &ECTA)NR(*?NOY(7^'9[AD]5JM]FM(X+^'&]SO.*'Q\C? M:\PV;*;Q9)/E9?([^UWPG59YY3=]IRB$8[_49RWR\P&[]>ZX;P134[VXZ5"W M5[NBS#8X1SE>\V=/R;:HQ;Z(.<5QLXGZWX:68/M;L/G/0NC MW.O>L^!D(#CE]T'MP& H-+TF!&B/KQ2N>73Z1Z$D@;NL4Z2Q_IG^T,-NUE=E)W.GU6 M1\OAJ\FH3V&N*$YF@5>5,;XX5!9F_I0:9=5C3=[ _ZNS],'R2D%*S]I<_W(; M?;DB53E/HK5JC*Z0]3F,T,+M]OZE@L'Y:8-.8%ST!34R$/:U#*("<%AS<<\,P>92B@(2WH I>Q@$EY9468TS9\--;K8 MAI2XHU90(QJ<$VR3+%NYI]VZ)*?35-.G*%R]U]D<1)E+\NX747\Q$^3F];\P'M@ZDB1W!*V'[4:*$L1UP/\;>@6O\$T1>Q M_%[LC.S]*Y*JU?+H%_;&_P)4(SM?ZC))\;S$&U7,-RF%J34Z!^3U0*8!D-D: MF&JN#AGY"U5%3%?+NF.N4@YO*;W.RILH+]E&V&U61&O25=IMIYG:='6JF;ZTU@\>.47"%/B371Y6!X]W)QZ9/<,P6R6FUL.>7 MK:8W?O*EBAB'JM[1S58 M,GY%:'"/60L-8*RM.E%<77T4WU#NHG#;[L?]2% M/VJ6QH?H17TP]Z)F-.ORH?I/>P>BRRB-%3[S1SZ#1A=,ESCT=S 5O -&V,[- M]DZ0_YWMDC5-J7VLSDOOHA?#/@BUK,?C0'JXG1-!.+:O.U;O%%(^_U-E03[-[MI2KAX 2R12@LV_4VS5] V31_66_S MGW=V^>O8I%/PVL08@?<:'J4T&$(9(0J-5'-"HZL1G%'*C>IL54GAO$D)Q&&B MG@-6QX>8!AB&6<$#$4E82';=,2B#"EY)A>@TP)+." M*=\:4ZNR&-;HP>4:W[(A/S4V*K@K;8%@IHV[]NVMPI ?'O_(>9S27%%8.Q.U MCQ-B5[ H4$<%=76 T_P:#X]&.>C!H6_'#7NJ$B5HU[[; I:LS4A"[ DB&L$) MR*!WJ\3@P*UNXYQ6S?O.1 LGA.V)&ATP;;LE4/E&Q:X>H]_D@"="#S!2*%B2<;MRLZT6L'O.,4$O#],44F#(9D1HCA(*4JZQ,-4^/BW M4D)4ZTAK ETZTWN0']/D=QP/;X67S6O;:GI;+W!SI5D]L%,+SBMWK$."]2)7 MWFBSI>$Z]]3Z(*L."JZ=97F>?:&IL0C5I9P:2GCCCAQ:PY'^8QA:4D#!*8X WY4,G7];U2 M8'FO@_==VCR<]-19B2^39YJ$LR3XZXF**<2-)Y>&LXFV*EZ73YW<*:WDFZA!X:E#F!EQV)U MG+RT.[@0FIC:C1Q&-2"$5&_K,.B\!2+:',0=L"\XX1P3T"GG !5?ZW#F :<[ M-'Z4/1(;*FU#6[0XL%_&=8Q#SN0I1DJ#^GV-R]D+30M/1FATWN=+LI9V\ZW4 MO(V>')QHQE$6.E 6)QSQ#FDE!&08RQ+N*Q)@%B,PA*$^^I#5^,$-3%0 M6((XH3GZMOSR60@K$IU[0U_H"99=4CRQ%;Z'!&*NQYJ*(!/!AX2"3!,$H+3Y@9KX11)0V!-_F. M#)#:$T-&ZJCD/;-'#WM (+DP) YI$4IH1.71Y>%2NJH6W?B;FD1LTN4A0<;? M$IL"7KNR-A (7N0Z5*IBAI,&KT)$HA=Q<'T7O5C&"ZE"@("A 2Z)&!+IX/RQ MAJ@B4Z41G$KG^ $3O#&!SF

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end

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end XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 194 444 1 true 64 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://medmen.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://medmen.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://medmen.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://medmen.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Sheet http://medmen.com/role/StatementsOfChangesInShareholdersEquity Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://medmen.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS Sheet http://medmen.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://medmen.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - INVENTORY Sheet http://medmen.com/role/Inventory INVENTORY Notes 9 false false R10.htm 00000010 - Disclosure - ASSETS HELD FOR SALE Sheet http://medmen.com/role/AssetsHeldForSale ASSETS HELD FOR SALE Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://medmen.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - INTANGIBLE ASSETS Sheet http://medmen.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 12 false false R13.htm 00000013 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://medmen.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 13 false false R14.htm 00000014 - Disclosure - DERIVATIVE LIABILITIES Sheet http://medmen.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 14 false false R15.htm 00000015 - Disclosure - LEASES Sheet http://medmen.com/role/Leases LEASES Notes 15 false false R16.htm 00000016 - Disclosure - NOTES PAYABLE Notes http://medmen.com/role/NotesPayable NOTES PAYABLE Notes 16 false false R17.htm 00000017 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY Sheet http://medmen.com/role/SeniorSecuredConvertibleCreditFacility SENIOR SECURED CONVERTIBLE CREDIT FACILITY Notes 17 false false R18.htm 00000018 - Disclosure - SHAREHOLDERS??? EQUITY Sheet http://medmen.com/role/ShareholdersEquity SHAREHOLDERS??? EQUITY Notes 18 false false R19.htm 00000019 - Disclosure - SHARE-BASED COMPENSATION Sheet http://medmen.com/role/Share-basedCompensation SHARE-BASED COMPENSATION Notes 19 false false R20.htm 00000020 - Disclosure - LOSS PER SHARE Sheet http://medmen.com/role/LossPerShare LOSS PER SHARE Notes 20 false false R21.htm 00000021 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES Sheet http://medmen.com/role/GeneralAndAdministrativeExpenses GENERAL AND ADMINISTRATIVE EXPENSES Notes 21 false false R22.htm 00000022 - Disclosure - OTHER OPERATING (INCOME) EXPENSE Sheet http://medmen.com/role/OtherOperatingIncomeExpense OTHER OPERATING (INCOME) EXPENSE Notes 22 false false R23.htm 00000023 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES Sheet http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxes PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES Notes 23 false false R24.htm 00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://medmen.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 00000025 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://medmen.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 25 false false R26.htm 00000026 - Disclosure - SEGMENT INFORMATION Sheet http://medmen.com/role/SegmentInformation SEGMENT INFORMATION Notes 26 false false R27.htm 00000027 - Disclosure - REVENUE Sheet http://medmen.com/role/Revenue REVENUE Notes 27 false false R28.htm 00000028 - Disclosure - DISCONTINUED OPERATIONS Sheet http://medmen.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 28 false false R29.htm 00000029 - Disclosure - SUBSEQUENT EVENTS Sheet http://medmen.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 29 false false R30.htm 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 30 false false R31.htm 00000031 - Disclosure - INVENTORY (Tables) Sheet http://medmen.com/role/InventoryTables INVENTORY (Tables) Tables http://medmen.com/role/Inventory 31 false false R32.htm 00000032 - Disclosure - ASSETS HELD FOR SALE (Tables) Sheet http://medmen.com/role/AssetsHeldForSaleTables ASSETS HELD FOR SALE (Tables) Tables http://medmen.com/role/AssetsHeldForSale 32 false false R33.htm 00000033 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://medmen.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://medmen.com/role/PropertyAndEquipment 33 false false R34.htm 00000034 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://medmen.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://medmen.com/role/IntangibleAssets 34 false false R35.htm 00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://medmen.com/role/AccountsPayableAndAccruedLiabilities 35 false false R36.htm 00000036 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://medmen.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://medmen.com/role/DerivativeLiabilities 36 false false R37.htm 00000037 - Disclosure - LEASES (Tables) Sheet http://medmen.com/role/LeasesTables LEASES (Tables) Tables http://medmen.com/role/Leases 37 false false R38.htm 00000038 - Disclosure - NOTES PAYABLE (Tables) Notes http://medmen.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://medmen.com/role/NotesPayable 38 false false R39.htm 00000039 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables) Sheet http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityTables SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables) Tables http://medmen.com/role/SeniorSecuredConvertibleCreditFacility 39 false false R40.htm 00000040 - Disclosure - SHAREHOLDERS??? EQUITY (Tables) Sheet http://medmen.com/role/ShareholdersEquityTables SHAREHOLDERS??? EQUITY (Tables) Tables http://medmen.com/role/ShareholdersEquity 40 false false R41.htm 00000041 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://medmen.com/role/Share-basedCompensationTables SHARE-BASED COMPENSATION (Tables) Tables http://medmen.com/role/Share-basedCompensation 41 false false R42.htm 00000042 - Disclosure - LOSS PER SHARE (Tables) Sheet http://medmen.com/role/LossPerShareTables LOSS PER SHARE (Tables) Tables http://medmen.com/role/LossPerShare 42 false false R43.htm 00000043 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables) Sheet http://medmen.com/role/GeneralAndAdministrativeExpensesTables GENERAL AND ADMINISTRATIVE EXPENSES (Tables) Tables http://medmen.com/role/GeneralAndAdministrativeExpenses 43 false false R44.htm 00000044 - Disclosure - OTHER OPERATING (INCOME) EXPENSE (Tables) Sheet http://medmen.com/role/OtherOperatingIncomeExpenseTables OTHER OPERATING (INCOME) EXPENSE (Tables) Tables http://medmen.com/role/OtherOperatingIncomeExpense 44 false false R45.htm 00000045 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables) Sheet http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesTables PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables) Tables http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxes 45 false false R46.htm 00000046 - Disclosure - REVENUE (Tables) Sheet http://medmen.com/role/RevenueTables REVENUE (Tables) Tables http://medmen.com/role/Revenue 46 false false R47.htm 00000047 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://medmen.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://medmen.com/role/DiscontinuedOperations 47 false false R48.htm 00000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies 48 false false R49.htm 00000049 - Disclosure - INVENTORY (Details) Sheet http://medmen.com/role/InventoryDetails INVENTORY (Details) Details http://medmen.com/role/InventoryTables 49 false false R50.htm 00000050 - Disclosure - INVENTORY (Details Narrative) Sheet http://medmen.com/role/InventoryDetailsNarrative INVENTORY (Details Narrative) Details http://medmen.com/role/InventoryTables 50 false false R51.htm 00000051 - Disclosure - ASSETS HELD FOR SALE (Details) Sheet http://medmen.com/role/AssetsHeldForSaleDetails ASSETS HELD FOR SALE (Details) Details http://medmen.com/role/AssetsHeldForSaleTables 51 false false R52.htm 00000052 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://medmen.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://medmen.com/role/PropertyAndEquipmentTables 52 false false R53.htm 00000053 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://medmen.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://medmen.com/role/PropertyAndEquipmentTables 53 false false R54.htm 00000054 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://medmen.com/role/IntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://medmen.com/role/IntangibleAssetsTables 54 false false R55.htm 00000055 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://medmen.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://medmen.com/role/IntangibleAssetsTables 55 false false R56.htm 00000056 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesTables 56 false false R57.htm 00000057 - Disclosure - DERIVATIVE LIABILITIES (Details) Sheet http://medmen.com/role/DerivativeLiabilitiesDetails DERIVATIVE LIABILITIES (Details) Details http://medmen.com/role/DerivativeLiabilitiesTables 57 false false R58.htm 00000058 - Disclosure - DERIVATIVE LIABILITIES (Details 1) Sheet http://medmen.com/role/DerivativeLiabilitiesDetails1 DERIVATIVE LIABILITIES (Details 1) Details http://medmen.com/role/DerivativeLiabilitiesTables 58 false false R59.htm 00000059 - Disclosure - DERIVATIVE LIABILITIES (Details 2) Sheet http://medmen.com/role/DerivativeLiabilitiesDetails2 DERIVATIVE LIABILITIES (Details 2) Details http://medmen.com/role/DerivativeLiabilitiesTables 59 false false R60.htm 00000060 - Disclosure - DERIVATIVE LIABILITIES (Details 3) Sheet http://medmen.com/role/DerivativeLiabilitiesDetails3 DERIVATIVE LIABILITIES (Details 3) Details http://medmen.com/role/DerivativeLiabilitiesTables 60 false false R61.htm 00000061 - Disclosure - LEASES (Details) Sheet http://medmen.com/role/LeasesDetails LEASES (Details) Details http://medmen.com/role/LeasesTables 61 false false R62.htm 00000062 - Disclosure - LEASES (Details 1) Sheet http://medmen.com/role/LeasesDetails1 LEASES (Details 1) Details http://medmen.com/role/LeasesTables 62 false false R63.htm 00000063 - Disclosure - NOTES PAYABLE (Details) Notes http://medmen.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://medmen.com/role/NotesPayableTables 63 false false R64.htm 00000064 - Disclosure - NOTES PAYABLE (Details 1) Notes http://medmen.com/role/NotesPayableDetails1 NOTES PAYABLE (Details 1) Details http://medmen.com/role/NotesPayableTables 64 false false R65.htm 00000065 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://medmen.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://medmen.com/role/NotesPayableTables 65 false false R66.htm 00000066 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details) Sheet http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details) Details http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityTables 66 false false R67.htm 00000067 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative) Sheet http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative) Details http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityTables 67 false false R68.htm 00000068 - Disclosure - SHAREHOLDERS' EQUITY (Details) Sheet http://medmen.com/role/ShareholdersEquityDetails SHAREHOLDERS' EQUITY (Details) Details 68 false false R69.htm 00000069 - Disclosure - SHAREHOLDERS' EQUITY (Details 1) Sheet http://medmen.com/role/ShareholdersEquityDetails1 SHAREHOLDERS' EQUITY (Details 1) Details 69 false false R70.htm 00000070 - Disclosure - SHAREHOLDERS' EQUITY (Details 2) Sheet http://medmen.com/role/ShareholdersEquityDetails2 SHAREHOLDERS' EQUITY (Details 2) Details 70 false false R71.htm 00000071 - Disclosure - SHAREHOLDERS??? EQUITY (Details Narrative) Sheet http://medmen.com/role/ShareholdersEquityDetailsNarrative SHAREHOLDERS??? EQUITY (Details Narrative) Details http://medmen.com/role/ShareholdersEquityTables 71 false false R72.htm 00000072 - Disclosure - SHARE-BASED COMPENSATION (Details) Sheet http://medmen.com/role/Share-basedCompensationDetails SHARE-BASED COMPENSATION (Details) Details http://medmen.com/role/Share-basedCompensationTables 72 false false R73.htm 00000073 - Disclosure - SHARE-BASED COMPENSATION (Details 1) Sheet http://medmen.com/role/Share-basedCompensationDetails1 SHARE-BASED COMPENSATION (Details 1) Details http://medmen.com/role/Share-basedCompensationTables 73 false false R74.htm 00000074 - Disclosure - SHARE-BASED COMPENSATION (Details 2) Sheet http://medmen.com/role/Share-basedCompensationDetails2 SHARE-BASED COMPENSATION (Details 2) Details http://medmen.com/role/Share-basedCompensationTables 74 false false R75.htm 00000075 - Disclosure - SHARE-BASED COMPENSATION (Details 3) Sheet http://medmen.com/role/Share-basedCompensationDetails3 SHARE-BASED COMPENSATION (Details 3) Details http://medmen.com/role/Share-basedCompensationTables 75 false false R76.htm 00000076 - Disclosure - SHARE-BASED COMPENSATION (Details 4) Sheet http://medmen.com/role/Share-basedCompensationDetails4 SHARE-BASED COMPENSATION (Details 4) Details http://medmen.com/role/Share-basedCompensationTables 76 false false R77.htm 00000077 - Disclosure - SHARE-BASED COMPENSATION (Details Narrative) Sheet http://medmen.com/role/Share-basedCompensationDetailsNarrative SHARE-BASED COMPENSATION (Details Narrative) Details http://medmen.com/role/Share-basedCompensationTables 77 false false R78.htm 00000078 - Disclosure - LOSS PER SHARE (Details) Sheet http://medmen.com/role/LossPerShareDetails LOSS PER SHARE (Details) Details http://medmen.com/role/LossPerShareTables 78 false false R79.htm 00000079 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details) Sheet http://medmen.com/role/GeneralAndAdministrativeExpensesDetails GENERAL AND ADMINISTRATIVE EXPENSES (Details) Details http://medmen.com/role/GeneralAndAdministrativeExpensesTables 79 false false R80.htm 00000080 - Disclosure - OTHER OPERATING EXPENSE (Details) Sheet http://medmen.com/role/OtherOperatingExpenseDetails OTHER OPERATING EXPENSE (Details) Details 80 false false R81.htm 00000081 - Disclosure - OTHER OPERATING (INCOME) EXPENSE (Details Narrative) Sheet http://medmen.com/role/OtherOperatingIncomeExpenseDetailsNarrative OTHER OPERATING (INCOME) EXPENSE (Details Narrative) Details http://medmen.com/role/OtherOperatingIncomeExpenseTables 81 false false R82.htm 00000082 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) Sheet http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetails PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) Details http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesTables 82 false false R83.htm 00000083 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative) Sheet http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetailsNarrative PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative) Details http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesTables 83 false false R84.htm 00000084 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://medmen.com/role/RelatedPartyTransactions 84 false false R85.htm 00000085 - Disclosure - REVENUE (Details) Sheet http://medmen.com/role/RevenueDetails REVENUE (Details) Details http://medmen.com/role/RevenueTables 85 false false R86.htm 00000086 - Disclosure - DISCONTINUED OPERATIONS (Details) Sheet http://medmen.com/role/DiscontinuedOperationsDetails DISCONTINUED OPERATIONS (Details) Details http://medmen.com/role/DiscontinuedOperationsTables 86 false false R87.htm 00000087 - Disclosure - DISCONTINUED OPERATIONS (Details 1) Sheet http://medmen.com/role/DiscontinuedOperationsDetails1 DISCONTINUED OPERATIONS (Details 1) Details http://medmen.com/role/DiscontinuedOperationsTables 87 false false R88.htm 00000088 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) Sheet http://medmen.com/role/DiscontinuedOperationsDetailsNarrative DISCONTINUED OPERATIONS (Details Narrative) Details http://medmen.com/role/DiscontinuedOperationsTables 88 false false All Reports Book All Reports medmenenter_10q.htm medmenenter_ex10-3.htm medmenenter_ex31-1.htm medmenenter_ex31-2.htm medmenenter_ex32-1.htm mmen-20220924.xsd mmen-20220924_cal.xml mmen-20220924_def.xml mmen-20220924_lab.xml mmen-20220924_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 105 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "medmenenter_10q.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 194, "dts": { "calculationLink": { "local": [ "mmen-20220924_cal.xml" ] }, "definitionLink": { "local": [ "mmen-20220924_def.xml" ] }, "inline": { "local": [ "medmenenter_10q.htm" ] }, "labelLink": { "local": [ "mmen-20220924_lab.xml" ] }, "presentationLink": { "local": [ "mmen-20220924_pre.xml" ] }, "schema": { "local": [ "mmen-20220924.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 648, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 40, "http://medmen.com/20220924": 68, "http://xbrl.sec.gov/dei/2022": 5, "total": 113 }, "keyCustom": 161, "keyStandard": 283, "memberCustom": 47, "memberStandard": 16, "nsprefix": "mmen", "nsuri": "http://medmen.com/20220924", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://medmen.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:AssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - ASSETS HELD FOR SALE", "role": "http://medmen.com/role/AssetsHeldForSale", "shortName": "ASSETS HELD FOR SALE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:AssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://medmen.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INTANGIBLE ASSETS", "role": "http://medmen.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "role": "http://medmen.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:DerivativeLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - DERIVATIVE LIABILITIES", "role": "http://medmen.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:DerivativeLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - LEASES", "role": "http://medmen.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - NOTES PAYABLE", "role": "http://medmen.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY", "role": "http://medmen.com/role/SeniorSecuredConvertibleCreditFacility", "shortName": "SENIOR SECURED CONVERTIBLE CREDIT FACILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SHAREHOLDERS\u2019 EQUITY", "role": "http://medmen.com/role/ShareholdersEquity", "shortName": "SHAREHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SHARE-BASED COMPENSATION", "role": "http://medmen.com/role/Share-basedCompensation", "shortName": "SHARE-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://medmen.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - LOSS PER SHARE", "role": "http://medmen.com/role/LossPerShare", "shortName": "LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:GeneralAndAdministrativeExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES", "role": "http://medmen.com/role/GeneralAndAdministrativeExpenses", "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:GeneralAndAdministrativeExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:OtherOperatingExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - OTHER OPERATING (INCOME) EXPENSE", "role": "http://medmen.com/role/OtherOperatingIncomeExpense", "shortName": "OTHER OPERATING (INCOME) EXPENSE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:OtherOperatingExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES", "role": "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxes", "shortName": "PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://medmen.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://medmen.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SEGMENT INFORMATION", "role": "http://medmen.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - REVENUE", "role": "http://medmen.com/role/Revenue", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - DISCONTINUED OPERATIONS", "role": "http://medmen.com/role/DiscontinuedOperations", "shortName": "DISCONTINUED OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SUBSEQUENT EVENTS", "role": "http://medmen.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://medmen.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - INVENTORY (Tables)", "role": "http://medmen.com/role/InventoryTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "mmen:AssetsHeldForSaleTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfAssetsHeldForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - ASSETS HELD FOR SALE (Tables)", "role": "http://medmen.com/role/AssetsHeldForSaleTables", "shortName": "ASSETS HELD FOR SALE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mmen:AssetsHeldForSaleTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfAssetsHeldForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://medmen.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://medmen.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "role": "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "role": "http://medmen.com/role/DerivativeLiabilitiesTables", "shortName": "DERIVATIVE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfLeaseCostTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - LEASES (Tables)", "role": "http://medmen.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfLeaseCostTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://medmen.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables)", "role": "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityTables", "shortName": "SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://medmen.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfSharesIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Tables)", "role": "http://medmen.com/role/ShareholdersEquityTables", "shortName": "SHAREHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfSharesIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "role": "http://medmen.com/role/Share-basedCompensationTables", "shortName": "SHARE-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - LOSS PER SHARE (Tables)", "role": "http://medmen.com/role/LossPerShareTables", "shortName": "LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "mmen:GeneralAndAdministrativeExpensesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)", "role": "http://medmen.com/role/GeneralAndAdministrativeExpensesTables", "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mmen:GeneralAndAdministrativeExpensesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "mmen:OtherOperatingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfOtherOperatingExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - OTHER OPERATING (INCOME) EXPENSE (Tables)", "role": "http://medmen.com/role/OtherOperatingIncomeExpenseTables", "shortName": "OTHER OPERATING (INCOME) EXPENSE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mmen:OtherOperatingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfOtherOperatingExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables)", "role": "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesTables", "shortName": "PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - REVENUE (Tables)", "role": "http://medmen.com/role/RevenueTables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "role": "http://medmen.com/role/DiscontinuedOperationsTables", "shortName": "DISCONTINUED OPERATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "mmen:GoingConcernPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "-5", "first": true, "lang": null, "name": "mmen:CashAndCashEquivalent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "mmen:GoingConcernPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "-5", "first": true, "lang": null, "name": "mmen:CashAndCashEquivalent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - INVENTORY (Details)", "role": "http://medmen.com/role/InventoryDetails", "shortName": "INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2021-06-27_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)", "role": "http://medmen.com/role/StatementsOfChangesInShareholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2021-06-27_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2021-06-272021-09-25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - INVENTORY (Details Narrative)", "role": "http://medmen.com/role/InventoryDetailsNarrative", "shortName": "INVENTORY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2021-06-272021-09-25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - ASSETS HELD FOR SALE (Details)", "role": "http://medmen.com/role/AssetsHeldForSaleDetails", "shortName": "ASSETS HELD FOR SALE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfAssetsHeldForSaleTableTextBlock", "mmen:AssetsHeldForSaleTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_DiscontinuedOperationsMember", "decimals": "0", "lang": null, "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://medmen.com/role/PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://medmen.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - INTANGIBLE ASSETS (Details)", "role": "http://medmen.com/role/IntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - INTANGIBLE ASSETS (Details Narrative)", "role": "http://medmen.com/role/IntangibleAssetsDetailsNarrative", "shortName": "INTANGIBLE ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "role": "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_us-gaap_AccountsPayableAndAccruedLiabilitiesMember", "decimals": "0", "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInDerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - DERIVATIVE LIABILITIES (Details)", "role": "http://medmen.com/role/DerivativeLiabilitiesDetails", "shortName": "DERIVATIVE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_DerivativeLiabilitiesOneMember", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - DERIVATIVE LIABILITIES (Details 1)", "role": "http://medmen.com/role/DerivativeLiabilitiesDetails1", "shortName": "DERIVATIVE LIABILITIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_custom_TopUpProvisionMember", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfWarrantsIssuedTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "mmen:March2021PrivatePlacement", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - DERIVATIVE LIABILITIES (Details 2)", "role": "http://medmen.com/role/DerivativeLiabilitiesDetails2", "shortName": "DERIVATIVE LIABILITIES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfWarrantsIssuedTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "mmen:March2021PrivatePlacement", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://medmen.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2021-06-272021-09-25", "decimals": "0", "lang": null, "name": "us-gaap:DeferredOtherTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - DERIVATIVE LIABILITIES (Details 3)", "role": "http://medmen.com/role/DerivativeLiabilitiesDetails3", "shortName": "DERIVATIVE LIABILITIES (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "mmen:DerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfLeaseCostTableTextblock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - LEASES (Details)", "role": "http://medmen.com/role/LeasesDetails", "shortName": "LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfLeaseCostTableTextblock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - LEASES (Details 1)", "role": "http://medmen.com/role/LeasesDetails1", "shortName": "LEASES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - NOTES PAYABLE (Details)", "role": "http://medmen.com/role/NotesPayableDetails", "shortName": "NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:FinanceLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfReconciliationOfNotesPayable", "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_NotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - NOTES PAYABLE (Details 1)", "role": "http://medmen.com/role/NotesPayableDetails1", "shortName": "NOTES PAYABLE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfReconciliationOfNotesPayable", "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_NotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "p", "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-01-292022-02-02", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfOtherAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://medmen.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "mmen:NotesPayableTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-01-292022-02-02", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfOtherAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details)", "role": "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails", "shortName": "SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_SeniorSecuredConvertibleTotalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative)", "role": "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative", "shortName": "SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_SeniorSecuredConvertibleTotalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfSharesIssuedAndOutstanding", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_MmCanUsaClassBRedeemableUnitsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - SHAREHOLDERS' EQUITY (Details)", "role": "http://medmen.com/role/ShareholdersEquityDetails", "shortName": "SHAREHOLDERS' EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfSharesIssuedAndOutstanding", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_MmCanUsaClassBRedeemableUnitsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfVies", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_custom_VeniceCaregiversFoundationIncMember", "decimals": "0", "first": true, "lang": null, "name": "mmen:CurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000069 - Disclosure - SHAREHOLDERS' EQUITY (Details 1)", "role": "http://medmen.com/role/ShareholdersEquityDetails1", "shortName": "SHAREHOLDERS' EQUITY (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfVies", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_custom_VeniceCaregiversFoundationIncMember", "decimals": "0", "first": true, "lang": null, "name": "mmen:CurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS", "role": "http://medmen.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000070 - Disclosure - SHAREHOLDERS' EQUITY (Details 2)", "role": "http://medmen.com/role/ShareholdersEquityDetails2", "shortName": "SHAREHOLDERS' EQUITY (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25_custom_VeniceCaregiversFoundationIncMember_custom_NonControllingInterestsMember", "decimals": "0", "lang": null, "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_custom_MMCANUSAMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000071 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://medmen.com/role/ShareholdersEquityDetailsNarrative", "shortName": "SHAREHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24_custom_MMCANUSAMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:TotalSharebasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000072 - Disclosure - SHARE-BASED COMPENSATION (Details)", "role": "http://medmen.com/role/Share-basedCompensationDetails", "shortName": "SHARE-BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:TotalSharebasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000073 - Disclosure - SHARE-BASED COMPENSATION (Details 1)", "role": "http://medmen.com/role/Share-basedCompensationDetails1", "shortName": "SHARE-BASED COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-06-25", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfLTIPUnitsAndLLCRedeemableUnitsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "mmen:LtipIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000074 - Disclosure - SHARE-BASED COMPENSATION (Details 2)", "role": "http://medmen.com/role/Share-basedCompensationDetails2", "shortName": "SHARE-BASED COMPENSATION (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfLTIPUnitsAndLLCRedeemableUnitsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "mmen:LtipIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "mmen:IssuedAndOutstandingBegningBalances", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000075 - Disclosure - SHARE-BASED COMPENSATION (Details 3)", "role": "http://medmen.com/role/Share-basedCompensationDetails3", "shortName": "SHARE-BASED COMPENSATION (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "INF", "first": true, "lang": null, "name": "mmen:IssuedAndOutstandingBegningBalances", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-262022-09-24_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "mmen:BegningBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000076 - Disclosure - SHARE-BASED COMPENSATION (Details 4)", "role": "http://medmen.com/role/Share-basedCompensationDetails4", "shortName": "SHARE-BASED COMPENSATION (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-262022-09-24_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "mmen:BegningBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-262022-09-24_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000077 - Disclosure - SHARE-BASED COMPENSATION (Details Narrative)", "role": "http://medmen.com/role/Share-basedCompensationDetailsNarrative", "shortName": "SHARE-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-262022-09-24_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000078 - Disclosure - LOSS PER SHARE (Details)", "role": "http://medmen.com/role/LossPerShareDetails", "shortName": "LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "mmen:GeneralAndAdministrativeExpensesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000079 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)", "role": "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails", "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "mmen:GeneralAndAdministrativeExpensesTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://medmen.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfOtherOperatingExpensesTableTextBlock", "mmen:OtherOperatingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000080 - Disclosure - OTHER OPERATING EXPENSE (Details)", "role": "http://medmen.com/role/OtherOperatingExpenseDetails", "shortName": "OTHER OPERATING EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfOtherOperatingExpensesTableTextBlock", "mmen:OtherOperatingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "p", "mmen:OtherOperatingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:SubleasesIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000081 - Disclosure - OTHER OPERATING (INCOME) EXPENSE (Details Narrative)", "role": "http://medmen.com/role/OtherOperatingIncomeExpenseDetailsNarrative", "shortName": "OTHER OPERATING (INCOME) EXPENSE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "mmen:OtherOperatingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:SubleasesIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000082 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details)", "role": "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetails", "shortName": "PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ProvisionForIncomeTaxesAndDeferredIncomeTaxesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000083 - Disclosure - PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative)", "role": "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetailsNarrative", "shortName": "PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "mmen:ProvisionForIncomeTaxesAndDeferredIncomeTaxesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-262022-09-24_srt_BoardOfDirectorsChairmanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000084 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-262022-09-24_srt_BoardOfDirectorsChairmanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000085 - Disclosure - REVENUE (Details)", "role": "http://medmen.com/role/RevenueDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:Revenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000086 - Disclosure - DISCONTINUED OPERATIONS (Details)", "role": "http://medmen.com/role/DiscontinuedOperationsDetails", "shortName": "DISCONTINUED OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:Revenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfAssetsIncludedInDiscontinuedOperationTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000087 - Disclosure - DISCONTINUED OPERATIONS (Details 1)", "role": "http://medmen.com/role/DiscontinuedOperationsDetails1", "shortName": "DISCONTINUED OPERATIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mmen:ScheduleOfAssetsIncludedInDiscontinuedOperationTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "AsOf2022-09-24", "decimals": "0", "first": true, "lang": null, "name": "mmen:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-08-012022-08-22", "decimals": "0", "first": true, "lang": null, "name": "mmen:SalesPrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000088 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)", "role": "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative", "shortName": "DISCONTINUED OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-08-012022-08-22", "decimals": "0", "first": true, "lang": null, "name": "mmen:SalesPrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - INVENTORY", "role": "http://medmen.com/role/Inventory", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "medmenenter_10q.htm", "contextRef": "From2022-06-26to2022-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 64, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r561", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medmen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "mmen_AccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccountsPayableAndAccruedLiabilities", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_AccountsReceivableAndPrepaidExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AccountsReceivableAndPrepaidExpenses", "verboseLabel": "Accounts Receivable and Prepaid Expenses" } } }, "localname": "AccountsReceivableAndPrepaidExpenses", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_AccretionOfDebtDiscountAndLoanOriginationFees": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accretion of Debt Discount and Loan Origination Fees" } } }, "localname": "AccretionOfDebtDiscountAndLoanOriginationFees", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mmen_AccretionOfDebtDiscountAndLoansOriginationFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccretionOfDebtDiscountAndLoansOriginationFees", "verboseLabel": "Accretion of Debt Discount and Loan Origination Fees" } } }, "localname": "AccretionOfDebtDiscountAndLoansOriginationFees", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_AccretionOfDebtDiscountIncludedInDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accretion of Debt Discount included in Discontinued Operations" } } }, "localname": "AccretionOfDebtDiscountIncludedInDiscontinuedOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_AccretionOfDebtDiscountsAndLoanOriginationFees": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccretionOfDebtDiscountsAndLoanOriginationFees", "negatedLabel": "Accretion of Debt Discount and Loan Origination Fees" } } }, "localname": "AccretionOfDebtDiscountsAndLoanOriginationFees", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_AccruedInventory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Inventory" } } }, "localname": "AccruedInventory", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_Advance3rdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advance 3rd [Member]" } } }, "localname": "Advance3rdMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_AmendmentFeeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amendment Fee Notes [Member]" } } }, "localname": "AmendmentFeeNotesMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_AssetsHeldForSaleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS HELD FOR SALE" } } }, "localname": "AssetsHeldForSaleTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSale" ], "xbrltype": "textBlockItemType" }, "mmen_AverageCapitalizationRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Average capitalization rate" } } }, "localname": "AverageCapitalizationRate", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "percentItemType" }, "mmen_BegningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Beginning Balance" } } }, "localname": "BegningBalance", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "mmen_BorrowingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Borrowing costs" } } }, "localname": "BorrowingCosts", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_BuyerCashPaymentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Buyer cash payment description" } } }, "localname": "BuyerCashPaymentDescription", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "mmen_COVID19PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COVID-19" } } }, "localname": "COVID19PolicyTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mmen_CapitalLeasesLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Capital Leases" } } }, "localname": "CapitalLeasesLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "mmen_CapitalizedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capitalized Software [Member]" } } }, "localname": "CapitalizedSoftwareMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mmen_CarryingAmountsOfAssetsIncludedInDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Carrying Amounts of the Assets Included in Discontinued Operations:" } } }, "localname": "CarryingAmountsOfAssetsIncludedInDiscontinuedOperationsAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "stringItemType" }, "mmen_CashAndCashEquivalent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalent", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_CashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CashAndCashEquivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_CashIncludedInAssetsHeldForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "CashIncludedInAssetsHeldForSale", "negatedLabel": "Cash Included in Assets Held for Sale" } } }, "localname": "CashIncludedInAssetsHeldForSale", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_ControllingInterestEquityTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Controlling Interest Equity Transactions" } } }, "localname": "ControllingInterestEquityTransactionsAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "mmen_ConversionOfConvertibleDebentures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of Convertible Debentures" } } }, "localname": "ConversionOfConvertibleDebentures", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_CostOfGoodsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CostOfGoodsSold", "verboseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_CurrentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "CurrentAssets", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_CurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_CurrentPortionOfFinanceLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "CurrentPortionOfFinanceLeaseLiabilities", "verboseLabel": "Current Portion of Finance Lease Liabilities" } } }, "localname": "CurrentPortionOfFinanceLeaseLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_CurrentPortionOfOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "CurrentPortionOfOperatingLeaseLiabilities", "verboseLabel": "Current Portion of Operating Lease Liabilities" } } }, "localname": "CurrentPortionOfOperatingLeaseLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_CustomerRelationshipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Relationship [Member]" } } }, "localname": "CustomerRelationshipMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mmen_DealCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deal Costs" } } }, "localname": "DealCost", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_DeferredTaxImpactOnConversionFeature": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "DeferredTaxImpactOnConversionFeature", "negatedLabel": "Deferred Tax Impact On Conversion Feature" } } }, "localname": "DeferredTaxImpactOnConversionFeature", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_DeferredTaxImpactOnConversionFeatures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred Tax Impact on Conversion Feature" } } }, "localname": "DeferredTaxImpactOnConversionFeatures", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_DeferredTaxLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities" } } }, "localname": "DeferredTaxLiability", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_DepreciationAndAmortizations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "DepreciationAndAmortizations", "verboseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationAndAmortizations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_DepreciationRecognizedForCapitalLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Depreciation recognized for capital leases" } } }, "localname": "DepreciationRecognizedForCapitalLeases", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_DerivativeLiabilitiesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities One [Member]" } } }, "localname": "DerivativeLiabilitiesOneMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mmen_DerivativeLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativeLiabilitiesTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "mmen_DerivativeLiabilityIncurredOnConvertibleFacilityAndEquityFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative Liability Incurred on Convertible Facility and Equity Financing" } } }, "localname": "DerivativeLiabilityIncurredOnConvertibleFacilityAndEquityFinancing", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_DisclosureAssetsHeldForSaleAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Held For Sale" } } }, "localname": "DisclosureAssetsHeldForSaleAbstract", "nsuri": "http://medmen.com/20220924", "xbrltype": "stringItemType" }, "mmen_DisclosureDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Liabilities" } } }, "localname": "DisclosureDerivativeLiabilitiesAbstract", "nsuri": "http://medmen.com/20220924", "xbrltype": "stringItemType" }, "mmen_DisclosureGeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General And Administrative Expenses" } } }, "localname": "DisclosureGeneralAndAdministrativeExpensesAbstract", "nsuri": "http://medmen.com/20220924", "xbrltype": "stringItemType" }, "mmen_DisclosureNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Notes Payable" } } }, "localname": "DisclosureNotesPayableAbstract", "nsuri": "http://medmen.com/20220924", "xbrltype": "stringItemType" }, "mmen_DisclosureOtherOperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Operating Income Expense", "verboseLabel": "Other Operating Expense" } } }, "localname": "DisclosureOtherOperatingIncomeExpenseAbstract", "nsuri": "http://medmen.com/20220924", "xbrltype": "stringItemType" }, "mmen_DiscontinuedOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]" } } }, "localname": "DiscontinuedOperationsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "mmen_DispensaryLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dispensary License [Member]" } } }, "localname": "DispensaryLicenseMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mmen_DistributionsNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Distributions - Non-Controlling Interest" } } }, "localname": "DistributionsNoncontrollingInterest", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_EarningsLossPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share - Basic and Diluted:" } } }, "localname": "EarningsLossPerShareBasicAndDilutedAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "mmen_EndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ending Balance" } } }, "localname": "EndingBalance", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "mmen_EquityComponentOfDebtNewAndAmendedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equity Component of Debt - New and Amended" } } }, "localname": "EquityComponentOfDebtNewAndAmendedAmount", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_EquityComponentsOfDebtNewAndAmended": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "EquityComponentsOfDebtNewAndAmended", "verboseLabel": "Equity Component of Debt - New and Amended" } } }, "localname": "EquityComponentsOfDebtNewAndAmended", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_Expenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total (Income) Expenses" } } }, "localname": "Expenses", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_FinanceLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease Cost:" } } }, "localname": "FinanceLeaseAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "mmen_FinancingCashFlowsFromFinanceLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Financing Cash Flows from Finance Leases" } } }, "localname": "FinancingCashFlowsFromFinanceLeases", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_GainLossOnSettlementOfAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "GainLossOnSettlementOfAccountsPayable", "negatedLabel": "Gain on Settlement of Accounts Payable" } } }, "localname": "GainLossOnSettlementOfAccountsPayable", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/OtherOperatingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "mmen_GainOnDisposalOfAssetsAndOtherIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on Disposal of Assets and Other Income" } } }, "localname": "GainOnDisposalOfAssetsAndOtherIncome", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_GeneralAndAdministrative": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "GeneralAndAdministrative", "verboseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrative", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_GeneralAndAdministrativeExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GENERAL AND ADMINISTRATIVE EXPENSES" } } }, "localname": "GeneralAndAdministrativeExpensesTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpenses" ], "xbrltype": "textBlockItemType" }, "mmen_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mmen_GrossProfits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross Profit" } } }, "localname": "GrossProfits", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_GrossUnrecognizedTaxBenefits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross unrecognized tax benefits" } } }, "localname": "GrossUnrecognizedTaxBenefits", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_ImpairmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ImpairmentExpense", "verboseLabel": "Impairment Expense" } } }, "localname": "ImpairmentExpense", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_IncomeLossOnDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Income (Loss) on Discontinued Operations", "verboseLabel": "Net Income (Loss) from Discontinued Operations" } } }, "localname": "IncomeLossOnDiscontinuedOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_IncomeLossOnDiscontinuedOperationsBeforeProvisionForIncomeTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations Before Provision for Income Taxes" } } }, "localname": "IncomeLossOnDiscontinuedOperationsBeforeProvisionForIncomeTaxes", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_IncomeTaxesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncomeTaxesPayable", "verboseLabel": "Income Taxes Payable" } } }, "localname": "IncomeTaxesPayable", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_IncrementalAdvanceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Advance One [Member]" } } }, "localname": "IncrementalAdvanceOneMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_IncrementalAdvanceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Advance Two [Member]" } } }, "localname": "IncrementalAdvanceTwoMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_IntangibleAssetNetExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "IntangibleAssetNetExcludingGoodwill", "verboseLabel": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetNetExcludingGoodwill", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_IntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "IntangibleAssetsNet", "verboseLabel": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetsNet", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_InterestCapitalizedToFinanceLeaseLiabilities": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "InterestCapitalizedToFinanceLeaseLiabilities", "negatedLabel": "Interest Capitalized to Finance Lease Liabilities" } } }, "localname": "InterestCapitalizedToFinanceLeaseLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_InterestCapitalizedToSeniorSecuredConvertibleDebtAndNotesPayable": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "InterestCapitalizedToSeniorSecuredConvertibleDebtAndNotesPayable", "negatedLabel": "Interest Capitalized to Senior Secured Convertible Debt and Notes Payable" } } }, "localname": "InterestCapitalizedToSeniorSecuredConvertibleDebtAndNotesPayable", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_InterestExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "InterestExpenses", "verboseLabel": "Interest Expense" } } }, "localname": "InterestExpenses", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_InterestOnLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest on Lease Liabilities" } } }, "localname": "InterestOnLeaseLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_Inventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Inventory [Default Label]", "verboseLabel": "Inventory" } } }, "localname": "Inventory", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_IssuanceOfSubordinateVotingSharesForCash": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of Subordinate Voting Shares for Cash" } } }, "localname": "IssuanceOfSubordinateVotingSharesForCash", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_IssuedAndOutstandingBegningBalances": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued And Outstanding, Beginning Balance" } } }, "localname": "IssuedAndOutstandingBegningBalances", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_IssuedAndOutstandingEndingBalances": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued And Outstanding, Ending Balance" } } }, "localname": "IssuedAndOutstandingEndingBalances", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_IssuedAndOutstandingForfeitureOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued And Outstanding, Forfeiture of Restricted Stock" } } }, "localname": "IssuedAndOutstandingForfeitureOfRestrictedStock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_LAXFundTwoGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "L A X Fund Two Group L L C [Member]" } } }, "localname": "LAXFundTwoGroupLLCMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1", "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "mmen_LessCurrentPortionOfNotesPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Less Current portion of notes payables" } } }, "localname": "LessCurrentPortionOfNotesPayables", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_LiabilitiesAssumedByBuyer": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Liabilities assumed by buyer" } } }, "localname": "LiabilitiesAssumedByBuyer", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_Liability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total Liabilities" } } }, "localname": "Liability", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_LicensesFeesAndTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Licenses, Fees and Taxes" } } }, "localname": "LicensesFeesAndTaxes", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_LlcRedeemableUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LLC Redeemable Units" } } }, "localname": "LlcRedeemableUnits", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "mmen_LossPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Earnings (Loss) Per Share - Basic and Diluted:" } } }, "localname": "LossPerShareBasicAndDilutedAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LossPerShareDetails" ], "xbrltype": "stringItemType" }, "mmen_LossesFromContinuingOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Losses from continuing operations" } } }, "localname": "LossesFromContinuingOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_LtipIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LTIP Issued And Outstanding" } } }, "localname": "LtipIssuedAndOutstanding", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "mmen_MMCANUSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MM CAN USA [Member]" } } }, "localname": "MMCANUSAMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_MMEnterprisesUSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MM Enterprises USA [Member]" } } }, "localname": "MMEnterprisesUSAMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_March2021PrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2021 Private Placement" } } }, "localname": "March2021PrivatePlacement", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails2" ], "xbrltype": "sharesItemType" }, "mmen_MmCanUsaClassBRedeemableUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mm Can Usa Class B Redeemable Units [Member]" } } }, "localname": "MmCanUsaClassBRedeemableUnitsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "mmen_MmEnterprisesUsaCommonUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mm Enterprises Usa Common Units [Member]" } } }, "localname": "MmEnterprisesUsaCommonUnitsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "mmen_NaturesCureIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Natures Cure Inc [Member]" } } }, "localname": "NaturesCureIncMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1", "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "mmen_NetAssetsTransferredToHeldForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Assets Transferred to Held for Sale" } } }, "localname": "NetAssetsTransferredToHeldForSale", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_NetDiscreteTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net discrete tax expense" } } }, "localname": "NetDiscreteTaxExpense", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_NetIncomeLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Income (Loss)" } } }, "localname": "NetIncomeLosses", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Loss" } } }, "localname": "NetLoss", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_NonControllingInterestsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Controlling Interests [Member]" } } }, "localname": "NonControllingInterestsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "mmen_NotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable [Member]" } } }, "localname": "NotesPayableMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "mmen_NotesPayableNetOfCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NotesPayableNetOfCurrentPortion", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayableNetOfCurrentPortion", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_NotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "mmen_OngoingActivityFromDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Ongoing Activities" } } }, "localname": "OngoingActivityFromDiscontinuedOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "mmen_OperatingCashFlowFromOperatingLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating Cash Flows from Operating Leases" } } }, "localname": "OperatingCashFlowFromOperatingLeases", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_OperatingLeaseLiabilitiesNetOfCurrentPortionDiscontinuedOperation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Net of Current Portion" } } }, "localname": "OperatingLeaseLiabilitiesNetOfCurrentPortionDiscontinuedOperation", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_OperatingLeaseRightofuseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "OperatingLeaseRightofuseAssets", "verboseLabel": "Operating Lease Right-of-Use Assets" } } }, "localname": "OperatingLeaseRightofuseAssets", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_OtherAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "OtherAsset", "verboseLabel": "Other Assets" } } }, "localname": "OtherAsset", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_OtherAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Asset [Member]" } } }, "localname": "OtherAssetMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "mmen_OtherCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OtherCurrentLiabilities", "verboseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_OtherGeneralAndAdministrative": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Other General and Administrative" } } }, "localname": "OtherGeneralAndAdministrative", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mmen_OtherNonControllingInterestsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Non Controlling Interests [Member]" } } }, "localname": "OtherNonControllingInterestsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "mmen_OtherOperatingExpenseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER OPERATING (INCOME) EXPENSE" } } }, "localname": "OtherOperatingExpenseDisclosureTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/OtherOperatingIncomeExpense" ], "xbrltype": "textBlockItemType" }, "mmen_OtherOperatingExpenseIncome": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Other Operating (Income) Expense" } } }, "localname": "OtherOperatingExpenseIncome", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mmen_PaidInKindInterestCapitalized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Paid in kind interest Capitalized" } } }, "localname": "PaidInKindInterestCapitalized", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_PartnerContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Partner Contributions" } } }, "localname": "PartnerContributions", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_PaymentOfStockIssuanceCostsRelatingToPrivatePlacement": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentOfStockIssuanceCostsRelatingToPrivatePlacement", "negatedLabel": "Payment of Stock Issuance Costs Relating to Private Placement" } } }, "localname": "PaymentOfStockIssuanceCostsRelatingToPrivatePlacement", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_PaymentsToAcquireIntangibleAsset": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentsToAcquireIntangibleAsset", "negatedLabel": "Additions to Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAsset", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_PaymentsToAcquirePropertyPlantAndEquipments": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentsToAcquirePropertyPlantAndEquipments", "negatedLabel": "Purchases of Property and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipments", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_PrincipalRepaymentsOfFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PrincipalRepaymentsOfFinanceLeaseLiability", "negatedLabel": "Principal Repayments of Finance Lease Liability" } } }, "localname": "PrincipalRepaymentsOfFinanceLeaseLiability", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_PrincipalRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal Repayments of Notes Payable" } } }, "localname": "PrincipalRepaymentsOfNotesPayable", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_ProceedsFromSaleDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from Sale" } } }, "localname": "ProceedsFromSaleDiscontinuedOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "mmen_PropertyAndEquipmentNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PropertyAndEquipmentNet", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyAndEquipmentNet", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_ProvisionForIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ProvisionForIncomeTaxExpenseBenefit", "negatedLabel": "Provision for Income Tax Benefit (Expense)" } } }, "localname": "ProvisionForIncomeTaxExpenseBenefit", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_ProvisionForIncomeTaxesAndDeferredIncomeTaxesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Provision for income taxes and deferred income taxes description" } } }, "localname": "ProvisionForIncomeTaxesAndDeferredIncomeTaxesDescription", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "mmen_RealizedAndUnrealizedChangesInFairValueOfContingentConsideration": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Realized and Unrealized Changes in Fair Value of Contingent Consideration" } } }, "localname": "RealizedAndUnrealizedChangesInFairValueOfContingentConsideration", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mmen_ReceivableForAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Receivable for Assets Held for Sale" } } }, "localname": "ReceivableForAssetsHeldForSale", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "mmen_RecentlyIssuedAccountingStandardspolicytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards" } } }, "localname": "RecentlyIssuedAccountingStandardspolicytextblock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mmen_ReclassificationsImpactedAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclassifications impacted accumulated amortization" } } }, "localname": "ReclassificationsImpactedAccumulatedAmortization", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_ReclassificationsImpactedNoncontrollingInterestAndAccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclassifications impacted Non-controlling interest and accumulated deficit" } } }, "localname": "ReclassificationsImpactedNoncontrollingInterestAndAccumulatedDeficit", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_ReclassificationsImpactedShorttermAndLongtermOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclassifications impacted Short-term and long-term operating lease liabilities" } } }, "localname": "ReclassificationsImpactedShorttermAndLongtermOperatingLeaseLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_RedemptionOfMedmenCorpRedeemableShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of MedMen Corp Redeemable Shares" } } }, "localname": "RedemptionOfMedmenCorpRedeemableShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_RedemptionOfMedmenCorpRedeemableSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption of MedMen Corp Redeemable Shares, Shares" } } }, "localname": "RedemptionOfMedmenCorpRedeemableSharesShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_RedemptionOfMedmenCorpRedemableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption of MedMen Corp Redemable Shares", "verboseLabel": "Redemption of MedMen Corp Redeemable Shares" } } }, "localname": "RedemptionOfMedmenCorpRedemableShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "mmen_RemainsDueAndPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Remains due and payable" } } }, "localname": "RemainsDueAndPayable", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_RestatementFeeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement Fee Notes [Member]" } } }, "localname": "RestatementFeeNotesMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_RestrictedCashs": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Restricted Cash" } } }, "localname": "RestrictedCashs", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_RestrictedStockGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock Grants [Member]" } } }, "localname": "RestrictedStockGrantsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "mmen_RestrictedsCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "RestrictedsCash", "verboseLabel": "Restricted Cash" } } }, "localname": "RestrictedsCash", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_Revenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Revenue [Default Label]", "verboseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_RevenueFromContinuingOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Revenue from Continuing Operations" } } }, "localname": "RevenueFromContinuingOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "mmen_RevenueFromDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Revenue from Discontinued Operations" } } }, "localname": "RevenueFromDiscontinuedOperations", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "mmen_SalesAndMarketing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "SalesAndMarketing", "verboseLabel": "Sales and Marketing" } } }, "localname": "SalesAndMarketing", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_SalesInCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sales in cash" } } }, "localname": "SalesInCash", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_SalesPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sales Price" } } }, "localname": "SalesPrice", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_ScheduleOfAssetsHeldForSaleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of asset held for sale" } } }, "localname": "ScheduleOfAssetsHeldForSaleTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfAssetsIncludedInDiscontinuedOperationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets included in discontinued operation" } } }, "localname": "ScheduleOfAssetsIncludedInDiscontinuedOperationTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of general and administrative expenses" } } }, "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfLTIPUnitsAndLLCRedeemableUnitsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of LTIP Units and LLC Redeemable Units" } } }, "localname": "ScheduleOfLTIPUnitsAndLLCRedeemableUnitsTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfLeaseCostTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of lease cost" } } }, "localname": "ScheduleOfLeaseCostTableTextblock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of net operating loss of discontinued operation" } } }, "localname": "ScheduleOfNetOperatingLossOfDiscontinuedOperationTableTextBLock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfOtherOperatingExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of other operating expenses" } } }, "localname": "ScheduleOfOtherOperatingExpensesTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/OtherOperatingIncomeExpenseTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfReconciliationOfNotesPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Notes payable" } } }, "localname": "ScheduleOfReconciliationOfNotesPayable", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities" } } }, "localname": "ScheduleOfReconciliationOfTheBeginningAndEndingBalanceOfDerivativeLiabilitiesAndChangeInFairValueOfDerivativeLiabilitiesTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Shares issued and outstanding" } } }, "localname": "ScheduleOfSharesIssuedAndOutstanding", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfVies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of VIE" } } }, "localname": "ScheduleOfVies", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "mmen_ScheduleOfWarrantsIssuedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrant issued" } } }, "localname": "ScheduleOfWarrantsIssuedTableTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "mmen_SecondRestatementFeeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Second Restatement Fee Notes [Member]" } } }, "localname": "SecondRestatementFeeNotesMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 10 [Member]" } } }, "localname": "SecuredConvertibleNote10Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 1 [Member]" } } }, "localname": "SecuredConvertibleNote1Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 2 [Member]" } } }, "localname": "SecuredConvertibleNote2Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 3 [Member]" } } }, "localname": "SecuredConvertibleNote3Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 4 [Member]" } } }, "localname": "SecuredConvertibleNote4Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 5 [Member]" } } }, "localname": "SecuredConvertibleNote5Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 6 [Member]" } } }, "localname": "SecuredConvertibleNote6Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 7 [Member]" } } }, "localname": "SecuredConvertibleNote7Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 8 [Member]" } } }, "localname": "SecuredConvertibleNote8Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNote9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note 9 [Member]" } } }, "localname": "SecuredConvertibleNote9Member", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SecuredConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Note [Member]" } } }, "localname": "SecuredConvertibleNoteMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "mmen_SeniorSecuredConvertibleCreditFacility": { "auth_ref": [], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Senior Secured Convertible Credit Facility" } } }, "localname": "SeniorSecuredConvertibleCreditFacility", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "mmen_SeniorSecuredConvertibleTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Secured Convertible Total [Member]" } } }, "localname": "SeniorSecuredConvertibleTotalMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_ShareIssuedToSettleAccountsPayableAndLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "ShareIssuedToSettleAccountsPayableAndLiabilities", "verboseLabel": "Shares Issued to Settle Accounts Payable and Liabilities" } } }, "localname": "ShareIssuedToSettleAccountsPayableAndLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_SharesIssuedForCashNetOfFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares Issued for Cash, Net of Fees" } } }, "localname": "SharesIssuedForCashNetOfFees", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_SharesIssuedForCashNetOfFeesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued for Cash, Net of Fees, Shares" } } }, "localname": "SharesIssuedForCashNetOfFeesShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_SharesIssuedForExerciseOfWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares Issued for Exercise of Warrants" } } }, "localname": "SharesIssuedForExerciseOfWarrant", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_SharesIssuedForExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued for Exercise of Warrants, Shares" } } }, "localname": "SharesIssuedForExerciseOfWarrantsShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_SharesIssuedForVestedRestrictedStockUnitsAndCashlessExerciseOfOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options" } } }, "localname": "SharesIssuedForVestedRestrictedStockUnitsAndCashlessExerciseOfOptions", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_SharesIssuedForVestedRestrictedStockUnitsAndCashlessExerciseOfOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options, Shares" } } }, "localname": "SharesIssuedForVestedRestrictedStockUnitsAndCashlessExerciseOfOptionsShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_SharesIssuedToSettleAccountsPayableAndLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares Issued to Settle Accounts Payable and Liabilities" } } }, "localname": "SharesIssuedToSettleAccountsPayableAndLiabilities", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_SharesIssuedToSettleAccountsPayableAndLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued to Settle Accounts Payable and Liabilities, Shares" } } }, "localname": "SharesIssuedToSettleAccountsPayableAndLiabilitiesShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_SharesIssuedToSettleDebtAndAccruedInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares Issued to Settle Debt and Accrued Interest" } } }, "localname": "SharesIssuedToSettleDebtAndAccruedInterestAmount", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_SharesIssuedToSettleDebtAndAccruedInterestShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued to Settle Debt and Accrued Interest, Shares" } } }, "localname": "SharesIssuedToSettleDebtAndAccruedInterestShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_SharesIssuedToSettleDebtAndLenderFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares Issued to Settle Debt and Lender Fees" } } }, "localname": "SharesIssuedToSettleDebtAndLenderFee", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mmen_SignificantAccountingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPolicyTextBlock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mmen_StockGrantsForCompensationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock Grants for Compensation" } } }, "localname": "StockGrantsForCompensationAmount", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mmen_StockGrantsForCompensationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Grants for Compensation, Shares" } } }, "localname": "StockGrantsForCompensationShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mmen_StockGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Grants [Member]" } } }, "localname": "StockGrantsMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "mmen_SubleasesIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sublease income" } } }, "localname": "SubleasesIncome", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/OtherOperatingIncomeExpenseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mmen_SubordinateVotingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinate Voting [Member]" } } }, "localname": "SubordinateVotingMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "mmen_SubordinateVotingShares": { "auth_ref": [], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Subordinate Voting Shares (no par value, unlimited shares authorized, 1,301,683,764 and 1,301,423,950 shares issued and outstanding as of September 24, 2022 and June 26, 2022, respectively)" } } }, "localname": "SubordinateVotingShares", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "mmen_SubordinateVotingSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinate voting, shares issued" } } }, "localname": "SubordinateVotingSharesIssued", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "mmen_SubordinateVotingSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinate voting, shares outstanding" } } }, "localname": "SubordinateVotingSharesOutstanding", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "mmen_SubordinateVotingStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinate Voting Shares [Member]" } } }, "localname": "SubordinateVotingStockMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical", "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "mmen_SubordinateVotingsSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Subordinate Voting Shares [Member]]" } } }, "localname": "SubordinateVotingsSharesMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "domainItemType" }, "mmen_TopUpProvisionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Top Up Provision [Member]" } } }, "localname": "TopUpProvisionMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "mmen_Total": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total" } } }, "localname": "Total", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails2" ], "xbrltype": "sharesItemType" }, "mmen_TotalAssetsOfDisposalGroupClassifiedAsHeldForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE" } } }, "localname": "TotalAssetsOfDisposalGroupClassifiedAsHeldForSale", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "mmen_TotalCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TOTAL CURRENT ASSETS (1)" } } }, "localname": "TotalCurrentAssetsAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "stringItemType" }, "mmen_TotalCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TOTAL CURRENT LIABILITIES (1)" } } }, "localname": "TotalCurrentLiabilitiesAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "stringItemType" }, "mmen_TotalEquityAttributableToShareholdersOfMedmenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Equity Attributable To Shareholders Of Medmen [Member]" } } }, "localname": "TotalEquityAttributableToShareholdersOfMedmenMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "mmen_TotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total [Member]" } } }, "localname": "TotalMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails", "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "mmen_TotalNoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TOTAL NON-CURRENT LIABILITIES (1)" } } }, "localname": "TotalNoncurrentLiabilitiesAbstract", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "stringItemType" }, "mmen_TotalOtherExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total Other Expense" } } }, "localname": "TotalOtherExpense", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "mmen_TotalOtherOperatingExpenseIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total Other Operating (Income) Expense" } } }, "localname": "TotalOtherOperatingExpenseIncome", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/OtherOperatingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "mmen_TotalSharebasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total Share-Based Compensation" } } }, "localname": "TotalSharebasedCompensation", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "mmen_TrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tranche Four [Member]" } } }, "localname": "TrancheFourMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_TrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tranche One [Member]" } } }, "localname": "TrancheOneMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_TrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tranche Three [Member]" } } }, "localname": "TrancheThreeMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_TrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tranche Two [Member]" } } }, "localname": "TrancheTwoMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "mmen_VeniceCaregiversFoundationIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Venice Caregivers Foundation Inc [Member]" } } }, "localname": "VeniceCaregiversFoundationIncMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1", "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "mmen_VestedBegningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested, Beginning Balance" } } }, "localname": "VestedBegningBalance", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_VestedEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested, Ending Balance" } } }, "localname": "VestedEndingBalance", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_VestedForfeitureOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested, Forfeiture of Restricted Stock" } } }, "localname": "VestedForfeitureOfRestrictedStock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_VestedVestingOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested, Vesting of Restricted Stock" } } }, "localname": "VestedVestingOfRestrictedStock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_VestingOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vesting of Restricted Stock" } } }, "localname": "VestingOfRestrictedStock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "mmen_ViesTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vies Total [Member]" } } }, "localname": "ViesTotalMember", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "domainItemType" }, "mmen_WeightedAverageExercisePriceBegningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Beginning balance" } } }, "localname": "WeightedAverageExercisePriceBegningBalance", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "mmen_WeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Ending" } } }, "localname": "WeightedAverageExercisePriceEnding", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "mmen_WeightedAverageFairValueForfeitureOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average fair Value, Forfeiture of Restricted Stock" } } }, "localname": "WeightedAverageFairValueForfeitureOfRestrictedStock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "perShareItemType" }, "mmen_WeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average grant date fair Value" } } }, "localname": "WeightedAverageGrantDateFairValue", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "mmen_WeightedaverageFairValueVestingOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WeightedAverage Fair Value, Vesting of Restricted Stock" } } }, "localname": "WeightedaverageFairValueVestingOfRestrictedStock", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "perShareItemType" }, "mmen_WeightedaverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WeightedaverageNumberOfSharesOutstandingBasicAndDiluted", "verboseLabel": "Weighted-Average Shares Outstanding - Basic and Diluted" } } }, "localname": "WeightedaverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "mmen_WeightedaverageSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-Average Shares Outstanding - Basic and Diluted" } } }, "localname": "WeightedaverageSharesOutstandingBasicAndDiluted", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "mmen_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://medmen.com/20220924", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r230", "r231", "r232", "r233", "r247", "r278", "r319", "r320", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r527", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r230", "r231", "r232", "r233", "r247", "r278", "r319", "r320", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r527", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r169", "r231", "r232", "r305", "r307", "r485", "r524", "r526" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r169", "r231", "r232", "r305", "r307", "r485", "r524", "r526" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r221", "r230", "r231", "r232", "r233", "r247", "r278", "r311", "r319", "r320", "r351", "r352", "r353", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r527", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r221", "r230", "r231", "r232", "r233", "r247", "r278", "r311", "r319", "r320", "r351", "r352", "r353", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r527", "r548", "r549" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r174", "r445" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "stpr_AZ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ARIZONA" } } }, "localname": "AZ", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ILLINOIS" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_MA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MASSACHUSETTS" } } }, "localname": "MA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_NV": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEVADA" } } }, "localname": "NV", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable and Prepaid Expenses" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Total Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r54", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r222", "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion of Debt Discount" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less Accumulated Amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of reclassifications from property, plant and equipment.", "label": "Reclassifications impacted customer relationships and accumulated amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r73", "r74", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r40", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r124", "r125", "r126", "r358", "r359", "r360", "r404" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Share-Based Compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r106", "r209" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Impairment of Assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r34", "r118", "r155", "r159", "r165", "r181", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r388", "r394", "r409", "r449", "r451", "r494", "r510" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r23", "r53", "r118", "r181", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r388", "r394", "r409", "r449", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r207" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held for Sale", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails", "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNet": { "auth_ref": [ "r19", "r533", "r535", "r538", "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net assets (liabilities).", "label": "Total Assets" } } }, "localname": "AssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r118", "r181", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r388", "r394", "r409", "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Non-Current Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r20", "r123", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "NATURE OF OPERATIONS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "June 29, 2024" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r21", "r29", "r108" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r101", "r108", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r101", "r410" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowInvestingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities:" } } }, "localname": "CashFlowInvestingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r13", "r101" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Used in Discontinued Investing Activities" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r401" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedLabel": "Realized and Unrealized Changes in Fair Value of Contingent Consideration" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r294", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical", "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical", "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical", "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r294", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical", "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r227", "r228", "r229", "r234", "r544" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r115", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Senior Secured Convertible Credit Facility Net" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r36", "r496", "r511", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Total Drawn On Senior Secured Convertible Credit Facility" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r35", "r495", "r509", "r534" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r86", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r87", "r118", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r409" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Goods Sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r369", "r376", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Income Tax Expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r116", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r258", "r260", "r261", "r263", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "SENIOR SECURED CONVERTIBLE CREDIT FACILITY" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacility" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r257", "r266", "r267", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Promissory notes" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r62", "r508" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r255", "r417", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less Unamortize Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r255", "r264", "r266", "r267", "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Less. Unamortization Debt Issuance Cost an Loan Origination Fess" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails", "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails", "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredOtherTaxExpenseBenefit": { "auth_ref": [ "r119", "r370", "r375" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.", "label": "Deferred Tax Expense" } } }, "localname": "DeferredOtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r367", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Local & State Taxes Payable" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r367", "r368" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liability" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r106", "r212" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation and Amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r106", "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r106", "r153" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r68", "r69", "r70", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r68" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Schedule of Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r324", "r325", "r355", "r356", "r357", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "SHARE-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Income (Loss) from Discontinued Operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r18", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "DISCONTINUED OPERATIONS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "verboseLabel": "Share-Based Compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r73", "r74", "r75", "r124", "r125", "r126", "r128", "r133", "r135", "r146", "r182", "r291", "r293", "r358", "r359", "r360", "r372", "r373", "r404", "r411", "r412", "r413", "r414", "r415", "r416", "r440", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2", "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ExplorationAbandonmentAndImpairmentExpense": { "auth_ref": [ "r106", "r488", "r489", "r490", "r491" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The adjustment to expense previously capitalized costs of drilling exploratory wells when proved reserves are not found or when the entity obtains information that raises substantial doubt about the economic or operational viability of the project.", "label": "Impairment Expense" } } }, "localname": "ExplorationAbandonmentAndImpairmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": { "auth_ref": [ "r268" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.", "label": "Extinguishment of Debt, Gain (Loss), Net of Tax", "negatedLabel": "Gain on Extinguishment of Debt" } } }, "localname": "ExtinguishmentOfDebtGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Extinguishment of Debt [Line Items]" } } }, "localname": "ExtinguishmentOfDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished." } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Schedule of assumptions to measure fair value" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r431", "r435" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "negatedLabel": "Interest Payments on Finance Leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r428" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current Portion of Finance Lease Liabilities", "verboseLabel": "Finance liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets", "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r428" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "verboseLabel": "Total lease payment" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "verboseLabel": "July 1, 2023 (remaining)" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "verboseLabel": "June 26, 2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "verboseLabel": "June 27, 2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "verboseLabel": "June 28, 2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "verboseLabel": "June 29, 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "Lease Liability Recognized" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r429", "r432", "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of Finance Lease Right-of-Use Assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r437", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r183", "r184", "r185", "r186", "r187", "r190", "r191", "r192", "r193", "r262", "r289", "r402", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r566", "r567", "r568", "r569", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails", "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Past Due [Line Items]" } } }, "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r200", "r201", "r204", "r205", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r204", "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Total Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r200", "r203" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnContractTermination": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.", "label": "Gain on Lease Terminations" } } }, "localname": "GainLossOnContractTermination", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/OtherOperatingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r400" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Change in Fair Value of Derivatives" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r106", "r210", "r218" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Loss on Disposals of Assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Loss on Disposals of Assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/OtherOperatingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": { "auth_ref": [ "r208", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.", "label": "Gain on Sale of Assets Held for Sale" } } }, "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfProperty": { "auth_ref": [ "r106" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of oil and gas property or timber property.", "label": "Gain (Loss) on Disposition of Oil and Gas and Timber Property", "negatedLabel": "Accretion of Deferred Gain on Sale of Property" } } }, "localname": "GainLossOnSaleOfProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r426" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Gain on Lease Terminations" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r106", "r268", "r269" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.", "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations" } } }, "localname": "GainsLossesOnSalesOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r188", "r505", "r506", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r505", "r506", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r32", "r195", "r196", "r197", "r198", "r451", "r493" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83", "r118", "r155", "r158", "r161", "r164", "r167", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r409" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit [Default Label]", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r75", "r85" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Net Loss Attributable to Non-Controlling Interest" } } }, "localname": "IncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r75", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc." } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r84", "r107", "r129", "r130", "r131", "r132", "r138", "r141", "r386" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net Loss from Continuing Operations", "totalLabel": "Net Loss from Continuing Operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows", "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r78", "r155", "r158", "r161", "r164", "r167", "r492", "r500", "r506", "r522" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss from Continuing Operations Before Provision for Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesDetails", "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r76", "r81", "r127", "r129", "r130", "r131", "r132", "r136", "r139", "r140", "r405", "r499", "r501", "r503", "r517" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc." } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r76", "r81", "r127", "r129", "r130", "r131", "r132", "r136", "r139", "r140", "r141", "r405", "r503", "r517", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "verboseLabel": "From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc." } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r11", "r16", "r387" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Net Income (Loss) from Discontinued Operations, Net of Taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r79", "r81", "r137", "r139", "r140", "r503", "r518", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc." } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r137", "r139", "r140", "r399" ], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "verboseLabel": "From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc." } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r120", "r364", "r365", "r366", "r374", "r378", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r134", "r135", "r154", "r362", "r375", "r379", "r523" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for Income Tax Expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other.", "label": "Increase (Decrease) in Accounts Receivable and Other Operating Assets", "negatedLabel": "Accounts Receivable and Prepaid Expenses" } } }, "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Change in Fair Value of Derivative Liabilities" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails", "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "Increase (Decrease) in Income Taxes", "verboseLabel": "Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Operating Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r105", "r435" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Cash Payments - Operating Lease Liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other Current Assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Other Current Liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other Assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "verboseLabel": "Other Non-Current Liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r199", "r202" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r504" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r95", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Paid-In-Kind Interest Capitalized" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r99", "r103", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash Paid for Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r45" ], "calculation": { "http://medmen.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r51" ], "calculation": { "http://medmen.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total Inventory" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r22", "r51", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r47" ], "calculation": { "http://medmen.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw Materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r46" ], "calculation": { "http://medmen.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work-in-Process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r91", "r93" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Interest Income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentSecondaryCategorizationAxis": { "auth_ref": [ "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by second categorization of investments, which may include, but is not limited to industry.", "label": "Investment Secondary Categorization [Axis]" } } }, "localname": "InvestmentSecondaryCategorizationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsBySecondaryCategorizationDomain": { "auth_ref": [ "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Investments in the \"Investment Holdings [Table]\" and the \"Summary of Investment Holdings [Table]\" are often categorized at two levels. The first categorization is the investment type. The second categorization can vary. The usual secondary categorizations are industry, country or geography." } } }, "localname": "InvestmentsBySecondaryCategorizationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Land": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land and Buildings" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "LEASES" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r59", "r118", "r160", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r389", "r394", "r395", "r409", "r449", "r450" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r44", "r118", "r181", "r409", "r451", "r498", "r515" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r24", "r61", "r118", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r389", "r394", "r395", "r409", "r449", "r450", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r26", "r27", "r28", "r36", "r37", "r118", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r389", "r394", "r395", "r409", "r449", "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Non-Current Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r3", "r4", "r14", "r15", "r17", "r219" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Carrying Amounts of the Liabilities Included in Discontinued Operations:" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r3", "r4", "r14", "r15", "r17", "r211", "r219" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Liabilities Held for Sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r60" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Current Portion of Notes Payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Represents the assets held for sale.", "label": "Long-Lived Assets Held-for-sale by Asset Type [Axis]" } } }, "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "A name of the assets to be disposed." } } }, "localname": "LongLivedAssetsHeldForSaleNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r36", "r256", "r265", "r266", "r267", "r496", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Net Amount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r67", "r118", "r181", "r236", "r240", "r241", "r242", "r245", "r246", "r409", "r497", "r514" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Non-Controlling Interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "auth_ref": [ "r101" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.", "label": "Net Cash Used in Discontinued Operating Activities" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r101" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r101", "r104", "r107" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r101", "r104", "r107" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r71", "r72", "r75", "r80", "r107", "r118", "r127", "r129", "r130", "r131", "r132", "r134", "r135", "r138", "r155", "r158", "r161", "r164", "r167", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r405", "r409", "r502", "r519" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Total Net Income (Loss)", "totalLabel": "Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShareDetails", "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r71", "r72", "r75", "r134", "r135", "r392", "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net (Loss) Income Attributable to Non-Controlling Interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.", "label": "Net Income (Loss) from Discontinued Operations" } } }, "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestInVariableInterestEntity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).", "label": "Noncontrolling Interest in Variable Interest Entity", "verboseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestInVariableInterestEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r124", "r125", "r126", "r293", "r384" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Non-Operating Expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes Payables, net of Current Portion" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r110", "r111", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes payable, Net of Current portion" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r36", "r496", "r512" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "verboseLabel": "Total notes Payables" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets", "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "periodEndLabel": "Balance at End of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails", "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r63", "r122", "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Notes Payable, Related Parties, Noncurrent", "negatedLabel": "Less Current Portion of Notes Payable" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:", "verboseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails", "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r158", "r161", "r164", "r167" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r433", "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r430" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Total Lease Expenses" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r428" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current Portion of Operating Lease Liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r428" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r427" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right-of-Use Assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r437", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Total lease payment" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "June 26, 2027" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "June 27, 2026" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "June 28, 2025" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "July 1, 2023 (remaining)" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Lease Liability Recognized" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesIncomeStatementInitialDirectCosts": { "auth_ref": [ "r425" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of incremental cost of lease that would not have been incurred if lease had not been obtained.", "label": "Non-Cash Operating Lease Costs" } } }, "localname": "OperatingLeasesIncomeStatementInitialDirectCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r106", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/InventoryDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r52", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Non-Current Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r89", "r106", "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Total General and Administrative Expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expense:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r60", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Non-Current Liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Operating (Income) Expenses:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNotesPayable": { "auth_ref": [ "r36", "r496", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes payable classified as other.", "label": "Other" } } }, "localname": "OtherNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Current", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Income" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/OtherOperatingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r38", "r276" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r38", "r276" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r38", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": { "auth_ref": [ "r97" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.", "label": "Proceeds from Issuance of Notes Payable" } } }, "localname": "ProceedsFromIssuanceOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r97" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherDebt": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from debt classified as other.", "label": "Proceeds from Other Debt" } } }, "localname": "ProceedsFromOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.", "label": "Proceeds from (Repayments of) Debt" } } }, "localname": "ProceedsFromRepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherAssets1": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of other assets as part of operating activities.", "label": "Proceeds from Sale of Other Assets" } } }, "localname": "ProceedsFromSaleOfOtherAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities.", "label": "Proceeds from the Sale of Assets Held for Sale" } } }, "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r96" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Exercise of Warrants for Cash" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r536", "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r17", "r71", "r72", "r75", "r100", "r118", "r127", "r134", "r135", "r155", "r158", "r161", "r164", "r167", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r387", "r391", "r393", "r397", "r398", "r405", "r409", "r506" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net (Loss) Income", "totalLabel": "Net Income (Loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2", "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r220", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r215", "r451", "r507", "r516" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Equipment and Software" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Accumulated Depreciation", "negatedLabel": "Less Accumulated Depreciation" } } }, "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": { "auth_ref": [ "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Reclassifications impacted leasehold improvements and furniture and fixtures" } } }, "localname": "PropertyPlantAndEquipmentTransfersAndChanges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r272", "r273", "r274", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r313", "r443", "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails", "http://medmen.com/role/ShareholdersEquityDetails1", "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4", "http://medmen.com/role/ShareholdersEquityDetails", "http://medmen.com/role/ShareholdersEquityDetails1", "http://medmen.com/role/ShareholdersEquityDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r441", "r442", "r444", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Cash payments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r106", "r223", "r225", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring and Reorganization Expense" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/OtherOperatingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r41", "r293", "r451", "r513", "r531", "r532" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r124", "r125", "r126", "r128", "r133", "r135", "r182", "r358", "r359", "r360", "r372", "r373", "r404", "r528", "r530" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r151", "r152", "r157", "r162", "r163", "r169", "r170", "r172", "r304", "r305", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r306", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r77", "r118", "r151", "r152", "r157", "r162", "r163", "r169", "r170", "r172", "r181", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r409", "r506" ], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesNetOfInterestExpense": { "auth_ref": [ "r151", "r152", "r157", "r162", "r163", "r169", "r170", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "RevenuesNetOfInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and Benefits" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/GeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of accounts payable and accrued liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "verboseLabel": "Schedule of assumptions to measure fair value" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of income tax expense and effective tax rates" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ProvisionForIncomeTaxesAndDeferredIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of notes payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of basic and diluted loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExtinguishmentOfDebtTable": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to debt extinguished, including the amount of gain (loss) on the debt extinguished, the income tax effect on the gain (loss), and the amount of gain (loss), net of the related income tax.", "label": "Schedule of Extinguishment of Debt [Table]" } } }, "localname": "ScheduleOfExtinguishmentOfDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "auth_ref": [ "r185", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about aging analysis for financing receivable.", "label": "Financing Receivable, Past Due [Table]" } } }, "localname": "ScheduleOfFinancingReceivablesPastDueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r200", "r203", "r486" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r200", "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of future leases payments" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r25", "r48", "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of senior secured convertible credit facility" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Restricted Stock Grants" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of other non-controlling interest" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Warrants" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r337", "r344", "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of share-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r321", "r322", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative", "http://medmen.com/role/Share-basedCompensationDetails", "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r328", "r344", "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails", "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r148", "r149", "r150", "r155", "r156", "r161", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://medmen.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r105" ], "calculation": { "http://medmen.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average fair value at ending", "periodStartLabel": "Weighted average fair value at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/DerivativeLiabilitiesDetails3" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails3" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative", "http://medmen.com/role/Share-basedCompensationDetails", "http://medmen.com/role/Share-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of Stock Options, Stock Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted Average Exercise Price, Stock Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "negatedLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Stock Options, Ending Balance", "periodStartLabel": "Number of Stock Options, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "negatedLabel": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/DerivativeLiabilitiesDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/DerivativeLiabilitiesDetails3" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails", "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails", "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails", "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/NotesPayableDetails", "http://medmen.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r114", "r123" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r66", "r73", "r74", "r75", "r124", "r125", "r126", "r128", "r133", "r135", "r146", "r182", "r291", "r293", "r358", "r359", "r360", "r372", "r373", "r404", "r411", "r412", "r413", "r414", "r415", "r416", "r440", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetails2", "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative", "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r124", "r125", "r126", "r146", "r485" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquityDetailsNarrative", "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r65", "r259", "r291", "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares Issued for Conversion of Debt, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r38", "r39", "r291", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedLabel": "Number of Stock Options, Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Shares Issued for Conversion of Debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Value", "verboseLabel": "Redemption of MedMen Corp Redeemable Shares" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r39", "r42", "r43", "r118", "r175", "r181", "r409", "r451" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Equity Attributable to Shareholders of MedMen Enterprises Inc." } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r74", "r118", "r124", "r125", "r126", "r128", "r133", "r181", "r182", "r293", "r358", "r359", "r360", "r372", "r373", "r384", "r385", "r396", "r404", "r409", "r411", "r412", "r416", "r440", "r529", "r530" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets", "http://medmen.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r117", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r293", "r295", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r434", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/AssetsHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://medmen.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income Taxes Payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r262", "r289", "r402", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r566", "r567", "r568", "r569", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/DerivativeLiabilitiesDetails", "http://medmen.com/role/DerivativeLiabilitiesDetails1", "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/SeniorSecuredConvertibleCreditFacilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medmen.com/role/Share-basedCompensationDetails4" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r18": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r20": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "40", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905841&loc=SL51729484-110225" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "40", "SubTopic": "30", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123393937&loc=d3e44908-112734" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org/topic&trid=2208923" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916655-209961" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r448": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "35", "SubTopic": "360", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=66906256&loc=d3e66150-109466" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "360", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=6475089&loc=d3e66584-109467" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "360", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=6475089&loc=d3e66610-109467" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "40", "SubTopic": "360", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=6475089&loc=d3e66625-109467" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.2(ii))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r551": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r552": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r553": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r554": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r555": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r556": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r557": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r561": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r562": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r563": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r564": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r565": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r572": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)" }, "r573": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)" }, "r574": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r575": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r576": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)" }, "r579": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)" }, "r581": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)" }, "r583": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406" }, "r584": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r585": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r586": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r587": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" } }, "version": "2.1" } ZIP 106 0001829126-22-018581-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001829126-22-018581-xbrl.zip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